<SEC-DOCUMENT>0001493152-24-019970.txt : 20240515
<SEC-HEADER>0001493152-24-019970.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515170040
ACCESSION NUMBER:		0001493152-24-019970
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		24952295

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		SUITE 100
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GTBP="http://gtbiopharma.com/20240331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_GTBP_gtbiopharma.com_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000005" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000007" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0143" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0167" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:StockBasedCompensationCommonSharesForServices" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:Extinguishment" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:Extinguishment" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember" id="xdx2ixbrl0621" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember" id="xdx2ixbrl0623" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember" id="xdx2ixbrl0647" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember" id="xdx2ixbrl0649" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0734" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0736" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0738" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0740" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0742" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0744" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0803" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0805" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0807" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0809" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0811" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0813" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-03-31" id="xdx2ixbrl0841" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-03-31" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-03-31" id="xdx2ixbrl1002" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="GTBP:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" contextRef="AsOf2024-03-31" id="xdx2ixbrl1004" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20240331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-01_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_WarrantMember63927609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_MasterServicesAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ThirdPartyProductManufacturerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ThirdPartyProductManufacturerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_CommonWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_PlacementAgentWarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PlacementAgentWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AccountingStandardsUpdate201602Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AccountingStandardsUpdate201602Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwentyTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwentyTwentyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-042023-01-04_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-04</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_PrefundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PlacementAgentWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_CommonSharesAndCommonWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesAndCommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_PreFundedWarrantsAndCommonWarrantsMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PreFundedWarrantsAndCommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-022023-01-04_custom_CommonWarrantAndPlacementAgentWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantAndPlacementAgentWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-02</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:BoardOfDirectorsEmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-132023-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-13</xbrli:startDate>
        <xbrli:endDate>2023-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-13_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-15</xbrli:startDate>
        <xbrli:endDate>2021-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SeriesKPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesKPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-272023-01-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-27</xbrli:startDate>
        <xbrli:endDate>2023-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-272023-01-27_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-27</xbrli:startDate>
        <xbrli:endDate>2023-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-132022-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-13</xbrli:startDate>
        <xbrli:endDate>2022-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-202024-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-20</xbrli:startDate>
        <xbrli:endDate>2024-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ScientificResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ScientificResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-25</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-18</xbrli:startDate>
        <xbrli:endDate>2021-11-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-08_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_LeaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-30</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20240101__20240331_zBIejbZHpdAl"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000014" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentQuarterlyReport_c20240101__20240331_zHVUX3fJ0oi1"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarterly
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_902_edei--DocumentPeriodEndDate_c20240101__20240331_zxorZJ3tRiIe"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate">March 31, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20240101__20240331_zCRxeRl6qLqc"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20240101__20240331_ziodU40SWphe"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transition
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from __________ to ____________.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_900_edei--EntityFileNumber_c20240101__20240331_zdjGQ5Tar1mk"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000019" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityRegistrantName_c20240101__20240331_zOQZk0v6BZq"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000020" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20240101__20240331_zIJcdtobpuT7"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240101__20240331_zOJPUGl6Ddub"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction of </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incorporation
    or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
                                            Employer </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20240101__20240331_zo3n5eANtv8l"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000023" name="dei:EntityAddressAddressLine1">8000
Marina Blvd</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20240101__20240331_zElFFKB2S4A2"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20240101__20240331_zrbmQDFZDg42"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000025" name="dei:EntityAddressCityOrTown">Brisbane</ix:nonNumeric></span>,
<span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240101__20240331_zrvM15QVk2q9"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000026" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20240101__20240331_ztZtp464YvDd"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000027" name="dei:EntityAddressPostalZipCode">94005</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices and zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--CityAreaCode_c20240101__20240331_zeLnOSnym0E4"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000028" name="dei:CityAreaCode">415</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20240101__20240331_zBilt4xVk3c7"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000029" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20240101__20240331_z5UyW0an0RUf"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000030" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20240101__20240331_z1rzZxHRegXl"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000031" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SecurityExchangeName_c20240101__20240331_zQzRkO16QrE6"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_900_edei--EntityCurrentReportingStatus_c20240101__20240331_zTOBHMoaoKKj"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_909_edei--EntityInteractiveDataCurrent_c20240101__20240331_z87gHNVoyfr1"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--EntityFilerCategory_c20240101__20240331_znE3nEi4n2s3"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90A_edei--EntitySmallBusiness_c20240101__20240331_zNRRHAtDS1aa"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20240101__20240331_zQxlghLz0sq1"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_903_edei--EntityShellCompany_dbF_c20240101__20240331_zINYYPnJcixl"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 15, 2024, the registrant had <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20240515_zg20ycMmyzCg"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-05-15" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,416,651</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
Biopharma, Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-Q</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three Months Ended March 31, 2024 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_001">Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_002">Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_003">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_004">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_005">Condensed Notes to Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_002">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_003">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_004">PART II OTHER INFORMATION</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_005">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_006">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_007">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_001"></span>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except shares and par value)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_pn3n3_zPRrSr4Ybane" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49E_20240331_zdPevtyWpoU2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zHpISenvBi8a" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zQfyNPKpwTLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zr2lVcCfVrgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACz3bi_zqe4NZiTfJcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-03-31" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,950</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,079</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShortTermInvestments_i02I_maACz3bi_zZjHhb7MHTE2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-03-31" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACz3bi_z8D0JFK35oX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtACz3bi_maAzZ68_zsriEs0XGU6e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzZ68_zo7V105NBpr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact000059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_mtAzZ68_zkGBDbtNLaQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-03-31" id="Fact000062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,109</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_ze4nQFlsjsa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zr0DWFqSrR24" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCzqF6_zkhlk1sQiSLc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzqF6_zqG4PXs3XyT1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzqF6_zr3uHglVI41g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--WarrantLiabilityNonCurrent_i01I_maLCzqF6_z2MyQMvdMgc4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityNonCurrent" contextRef="AsOf2024-03-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityNonCurrent" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,052</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i01TI_mtLCzqF6_maLzyn1_zZIZ3OhPJ2Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i01TI_mtLzyn1_maLASEzEek_zYPTLtqtdFK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-03-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_maSEzWnM_zVh69D72l2ya" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Preferred stock,&#160;&#160;par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zEbrwcmZ2g0c" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331_zEoAbhg9MMxj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zJBGbZRY4Mlh" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331_zaxDDuMwGzck" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized Series C - <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zx0Rqzxt9nFe" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zi30MD2p8Ajg" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFIrvesA1Xsa" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5wKFUfCzJr3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000107" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockValue_i02I_maSEzWnM_zsZwtFQfdmQh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Common stock,&#160;&#160;par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zsyjVj1XdHq3" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zZJCV4vyFIQj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zAzthDccqYe3" title="Common stock, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zmcmHesq6ttg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zAmOpLOELmU6" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zs7XNoeNSrxh" title="Common stock, shares outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20240331_zY9LlWpOyWI2" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240331_zUo0quCKoir2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-03-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_maSEzWnM_zLIjtYRW72r3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-03-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzWnM_zRhsU5scKO4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">684,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">682,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzWnM_maLASEzEek_zBWwutkXmZc5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,312</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,476</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzEek_z9heJ1RjZR3h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,109</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_002"></span>Condensed
Consolidated Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_pn3n3_zGqSwNRUn6S5" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20240331_zujnThwfiRj6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230331_zWTy2w9pVXWj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For The Three Months Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maOILzuKp_zKHxdb17gUT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILzuKp_zmu7JjYYVt6c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">777</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,650</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_msOILzuKp_zg6MiOd1r078" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Selling, general and administrative&#160;&#160;(including $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_z3w0DziY3Gz3" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zBryywVzCbza" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">718</ix:nonFraction></span> from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,314</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iNT_di_maNILzVN8_mtOILzuKp_z6fWngBJA1p4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from Operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,091</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,665</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (Income) Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestIncomeOther_i01N_di_maNIEz4VS_zhGcU7zhW2O" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-01to2024-03-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-01-012023-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_i01_msNIEz4VS_zwe5huBL9uuf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueAdjustmentOfWarrants_i01_pn3n3_msNIEz4VS_z6NQEIn3g9n7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-03-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_maNIEz4VS_zWu8NRTyycfk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01N_di_maNIEz4VS_zhxmPF7z1nH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss (gain) on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-012023-03-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maNIEz4VS_zkOiBleFaY9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0180">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01NT_di_maNILzVN8_mtNIEz4VS_zn08wMLXbMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILzVN8_zQo5sipqRtL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000186" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240331_zEsKYsBdv5Y8" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240331_zrDQDkeve472" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-03-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.64</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230331_z1jllhOhUmzi" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230331_zjmRqgEf1W89" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.21</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240331_zjp65FcBRWxi" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240331_zR1K5x644P4h" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-03-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230331_zUEUgUcUBuE8" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230331_zaBFEykznfVb" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,082,871</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_003"></span>CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands) </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_pn3n3_zrsg6Prnx2a8" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zxLUFyaqpvk5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zVWGzlVZDU79" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zkCmmf43LjMi" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Capital</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zpnGd97pFg09" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Deficit</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_4BD_zbey9f1Elxeb" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Total</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    The Three Months Ended March 31, 2024 (Unaudited)</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Preferred Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Paid in</p></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated </td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Capital</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Deficit</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Total</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_ze2e0E8crgZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Balance, December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYR9uKNFtDQ8" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0k9bfjtayd6" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689,539</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">682,065</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,476</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zvR7QdoLxSs1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-01to2024-03-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zma4UxE8EA88" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0221">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zKZcDWBIOCDj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zL6ZX55iUGih" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpkYoDBuiib5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,381</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">684,331</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,312</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold">For The Three Months Ended March 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Preferred Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Paid in</p></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated </td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Capital</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Deficit</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Total</b></td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zxPrE2p6pnlj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Balance, December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuga5k2N6Pad" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYmR4yApmUba" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,091</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686,200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,468</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zv8rTPoLuXo6" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zinYK84CzRF4" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDc2WhGn58Bh" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">686,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zgo6mLzfAGxj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Private placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxENmWuxbVJ6" title="Private placement of common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">120</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_iN_di_zhkReG9iIgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial recognition of fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,831</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-03-31" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,831</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zB2vAc1EgfDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zNwUjH1w64Ug" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBIZzNKCiDs8" title="Issuance of common shares for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_zYRZMrsbzhud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares in settlement of vendors payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrDWSwPrqVhe" title="Issuance of common shares in settlement of vendors payable, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-01-012023-03-31" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_z8iGimCMe34k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zAQ7gbPOpN" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z83tVyjRZNqg" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKSX3cEYWW3i" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,229</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">687,746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20230101__20230331_eus-gaap--StockholdersEquity_iE_zUBAWhgeOwa3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1XoN3TCPc4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze83B0pk6Ay" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,229</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">687,746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">674,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_004"></span>Condensed
Consolidated Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_pn3n3_zHHu5uWAzkG7" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240331_zfJpN9Ye3ima" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230331_zz4r2kucQ5T1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center">For The Three Months Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUzkoF_z5TisvQjA9Pk" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,266</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">227</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockBasedCompensationCommonSharesForServices_i02_pn3n3_maNCPBUzkoF_ziGnrCiXzEch" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation - services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationCommonSharesForServices" contextRef="From2023-01-012023-03-31" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_i02_pn3n3_maNCPBUzkoF_zyOPYWqyD6b3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation - officers, employees and board of directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" contextRef="From2024-01-01to2024-03-31" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" contextRef="From2023-01-012023-03-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_i02_pn3n3_maNCPBUzkoF_zjP0clkLh9he" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-03-31" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-03-31" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_pn3n3_di_msNCPBUzkoF_z7HZZ1oVKuD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on extinguishment of share settled debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-03-31" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_pn3n3_maNCPBUzkoF_zJC0Vp9Gooz7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-03-31" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_pn3n3_di_msNCPBUzkoF_zy8UkIAyDcQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized loss (gain) on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-012023-03-31" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_pn3n3_di_msNCPBUzkoF_zEoyjlB08D27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Decrease in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-01to2024-03-31" id="Fact000348" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-012023-03-31" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_pn3n3_maNCPBUzkoF_zLN2r460MWDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Decrease) in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-03-31" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,347</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-03-31" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pn3n3_maNCPBUzkoF_zdPQ7r7CC0q1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">(Decrease) in operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-03-31" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-03-31" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUzkoF_maCCERCzk1L_zWiNyY0wtqtj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,163</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-03-31" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,906</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsForProceedsFromInvestments_i01N_pn3n3_di_msNCPBUz7m2_zx9A3Lc8dMl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Sale (purchase) of investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2024-01-01to2024-03-31" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2023-01-012023-03-31" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUz7m2_maCCERCzk1L_zAk5CMXXVOsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash Provided by (Used in) Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-03-31" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_pn3n3_maNCPBUzWiy_zgITxB3og772" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock and prefunded warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-03-31" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUzWiy_maCCERCzk1L_zVPxa4v7NBD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Cash Provided by Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-03-31" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzk1L_zjnS9fykbx52" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Increase (Decrease) in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-03-31" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-03-31" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,627</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cash at Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Cash at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,950</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,045</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CashPaidDuringYearFor_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaid_i02_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxesPaidNet_i02_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAssumed1_i01_pn3n3_zXZ2WzGPmTba" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial recognition of fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="From2023-01-012023-03-31" id="Fact000403" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,831</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssued1_i01_pn3n3_zC6DX0vEtrCi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of common stock issued to a vendor to settle accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-03-31" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_005"></span>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000408" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zuKniZyAOYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_829_zw3rnRodgrXa">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. (the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms.
The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics designed to harness and enhance
the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Reverse
Stock Split</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240331_zdnGeCHni2Pl" title="Revers stock split ratio"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" id="Fact000410" name="us-gaap:StockholdersEquityReverseStockSplit">On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#8217;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol &#8220;GTBP.&#8221;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined
into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be
issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of
common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the
exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission
and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the
reverse stock-split from <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240201__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD51QIzkfSo" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-02-01_us-gaap_CommonStockMember" id="Fact000412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,419,000</ix:nonFraction></span>
shares to <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzwQiqLOInWi" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-02-02_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,633</ix:nonFraction></span>
shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock
remains unchanged at <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zvKDYFyJ4lti" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000416" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span>
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proportionate
adjustments will be made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise
of outstanding stock options for the Company&#8217;s common stock and to the number of shares of common stock reserved for future issuance
pursuant to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest
period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000418" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z2LbUE27wQTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_824_zvp92HVSTil3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000420" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKyLiYhH32Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zyYcfzOdQBgg">Basis
of Presentation and Principles of Consolidation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis
Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in
consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the &#8220;2023 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000422" name="GTBP:LiquidityPolicyTextBlock"><p id="xdx_840_ecustom--LiquidityPolicyTextBlock_ztvOBpbPDzn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zK55U4OwHnBa">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a
going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. For the three months ended March 31, 2024, the Company recorded a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn5n6_di_c20240101__20240331_zZjeFnGaQNyi" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">2.3</ix:nonFraction></span>
million and used cash in operations of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_di_c20240101__20240331_zcjp7FkflkT3" title="Cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-03-31" id="Fact000426" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">4.2</ix:nonFraction></span>
million. As of March 31, 2024, the Company had a cash and short-term investments balance of $<span id="xdx_901_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20240331_z5Ty4ChJRDzd" title="Cash on hand and short term investment"><ix:nonFraction name="GTBP:CashOnHandAndShortTermInvestment" contextRef="AsOf2024-03-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.8</ix:nonFraction></span>
million, working capital of $<span id="xdx_90A_ecustom--WorkingCapital_iI_pn5n6_c20240331_zQmvhpkx9zw8" title="Working capital"><ix:nonFraction name="GTBP:WorkingCapital" contextRef="AsOf2024-03-31" id="Fact000430" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span>
million and stockholders&#8217; equity of $<span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20240331_znLVYy7Bxlvj" title="Stockholders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000432" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span>
million. Management anticipates that the $<span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20240331_zDrTFXH2Muy7" title="Cash and cash equivalents, and short-term investments"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2024-03-31" id="Fact000434" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.8</ix:nonFraction></span>
million of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at
least one year from the date the Company&#8217;s condensed consolidated financial statements for the three months ended March 31,
2024 were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock,
issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to
secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and
financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which
could adversely affect the Company&#8217;s business prospects, ability to meet long-term liquidity needs or ability to continue
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000436" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zUVg9VrPMp53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6t4ee2Icaxd">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Significant estimates include management&#8217;s estimates for continued
liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of
equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000438" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1WACwPISCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zgZSVwxfG11b">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to
approximately $<span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_z1qIwaqjlvrc" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-03-31" id="Fact000440" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span></span> million and $<span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zEvm5EQIkkWe" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">443,000</ix:nonFraction></span> at March 31, 2024 and December 31, 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. Total short-term investments amounted to approximately $<span id="xdx_90B_eus-gaap--ShortTermInvestments_iI_pn5n6_c20240331_zqBU4sK70doh" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-03-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.9</ix:nonFraction></span> million and $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zwmFAX9C0CFg" title="Short-term investments"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000446" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.9</ix:nonFraction></span> million
at March 31, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000448" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziorEyji2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_zR0fvFg2ypda">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90B_ecustom--WarrantLiabilitiesNoncurrent_iI_c20240331_zg7MQ6A73nl3" title="Derivative liability"><ix:nonFraction name="GTBP:WarrantLiabilitiesNoncurrent" contextRef="AsOf2024-03-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,000</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--WarrantLiabilitiesNoncurrent_iI_pn5n6_c20231231_z41BwTznGcol" title="Derivative liability"><ix:nonFraction name="GTBP:WarrantLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000452" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million at March 31, 2024 and December 31, 2023, respectively,
was based on Level 3  measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, short term investments,
prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity
of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000454" name="GTBP:WarrantLiabilityPolicyTextBlock"><p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_z8IOXlHZtJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zAhXxLgpaH99">Warrant
Liability</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000456" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z8e9I1ofZKs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zpmiwBRniANe">Stock-Based
Compensation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees and consultants for acquiring goods and services from non-employees, which include grants
of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,
<i>Compensation-Stock Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time
vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation
cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees
is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated
using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility,
expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation
expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000458" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf4anFW7U5ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_861_zLctfluGIJxk">Research
and Development Costs</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000460" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zzz6StdiIpWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86F_z207zpcRr3Z8">Leases</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its lease in accordance with the guidance of ASC 842, <i>Leases</i>. The Company determines whether a contract is,
or contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease
term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets
and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000462" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zrSKWJL8FbG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zTjO7SIvIG17">Net
Loss Per Share</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000464" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_ziTwc5JANzOl" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember" id="Fact000467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,598</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember" id="Fact000469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember" id="Fact000470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-03-31" id="Fact000472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">431,227</ix:nonFraction> </span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-03-31" id="Fact000473" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">420,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zHA8mjrPcXB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000475" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zAwNsizvEos4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_860_znK4J0WXdxqh">Concentration</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember_zzjwvS7vwja5" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-03-31_srt_MaximumMember" id="Fact000477" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">250,000</ix:nonFraction></span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4 &#8211; Accounts
Payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000479" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztFFzE5GUkBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_863_znDNkrSM22G8">Segments</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment
to determine if it includes one or more components that constitute a business. If there are components within an operating segment that
meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting
units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the
segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000481" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zalqMxs3jpag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_862_zHxP7rgoIAAd">Recent
Accounting Pronouncements</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, &#8220;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>&#8221;
(&#8220;ASU 2023-07&#8221;), which introduces new reportable segment disclosure requirements related to significant segment expenses
and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable
segment&#8217;s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact
that ASU 2023-07 will have on our segment related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

</ix:nonNumeric><p id="xdx_85A_zzqzHA7mS5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000483" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zDWkE3gWpGy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82A_zYk4NlRReWBg">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000485" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z0JGDFi1Cl33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BD_zJRjVFMd1Z32" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztMhNO7KMYr3" title="Cost" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-03-31_us-gaap_ShortTermInvestmentsMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,859</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z75GnK4zHuN5" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zp666a7kKvb5" title="Unrealized losses">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zJBSCKjyYFGd" title="Fair value" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331_zIBgnI06Z5d1" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-03-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331_zFKY3IUdVtAb" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331_zALzbXn8tCcc" title="Unrealized losses">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331_zWxLHr3Cze82" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2024-01-01to2024-03-31" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztD6YbVVb1ah" title="Cost" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_ShortTermInvestmentsMember" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,845</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zKnlikL4Dmf4" title="Unrealized gains" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zc69T67D7b06" title="Unrealized losses" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTVqr9UN7zl" title="Fair value" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zo1kL0JkJFV2" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,845</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231_zXhPl2cGd6b9" title="Unrealized gains" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="From2023-01-012023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zdX4QI6oQTXa" title="Unrealized losses" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231_z49XaFaMCKca" title="Fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2023-01-012023-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z6kUn2CK73qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000519" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6N7hXlixww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_zlICH7SXekdi" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zI4CqUzkaq0f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zat1NRDsdKNf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaMvr4KLzTFa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49F_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzVZLZmo8op4" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlUo8F3oXLHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_MoneyMarketFundsMember" id="Fact000521" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,845</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,845</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zzMDrpR0qKij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_custom_CorporateNotesAndCommercialPaperMember" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk8h9fLN7Mz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,702</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,845</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,857</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zPt7Kezepuw5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0DshjjNxMf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLjCYqnJkp1j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO95dlZITBtb" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCy8B65m789g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_MoneyMarketFundsMember" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zuqbxTpRKdG9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_custom_CorporateNotesAndCommercialPaperMember" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zlE1xueli5Lf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,336</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="Fact000548" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,893</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zSVXB5MBAOv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the fair value of the warrant liability was $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeld04ELtMl" title="Fair value of warrant liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember63927609" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,000</ix:nonFraction></span>. The details of warrant liability transactions for the three
months ended March 31, 2024 and 2023, were as follows (in thousands):</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000553" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3X6zCdBQdJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zKaOILP8WDw" style="display: none">Schedule
of Warrant Liability Transactions</span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240331_zoEgPTSb6eq1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zWtO1ZXEo27i" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ending</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zDZXJi8Y42ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,052</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zvWZYgOyU3B9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-012023-03-31" id="Fact000559" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_zVpfyUou9429" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2024-01-01to2024-03-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-03-31" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--Extinguishment_pn3n3_zgbpFKBU3Ljg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zRGyrzfGHjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">394</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-03-31" id="Fact000568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,926</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zfEROGaAN4a5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000570" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGW5Emi670le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_823_z6MAQFpyjPD5">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000572" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z55uojEbEr1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_z7ui9O5coLsj" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zH4MAVKOBf92" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zhChP46WleE5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zQInsufFB5dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-03-31" id="Fact000574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,515</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zrcHkyXb61Bk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2024-03-31" id="Fact000577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2023-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz5ku_z8mP4v5MQFLh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,213</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,328</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zDG4bxIYvNL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently executed a number of Statements
of Work for the research and development of products for use in clinical trials. The Company&#8217;s commitments in relation to these
SOWs and any related Change Orders totaled approximately $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxZT0xfvYGog"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2020-10-31_custom_MasterServicesAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000582" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">15.6</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, existing agreements with the third-party product manufacturer were amended. As part of the amendment, the third-party
manufacturer agreed that services to be rendered in future periods, will be paid or settled at the Company&#8217;s discretion, in a combination
of cash and issuance of the Company&#8217;s common stock. The amendment also eliminated future financial commitments of the Company.
As of December 31, 2023, outstanding accounts payable balance to the third-party product manufacturer amounted to $<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zPBsKadKIgr5"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_ThirdPartyProductManufacturerMember" id="Fact000583" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024, the Company recorded research and development expenses of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zDmmXi0sFz57" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_ThirdPartyProductManufacturerMember" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></span>
to account for services rendered by the third-party product manufacturer. In addition, the Company paid cash of $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zzzbPZ0eISW4" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember" id="Fact000587" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span>
million towards the payment of accounts payable. As of March 31, 2024, the outstanding balance due to the third-party product manufacturer
amounted to $<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_z7QQGoIzNsxg" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember" id="Fact000589" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000591" name="GTBP:WarrantLiabilityTextBlock"><p id="xdx_803_ecustom--WarrantLiabilityTextBlock_zLBXuv206jP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82A_z5Evn97Nviue">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2023
Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zsXpY1iKlVCf" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_srt_MaximumMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,667</ix:nonFraction></span>
shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;), and placement agent warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__srt--RangeAxis__srt--MaximumMember_z4lRsGpCBP51" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_srt_MaximumMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock (the &#8220;Placement Agents Warrants&#8221; see Note 6 - Stockholders&#8217;
Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Warrant provides for a value calculation for the Purchase Warrant using the Black Scholes model in the event of certain fundamental
transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLoBESIUeu3g" title="Volatility amount utilized in the value calculation percentage"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember63927609" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% or greater.
The Company has determined this provision introduces leverage to the holders of the Purchase Warrant that could result in a value that
would be greater than the settlement amount of a fixed-for-fixed option on the Company&#8217;s own equity shares. Therefore, pursuant
to ASC 815, the Company has classified the Purchase Warrant as a liability in its consolidated balance sheet. The classification of the
Purchase Warrant, including whether the Purchase Warrant should be recorded as liability or as equity, is evaluated at the end of each
reporting period with changes in the fair value reported in other income (expense) in the consolidated statements of operations and comprehensive
loss. The Purchase Warrant was initially recorded at a fair value at $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240331__us-gaap--StatementEquityComponentsAxis__custom--PurchaseWarrantMember_zPmlmKZ5itid" title="Warrant  fair value"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-03-31_custom_PurchaseWarrantMember" id="Fact000599" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million at the grant date and is re-valued at each reporting
date. Upon the closing of placement, the fair value of the Purchase Warrant liability was recorded as a cost of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the fair value of the warrant liability was reduced to $<span id="xdx_904_ecustom--IncreaseDecreaseInFairValueOfWarrantLiability_iI_c20240331_zC85MaUmViNi" title="Change in fair value of the warrant liability"><ix:nonFraction name="GTBP:IncreaseDecreaseInFairValueOfWarrantLiability" contextRef="AsOf2024-03-31" id="Fact000601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
changes in the fair value of the warrant liabilities are recognized as a change in fair value of warrant liability in the Company&#8217;s
condensed consolidated statements of operations until they are either exercised or expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember" escape="true" id="Fact000603" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQqnUtf6DJn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zFmm3Da7Ieli" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common Warrants and Placement</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agents Warrants</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zgX4hwLo0IW3" title="Stock price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_z2QSCVtGDDqe" title="Stock price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGtU07RSD04c" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.21</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zxKCPjUGvB8j" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.26</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zEUGR9NUYtij" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103.9</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zzrFgCoZn1Ej" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">115.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zrB2KlOieMdd" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember" format="ixt-sec:duryear" id="Fact000617" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.0</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQYX5gLaxnph" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember" format="ixt-sec:duryear" id="Fact000619" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.25</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGVo7FcTT9Gb" title="Warrants measurement input" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zbLdhCL8hEVi" title="Warrants measurement input" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zOjR9XpeBfOd" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zFbN9ZDk9WS" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_TwentyTwentyThreeWarrantsMember" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zcCr9j28pP8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2020
Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued certain warrants during the year ended December 31, 2020 that contained a fundamental transaction provision that could
give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance
with ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheets and will be
re-measured at the end of every reporting period with the change in value reported in the Condensed Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember" escape="true" id="Fact000629" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zagaFcjcLmP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zIzFK6VVkV5c" style="display: none">Schedule of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZDgjZpvR0Xk" title="Stock price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.43</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZEZmFaYpCMj" title="Stock price" style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zazWhJfVHMqk" title="Warrants measurement input" style="text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.21</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z99g2NXT9Su1" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.54</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zbP6o7EEGvQh" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">89</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_znim9ugh62Me" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">89</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znn9f4bEwZq1" title="Expected life (in years)" style="text-align: right"><ix:nonNumeric contextRef="AsOf2024-03-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000643" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.2</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgtzzt3R7Hd4" title="Expected life (in years)" style="text-align: right"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact000645" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zjgWYePrXu17" title="Warrants measurement input" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zv9TvHP75Oxf" title="Warrants measurement input" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zRy7N8jay5ca" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z869XvUVSoy7" title="Fair value of warrants" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_TwentyTwentyWarrantsMember" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zVGwXgiDRV1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. For derivative instruments that already matured, the Company used the estimated
life. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized a gain of $<span id="xdx_902_eus-gaap--EquitySecuritiesFvNiRealizedGain_c20240101__20240331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zHEW7KbaOjlk" title="Recognized gain of change in fair value of derivative liability"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedGain" contextRef="From2024-01-012024-03-31_us-gaap_AccountingStandardsUpdate201602Member" id="Fact000655" format="ixt:numdotdecimal" decimals="0" unitRef="USD">658,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiRealizedGain_pn5n6_c20230101__20230331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zIH8kAO1q2Vb" title="Recognized gain of change in fair value of derivative liability"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedGain" contextRef="From2023-01-012023-03-31_us-gaap_AccountingStandardsUpdate201602Member" id="Fact000657" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million to account for the change in fair value of the warrant liability related to all
warrants between the reporting periods for the three months ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000659" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z6eadgVTQBvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_824_zbL92Mvdhzvh">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of March 31, 2024 was <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zZeIwkjlAwLk" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span>
shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zAW4fZvDzj1a" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331_zafpZSKjGZ47" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331_zhbf6OmuyRd9" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Private
Placement of Common Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, GT Biopharma received gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsvccVIaL47d" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-01-042023-01-04_custom_PurchaseAgreementMember" id="Fact000669" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.5</ix:nonFraction></span> million, before deducting placement agent fees and other offering expenses
of $<span id="xdx_901_eus-gaap--NoninterestExpenseOfferingCost_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvFVG8bGZeXd" title="Other offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2023-01-042023-01-04_custom_PurchaseAgreementMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,000</ix:nonFraction></span> in relation to a purchase agreement (the &#8220;Purchase Agreement&#8221;) signed on December 30, 2022, between the Company
and an institutional investor (the &#8220;Purchaser&#8221;) for the issuance and sale, in a registered direct offering (the &#8220;Offering&#8221;),
of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbpkpmXp2wRi" title="Direct offering"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6bqrRbfzphh" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Shares&#8221;), pre-funded warrants to
purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4KvcLLQhTQ7" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_PrefundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,667</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Pre-Funded Warrants&#8221;), warrants to purchase up to
an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsWANHk0Y4Q6" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,667</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;) and placement agent warrants to
purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrcrcoVzKo5j"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> of the Company&#8217;s common stock (the &#8220;Placement Agents Warrants&#8221;). The Common Warrants have an
exercise price equal to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyVVX9C51rV8" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span>, became exercisable commencing six months following issuance, and shall have a term of exercise equal
to five years following the initial exercise date. The Pre-Funded Warrants had an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zkzwSBRf3i99" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-04_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.003</ix:nonFraction></span> per Share, were immediately
exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The
Placement Agents Warrants have an exercise price equal to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z64WUh9dvlAk"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span>, exercisable commencing six months following issuance, and shall
have a term of exercise equal to five years following the initial exercise date. The Shares and Common Warrants were sold at an offering
price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zFFHwbAaGhzj" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-04_custom_CommonSharesAndCommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span> per Share and accompanying Common Warrant and the Pre-Funded Warrants and Common Warrants were sold at an offering price
of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zagF6hVz1oca" title="Price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-04_custom_PreFundedWarrantsAndCommonWarrantsMember_custom_PurchaseAgreementMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.997</ix:nonFraction></span> per Pre-Funded Warrant and accompanying Common Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants and the Placement Agents Warrants contained a clause not considered to be within the Company&#8217;s control. The Company
determined that the provision represented a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option
as defined under ASC 815-40, and thus the Common Warrants and the Placement Agent Warrants are not considered indexed to the Company&#8217;s
own stock and not eligible for an exception from derivative accounting. Accordingly, the Common Warrants and the Placement Agent Warrants
were classified as a warrant liability, and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230102__20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantAndPlacementAgentWarrantMember_zfmzVSmNCkci" title="Change in fair value of warrant liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-022023-01-04_custom_CommonWarrantAndPlacementAgentWarrantMember" id="Fact000691" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million of the initial common stock offering was classified as a warrant liability (Note
5 &#8211; Warrant Liability).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issued for Services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zwxPF1EHfUMb" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,449</ix:nonFraction></span> shares of common
stock with a fair value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zf0jcw5LmQpk" title="Shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,000</ix:nonFraction></span> to members of the Board of Directors, employees and consultants. The shares were valued at the respective
date of the agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issued for Vendor Payable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2023, the Company issued <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zLdDiHJTc01f" title="Issued shares for vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-03-132023-03-13" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,228</ix:nonFraction></span> shares of common stock with a fair value of $<span id="xdx_906_ecustom--StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zxes7k1OcUl" title="Fair value for vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" contextRef="From2023-03-132023-03-13" id="Fact000699" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></span> as settlement of accounts payable of $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20230313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjKWgCTNh678" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-03-13_us-gaap_CommonStockMember" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,000</ix:nonFraction></span>.
As a result, the Company recognized a gain of $<span id="xdx_904_eus-gaap--DebtSecuritiesGainLoss_c20230313__20230313_zwh4SWNYZlQ4" title="Debt securities gain"><ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2023-03-132023-03-13" id="Fact000703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,000</ix:nonFraction></span> to account the difference between the fair value of the common stock issued and
the accounts payable settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2024 and December 31, 2023, there were <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDID1ATxVCYd" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYmJJO5K8xv2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></span></span> shares of series C preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zgthDmlXk1M4" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaFk8ckhh8Je" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> per share (the &#8220;Series
C Preferred Stock&#8221;) issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNR2ORFnhtK2"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span>
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#8217;s board of directors
(the &#8220;Board&#8221;). No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2024 and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
K Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zCnF2Iqf9Vp5" title="Preferred stock shares designated"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,000</ix:nonFraction></span> shares of Series K preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zoal3xURm6Pa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" id="Fact000716" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span> (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zfWaCn0IcVp4" title="Convertible shares issuable"><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100</ix:nonFraction></span> shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred
Stock have the same voting rights as the shares of the Company&#8217;s common stock, with the holders of the Series K Preferred Stock
entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in
any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or winding
up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s common stock and will participate,
on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024 and December 31, 2023, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zDMRUNVAwg5k" title="Preferred stock, shares Issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zZWZCRTrcI27" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zxw5MZ4IF5B1" title="Preferred stock, shares Issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zkTYGUArUIt" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31_custom_SeriesKPreferredStockMember" id="Fact000720" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31_custom_SeriesKPreferredStockMember" id="Fact000722" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesKPreferredStockMember" id="Fact000724" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesKPreferredStockMember" id="Fact000726" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of Series K Preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000728" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2tPo8CIo4ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zJSsz6wWDxN7" style="display: none">Schedule
of Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331_zFgQFfaV9pq4" title="Warrants outstanding, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zIGIdThyDFg3" title="Weighted average exercise price, beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240331_zG9izbUoO0Na" title="Number of warrants, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240331_zyiVyk7gfszk" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240331_zrN6MpnB5kn6" title="Number of warrants, forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240331_zqjcpfPExbb2" title="Weighted average exercise price, forfeited" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331_zELmq5581LK2" title="Number of warrants, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z0WfWztEl4k2" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240331_zAADC3aQD8g" title="Warrants outstanding, beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-03-31" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zfBUQ6XTWVb1" title="Weighted average exercise price, beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240331_zLod2FftuVD7" title="Warrants exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2024-03-31" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zLit3LkKzhD6" title="Exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z6rNClZLJAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, all issued and outstanding warrants are fully vested. The warrants had an exercise price greater than the market price,
which resulted in <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20240331_zyGekKgKbU95" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-03-31" id="Fact000754" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> intrinsic value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_WarrantsMember" escape="true" id="Fact000756" name="GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLghJun5l3oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zFsysDk5g4db" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zHSXupPjHcl8" title="Range of lower excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFl86VL9kfyf" title="Number of warrants outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zaDMAyWFSLt5" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact000762" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrZ18LkAiiu6" title="Warrants outstanding, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2tqakX7I8M4" title="Number of warrants exercisable" style="width: 13%; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><p style="margin: 0">$</p></td><td style="width: 13%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWK5HAPKw5Rh" title="Warrants exercisable, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember__srt--RangeAxis__srt--MinimumMember_zq7kwz31DJJj"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember_srt_MinimumMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span> &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfGc974mkT82"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Number of warrants outstanding" id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpDhACuY5xZj" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">229,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNKpgoJuj9a8" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact000774" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztykbqq9dBQc" title="Warrants outstanding, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.42</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Number of warrants exercisable" id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgTFTPjeIgvc" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">229,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZayCWSq0m22" title="Warrants exercisable, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.42</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcCzcyF5N1Dg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zb9ESKTsNg5j" title="Number of warrants outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4PbyfDlbyB5" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact000785" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.9</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDx2yi10Rg2j" title="Warrants outstanding, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z6VPcThUb686" title="Number of warrants exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zm0QuDITJYRi" title="Warrants exercisable, weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHv4f51WjhB7" title="Number of warrants outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zBoEGCRAsyga" title="Number of warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2024-03-31_custom_WarrantsMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">304,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zMCWz3yZTG5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000797" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXZMBd9rtAbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock option transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zoaMKYCdkRq1" style="display: none">Schedule of Options Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zcVqTVH0N2K9" title="Number of Options outstanding, Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zNGchUfePBZ6" title="Weighted-Average Exercise Price, Options Outstanding Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">39.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240331_znlrYWxW9IH1" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zGX43NE281Ek" title="Weighted-Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20240331_zzsIcVpT9Ei8" title="Number of Options, Forfeited/cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z1AyspYR5ZYi" title="Weighted-Average Exercise Price, Forfeited/cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20240101__20240331_zuuz5VEEG3Y" title="Number of Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zJ5CFwpa7Ehk" title="Weighted-Average Exercise Price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_znrqOLcJ9Nn6" title="Number of Options outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_z1AkLGh0qJwg" title="Weighted-Average Exercise Price, Options Outstanding Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">39.60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240331_zh1U7KDOLYL8" title="Number of Options Exercisable, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-03-31" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zR3HGKbcfKd" title="Weighted-Average Exercise Price, Options Exercisable Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zpJSv0EPpID6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is recognizing the corresponding stock compensation expense for options granted to certain consultants, employees, officers and
directors based upon their vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2023, the Company granted stock options to employees and members of its board of directors to purchase an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230127__20230127_z5KcVKInIGNf" title="Purchase an aggregate"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-272023-01-27" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></span>
shares of common stock. The stock options are exercisable at $<span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20230127_z9gD8Tkc0IOf" title="Exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2023-01-27" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span> per share, expires in <span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230127__20230127_z7YO7G1OH8K4" title="Stock options expire"><ix:nonNumeric contextRef="From2023-01-272023-01-27" format="ixt-sec:duryear" id="Fact000827" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span> years, vest over twelve months and had a
fair value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn5n6_c20230127_zfijgjyT7Zk2" title="Fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-01-27" id="Fact000829" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">1.4</ix:nonFraction> </span>million at the date of grant. determined using the Black-Scholes Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000831" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDKnzZsy89Hj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z64iAGTdjEh" style="display: none">Schedule
of Stock Granted Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240331_zlLUphoekLNa" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.85</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20240331_zmVDb47kBZjg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-01to2024-03-31" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.62</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_z37MaOpycdxc" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-01to2024-03-31" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">121</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zuk9yHJ3G7K7" title="Expected life (in years)"><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" format="ixt-sec:duryear" id="Fact000839" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20240331_z851IfkqMDy7" title="Expected dividend yield" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zJivgjuq3bvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2024, the Company recognized stock compensation expense related to the vesting options of $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20240101__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z0IeEY6zHwC5" title="Options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2024-01-012024-03-31_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,000</ix:nonFraction></span>. For
the three months ended March 31, 2023, the Company recognized stock compensation expense relating to the vesting of options granted on
January 27, 2023 and prior years of $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230127__20230127__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zSYaefcCmem" title="Options granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2023-01-272023-01-27_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact000845" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">507,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000847" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFFWobc17Um2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zk0iKTjrTA1f" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEu5lvIcQeD1" title="Range of excercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-03-31_custom_RangeOneMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIlgHWsDRiyj" title="Options outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_RangeOneMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4emyU2pKeb9" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact000853" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlr2bLcigTj6" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_RangeOneMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCOru1e9nLwe" title="Options exercisable" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-03-31_custom_RangeOneMember" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,888</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zTH2nGfEPzz5" title="Options exercisable, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2024-03-31_custom_RangeOneMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZMmrm9gsfZa" title="Range of excercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-03-31_custom_RangeTwoMember" id="Fact000861" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zx28sGLBYmJg" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_RangeTwoMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJmBSepkNhK8" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact000865" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKeMlT7s7BF6" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_RangeTwoMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeBMZmMjCsUb" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-03-31_custom_RangeTwoMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zvlKbe2sMeV" title="Options exercisable, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2024-03-31_custom_RangeTwoMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zYDjUUnRoUM" title="Range of excercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-03-31_custom_RangeThreeMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzfqVJGqVc1g" title="Options outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_custom_RangeThreeMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPpDH0Rgs3m8" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2024-01-012024-03-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact000877" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.3</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGh62hqNMmt6" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_RangeThreeMember" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpo6d4ydV4p8" title="Number of options exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-03-31_custom_RangeThreeMember" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z89HeQBVZbyh" title="Options exercisable, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2024-03-31_custom_RangeThreeMember" id="Fact000883" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331_zTK6HreRNjRe" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331_zKGqKNtlxUk9" title="Number of options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-03-31" id="Fact000887" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">123,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zl4emZr4pBzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2024 and 2023, there were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331_z0UhHnasdJda" title="Stock compensation expense unvested options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,778</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230331_zhKSoFcBpqE9" title="Unvested options, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-03-31" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,225</ix:nonFraction></span> unvested options with a grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20240331_zCWpb7ql73pf" title="Stock compensation expense unvested options"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-03-31" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction> </span>and $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn5n6_c20230331_zMECEqnUi4a4" title="Stock compensation expense unvested options"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-03-31" id="Fact000895" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million, respectively,
which will be recognized as stock compensation expense in future periods based upon the remaining vesting term of the applicable grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no intrinsic value of the outstanding options as of March 31, 2024 as the exercise price of these options was greater than the market
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000897" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zpbGazLfjp99" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_826_zkuQmjEfQone">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being
handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 14, 2023, former interim Chief Executive Officer, Dr. Greg Berk filed a lawsuit alleging that GT Biopharma
discriminated and retaliated against Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX").
The Parties are proceeding with litigating Berk's SOX claim. GT Biopharma is vigorously defending this matter and believe it to be without
merit. At this early stage in the proceedings, GT Biopharma is not able to determine the probability of the outcome of this matter or
a range of reasonably expected losses, if any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he
    breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among
    other relief, monetary damages estimated at $<span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20220513__20220513_zDlBgfPdifVi"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-05-132022-05-13" id="Fact000898" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">470,000</ix:nonFraction></span>; the return of <span id="xdx_901_eus-gaap--TreasuryStockCommonShares_iI_c20220513_zLqRlBJhDtB2"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2022-05-13" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,903</ix:nonFraction></span> shares of our common stock received without authorization;
    and an award of the Company&#8217;s attorneys&#8217; fees and any forum and arbitration fees. As a component of Mr. Handelman&#8217;s
    contract with the Company, disputes shall be fully addressed and finally resolved by binding arbitration conducted by the American
    Arbitration Association (AAA). In connection with any such arbitration, the Company shall bear all costs not otherwise borne by a
    plaintiff in a court proceeding. On March 20, 2024, the Arbitrator issued an interim award in favor of the Company in the amount of $<span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_c20240320__20240320_zGK1Mi3WgfYh" title="Shares return, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-03-202024-03-20" id="Fact000901" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">409,000</ix:nonFraction></span> and directed
Mr. Handelman to return the disputed <span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20240320__20240320_znKlwXj4fES8" title="Shares return"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-03-202024-03-20" id="Fact000903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,903</ix:nonFraction></span> shares of common stock . The Arbitrator also awarded the Company its attorney fees and forum
costs in an amount to be determined at the time of the final award.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles
    naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;)
    and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated
    damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the
    terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its
    Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint
    for Interpleader against TWF and Z One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme
    Court to determine if the Company&#8217;s shares of common stock are properly registered to TWF or Z One LLC, as both of these entities
    have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for
    entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One
    and that the Company be released from all associated liability and claims. The Court has not yet ruled on the Company&#8217;s motion.
    The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these
    claims. The Court denied the motion without prejudice, and will reconsider the motion without further briefing upon the filing
of a party affidavit. &#160;Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled
their dispute over the entitlement to GT Biopharma shares.&#160; The Company believes that any claims related to the Notes are without
merit and will continue to defend vigorously against these claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota (&#8220;UofMN&#8221;), effective
June 16, 2021. This scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#8217;s
TriKE<sup>&#174; </sup>product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans;
and (3) investigation of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE<sup>&#174;
</sup>constructs in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> platform drug delivery
changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of
changes in the patient&#8217;s native NK cell population as a result of TriKE<sup>&#174; </sup>therapy. Most studies will use TriKE<sup>&#174;
</sup>DNA/amino acid sequences created by us under current UMN/GTB licensing terms. This agreement expired on June 30, 2023. The Company
and UofMN are negotiating the terms of a new scientific research agreement and expect to finalize it in the first half of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zfCU2cbFMxHc" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_ScientificResearchAgreementMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zv2YFuaqDUD5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_ScientificResearchAgreementMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,000</ix:nonFraction></span> pursuant to the scientific research agreement, for the three months ended March 31, 2024
and 2023, respectively. The Company has recorded an expense in the aggregate of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240101__20240331_zeIq1F6V3uy1" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-01to2024-03-31" id="Fact000909" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million as of March 31, 2024 pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2016
Exclusive Patent License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zYwo2fdewkec" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, and an annual License Maintenance fee of $<span id="xdx_90B_eus-gaap--CostMaintenance_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrcTZsX8fg8k" title="Maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> beginning in
2021. The agreement also includes <span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zHvLYnrU9msc" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% royalty fees, not to exceed <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z4gHd9UT17Vi" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20240101__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zh2PtjoVOpji" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> to $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZxBKxXuRlLj" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact000921" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million. The agreement also includes certain performance milestone payments
totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zE0tiY6rn7e7" title="Milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000923" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone payments of $<span id="xdx_903_ecustom--SalesMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zTNuAZL6d4h5" title="Sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000925" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million upon reaching $<span id="xdx_909_ecustom--GrossSales_pn6n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zahPrlRR3LSl" title="Sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000927" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in gross sales, and $<span id="xdx_90D_ecustom--SalesRevenue_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFSCZ4h0vOtl" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000929" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million
upon reaching $<span id="xdx_903_ecustom--CummulativeGrossSales_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zfzQgI4kdSPk" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000931" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">500</ix:nonFraction></span> million dollars in cumulative gross sales of Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zlFs0RZ7GEr9" title="Research and development expense"><span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJ24rCVrRzoj" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000933" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact000935" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t incur any research and development expense relating to the 2016 Exclusive Patent License Agreement for the three months
ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021
Patent License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_90C_ecustom--UpfrontLicenseFee_pp0p0_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zC8YYMr4Y4y7" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> and will receive an annual License Maintenance fee of $<span id="xdx_900_ecustom--LicenseMaintenanceFeeReceivable_iI_pp0p0_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAekNhVjLpM1" title="License maintenance fee, receivable"><ix:nonFraction name="GTBP:LicenseMaintenanceFeeReceivable" contextRef="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> beginning in 2022,<span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zbKgAI24RvZk" title="Net sales percentage"> <ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% to <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsfxhzfaQGUl" title="Net sales percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty
fees, or minimum annual royalty payments of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zcVROWjNFwi9" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> </span>beginning in the year after the first commercial sales of Licensed Product, and
$<span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zrFU9TBLljNj" title="Maintenance fee"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000947" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2.0</ix:nonFraction> </span>million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8SESXBk1IJf" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000949" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zP6KlujjvTd1" title="Sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million upon reaching $<span id="xdx_904_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPAw0UjFYQo7" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000953" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million
in gross sales, and $<span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zlHPwsdWeIw1" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000955" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million upon reaching $<span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zMU48DRCz5kb" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000957" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction> </span>million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 2; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zGASnhLh5sY4" title="Research and development expense"><span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z1OEprRL42L8" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000959" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact000961" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t incur any research and development expense relating to the 2021 Patent License Agreement for the three months ended March
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000963" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_z4V9GplAVXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_823_zUp3xSVRmYO2">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components
of its leases as a single lease component. Rent expense is recognized on a straight-line basis over the lease term. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease Right-of-Use (&#8220;ROU&#8221;) assets and liabilities are recognized at the lease commencement date based on the present value
of lease payments over the lease term. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and
lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Generally, the implicit rate
of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present
value of lease payments. The Company&#8217;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its
understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2021, the Company entered into a sublease with a third party for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4uzA9sYnlFk" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">4,500</ix:nonFraction></span> square feet of office space located in Brisbane,
California, with a <span id="xdx_909_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z7JfDtSs6Rwa" title="Lessee, operating sublease, option to extend"><ix:nonNumeric contextRef="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember" id="Fact000967" name="us-gaap:LesseeOperatingSubleaseOptionToExtend">commencement date of January 1, 2022 and maturing on June 30, 2024.</ix:nonNumeric> </span><span style="background-color: white">As a result
of this agreement, the Company recognized</span> ROU asset and liability of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z5HWeoxXsaJ5"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,294</ix:nonFraction></span> <span style="background-color: white">pursuant to
ASC 842<i>, Leases.</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022, the Company entered into a copier lease which will end on February 7, 2025. As a result, the Company <span style="background-color: white">recognized </span>additional
ROU asset and liability of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20220208__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwUDstuSnJOg" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-02-08_us-gaap_LeaseAgreementsMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span>.
In October 2023, this lease was cancelled and the remaining ROU asset of $<span id="xdx_901_ecustom--WrittenOffRightOfUseAsset_iI_c20231031__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zkm0vN5wWo9l" title="Written off right of use asset"><ix:nonFraction name="GTBP:WrittenOffRightOfUseAsset" contextRef="AsOf2023-10-31_us-gaap_LeaseAgreementsMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction> </span>was
written off against the cancelled lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these lease agreements, the Company recognized ROU asset and liability in the aggregate of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zU1LwKRVGscf" title="Operating lease, right of use asset"><span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zh7O5CRvq3v7" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31_us-gaap_LeaseAgreementsMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-03-31_us-gaap_LeaseAgreementsMember" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,294</ix:nonFraction></ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total rent expense related to these leases reflected on the Company&#8217;s Condensed Consolidated Statements of Operations totaled $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20240101__20240331_zM1YPSkg3YHk" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2024-01-01to2024-03-31" id="Fact000978" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230331_zs5BUmHYGhs3" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-03-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,000</ix:nonFraction> </span>for the three months ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000982" name="GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zgyhERp1OFh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zHTu9T5tgbwl" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zjZ0ZDAuVWH7" title="Operating cash flows from operating leases" style="width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-03-31" id="Fact000984" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zZBCB8oTyJX9" title="Operating cash flows from operating leases" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-03-31" id="Fact000986" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30</ix:nonFraction>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zueD2O4kKHTg" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2024-03-31" format="ixt-sec:duryear" id="Fact000988" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.25</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zNwuuCxB1ZYj" title="Weighted average remaining lease term operating leases"><ix:nonNumeric contextRef="AsOf2023-03-31" format="ixt-sec:duryear" id="Fact000990" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_z9iTzikCOhih" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-03-31" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_ztH3xINMvmsd" title="Weighted average discount rate operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-03-31" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zNSnTTZlmjPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 3; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact000996" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8XIVHA2puYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zES8LvCr8qmg" style="display: none">Schedule of Future Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240331_zrBxMW6DDhQ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maOLLza2F_zXaoO2aCjEGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-03-31" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLza2F_zCWaZYDpAHGj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLza2F_z2lWo4z7ZMT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maOLLza2F_z6XOr6JiqEVf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLLza2F_znT7mT1b0eEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-03-31" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXgqXZWxrnD7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-03-31" id="Fact001008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z7j9PSEov4Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-03-31" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zY3eELXOJT3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-03-31" escape="true" id="Fact001012" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zRtpbyyxFbX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span><span id="xdx_820_zjcaH3K39nVa">Subsequent Event</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsyzOAe4Xw11"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001013" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,018</ix:nonFraction></span> shares of common stock to settle $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLgB68NJvmdk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">278,500</ix:nonFraction></span> of vendor accounts payable. The shares were valued at
the month-end closing price of the Company&#8217;s common stock for the months for which services were provided by the vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p></ix:nonNumeric><p id="xdx_813_zDJUs69TqS5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_001"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; within the meaning of the safe
harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating
results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical
facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking
statements generally can be identified by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;foresee,&#8221; &#8220;may,&#8221;
&#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221; &#8220;target,&#8221;
&#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe our objectives,
plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will
turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than
our expectations for various reasons. You should carefully review all information, including the discussion of risk
factors under &#8220;Part I. Item 1A: Risk Factors&#8221; and &#8220;Part II. Item 7: Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations&#8221; of the Form 10-K for the year ended December 31, 2023. Any forward-looking
statements in the Form 10-Q are made only as of the date hereof and, except as may be required by law, we do not have any obligation
to publicly update any forward-looking statements contained in this Form 10-Q to reflect subsequent events or
circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc., a Delaware corporation formerly known as Oxis International, Inc., DDI Pharmaceuticals,
Inc. and Diagnostic Data, Inc, together with our subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager (TriKE&#174;) fusion protein immune cell engager technology platform. Our TriKE&#174; platform
generates proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer
cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more
specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cell&#8217;s
death. TriKE&#174;s can be designed to target any number of tumor antigens on hematologic malignancies or solid tumors and do not require
patient-specific customization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE&#174; platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies
and solid tumors. The platform is scalable, and we are putting processes in place to be able to produce investigational new drug (IND)
ready moieties in a timely manner after a specific TriKE&#174; conceptual design. Specific drug candidates can then be advanced into the
clinic on our own or through potential collaborations with partnering companies. We believe our TriKE&#174;s may have the ability, if
approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also using our TriKE&#174; platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment
of patients infected by the human immunodeficiency virus (HIV). While the use of anti-retroviral drugs has substantially improved the
health and increased the longevity of individuals infected with HIV, these drugs are designed to suppress virus replication to help modulate
progression to acquired immunodeficiency syndrome (AIDS) and to limit further transmission of the virus. Despite the use of anti-retroviral
drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon cessation of anti-retroviral drug therapy, can
reactivate and re- establish an active HIV infection. For a curative therapy, destruction of these latent HIV infected cells must take
place. The HIV-TriKE<sup>&#174;</sup> contains the antigen binding fragment (Fab) from a broadly neutralizing antibody targeting the HIV-Env
protein or a protein that binds infected CD4+ T cells. The HIV-TriKE<sup>&#174;</sup> is designed to target HIV while redirecting NK cell
killing specifically to actively replicating HIV infected cells. The HIV-TriKE<sup>&#174;</sup> induced NK cell proliferation and demonstrated
the ability in vitro to reactivate and kill HIV-infected T-cells. These findings indicate a potential role for the HIV-TriKE<sup>&#174;
</sup>in the reactivation and elimination of the latently infected HIV reservoir cells by harnessing the NK cell&#8217;s ability to mediate
the antibody-directed cellular cytotoxicity (ADCC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr.
Jeffrey Miller, Professor of Medicine, and the Deputy Director at the Center. Dr. Miller is a recognized key opinion leader in the field
of NK cell and IL-15 biology and their therapeutic potential. We have exclusive rights to the TriKE<sup>&#174;</sup> platform and are
generating additional intellectual property for specific moieties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was our first TriKE<sup>&#174;</sup> product candidate. It reflected our first-generation TriKE<sup>&#174;</sup> platform. It is a
single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains
of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We studied this anti-CD16-IL-15-anti-CD33 TriKE<sup>&#174; </sup>in
CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia, or AML, and myelodysplastic syndrome, or
MDS. CD33 is primarily a myeloid differentiation antigen with endocytic properties broadly expressed on AML blasts and, possibly,
some leukemic stem cells. CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3, gp67, p67) is a transmembrane
receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid
cells. The anti-CD33 antibody fragment used for these studies was derived from the M195 humanized anti-CD33 scFv and has been used
in multiple human clinical studies. It has been exploited as a target for therapeutic antibodies for many years. We believe the
approval of the antibody-drug conjugate gemtuzumab validates this targeted approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was replaced by a more potent next-generation camelid nanobody TriKE<sup>&#174;</sup>, GTB-3650, both targeting CD33 on relapsed/refractory
Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndromes (MDS). The pivot from GTB-3550 to GTB-3650 in our clinical development
was based on a solid preclinical foundation that showed markedly enhanced potency of the camelid modification of the first-generation
TriKE. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared to GTB-3550 (blue
dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the 2<sup>nd</sup> generation
TriKE platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Next Generation of Camelid Nanobody TriKE<sup>&#174;</sup>s</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid
tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred
as nanobodies) are smaller than human immunoglobulin and consist of two heavy chains. These nanobodies have the potential to have greater
affinity to target antigens, potentially resulting in greater potency. GT Biopharma is utilizing this camelid antibody structure for
all its new TriKE<sup>&#174;</sup> product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Generation
of humanized single-domain antibody targeting CD16 for incorporation into the TriKE<sup>&#174;</sup> platform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
develop second generation TriKE<sup>&#174;</sup>s, we designed a new humanized CD16 engager derived from a single-domain antibody. While
scFvs consist of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain
capable of engaging without the need of a light chain counterpart (see figure below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability
to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation
against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFNg with the single-domain CD16 TriKE<sup>&#174;</sup>
(cam 16-wt15-33; GTB-3650) compared to the original TriKE<sup>&#174;</sup> (scFv16-m 15-33; GTB-3550) (see figure below). This data was
published by Dr. Felices M et al (2020) in Cancer Immunol Res.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>CD33+ HL60 Targets in
Killing Assays</b></p>

<p style="margin: 0">(Purple line represents the GTB-3650 and Blue line represents GTB-3550)</p>

<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><img src="form10-q_005.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3650</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3650
is a CD33 targeted TriKE&#174; which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating
receptor on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650, no longer needing the
mutant IL-15 included in GTB-3550. The TriKE&#174; approach provides a novel way to specifically target these tumors by leveraging NK
cells, which have been shown to mediate relapse protection in this setting, in an anti-CD33-targeted fashion. We are moving GTB-3650
clinically based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an
enhanced efficacy signal in AML and MDS. We are advancing GTB-3650 through preclinical studies and have filed an Investigational New
Drug (IND) application with the FDA in December 2023. The Company continues to be in a productive dialogue with the FDA with respect
to its IND Application in relation to GTB 3650. We further anticipate approval to start study enrollment targeting patients with relapsed/refractory
AML and high grade MDS by the second half of 2024. This initial study will test GTB-3650 as monotherapy testing administration 2 weeks
on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy. The design of the trial has been agreed on with
the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 8; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black"><b><img src="form10-q_003.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>GTB-5550</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-5550
is a B7-H3 targeted TriKE&#174; which targets B7-H3 on the surface of advanced solid tumors (figure above). B7-H3 is an exciting target
as it displays specific expression on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies through
GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumor settings, including
head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer
(amongst others). We are advancing GTB-5550 through preclinical studies and have initiated a GMP manufacturing campaign in anticipation
of filing an IND in the late second half of 2024. A pre-IND packet was submitted to the FDA in October 2023 with a written response from
the FDA in December 2023. The main question to the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The
initial trial is designed as a basket trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and
2 weeks off to prevent immune exhaustion). This is dependent on manufacturing of clinical materials. We expect a study targeting patients
with B7-H3 positive solid tumors in the first half of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black"><b><img src="form10-q_004.jpg" alt=""/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#8217;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024, under our existing trading symbol &#8220;GTBP.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into
one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued in
connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will
be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the
fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proportionate
adjustments were made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of
outstanding stock options for the Company&#8217;s common stock and to the number of shares of common stock reserved for future issuance
pursuant to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest
period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Economic
Disruption</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we make our strategic planning decisions based on the assumption that the markets we are targeting will grow in the long term, our business
is dependent, in large part on, and directly affected by, business cycles and other factors affecting the economy generally. Our industry
depends on general economic conditions and other factors, including consumer spending and preferences, changes in inflation rates, supply
chain issues and impediments should they arise for us, as the U.S. and various other major economies are now experiencing, consumer confidence,
fuel costs, fuel availability, environmental impact, governmental incentives and regulatory requirements, and political volatility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the outbreak of full-scale wars between Russia and Ukraine and Israel and Palestine (&#8220;Conflicts&#8221;) and global reactions
thereto have increased U.S. domestic and global energy prices. Oil supply disruptions related to the Conflicts, and sanctions and other
measures taken by the U.S. and its allies, could lead to higher costs for gas, food, and goods in the U.S. and other geographies and
exacerbate the inflationary pressures on the worldwide economy, with potentially adverse impacts on our business, results of operations
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three Months Ended March 31, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses (&#8220;R&amp;D&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024 and 2023, we incurred $777,000 and $1.65 million of R&amp;D expenses, respectively. R &amp; D
expenses relate to our continued development and production of our most advanced TriKE&#174; product candidates GTB-3650 and GTB-5550
along with the progression on other promising candidates. R&amp;D expenses decreased by $873,000 primarily due to reduction in raw
material purchases of $657,000 as we benefit from the near completion of product development for GTB 3650 and continue to advance
our progression to the new stage of our product development of GTB 5550, and reduction of $216,000 in consulting fees due to better management of other
research and development costs. We anticipate our direct clinical and preclinical expenses to continue to increase in 2024 as we plan to advance
our next generation GTB-3650 camelid nanobody product into the clinic and enroll patients, perform tests for data collection, complete
the product development of GTB-5550 and anticipate submission of IND application for GTB-5550 in the fourth quarter of 2024. We do not,
however, anticipate an increase in related R&amp;D licensing and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
General and Administrative Expenses (&#8220;SG&amp;A&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative expense (&#8220;SG&amp;A&#8221;) was $2.31 million and $2.02 million for the three months ended March 31,
2024 and 2023, respectively. SG&amp;A expenses increased by $299,000 as compared to the prior year comparable period, primarily due to reduction in stock-based compensation
expense for officers, employees and board of directors by $616,000, offset by an increase in legal and professional fees of $794,000 and
an increase in costs of filing regulatory fees and other SG&amp;A expenses of $121,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded interest income of $142,000 and $164,000 for the three months ended March 31, 2024 and 2023, respectively. The decrease in interest
income was due to lower short term investment balances during the three months ended March 31, 2024 as compared to prior year comparable
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded interest expense of $0 and $212,000 for the three months ended March 31, 2024 and 2023, respectively. The interest expense for
the three months ended March 31, 2023 was due to the financing costs incurred associated with warrants accounted as warrant liability
sold during the three months ended March 31, 2023 which did not recur in the current year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in Fair Value of Warrant Liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded a gain of $658,000 due to a change in fair value of warrant liability for the three months ended March 31, 2024, compared to
a gain of $2.92 million for the three months ending March 31, 2023. The decrease in gain resulted due to a reduction in our warrant liability
because of the decline in the Company&#8217;s stock price at March 31, 2024 as compared to the prior comparable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gain
on Extinguishment of Debt</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded a gain on extinguishment of debt of $0 and $533,000 for the three months ended March 31, 2024 and 2023, respectively. The gain
in the three months ended March 31, 2023 was as a result of share settlement of a greater amount of vendor accounts payable than the
fair value of the shares on the date of settlement. There was no similar transaction during the current period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrealized
(Gain) Loss on Marketable Securities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded an unrealized loss on marketable securities of $2,000 for the three months ended March 31, 2024 as compared to an unrealized
gain on marketable securities of $29,000 for the three months ended March 31, 2023. This resulted from lower investments balances for
the three months ended March 31, 2024 as compared to prior year comparable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, the Company recorded a net loss of $2.27 million for the three months ended March 31, 2024 as compared to a loss
of $227,000 for the same comparable period in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current operations have focused on business planning, raising capital, establishing an intellectual property portfolio,
hiring, and conducting preclinical studies. The Company does not have any product candidates approved for sale and has not generated
any revenue from its product sales. The Company has sustained operating losses since inception and expects such losses to continue into
the foreseeable future. We anticipate that cash utilized in the twelve months following this filing date for selling, general and administrative
expenses will range between $3.0 and $3.5 million, and used for research and development expenses will range between $3.5 and $4.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reported cash and cash equivalents of $1.95 million and short-term investments of $7.86 million as of March 31, 2024. Management
believes that the Company has sufficient cash and cash equivalents, and short-term investments to fund its operations for more than twelve
months from the date of this filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are
not limited to public offerings of equity and/or debt securities, payments from potential strategic research and development, licensing
and/or marketing arrangements with pharmaceutical companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider the following accounting policies to be critical given they involve estimates and judgments made by management and are important
for our investors&#8217; understanding of our operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Basis
of Presentation and Principles of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. These condensed consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. Intercompany transactions and balances have been
eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Accountin</span>g
<span style="text-decoration: underline">Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation
of deferred tax assets. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock-Based
Compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based awards to employees, nonemployees and consultants in accordance with the provisions of Accounting
Standards Codification 718, <i>Compensation-Stock Compensation</i>. Stock-based compensation cost is measured at fair value on the grant
date and that fair value is recognized as expense over the requisite service, or vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. Use of the
Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free
interest rate. The Company estimates volatility using its own historical stock price volatility. The expected term of the instrument
is estimated by using the simplified method to estimate expected term. The risk-free interest rate is estimated using comparable published
federal funds rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that inflation has not had a material adverse impact on our business or operating results during the periods presented other
than the impact of inflation on the general economy. However, there is a risk that the Company&#8217;s operating costs could become subject
to inflationary pressures in the future, which would have the effect of increasing the Company&#8217;s operating costs, and which would
put additional stress on the Company&#8217;s working capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_002"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f)(1) and is not required to provide information
for this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_003"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act
of 1934, as amended), as of March 31, 2024. Based on that evaluation, we have concluded that our disclosure controls and procedures were
effective as of March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by,
or under the supervision of, a company&#8217;s principal executive and principal accounting officers and effected by a company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles
and includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
    of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance
    with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
    with authorizations of management and directors of the company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s
    assets that could have a material effect on the consolidated financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our
company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, our management, including our interim Chief Executive Officer and Chief Financial Officer conducted an assessment
of the effectiveness of the Company&#8217;s internal control over financial reporting. In making this assessment, we used the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission in internal control integrated framework. Based upon
our evaluation, we concluded that our internal controls over financial reporting were operating effectively with a significant level
of precision as of March 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_004"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_005"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles
    naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;)
    and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated
    damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the
    terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its
    Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint
    for Interpleader against TWF and Z One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme
    Court to determine if the Company&#8217;s shares of common stock are properly registered to TWF or Z One LLC, as both of these entities
    have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for
    entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One
    and that the Company be released from all associated liability and claims. The Court has not yet ruled on the Company&#8217;s motion.
    The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these
    claims. The Court denied the motion without prejudice, and will reconsider the motion without further briefing upon the filing
of a party affidavit. &#160;Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled
their dispute over the entitlement to GT Biopharma shares.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer,
asserting that he breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company
seeks among other relief, monetary damages estimated at $470,000; the return of 13,903 shares of our common stock received without authorization;
and an award of the Company&#8217;s attorneys&#8217; fees and any forum and arbitration fees. As a component of Mr. Handelman&#8217;s
contract with the Company, disputes shall be fully addressed and finally resolved by binding arbitration conducted by the American Arbitration
Association (AAA). In connection with any such arbitration, the Company shall bear all costs not otherwise borne by a plaintiff in a court
proceeding. On March 20, 2024, the Arbitrator issued an interim award in favor of the Company in the amount of $409,000 and directed Mr.
Handelman to return the disputed 13,903 shares of common stock. The Arbitrator also awarded the Company its attorney fees and forum costs
in an amount to be determined at the time of the final award.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">On November 14, 2023, former interim Chief Executive Officer, Dr. Greg Berk filed a lawsuit alleging that GT Biopharma
discriminated and retaliated against Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX").
The Parties are proceeding with litigating Berk's SOX claim. GT Biopharma is vigorously defending this matter and believe it to be without
merit. At this early stage in the proceedings, GT Biopharma is not able to determine the probability of the outcome of this matter or
a range of reasonably expected losses, if any.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_006"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Herewith</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
    File No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/15/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/30/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">3.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">8-K</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">001-40023</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">2/1/2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000017/exhibitthreeone.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/4/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/16/2021</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the
    liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the
    Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_007"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
    Biopharma, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    May 15, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Manu Ohri</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu Ohri</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Breen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2024</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer and Executive</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
<FONT>Manu Ohri</FONT>, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2024</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
<FONT>Manu Ohri</FONT>    </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manu
Ohri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT
Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2024 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2024</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Executive Officer and Executive</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Manu Ohri, Chief Financial Officer and Principal
Accounting Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2024 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 15, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
<FONT>Manu Ohri</FONT>    </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT>Manu Ohri</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10-q_001.jpg
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J =D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBL3Q)X
MJT;PGIYO-9O$MXSPB=7D/HJCDT ;=%>6)XT\>^*QN\*^&(K"Q8?)?:NQ7>/5
M4'/\ZVO#6A^.K;6DOO$7BBVO+;85:RM[8(F2."&P.0: .N_M"V_M,Z=YG^E"
M'S]F#]S=MSGIUIUO<1W",Z!L*[1G>I7D'!Z_S[U@7R:A9^,UU*#3+F]MGT\6
MY,#Q@J_F%N0[+V]*YC6;;^SX5?6K>.>%_M[Q6LMRB%79]R2#<P!(7C@[ESP#
MS0!Z'#J%M.]TD<H+6K^7-D8VMM#?R(J*?6+"WTO^TY+N,614.LP.0P/3&.N<
MC '6N!TGPC=R:3;73V"_;9+FW?S'<;O(\A$<')Z=01U/I6U'HE]'X*T:UMK!
M8;S39(9C9LR*)3&?F () SR0?7&<4 ;4'BC2[D$"66*198XFBG@>-U:0X3*L
M <'UZ5L[A@'(YZ>]<AJMIJ7B1!#/H_D6BW5JY2>1/-D59-SEMK$!0.@SD\US
MNK>%]9,=S9V>E*8 ]PUBT;1GR27#*!N8",8Y!4$]N* /2H;I+@R;-P\N0QMN
M4K\P],]1[BK->=W'A*^OK[5);VR$R/!=_9=\H($KE"A SP>#@]O:NZL$ECTZ
MU2XSYRQ(),G)W8&>>_- %JBBB@ HHHH **YWQ?XNTSP;H[7^HEF9CL@MX^9)
MW[*H_KVK%\(77CO5]3_M;7HK/3-)DC(BTT+NF&?NLS=C[>_04 =V2 "3T%9L
M.N:=/;V%Q'/F+4'V6S;#\YP3Z<<*>OI6@X)1@.I!KS-/ ^JPZ!HJ6US>1ZC
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M4J*:"& (((/(([TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ASQ+'9&+3M1D"([B."1SQN/13]>U8>M20>%;[R+ZY6.-P6C9L_,OL/6O/\
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M:9X<?2;R5[75+H6DLS3-:,D97)&,;MN[' [UOT %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'C?QF_Y"^E?]<7_]"%><S?ZH?2O1OC-_R%]*_P"N+_\
MH0KSF;_5#Z5XN)_BL_1<F_W&/I^K/7M M_%K>$+)[2^L4M#; HCQDL%QT)QU
MKQ^V_2O7] D\8CPC9BTATPV7V8;"[-OVX[\XS7D%MTJ\1\,=_F893?VU2_+O
MTMY[G8_"_P#Y'R#_ *XR?^@U[T*\%^%__(^0?]<9/_0:]Z'2NS"?PSY_/_\
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MA]*]&^,W_(7TK_KB_P#Z$*\YF_U0^E>+B?XK/T7)O]QCZ?JSZ"\*?\D]T_\
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M #XP_E1_8&E?\^,/Y5I44 9O]@:5_P ^,/Y4?V!I7_/C#^5:5% &;_8&E?\
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M(4[F(+$CC/6K\?ANPBL+.Q7SO)M+K[7'E^=^\OR>XRQXK:HH **** "BBB@
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M!%;U% %'3M-L])MVM[*'RHVD:1@7+$LQR2223DFKU%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6(?#&C?:I;AK)7>0N65G8IEQAR$
M)V@D$Y(&3D^M;=% &=IFCV6DI(ME&R>8079Y&D9L# !9B3@#@#/%4YO"6B7$
M,<4EE\L:[4V2.A W[QR"#PW(]*W:* ,)/"FCI$(TM74B4S>:L\@E+D;23)NW
M'@D8)Z5I6%A:Z98PV5I"(K>%=L<8)(4>G-6Z* "BBB@ HHHH **** (Y(DFB
M:*10R.I5E/0@]17.V>D7'AK1X++1]US(UUF1[ENJG/4@'  "J..@%=-10!S5
MEH;WFF:E)?22QW6KP!+E5 'ED)L^7(]/6I-9\,1:QIMO8M=-'%"NPAHDD#C&
M,X8'##'##!%=#5:[NH[*V>YFW^6@R0B%V/T5023]* ,*V\'6EK)=-'<W)^T0
M2P'<02!)MR<XY(VCK6)+X.OWO8M.B>6'1TN//8^:C!OW94D#;N#$G./N]_:M
MZ7Q-'>Z1?3Z$HN[JU0[HYU>$(V#][<N>,=.M8U[XEUF.+2KK)MK&33X[J\NE
ML6G168C(R&&T 9/<X[4 :8\&6R7T<\5TZ)MA$J&*-C(8P IW%<KD  XZX[59
MUCPW_:D\\L6HW%D;FW^S7(A53YB#./O [2-S<CUJ#6_$Z:/KNGVDC!H[V%_)
MC09DFEW(%53G'1B>>*RAKVOQ07VLR7%J]A:ZBUJ]EY!#B,2!,B0-RPSGI@T
M7YO ]O-;M92:A='3AYC0VWRXB=P06#8R<;F(!X&:T7\.6[W<\YGFW32V\I&1
M@&'[H''?O3-+\3P:IK$VF""2&>.,RKN=&W(&VDD*25.<<'!YK?H XRV\ 6MO
M?V]V;ZX=K>7S$'EH"W[P/\[8RQR,9)Z5L6?ARWLI-/=)Y6-EY^S=CYO-;)SQ
MV[5MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!#/"L]O) ^=DB%&QUP1BL.Y\)VEQ;PV_P!J
MO4MDMTM9(8YL+-$O17&/J"1@D'%=%10!CZGX=T[575[J-LK;O;IM;&P,5.5]
M&!12#VQ5*+P;91SEY+S4)X&N#<M:RS#RFE)SN( !//."<9[5TM% '/Z/X4L=
K$NUN+::Y<I"T$:2.NU$+!B  !DY'4Y/O70444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-q_002.jpg
<TEXT>
begin 644 form10-q_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *F D # 2(  A$! Q$!_\0
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M$V%WJXFGWFR2PCLD@29T)168E7((W*00,'.<5H3^)M.MG99FFCQ&9/FB89
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MAT[0X!-KFKRR0V\2I]HQ(PC<*WR%U'7!;BM%M&M)-+M;)#*D5L%\ATD(=,#
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M3[B_2@#C-GQ,_P">_A3_ +]W'^-'E_$W_GY\)_\ ?FX_^*KM** .+\KXF?\
M/UX4_P"_%Q_\51Y7Q+_Y^_"G_@/<?_%5VE% '%^1\2_^?[PL/^W:?_XNE^S_
M !)_Z"'AC_P%G_\ BZ[.B@#C?LWQ(_Z"7AG_ ,!)O_BZ/LOQ&_Z"GAO_ ,!)
MO_BZ[*B@#COLGQ$[ZMX=_P# .7_XNE^Q_$/OK'A_\+*7_P"+KL** /.]$OO'
MVM'40FJ:%%]BO9+0YLI#N*8^;[_?-:OV#X@'_F.:&/I8/_\ %T> _O\ B;_L
M.7'_ ++77T <A_9_C[_H/:+_ ."]_P#XNG?V=X[_ .AAT@?]PYO_ (Y76T4
M<C_9GCS_ *&/21_W#6_^+I/[*\=_]#-I8_[AA_\ BZZ^B@#D/[)\=_\ 0TZ:
M/^X7_P#9T?V/XZ_Z&S3Q_P!PK_[.NOHH Y#^QO'/_0WV(_[A(_\ BZ3^Q/''
M_0XV8_[A"_\ Q==A10!Q_P#87CC_ *'2U'_<(3_XNJ\-QXGT3Q=HVGZIKEOJ
MEKJ0F5E%B(#&43<""&.?2NXKD?$7_(_^#_\ ?N__ $50!UU%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1KT1
MDAMRY(MUDS*1VXX)]LU22SA66*> A=N<D'.Y2.GYX/X5T,TGE0L^QGP/NKU-
M<,^JVEAJJK<74UI:HLCQH &B<'YB"1GE<$@=P: -=K*)I)IIVR6.=V[&U>PJ
M_H$1BLI0IS 96,)QC*\<CVSFN7@U6UU#5G$-Q->V)9)G# +$I"_*BEL9R?F;
MTP*[N&3S85?8R9'W6ZB@!]%%% ')^"+2YM)O$YN;>2$3:Y<2Q;UQO0JF&'J#
M@\UUE%% !1110 5S L;K_A:+7_V>3[)_8PA\['R[_.)VY]<<UT]% !1110 4
M444 %%%% !1110 4444 <O\ $2UN+WP+J-O:P23S.8ML<:[F.)4)P/H*Z=?N
M#Z4M% !1110 4444 %%%% !1110 4444 <QX-L;JR;Q ;JWDA\_5YYHMXQO0
M[<,/8UT]%% !1110 4444 %%%% !1110 5SVLZ3=WGBWPYJ$**;:R:X,[%@"
MN^/:N!WYKH:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!KA#&PDQL(^;=TQ5.:PT]K::*YCB>%V\QQ+C ]
M/H!VJ#Q+9RZAX7U6S@B\V6>UDC2/.-Q*D8SVKB[OPUJZ7%U;SV<]Y96\=O':
M7$;QM(R*[L T;\.4W $'&X8/44 =T+33K>VMXD6&"%&!B"D*"?0>N?UJ\JA%
M"J % P .U>:_V%J"6@-[X>6Z#VA@MHXX8G%L?,<DM$SA5+J4SM)"[<=*[_2$
MN8]'LDO8XX[I8$$J1DE5; R 3VH N4C.J#+,%'N<4M4-6T33-=@2#5+&&[BC
M;>J3+D!L8S^M '+^(=?UK1=>L\W=FMO=WD=O;6)A),T9*AW:7(",,D@=\ <D
MUV]<EJOA34M4>>P?6%_L.XFCE>W:',L80J?+C?( 4E0>02,G%=;0 4444 %<
M#_PE6KEWUH36PT=-6&FFS,)WE/,$7F;\_>WG.,8Q[UWU<?\ \(7<?;F@&H1_
MV(VH#4FM?(_>>;NW[-^<;-XW=,]LXH ["BBB@ HHHH **** "BBB@ HHHH P
M?%=S>Z?I4NI0:M%I]O:1M).7M//+CL%^9>>P]215CPTVKR>'[2776B.HR+OE
M6*/8$SR%QD\@8!]\TGB+1#KUE;VAN##$EW#/* ,^8J,&V?B0*UZ "BBB@ HH
MHH **** "BBB@ JEJNK6&B:?)?:E=1VUM']Z20X'L!ZGVJ[7*?$/3;:]\&ZE
M/+:)/<6]M(8"R;BC$8)4>OO0!OZGJUCHVG27^HW*6]JF-TC],DX ]R20*M@@
M@$=#7FGQ*L-<O+*]G_LZ"[TNVLLVZ_:"K+,?O2%-IW$#A>>,D]<5Z+9-,]C
MUQ"L,Q0%XU?>%..1NP,_7% $]%%% !1110 4444 %%%% %;4;MK#3KB[6VFN
M6AC+B"!<O(1T51ZFN?L/%=VNH76GZUIGV2ZALQ?!;:0SYC+;=N ,[\\8QSVK
M=U5[^/2;I]+BBEOQ&?(29MJ%^V3Z5SO@O3]5L'N6U?2]EY< /<:@]XLSSN.-
MNT*-J@9P!P!^= &EX6\0GQ+IUQ>&REL_*NI;?RIC\XV'&6'8^W:MRL'PKI-U
MI%MJ:780-<:E<7,>QL_([97/O6]0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q/':VTMQ,2(HD+
MN0,X &3Q4E% 'F7@7QSK6K^+-1M=9L9;>RO7\S3,K_J@$5O+?T)1E?GOFO3:
MYWP\H_MWQ0W7_B8)_P"D\5=%0 4444 %>67/Q#U2+XF+$+27_A%XP;2239R9
M-X4S ==H<A,].2:]3KE9 #\4X1@8_L9__1RT =51110 4444 %%%% !1110
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M8]6T:+=Y=]9)N.YMLBC)]36?X@U;3I]&ECBOK=Y&DB 59 2?WB]J .BKE_\
MFJA]M%'_ *.-=17+K_R523VT1?\ T>U '44444 %%%% !1110 4444 %%%%
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MKXDU!O#6M:M-$!>6I?&G%?FMMHX5R.6)&&)'&#Q0!L_VGJ'_ $ ;S_O]#_\
M%T?VGJ'_ $ ;S_O]#_\ %UA3>(;K1!%'+J,6L7%WY7DQQQA"A<,=Q*@_(<?+
MP6]SVHCQQJ#71FCM=\+)N2U.W>"5C(&X9S@N3QDGMF@#J9=8O887E?0KP(BE
MF(EAZ#_@=:5M.MS:Q7" A)4#J#UP1FLR'4DU?PH]_'MVS6TAPK9 (!!&<#N#
MVJWI'_(%L/\ KWC_ /010!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]%_Z ^G_ /@,G^%'_"/Z+_T!]/\ _ 9/\*TJ* ,W_A']%_Z ^G_^ R?X4O\
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M;2V<CK@=*XK6/B9XGL_ FF:M#/;"[N+QX9"8 05 )&!7*#XU^.%_Y:6#_6W
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MJP/!&#7MOA;1=-L=!TZWD"QW&TR2+C# GGFL#XB:+87BQRI$%G0?(X&,^QH
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MVKU"QT&6\N?M+3'@G>/49KR+P3ITEUXIA*L5^S_,Q'Y5]"Z4ICM -I /7UH
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MTYK4HHH XCXL_P#)/[S_ *ZQ?^ABOGSM7T'\6?\ DG]Y_P!=8O\ T,5\_P
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MEEU.8EB#SY:<8_$USLV%B)'YU[8^K_"JZAM[>32I&2!=D*;&X!/0?-ZTD_\
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M^H[US7P=_P"1?U[_ 'Q_Z#73>#DE.K7920*@ACW+MSNY?OVK'DN^;L>#BO\
MD:4/21W%%%%,]T**** "BBB@ HHHH **** $)"C)( ]Z 0PR""/45Q/Q3B2?
MPS8P2#=%-JUG'(N<;E:501^(-9VH:=8>"O&^@-H2"TCU 7,=Y:B4B)T2(NKD
M$D+M8#YO0T >D45Y3I'COQ#?ZU8V"7%G=-J=K<-"Z6,L4,4J)N4)(Y'FKV)
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MWGSN#AC9UIJ6D4[6]-4SE%8^;&0!R>XS6K'"DNF75T;LH]J56&'/7)YXK."
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M$8^6N1^!AG,NK[#'Y>(=^X'=_'T[5[&&5\NKOSC^IQU(WQ$)>3/::***\<[
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M5ELO-F52M3I+WV<5<1Q\811\P!X]Z6&.,"Y^1<;5/3_:K0OM/=9/, 8Q9W9
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M^VQ &FGQ$>V6/?WXKB/"5T(M=AMVC#*K>9@=>.U>@_%Q);?3;:$#,;W')/\
M#Z5YQX4WIXTT]XT+MYI!4=Q0!]%?:Y;J*V1V\IF(\O=Z^@KSCXDZ;<W>D2W]
MVC*UH2\;]F!."*]?3+1 @?-+]WVKE_&VDRS^!;ZVG="?*8KM]<T ?.5I'YUY
M"P./,(3'UKZ0\.W+'28;&WM/+6 !$++V'4Y]Z\$\*V8N?%.DVD@R#<*&^@KZ
MJCL8;>)$6,+R%R/2@#AO&EU#<Z9/8^2I=HBRL/[P':O!-.G+:I;NQQOF ?CL
M>M?1OC)HM.T:^9(D;:A*''0X]:^:H/,9HGCXE\P,/KFFMP/:/"MW?S:;Y43!
M;>&Y"(L28'(J[XVTRXL=&6WM8URJDHJ^IR2/QKK/!UC%+X6L@L(4; 3M&/F]
M:DU^VCD@*NI9\=3VK:O5C4J.4%9=BI23>A\P%W.I!TCV,)E^5EZ'H>*^B+.S
MN=,T2&TLV!=AYC!1D'/8^E>"7 $_BEQ$N[?>*% _WA7TII\;(4#KSQFL"3EK
MA[^[M+HW@EC7RO+6,CY5(_B'UKQ+556/5)8UQE#AL=":^F-4BC:VG#-PRG'I
M]:^;-?@2WU^ZC0Y&0V?K3;N![%\(4+>"=>55+,Q?  R2=E7O@]87-H^JFZLK
MB#*P[3-"R9^]G&0*A^"+?\4WJI+%0)OO#M\O6NB\U(70)XP*VZD?(Z<ELC/S
M=^>WO71#$RA1G12TE;\!G<45Q<ETT46V7Q<5F52&8PX[Y!Q[#(__ %5O6VOZ
M;(D4?VO,I"C#(58YXR1VYKF$:U%%% !1110 4444 %%%% %/4]*L-9LFL]3L
MX;NV8AC%,@921T.#5?2_#>B:)'*FF:59VBS#$@AA"[QZ'UK4HH PK7P?H.F-
MYVEZ18VETI9HID@&4<@C(]N3Q1X8\._\(_:79FN1=7]]<M=7=P(Q&))&P.%'
M0   "MVB@#!U#P3X8U6]EO+_ $*PN;F7'F2RP@LV!@9/TK3?3+&6"U@>TB:*
MU='@0J,1,GW2OH1VJW10!Y[\:.?AY*.YNH0/^^J\6B5H[=,CG&".PKVWXPQF
M3P(RK@'[7">3_M5XDKM)"3M/H,U]EP[%<DF^YO!V@S;\-7]M8&[>:5T,KK&I
M09VX&23[<BL_Q,FHB^BGN[GS[64?N98V^4^WUJ*%-L$;9'SKN&/KS^.:W]$L
MDUBRN=)N S(")4"C)7LQ_E^=> ^(_JV<3==+V=[:K56ZW'F'#-.E@?[4HWE-
MV<ENFGIIYHY73='GU*:22*2..&'F6:9L*O\ C6[X::.WFU>UOO*>&+;(TB<Y
MYP-OUXJ&_>-YO(BB6*VM\QQ*#UP>2?4FH-"DM8M0N[:_8PP72!-_3# Y'/;-
M=$\]Q6:K$4\(K*,;QLM='^O8Y\?D,<+@Z5;&R?+-IRBOLK?UN7)M,TG5W>*R
M2X@O'!*!P-IQSCCIQ6'I^EW5XTI5DCCMN)993\J?3UKN=-TW3K>9KBWU SRQ
MJW0@*,C'/K68V@W;6,!M564>8[2J' ()/'!J<+G>983+JL\2GS)I1YEKKW/.
MC_9%;-88;!57&D[7<NCUO9NW0J^'[U]*O[RVN9RMK-%YD4R(?G((!(!^N*IZ
MII?[N;5([E+NTW!6W9#H3['M4DMQF5=-D6,/; X9WSELY*H>@^GUI;>Z^Q3&
M1HE<$%)(F[@]1]:QKY_C,%B:=2K"T9).6F]][,]S"\,X?$0K8G#3O54G9:6:
M6U_7N3^&;^2U@U#YVDMK:$2)&W(5R< BG6B6MY9:@NHRCRR%EW$\B0D\CZUL
MV&C:99VE\EM<*RS0@S;W!\I2,C/IBN;\17-DJQ:98HIMX\/),#DS,1P<^E.G
M*>;9W'$85OV4;.^WK\[GC4,1AJ>#Q&#E2<:\Y+=;)6UO^7<KKX::^M);O3Y8
MY%3(\HGYFQU(IVFZM:II\%G>Q7 >UD)B,! W,3T;/OBI_#<%\;FV:T@;;%-Y
M8DQ\O)R0Q[#!J]J7A@P^*$F\V,6<EP'('4<\_K7MRS&EC<1B,NQ:OR>]'SL<
M>(H?V:J-25;XT[;7B]FGOT*,NF-;:DUP9XY6MI/M$\0!^5LYV^XR0#Z5JV7B
M*\2]62]N'DMG.)$QD*/;TQ_*JNJVXTBXD-U)',\Y/[N,[CL)^9C[],>]/N-
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M>X\+R:?.))!\GD/UP!VJLEQ<Q207,#F.6+)#8Z<5[&$AB/8-UFG/6SZ6Z?\
M!/-H5\1RU(-:IZ&'K&G/8:DZEU96&]64$;@>,X/(K9T=8'AM1,C,I&UU0[2>
M<=:PM8O[V_O6FN6D?<0N]Q@D#^E=)X=U*+34A-Q:)<6SH/,!&2ISP17R=&G7
MG*M'#/\ >\JUV5[ZV['IQJPI1YZT7)):I;_(DEL_L-[>6TC;GMG\O?TR.U2Q
M:?J%_ KHL2AQB)99-K2 ?W1WJ$-)XB\030P.J?:I68LW90/YX%=1J-EID4]N
MTFH"V>T1%96'+*HX(]#7LYIC\9A*5.-&'/4=KK>VW3S9Y5+'X>4XX>I4=.Z;
MO:_HG^1Y]>HZ6#"0$'S,8/8YYK.6MS7KF&Z>YEMPPA:8NN[KR<\U@]J^>SN;
MGBN:2LVE^1WT=*:/0_A,?.UF>$9Q'F1F Z \5[O!;I@%7STKPWX<:'!K.B.4
MNYK>YCN?,8PG!8#H#[5[7I\P^SDDY)/Z5Y#C'E33U_(V:TN>>_%VS1O#K2(
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MNVG22W>"2%PK*S!NH!!R#[U<K-TXYU'4R.\J?^@"M*@ HHHH **** "BBB@
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M?WL\ MM8O-.1ELKI8XY\,4;UQUK4@\2+'HETUY>+<7LB[4C*8*GW]O>O;I/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#N,29R.AS[9/YT >DT5R7AGPEJ^AZD]U?^+]3U:(QE!;W(4("2/F^O'ZUUM
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M16!90J#</2O0^U !1110 45S/BGPQJ>O3V\NG^*-1T81*5=+4*5D]SGO7/\
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M YP?:N,^)EEI]MK8UC7M!,VEJB#[;8ZD8+CY<Y#1[AY@&3@@Y -=SIK:7>^
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M[?ZB;#Q)?:=IVJ.7O[.)%82,5"L48\IN P:[.UMHK.TAM8%VPPHL:+Z*!@4
M345S7C?5=6T;1$O-*%L-MQ$L\DV251I%7Y5Z$G=W/'O7)ZQX\UK2]5U65)+.
M2TB>[MX;0QX>)H8E<2,V<D$D\8'!% 'HFL//'H]X]K9+?3K$QCM6( E;'"DG
MCFN ^"\X@\!7]Q=HEH$U.Z>5"PVPX()&>F!_2K]EXWGT;PQK-_KSG4O[)NQ
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MTTZUMFF:=HHE0RMU?  W'ZT 6:**\W\3:MKNF>)M=6+4F,::"]U:P1Q<0L)
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MY%1(8RQR0>BCK]!7'? *-HOANT; ADOYE(88((V]1VKT#7X#=:!?P"TDO#)
MR_9XY1&TF1]T,?ND^M<+\#8_*\"7,?E-#LU.X7RF;<4P1\I/<CUH [O71J)T
M&^&DE1J'DM]G+8QOQQUXKG_AVOBA=#F_X2DR>?YQ\D3%3($P.N/?.*["BMXU
MK4G2Y5JT[VUT[,EQ][FN%%%%8%!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<WXS\)+XOTVUM3J$]A);7*W,<\ !964'&,
M_6NDHH \R@^%&I6U[=WL'C[7([F\*FXE4*&D*C"Y^@XKT:R@>UL;>WDN)+B2
M*-4::3[TA P6/N>M3T4 %%%<_P"-K>ZN/!NJBTO;BTE2VDDWVX&]MJD[02#C
M/J.: -\D*"20 .236!XAD76O"&H#3(+'52\;*L,SYAD(/(8BN%U4:C>^*;*S
M\_4%FN([2*!$,GEFV>)Q<L1]TD'')Y!"XKJ8_#NNZ#X*ETS0KVTFU N/*:[C
M*Q(G (P"3T!/7J: ,SX( CX76(*A2)[C@=!^]:O1*\@\-^%_BEX5T2/2=.N_
M#AMHW=U,J2,V68L>1CN33]=U7XO:%9PW#IH5V)9T@V6MM*[+N_B(SPH[F@#U
MRBO-_*^,'_/UX7_[]2?XT>5\8/\ GZ\+_P#?J3_&@#TBBO,Y_P#A;\%O+,9_
M#+"-"VU8923@9P!GK5+0]0^+VN:-;ZDHT"U$X)$-U;RI(F"1\PSQTH ]9HKS
M?ROC!_S]>%_^_4G^-'E?&#_GZ\+_ /?J3_&@#TBBO(;+6/B[?>(-1TA8]$B:
MQ"$W$MK*L4NX9^1L\X[UK>5\8/\ GZ\+_P#?J3_&@#TBBO-_*^,'_/UX7_[]
M2?XUEZKJOQ=TJ\TVV9-"N#?3^2'@MI66+_:<YX'O0!ZY17F_E?&#_GZ\+_\
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M:OJNE6L9TG2'U&9@[N Q 5$7)' )+'HH[F@";Q1<ZE:>&[VXTE%:]C4%<X)
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MHHY0.6 '&3T)'7 K<H *HZQJ]EH.ES:EJ,IBM(=OF/M)VY(4<#W(JZS!1EB
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-q_003.jpg
<TEXT>
begin 644 form10-q_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #3 D # 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=II]4E'Z5W=<%:G'BK2#ZM*/_':[RIH[,VS'XX^GZL6BBBMCS0HHHH ****
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M-Y5[ID^<>7>)D^QX_K7H8'%31ZFN8K6#\G^8ZB@45N>8%%%% !1110 444E
M$<T\4"AI9%12< L<<UYY?P?;?%ER5(*[L@COC%=#XV#OI<$<8)=IA@#KT-4K
M&T2TME10<]23UR:]7"+V</:)ZNZ/E\UF\166':]V-G?]"UWHHHJR HHHH *J
MZD-VG3@#/RYP*M4A&01ZC%"W)DKQ:.BL9DN+*&:,Y5T!'Y58%<?X5N[HWS6L
MSDPQQD1IV&&QFNP%>;7I^SFXGT&!Q"Q%%32\ON%HHHK$[0HHHH PS_R/:_\
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MH0X4^H)YK6TC_D"V'_7O'_Z"* +M%%% !7':E\2-'TO4K^REM[MGL&"SLIB
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M!NY(^E13:KI<L$D9U"WPV4^__$>WU]J[@P0EPYB0N!@-M&0/2F+96J!@MM"
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M9J,V\)D#F&,NIW!MHR#ZU)10 4444 %%%% #!#$)C,(T\PC!?:,X],T^BB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-q_004.jpg
<TEXT>
begin 644 form10-q_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "/ D # 2(  A$! Q$!_\0
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M::NFVLLEF)T:X>)ERXR05(/1<<Y^E96F3^(V\/:N99+EKP(AMV:,Y5R/F !
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MG@8J6P0"23 '08JI!+O7.1S6AI_+R^P% %K:54D+DU-\K#!Q49) JI>WL=E
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M_KNW]*QM?TS5+S5K*XT^XEBC6)HI2DNW;ET).".3M##/:MFQ_P"7G_KNU6Z
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M6-*<W3DIKH<-8%I=0W0KMCW<+Z5Z#&6\M-H)) R15:RT:ULQNC09]:OCA0.
M/:FE96%.7/)R?43[H)/K6]X/_P"/^Z_ZYC^=8#G QU^M;O@X_P"GW7_7,?SI
MD'94444 %><_%)P4L((K?[1<.LK!$,^]% &Z3$3#A>.OMBO1J\Q^)>D:S?7U
ML\<3WEAL?8D&G^=)#)M "DJRG:_.>W% '>>'MI\.:;LNOM2?98\3@$>8-H^;
MGGGWK2JAHB3QZ%8)<P)!.MO&)(D "HVT9  X %7Z .7\9[]FC[1+M_M.WW;'
M"K]\?>!Y(^E=17)^-_+_ .)'O^S[O[4@V>8I+YWC[A'0_7M764 %-=%D4JP!
M4\$'O3J* .?U/20)6N;:1;.5C&OG0QY<JK9VG/!%01ZC);W:PZC&+:66:7RF
MA8LC #.6/0'V-=,15"XLAM9516A8,9$;+%LC!J;=C12Z,2"^(A5G_>1[%;S%
M.2V?I5Y75AE2#^/2N8-A?6,3'3718A'$J64R[4CPW)!'(^E30:G:27(B<O:7
M!N)$1)1L+D#.5[,*+@X7U1T=#*&&" 1[UGQ7DD<:F4>8OEJY91\Q)]JNQS1R
M9V.#M.#CL:9%B%["%L[0R$C;\AQQZ8Z5&;.4/N$JN-Y<JR=<C&,U>S119",2
M33<VQC:QC/[H)A"/7/M36L[99PWES1$S[LY8?PXS6[12<4.[.<%OBU/DWTJX
MMR!E@W\7O5DQWJW7RSQ./M ^\F.-OM6L\$4F=\:-GKN4&HC8P;]RAE.[=\K$
M<TN4+F.KWR1<PPR'[._W7Q_%[U-]KF6X;?92_P"O094@_P -7CIY (CG<?(4
M^8 \$Y-(;:X60MNC?,@?N.@Q2L^X7,W^TH1;?.LR?N)#\T9_O5+]NM7N0/-7
M/G1#!&.=M3LEPL&UH&.(W'RD'DGBFO\ -*-T,F#(AYC/8<T:AH7K( 6^  /G
M;H/]HU8JGID;Q685Y3(0[?,1CN:N5:$)BLQ_#ND/J9U%K&)KLN)#(<G+ 8#8
MZ9  YK4HI@4X]*LHEMUCMHU%N[20X'W&;.2/<Y/YU6E\-Z/-<).^GPM(CF0-
MCJQ.XD^O///>M6B@"M/86MU*DL\"22(C(K,.0K###\<5#'HNG17*W"6<*S(H
M17"\A0NT#\N*OT4 8J^$M"25)8].CC=  I1F7 '0<'M6U110 4&BB@#-MH9W
M>Y,=R8U\]OEV U/]GNO^?T_]^Q18_P#+S_UW:K= %3[/=?\ /Z?^_8H^SW7_
M #^G_OV*QO$NO7.CW=JD7E"%T+2-(.GSHO7MPQJQJNLRIIE[+I:K)+# 94FD
M1C"P'4!AU/M0!H_9[K_G]/\ W[%+]GNO^?T_]^Q6#::Y>2>*_L,S1FVD7$21
M ,P(16)?NO4X[5U% &5J4-RNF7):[+ (<CRP,UR)ACVCEOSKM]6_Y!5U_P!<
MS7$NV%R!TH B:TMB#OR?QJO]FM5;YMP]#FAYV8D<XH#A0">M  ;:WR5RWYT]
M8+88&6YX%0EM_P PD!0]!C.136D(95(!4#.* )+BR2>+:DTT)S]Y",X_$&DL
M+(VLTK&[N)@P VRD87Z8 HBF9R>5//&/2K,1R6SZ4 2[0QY)I[1KMSR:CS@]
M:1KA4ZT 2+%$XYW#'O2&%,]3^=9L^N6MNVTD9SVJ2VU&&Y?='+[;: +;P)SR
MWYUF7.GF:8NMY<Q+MQLC*X^O(S5^23<.*BW;AS0!/8Q&&RBC,KR%1C>^,GZX
MJTB GDFH8/\ 4K4F[!SF@!SHJD<$CZT[R(OO MD^IJK-?QQ*=[# ]:S'\1VX
M?8&H VC!$0>6_.H9+>,KU;\ZAM;Z.=,J^<U+))SD4 9T6E,D\3'4;QMK@D,4
MPWL?EZ5L%,\9.*@3YI$^M63QWH <L"%>Y_&FK#$S%6##/<&D,PC&21BLV\UV
MVM?O,"W2@#4:UA' 9OSIC6L7JWYUBP>([>Y8+N*\]16PLZR*"K CVH J7>GI
M,@59YXB#DM&1D^W(-;'@RQ-IJ%VQNIYM\:\2D?+@]L 5GA^<'I6WX8_X_;C_
M *YC^= '44444 %<EXV\5W/AN."&TTR>\FO%=8WC) 1ACJ0#C@D_A76UX_\
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MHG=0",+U4YXX^M '=Z?')%IUO'+())$B4,X8L&..N3R?J:9JU_\ V7H][?\
MEF7[- \VP=6V@G'Z4:3:?8-)M;3RDB\F)4V(Y8+@=B>35ME5U*L 5(P0>A%
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ME<BREQG.#V]<UT0Y%(  , 8'M2T %%%% !1110 4444 %%%% !1110!4L?\
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MH_L#33_R[#_OH_XT >>FW3(.T9^E/*[17??\(_IG_/L/^^C_ (TG_".Z6?\
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J(:'J$(BN;+>@8, )77G\#4FC>%](T"::73;4PO, LA,KOD#I]XF@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-q_005.jpg
<TEXT>
begin 644 form10-q_005.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #O I8# 2(  A$! Q$!_\0
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M'!K^&C]J;]H7]I/2/VG_ -H+2=&_X.9OV:_@KHMA\7_B3HFF? [7O@\=7O\
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M )XX('7)%-6[1C\J.1DC)P"-O#$H3O 7CG;SD8H M44Q'#Y(! '0D8#>XI]
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M2>U 8%BH[ DGMD8X_7G_ #B#S%8'&%Z\C/;J <#H.N<<'CUI P0GY@N%'W^
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MM87\BPA[=EXA?[_^'/\ P1 _X*?^&O!W@3P^?^"S/Q+\'6OA70_#]D?!^C>
M!K&F:!)IAL6?2-+U:YU^&2YL+.$3VMI)=V\[!!'YJ.A8+_3&?>"'@%EGA]PG
MQ5EOTM_#_,,^SO&YAA<QR6GPQQ=;!TL+.I##U,-"G@98B$ZSA!-9G"C1DZC^
MINHH*WSV'S?,ZN,E0J\/XF%*,G^\YHKFCS-<WO-1=U[VC:UWVO\ U>I>1OYF
M-H,6!*#(O[LGY@'(RJY0@@EL;B$8KUKB7^*GP[CTR76)O&WA6#2(=6@T"75V
MU_3UTU-=GD,,6C_;7D6!M1DN1Y"V8)N"QP\2,R(V+9>$]?7X92>#-6UV?Q/X
MA7P)+X5OO%^J8TVY\0:O+X?73+GQ%=VMB)!:-J^H,UY+Y3AK,L[PJ!A*_#KX
M>?\ !._]J7P'IVF_VSX'^#/Q.\$>'?&'B2/PS^SKXV^*'B*YT;R?&%D(;OXK
MWGQ)M]#AN-4U'PY.7DT/P;>:#!?1Z=<ZLL'B);O[#-!_*M2"C5]QMQLF[MZ-
MI75FWMVM=:I]6?1GZJ^$_P!M+X7^-_C7XU^"WAWP_P#$*;4/ ?B:\\%^*/'5
MQX5GL?AS8^*;"TL;V;23XGN62UEG>/4K6&UD3$=S<SQQ*R^:KCT7X@?M*_!?
MX7^._AC\,O&7C73K'X@_%_Q->>%/ 'ANTCNM5U'5-:TZR.I7]O<K8P3)I*6E
MDK37%QJ36UM'A4,H9@Q^#_AM_P $XK72O"W[36J^,WBM?C#\9/%OBG7?"7B?
MPSXO\5KH'AR.X\,>'K/P$8]/FNY+-F\/>(M&M[U'DTY[V6*&V6=Y?,D<Z?PX
M_8W^-6G_  [_ &6M7^*6K_#KQ'^T)X4^-%Q\:OVB_'%A)>RVFL>)M7T>YTCQ
M#+\/KW4+6'4;:Q-M:Z0BZ0SV5I*8[A'>(EIG /L;X.?M6?"?XW^-O''@OX?7
M.OZA=^#+J\@DUJZ\/ZM:>&?$<6F7)T[5+SP[KTEF-,U&VT_50]B\EO.Z7 \N
M>U:=3*L7L5S\3_AY9:C/I%YXV\)VNJVUS#9W6G3^(M)BO;:[N)%BMK2>T>Z%
MQ%=7#DK% \8?<C))L?Y:_'7]FC_@F_\ &_X1^(]1\/:?\5-2^#'@_P +^'M>
M\+Z?\2_A9XPNM9\=?'JVU+XBS>-/#GBSQUX0\3:3=Z%X!U'1-*NKO0=2L=#E
MNEU22>1DN88$05Q_B?\ X)0^)/$4?BS7H4\%:A\0=8N_VF-9MO%]]XI\7_;M
M6\0_%#XCQ>*_A=XFU.:.2V2+4/#>E1O!>65I"MKI<LD5O8EUEG*@'Z_?%#]I
M#X/_  @\7?";P%X\\6P:-XR^./C&'P-\,?#PM+N[O_$NORP37 CC2WMI1:62
MQ0MNU&]>"R$Y6W$^]@*\]^"'[7'PO_:$^('Q/\!?#*+Q'K$OPJUK4/#_ (D\
M47NF-;^%VUG1=6N]"U?2]+NV=6EN[+5K&[M)$\H@- Y#G&!E_&[X#^(?B':_
MLWSZ*OA:;Q-\(OBY\,_%_B+Q%KUN%U=_#?A!))?$.E^&;[[)+<VU[JUYY<J0
MK,%D0-Y\KA]M?(7@7]ASXUGXY>+?'<6K^%_V5M$@TKQCI!\3_LY:[J%YKGQK
MO?%_CB^\56'B?QCX5\265QH'A:X\/P3W U5!'?WNK:YJ4]S:7UM81):H ?6]
M[^W5\#=)\<^._A]JC^-['5? NB^)==BN+CP;X@^R>,8?!\NE6_B:V\%2"P+>
M(Y]+N=>TJ C3A-#(UV-LB&)@.J\)_M;_  >\4?!SQ1\;QJ.NZ)X1\#ZC_8'C
M#3?$N@7>F^)O#_B+[;ING1Z%>Z.Z"[74[F^UC3+6T@"-]HEO(%4J&)'Q;XK_
M &=/VS=>_:'T[XP:9!\$K3Q#\)_AC\3? WA?XAZEK/B'5XOC=H?BVY\*WGA[
MP1X\^&92VTWX>S6:Z5JTVK>-=%U:]N]1U::U=[06"I;+Q.I?LO?&/X<?L=_%
MV#4O"]OIVL:K^TOX._:/L_@EX"\1ZA\0I="\)Z9X_P# ^K>*/!<GCG6(+'5/
M&+A=)U_QM!/):F6SBM+31(!.D$:@ ^T)?V\/@(/B9+\,K:?QUJ5^NMV_A*_\
M367@G7M0\%Z)XVN-&&LP>"[[Q+;6+:9IFOR6SQ682ZF6"/6)8=.>5KAT1_(=
M+_X*F?L^7]C\4-1N/!?QMTE/A)X@TWP1XN_MKX:ZU:W,WC76->L_#7A_P?IJ
MOL&H:SKNL:GI4%F8B;9H[Z&9IO+#E?#'_9+_ &J!XCL?"O@#4_#>E_">_P#V
ME-._:2\-?&:'QUJOASQEIGA;7/%.B>-_%?PN\;_!J?PW?V/C/5[^VLK[1+#Q
M'-X@L3ID=VMY]A!M%M6ZO]H']B/XQ_$3X3?M;^$-.M?!WB^Z^-7[3WPP^,_A
MKPIJGC#7/"%EKO@+P-XQ\%>(=7\(:IXNTFRFU/PAK&KV>@WMMIVJ6,<QM;F2
M,@QH 0 ?H3^S_P#M#_#W]H?P=JGBSP$=8M%\/>(]4\(^*_#WB72;W0?$7A7Q
M/HKQ)J>B:MIUZ@D6X@:9&BECW07$3*\<G.*]ZCF64N%# IMW!E93\PR,9 !&
M.X)YR#@BORD_8R_8U^-?PFU#7_%'BSQ[J/P8\-:W\7/$/Q&T[]FSX=>+I/B)
MX2L+/78K:.\TOQM\2?$ND0Z_XPU"ZEM$G=X!86MDGE6MJ0 6;]3=*4);B-8'
MM@N7:*1=CK)+)([C:99B$Z>7EVRF.<Y  -.FLP49.<>PS2Y^;'MG]:J7,KK"
MY4*6X" ML7=S@,Q#_483/RT!T;[;BO=0Q<MD!C]X@XSD\=./Y]<XQ3_/C<+S
MC<1U...1D<'/TP/K7P]\9/\ @H5^QU\ O'DOPO\ C/\ M!_#CX??$"TTJ/6)
M_"'B:^O++5DTV225!J:EK;[/-:$QL$EC8^:ZL5105!]K^"'[0OPC_:0\$V?Q
M'^!WC_PW\3? <]U<V0\4^&IYI-+-[;2B-[>!I;8-<-&=ZRA"H#*29 /EJW@L
M?3A#%58RCAJLG&G4<'R/>VO*EM:[YFK]^G34P>*HX>GC*E"K'#U74C2JN$N6
MK*E",YQIMQ2G*,9KW8MN^FG7WZF&102.>.^#C/IGUSQ]>*<#D?E_('^M0L5+
M8 &20-PZ]LG/3CN.X^M1Y_\ #_\ #G,O>U7:_P A/M*Y*[6R,]!D<'!''^?S
MJ8.",YQZ@GD'_/YUF2?:"Y,;QHF<$G!)'KP0<D\'/3\.;,8+@ LI8#DJ 1QC
MJ3G/4= ._6HY7!ROK[JE:/O.TI::*W?5;K[T&EDU.$K](S3DO6*U7]=RYD'H
M0:*@@SAB=O)&-O' SU]^>O?I@$$5/5)WZ->JLP"BBBF 4444 %%%% %0X79'
MR1'Y>3@G(9QD8&=P(Z#KP1S7\87_  37^-O[*_[(G_!8O_@L!I/[<OBWPU\*
MOVJ_'?[0/B#Q=\&/BE\7KI=$L_$/[/NJWUSJ>E:!X)\0:KF)5M]+6PEC$!BA
MU#3+%;='9[>2$?V<ME0"IP\B,0,CY0O(!SV!SSP#CG%?GI^V;_P2W_85_;^E
ML+W]J?X ^%OB)XFTG3DTK3O&L:7>@>,[318Y7GBLK?Q+HBQ7\EK;S2,T,0E)
MB5BH9(\H847*2JW5M/=?Q:-/;;IZ%I7IMZ:W7FKJ]S^=+XN_$K]EK]I#_@XW
M_8+\9_\ !.'4?"OQ&^(WAGPWXVUO]MGXF_!G4H9O FJ> +C3YX--LO%_B#2I
MCI6M>)+*V:Q>XCC6X$\<]M:7$_VNU,4?]AOB'Q3X8\'>'=1\2>+?$&C^%O"^
MEI+>:IX@\2WUMI&D:?:W$LA:>ZU"\E@M80C XDFD2.,..2BE&^/_ -C;_@G-
M^QA^P!H.JZ!^RG\"O"?PUGUP6EOX@\0VDG]I>+_$ MI&GMM/U?Q1JTDFL7D,
M#2/<QVOF>6\C-O7.TC\R?^"_UM\4?%ND?\$]/@OX(U/P;;>'/C5^V?X=\">-
M+'XKQZA#\%=::;PSJESX:T[XLMICQ75SX=^U+<WL/A?Y8?$5W!% [%U2)EB9
M\M%4^5M\RE?I:ZT[_P"77<SI4^:LZBE%)0Y7>][I/7M;^MD?N7J'Q>^$^E^#
M]+^(-S\3? -AX"\0SVUOH7C.\\6Z-!X9U>XO%86<%AJTMP;*_FE$,TL:13J"
MBNX:1-WE7/B=<PWOPB^)%S9S0W=A??#7Q==VUS;31W%O<V\_AN\:&>VN(9)(
M9H)87,D,L+F-XV1@2037\/O@/5/A!\=?$'["/[/_ ,6?AEX"\&? #X4?#C_@
MK?X9U_X9:3XHU&;X,>*_CW\#XO#4&G?%#P _B.:.\ATVP_M'49O!FCZG=I=>
M%)UQ%;V=N;4WWZ;?"S]J+_@H7\+?^"%_[&/CK]FK]F/_ (; ^('BSX>^)/"O
MQ.MO&'CB'0M7\(?"!-*\;0^'OB"FIW%[##XBG@T[3=$L#8K-<SM#-$Q . O3
M[)JA3GS*UE[NMU=7OVLK6]7IU&X\LI*Z=W>ZO^IZ1_P:I_-_P2VO5P#G]JK]
MI GMT\=L3_+.#D<#@U_2.8"5"MM"EM[HV7&<$#'RD$@#(4@@'IG (_FN_P"#
M3^>>]_X)1VUS?0"RU6Y_:5^/]SK&GJP TS5;CQBL]_8QR N'2VFDDB1E9@RH
M""<AC_2VBKM&<G@X)SDGGKUR.."<<<YYKBKTE4@XJ4Z<E*G4<Z=65&5J=2,[
M*I#FDM8ZKDE&2O%K6ZJZY6FKJSNKI:==6['EWQ1^$WPY^,W@C7_AI\4/!V@^
M-O /BFR>P\0^'-<TZWN]-U*U8 -%-"ZXSQC>FUP,[6'.>2^!O[.?P5_9I\$1
M?#GX$_#GPU\._!\5U/J2Z!X>T^&PCN=1O!MN+^^= %N78'+EBY*D@ -P?>'.
M.5C9_<,NWVZ$\>F3D<5#&68 "%B%X <J< $'  (Q['G&.@XKU*6>9X\JQ>14
ML]S6MDE;'T\RKY%+'8JAE%3&TX>SH8JM@Z&)A0KXFC!35/$3H^UM+EYHK58Q
MPE)2=5X>%2]N64YTWR=6M7?WGV:VU0^*+"QDQJA!S^[P(U/S$L!@+@G[V "Q
MR3GK7,S^#/";ZCK6LS^%_#\NJ>(-/&G:]K%QIMA->ZOIJ6J6HL-5N&A:>]LQ
M;QQPM!(S!E1 $XR.L4\ %2O.0!SP?0>Q]<@Y.">34J10N &C!.[=S_>4D@GG
MJ",XZ9[5YE.$Z=2;C05.%1\\W&4;RFTKRFG4J-RLDD^9^ZHJUS9N^BC"*UT@
M[K1[=E9;K[NQRFA^%_#6@V.GV?A_P_HFD:?I]@--T^WT73[2P@L],BG>\CLK
M"*UCB$%E]LD>9;4A0+B5Y-N6?-R+1=(6/5(TTNS1-<O'U/5X9K6W O;QHHK>
M26]CV&.>:2"VMX@\F]S'$%)P !TGDQ89-@ 8AF X!(/!XQR",U6N_+0*?+E=
MLO(!$I8L0H4Y+$(" P==[ 8C.,]*UBT[V=_>?WZ77R9-DMMO,YR3PIX8DUC3
M_$W]@Z(=<TS3YM)TW6YM-MGUG2M,N)!*^GV%YY336UJ94#K#$Z!0=B@(2#9D
MT31[D7,MSI.GW4\YM;F5[BPA,]W<:;,)+:6X;RRT[VTZB6T:0N80WR%06Q9-
MU;L(@)X93=#S$D+NJW+6P4E+9$)-Q(4),B6[2,I0DQCY260&8W1D>7>2CK9Q
MEU*-$S9:5E5([E)8\%&1T)7E<D\U0#8M&TN&P?2HK*TCLKO[2EW8PV=O]@G%
MVI^V175NR".2.Y1B)T=2LBDALYR<UO!OA!]:TOQ,?#&B#Q%H^GR:'I&O_P!E
MV;ZGIFF3M$\EII]Z8S/;VA:&(M%&Z*NQ,8"[1NHH_=%59)"[+"SQ71+N>9S,
MA ^4)Q%+*RC(^F:+W1M1M$D;>89WMXXI$F9H3\JF:T/EW<H:4N%_LV.Y=V0!
M<DT 9VH>%O#>JZYI.M:AX>TK4]?\/R3WN@ZWJNFVM[=:)]J!2ZCTJ^,37-J\
MD3R*PB<%MS'()S45AX6\+Z#/XBNM*T#P_ILWBJZ^V^*9;72HK9M>NIT%K->Z
MT\4,<NJ7<T+F!YK@R,PE+2Y0-G8^TM%:)*TLBOEFE@6VN%FN9&0R-%;6OEQ7
MK3%0988XDD?RP?,50=P<UX@8#/VF-7:VQ;H^HDB1V"&6*U0W$,G!262Y$%O&
M5\LLSE6(!Y/X2^ 7PJ\'^!?#GPY@\&:=KOA7PCK.JZOX5TSQ-8VVOOX;O]6U
MF^UZ4Z=-J"7*VUI;7FI7$EFL#A;:V:*W11%%'&OJDNF:6UX)6L-/>^>T:S:Y
M%K;R,ULJ,!9-+*F8[3:67[.I\GYBI3;P;3RR1J2YB'[PI;K%(J!G$2Q^5)+-
M*(C(+E9H/)C$BQ%8Q-D$FJ9NQ<0QAIHHV6)1):W#1K<N=H#PSQ0G[8EY$<X2
M" I*2FW(;% &+X5^'_@7P++JZ^"?!WACP@-=>&^UP>&-%TW1WO[T_:-E[>OI
M\%O]KE3<_EM*6\HO(R$&5RTD7@WP;_:?B#5!X0T)-1\3V<.F^)K^30[,ZCXA
MM;96,4>JS^2RW]F!(0J71<&4RLRL<,=QY8KF+R8)!&0[V\<7F6[O(BQ)_H]P
ML;2-&F[<SJ[)/#A Z;I<"-9I&FN(%21!;QVS2/+(DL,\ &9UC@MWGNK5X0RF
M/[6ML]R7/EAHXG8 ?*YSH^'_ ("BT[0-,'@GPHMGX1U$:IX6TV/1+&2U\.ZD
MHD$.HZ1&(/*TVZVRLQFM0DBD@YW*-O)?$#X*_#KXDZ%XQ\-^)?#MG!:_$&#2
MH_'=[HEK#IVI^*;/1[N*\@TS5=4A6*YO+*5($@DMGD9C"TD3*5<D^JQ3QI&D
MLDB(&<>4TUQ;+#AV*&.&[A\V&62$ E8'VRR$9)ZM488O,3*OFR0L9##(Z9CA
MD0Q*5$!G1Y+C*O$)/+D"@DD]*B<>9;VY6G?I_6^Q,KN2A%ISWMVMKKV5].G;
MN?%G[8GQX^//[//@OPOJ_P"SS^REK7[3K&2[M==T+1/'?A_P*_@G0- L([H:
MA=MKD,T=TL=O:O#%#:;I!(F "2 ?GG_@F[_P4+^,W[=.ES^._$'[(GB7X&_!
MR]L+Z?P;\1]=^)?A/Q</%5]I.J3Z5J-@-(T.UAN[&3S[69%,QV@DC.5!K].O
M&P1O!?C1E=6?_A%/$T: !E*O'H5^K[W(4%0^?G"J&)#<$@5^4W_!"2" _P#!
M-#X)O+&-TOB'XJ;G;<2Y_P"%B^(2JK@\@MD$# )^7H=M?38;ZM+(<;7G0A5J
M4L5E^%IU+M.+Q5+&3<EK:T?8)-=;[7/K,+/!2X6S;$5L'3KXFCCLKP-&HV^>
MA+&4\PG*:7/&+5\/!---O79Z/]C8CN7#8!(R<<'+\'G&#\O'&"3SQCB&;86=
MF(RJ#=D/(H5,XW*F"-I(WG/"@M@YX<K$!3@9/"(0025W9R>Q[\^_')J%ED+9
M**^[.1NP2.N"#U!R<C'/(QUQ\Y[&-1J\8QBIN,E&48KW6TWJUN]-=3X]SJX:
ME%OG<(U.6I^ZE5ERIZJ$*+J3Y6EI*2Y>^Q\??$W]O+]D'X.>.=5^&?Q8_:,^
M%?@+QUH-K9WNL>$_$7B2UTK7K"VU"(W%E=7-M/O6'3;F H]G<%9))8C\^)1N
MKW+X(?&OX3?'[P='\1/@O\0?#?Q-\#7][=:=9^*_">I0ZKH-U>Z=(T5[!:7<
M/$CVLLBQ399OG&0%'!_$K_@N9\ O@;>^ /V?_B/J/PB^']U\0?%_[8G[.GA?
MQ3XPN/#EA)XCUWPS=>)H]/O- U/5O*^U7FE7-B?LLUG+(T1APH5><_N)\)?A
M=\-_A'X1L_!_PF\#>%_AQX0MY'U"T\+>$-'L]"T6UN[\A[ZYAT^RCB@2:[E4
M23R!-TC89B3S7OXO+L!0RC+L?2A75;&SQ5*,I2HNC#ZI5C2E?E;J/GD[QWNM
M[-6/I\PRW)J.39/F^'I8U8K-,1B<,IU'AU1ISP<8.<G&$O:J,U+W$X\V_/:U
MCU=.AYSS[^WJ!3Z8G0_[Q_'IS3Z^?3;5WOUTMLVMO1(^>O?7O_7778****8!
M1110 4444 %%%% #)/N_BO\ Z$*B!RA!Z>85_  L/I@^E3D C!&0>U0RJ
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M0E=IQZ9'7'?GKS0(8P5.W.PEESSABI3=@]]A9,_W68=S4M% $8B0=L\$<D\
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M^ ]0_P""I'_!//3!=1ZG^U_\"[$Z??75A>O/XVM4,.H6=RUG>60BV>=-/#>
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M>ZM+JXM)WB8>?9W$ELP*LRD _"#PW\4?V@?VBM/_ &P].\6?'KQ9\-K/Q_\
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M_B&*T^&FF>#+.#7OV;M4O$NXHM,T]+/Q4+?0?"<6G1)>^(-)-XK13VZ2NO\
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M#MGXS^(O@ZV_X1&^U#R9)C),&MI8%:."50R$#]A+:0/OZ @@X!8[5W.JJ6(
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M8_''AN=5E9)D=UNU6X0.KR2QV+1.ZNT?)S^SO[$__!,O]E;_ ()Y>#9S\)O
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MII+L]DNJZ^OH:1?[OEZK5]>C\ON^9^>/_!&7_@W(_P"%"?M(^#?V[?VJ=?\
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MR/F3PWJBL.<?=8$'M^%9:W6UK._>_3Y&A_/E_P &IO\ RBYOO?\ :K_:3_\
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M'O#^H2Z5\;OCCHD5UYL:^-M0MO)U3PWHVKQ"WDDT]9HQ)$^TQ/G)^P_V+_\
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M34& ><\_T XX'%.KQ8_"K-272232>KV3;?EJ^AX"T_JX44450!1110 4444
M%%%% $<O^K;\/_0A3694\SN,;FSP%!' R>.>I] <T^491@/3/Y$$_H*@F(:&
M3<"ZA2Q0$@MN)9 2".,8R.PY[5'*U*Z;U;OZ6V\]?\^B![;V/F']L']G?X:_
MM;_LR?&S]FSXPW4NG_#3XP^!;[PEXJU:WU"+2YM(M))[2[L=7@O;AT@MY]*U
M:SLKZ.9IU0O:HN0S '^(3XF_&C_@L/\ L3^)/@S_ ,$0O%O[4OPO^%7PC^,7
MB"\\'?!#_@H[XHU=[K6K[X(7_FZ=IW@P>(TNYF\.^+]-5H-&MGFGAU[==VT5
MGJ*6I\]/[&?^"F-O^S[<?L#_ +4R_M;:UXS\._LXM\.)I?B[J7@&6_@\9Z1X
M2CU/179?#4VC(;WSY+R*V#B%)//BFFCE!C\Q3_ ZW@7_ (-+]76."\^//[<^
MIP6ZRWEC:75KX]O%L%#!IS9!M.F3S9%CA@N+F**.(BU#LZ(?EBA?VTXN[3:?
M7SZ[7_'2VB-)*].+OT:Z7^SY7U^[SNS^VS_@E9_P2O\ V</^"9?PX\8>'/A-
MXTUKXM_%/XFW6DZ[\<OB_P")/$TFN>*/&GB:W%S=V-U-:P7MS!H]C'<7M_+:
M&0?:=3$KRZE<7$SDM]W^.OV4OV:_B;JU[XF\?_L[_ _Q_P"*M0*_:?$_C/X7
M^#/$&OW3P1>7!+=ZSJ.C7&HN;=F(A47.81N,3(W)_!O_ (-Z;?\ X)06G_#3
M,'_!,3XH_'#X@&=_ MQ\5[;XSWOB*>YTQF75HO#<VA1^(0-\,NV^CU&ZM6#2
M21VZ.0L4<:_TW6_RQJA&&4#< <_,>2>O ))QVX('2NBM%2M!O16E=6WU]5Y'
M-32YI2MJG;7T3]>OET1YE'\'OAJOC>P^)J_#KP/#\1=*\/P^%]-\<1>&=(7Q
M;I_AU$17\/V7B+[*=1ATA-BQV]JDRI! &CB15(Q_/#_P=7QN/^"8=FTR.F/V
MFO@9L1/*:*;'BNU"%U8,8$E*8*(3@J6.2[&OZ<J_F:_X.NO^48.G?]G+_ ?_
M -2Z&E=VMTM;]#6R]#^BWX=JW_""^"'VB('P;X7_ ',07R8R-$L<QHV%9E7&
MU25^Z0!C  [BN.^'G_(@^"/^Q0\,_P#IDL*[&D PIDDYZG/3_P"O2>7[_I_@
M:DH)P"?09IW?<+R_F_!',WUQ:VMA?7&HKC38-/O;N[ADB$T-O:V,=Q)<RRQ@
M.)XYX@5D@8,9%)1DPV*_&T^._P#@G'+X?^)2W/[*,UCK.G_$#2M7L/AMJ_PB
ML].\;_%CQ1XO351X<OO >E7\HFNX=;T^SU[9HXETZ&/29+N:2V\F\*U^R>HQ
MZK-87\>F3#3M1FM=1^PW<L*W4-MJ$MK+!IUU+;,46:&"=H[F6 NJR!#&6"FO
MP_\ 'O\ P3G_ &@OBAXK\2?&;X@Z3\!-<\<VGC;P3XNM_A#9WWBFS^$7QIU;
MPEH7B'P?<>+/B1(;=M1\/ZS>^&/$#B+2M"B?2%N+01W4%W!<3Q2H#Z0T[X__
M +&DWQ#^'_P,T;X)-97OB#P/<?$>\M[KP#9:/IWPT\+^*O#VL>&]4U+Q6+AD
M70YI="LM5TG57A6X<:1'/&A\A68=;X&_:^_9-^+/A_0O 4G@K6M$\#0>*_ G
MACP=H?CGP#-HGAS4=.U"_DMOAAXS\-6,Z&$^%=1UK1H[30=5542*[>R0@/.H
M/RK=_P#!-'XP:YH?PU^&GBR\^#NJZ+IND^%[?6?VA+:QU;3?VBO NBZ)XBUG
M69/A=X-\26D<0UCP)9Z)J<?@G1K+6;B."'PX]]!)"7N56.AXC_8Y^/MGH^@:
M+XTT_P .:[KEWK/P-^!/PU/PP34DM-!^%?PU^(L7CW5_BAXYU'5EB6TUFWTZ
MQ@.FV4):*UU&W$=K*PN0M 'ZZZ9\!OA)H?Q3UKXX:#\-?".G_%CQ%I_]D:[X
MVM])M8M?U&RB:551KU%"P3W"N$U"]B1;J\@ BNFE8$"34O@+\(-=\0ZEXQ\1
M?"[P)X@\7ZS?^$-5UGQ/K'A?2;W6M5U3X?2++X%U&]O)[:22>]\)2J)-!F+!
MM,<M-:F.222O6-.C9(FWL78B+$K*R-,@C4)/)&P4QRRG>\RE0?,+$]<#0H \
M8TWX$?";1X=4L].^''A6UT_5/'(^*5W:KI4#V]S\2VG6YNO'+6WRQ1>)[JY$
M=U-J\2B[GNTFN)G:20EJGA#]G[X1>!/B'XS^+'A'X7^#?#?Q'\?I&?%?C'2-
M(L[77-999O/FCNKU80\:7LNRXU$6XB%_=IYMR7D".ON5% 'SO=?LS_!&_P#'
MOB/XHZC\'_ .H?$7QCX=NO"?BSQ?J'AK2;W5_$'ARX3[+?:-J-U- TLMIJEA
MY=M<.VZ>[AMK6VNY3! BURVJ_L??!F7X(>*O@'X0\%Z1\,? WBRYLM1GMO E
MC:Z2;'6M)US1_$>A:[%#$J1/?:/J^@:1+:QMNACMK9H!F-MC?6-% 'S5/^RO
M\#]7^(6A?&#Q1\*/ GB;XP:'9:7&/B3JGAW36\17VJZ/9K:VNNSRQ0+%_:(8
M&6VE=)&L#+-Y)S' 1L>,?V<O@]X^\,>,_!?C#X:^%_$?A7XC:S9^(?'>BZE8
M0RP>)=?M)X+FTU^_D 5I-8T^[MK6:&^X;9;*%4$!:]]IN]2VW(W<\?0X/Y'B
M@#R?X7?![X?_  2\,Q^"/A)X(\.> O"XN;R].F^'-/M]/M)=1NBAGU/45AC2
MXU#4+KRT$EW)*TFQ5#'"JJ^G6<!A60E75I6$K!W:5E=QED$KLS,JMD@$X4L0
M"15RB@!I95P"0"<X_#DUCZDXEAQ$X.9U7/(/!5'"Y W98[?E#!CP.0V+EXPQ
MLQG< A*X+(LA8,Q[@ #K_+.:_+'_ (*G_P#!0"U_85^ D=UX3LYO%'[0OQ<N
MY/AS^SQ\.[&#[9J?B3QSJ#365E?S6**UQ)8:6\AOIW0+$ B(6+/D=>78/$YG
MC:6!P<5*O5ERKFNU!-J]2I%-.%&,;RE6;4$HMO:S]#*LOQ>;9CA,MP%)U<9B
MJC5.,KJG"C37-B,35DK<E+#T[U)MRB^6+:N[(_D__P"#D6_'Q8_X*4>&_"WP
MRGU?QOJ/P]^"GP_\'>+_  ]H$EUJ%AX<\>>(/&'B&Z\.V-_:0%K"PUW4[>>V
M%I-<*LY^54D#(RK^ZW_!%'_@E9\&?@I\ ? '[0'QU_9Y-I^UWXH&J:GXKU#X
MLV#:YXE\.S1:Y>6^ESVUCJ;W5E9.NEI:SV]]&AOA'(%68E64?!_Q*_8%U']C
M+_@F_P##[XE?%:]'BC]K7]J']M?]FWXC?M'>/[U+BYU?5;_6OB+<:WH?@R6X
MO7^W6FF>$TO&A^RVDD(6_$@4?9QY=?V%Q(P6W,6\21):K+,?OO;%(F\HNS/N
M49.8R N20N 17ZAQ9Q34PO W#7">2452P]#,,7A\=BZ?*\15Q>6XR,,;4H8N
MFU+V%6I7KRBE/^%&EROE?O?LG&?&M/+?#OAO@W(:48X:CFF;4,?F-)6Q6;8G
M!5\/1JK"XF/+*%&I5JUV[3CS4H4DI<M^:Y%;K$K.L*HSJ8V\K"QA&&#*L9(5
M#@;@B*H.<$@9-1M;2_(\>&\ML@N )%W'&8MCX!4 DY9=P!4Y%;$B(\>TJ0<
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M ."K'BI/C?\ M!RSG7/ 7P'61YO@5^SOIBW3SZ!X?T?POC^S?$>N:7"5DO\
M7]1@DGEN[F2%C(8O/E]"AD>$HT*F:9SCUEV5J;AA:$W*GFN/JPM)8>EA5^^I
MPK)*$L7-1PO).;C*3E!/VL+P[@,'3J9IG..G@,FE*H\OPM2U+.LSA%2<,/3P
M\_WF'<UR^UQ551PSIJO&FW*5-R\ >R_;7_X+<ZOITNMVGQ!_8N_X)IV^L_:)
M=,34;OPO\=OVD]+!8Q1S+!;#5?#?@C43+$EW9>;%'<6]R^TOY*FN9_X)M?\
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MQ>(AS5*];$RI8C&8FO!2<ZU%U(J3GM%PO_3[  LRD!6(B8'C:(R6&%@! PO
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M!7]E'X2A<$#]LS]F7OC@>+IQ\HY)Y]SQ^ K]GK7!MK8DX(MK9>>GRP1MU_\
M'1[CW%>?C:DI<.\/J#T6:\125MU[6M@82L[W^&*Y7]EIN.K9X&8OGX8R"I?E
MBLTSU0NW:'^U8%7IW^"4K^]*+O+KOKK!2!C(ZY[_ /UN_-.P0.,9R3[<G/O2
MT5X;UWUZGSEM>;KL&!UQSZT$ ]0#]:**!A@#H **** "BBB@ HHHH **** *
MS] IZ*NPDCC#$ D#G^$'/49XQU%?A?\ \%._V/OBC^U)^T/_ ,$^?CK\'/!W
MPA^/&B?LP?'/Q-IOQR^$GQ"U#3I]%_X5_P#$/0AX=\4ZY TDU_#9>*/"UJ9M
M2T^SN((;Y)T@58V"E3^YXW94'!QM&>?O!E+=,<<@X^O3)K^!K]@SX1?\%+?$
M?[77_!8/]I'_ ()Y?M*:)%\3/A'_ ,%#OC%X6\8?LG?%^.YU7X+_ !Q\*2^*
M=?U)!::X]Z[^$?&>GR)+I6G7Z&*W@M$A@><QQQ1URQ7M:L>9\J@URK^6UGI_
MP?T5](:0<UI)JTI=6FI)W]?1?J?8G[.G[%W[?W@O_@IC^RM\';;]EGX9?!_]
MG+]A3XM_'OQM;_MF>#H;6PUO]HWX"?%O5]>UWPK\-_$,=IL26\T2#7],T.19
M!]H$GAP3LD):1)O['$A@N'28JI:*2<1LO(RLK(6^;<"Z[%._DJ=NPJ,J?YV/
MV7O^"S?[57B_]HKX:_L@_MB?\$IOVC/V=?BG\0/$+Z+J'Q&\,7R>/_@-H4 A
MN9QX@NO%<=H"FEO=VLD(:.\NXH?.B!N)(_G;^BJT( 9<CY"R  84!'/((4*T
MAW?OBAV!\*!G)/?63:IMKFUW>OG?[WYHYX_%(5K&!L%PSD;N7.\DELJ69P69
MHU+1QL266-V4DD@CS_XMQ);_  F^)[("Q_X5_P"-9#YC.VX_\(WJK;2=P*H"
M2 B%54<*  !7I=><?&#GX4?$U3T;X>>-L_\ A-ZB/ZFL7%-IM7:VW_S-#^>_
M_@U/ ;_@EQ?=L_M5_M)'CL1XZ8C&<X' X_K7]*P  P!@#M7\U/\ P:F_\HN;
M[V_:K_:3_P#4Y:OZ5Z8!1110 4444 %-+$,B\8;=GUX&1BG4A4$@]USC\1@T
M 0F5MQ'RC!(&0><$C^\/Y>O%,D=E#'S%!"Y&0VT'ITRIZ\XW>O/HUW54#'&6
M8DDMCJ6'& >,^F.3W!./D[]HS]MG]E[]E6]\.:1^T#\8/"7PTU3QC#>7'A;3
M=?NWCN]8M=.*"]DM(XXW8)"77S)IG6) !C.>=*=&OB)*CAJ7M,3/2C32NYMZ
M+1.[U?\ 6IKA\)B<56C0P=*MB<35_A8>,7)3ELE%15WK;KWU/JPS/V<D9&6&
M-@&!GKD^N?FXIJSE48O.KCG&%8$Y.0<9 QZ#J#R>>ORW^SQ^V1^S;^U3!XFD
M_9_^+/A7XI#P7-9VOB:W\+W379T>YU!9/L4-].Z(B&<J[-M5_+95!.PD'E?V
MOOVY_P!G/]B#X?7OC_XY^-K/1GDMC_PCGA&T9+_QIXRU:0K%9:'X5\,VN_4M
M7O+R[:.W>6UMC#;*[R.X"AA2R_,JU6K@\/AYSS6G#D5#ED\/&K%\LU525U*$
ME)3]Y<O+LNFE'+,VK9C'*J&#J5L?&I..-PW*W4PBBY)Q4;+E<6FGS:+E;DXI
M,^E/$OCKPOX+\.:EXP\7^)M'\,>%- MY[_5_$.NW46FZ?I>FV2LUW>:A>W<U
MO:VD5N8VWSR2; !N\LX*U_G,?\%/?VV/B-\<O^"AOC#XR?LL?&'XPZK\-M+O
M=+T+X&^*_ \>N0:=ID,6D:?X=^)%[\/A!&CZE9SZK:W<TKZ7)]DNH@+F67R9
M0J_T7>$_V=_VT_\ @L%J^A?&']MR35OV5?V%(I[?6O G['_AR^N$\?\ QATA
M9$GL[GXS:VJ61@T75XPLU[X>@A2X2&66 [!*S'V3X[>$/@7\&_\ @I)_P3+^
M'G@/2OAIX2^&W@#P9\<-'B\-:?#X=T_1/#>GOH.EV]E97=H&CBLYY"OEQK<1
M%OM1G  G=I#^I<%T\OX;S#'8/&*AQ#GTLGS*6.P>$<:N!HJG@\1.4J<J<I<U
M;F3BN2;A!K7F:Y9?M_AS6R_@3.\?"C[+BOBFID>:5\TRK#0I8K 9?['"8BKR
M>WE1JT:\VZ;4H4TO<O"+<I6?VI_P35_X)\_L[?LE?![P?XX\#^'M3\1_&#XJ
M^#?#7CKXH?&KXB3?VY\5/&OB?Q5I=OKNJ7FK:M?0M+ID8NK^>.+2M.\F&TB"
M12B653*WZ?06T)P!O^5?FW,"S'IF1MHWEA@GW5<C()JEI4MM<V%M-:SVMQ:O
M$&LY;)HS:/;'*1&W\IGC,(5 L1C8H$7:O'%:D ((W==K'_QX?_7_ )=J_+L7
MC<1FF*>/Q3K2JR>(IQCBFY5:-*-62ITH*2M&%.,80BE!6C%.][M_BF:YCBLW
MQ]?%8^5>K7KU<3B&J]FL,I5:BCA(+D4:=.C"I[*-.$8)*"TOJ1'3X3+YVZ4.
M4"-M8*KJ,XW*JA20&(!QD GU;,:Z39H\LB(5DF"!W58E)V!@,8C  PQRH&TG
MYL;RS-I45FJE2.D9R2:LTI-76]GKJK]'>W2QR.<Y0=-SGR.G[)Q4I13IJUH/
ME<&XJRLFW;HT4Q:1Q,9$R3QD2,6&>G?GOP 0%P H XIDC!8R58>8@8X894'L
M"%P< ]3G/?FKDGW2.YZ?4<Y[\#Z<].]49"H63C)"N6<X&Q5'# 8(9ACG(QGC
MC)SP5I0A.4IU:C4(-^S@VI::VA-0FX/31M-/2+LG=3?5=6E&*[VBN5*^^D=%
M>_JWJ53=.$W,@7?A%W9&),9.\,5V)NSM))&"K9.135GC55\F3>C#!<C*(3_
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MC_">'XT? ;6M7U_P!=:[J_AE-1UOP]K'A?4&UOP^\,&KPRZ5KEE97@%O)/#
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M5<\#/6[:Z-9:7:K::=;VMA;[F<VNGVT%C )&<2,ZPV\<4:R,5!:55WG&TG:
M#W5\?0EEF!P,*$8O!5:]71MVEB7"565GJG.5.%]7\.B1WX_,\+B<BP&60PTX
MSP-:M64HR;]_$2I2JODY5;GE1IMOFE\*TU9T5-<X4\D<KR.O+ <9H#@C(SC]
M>F?Y<_2LR]U"&U@GFNI%M((-[37,LD:1V]M&N^6]E>13''% H:1FD_=!5)D(
M7./)NY2E3CI)+>W-9O9\O6VFE]=NJOX_K\RT7?<5#'@ YZGDD<C/H,\9]>G
M:))"3\P'S$8.< #/<$<Y'KT(ZU\F77[=?[&MM<2P2_M5_L]Q3V]X]A<1R?%?
MP<OEW:.4-E<$ZLODW PR[&VN9QL"-M*U]4:7J%EJ-K%?V-U!?V%Y%#=6=Y:N
MD]O=6UQ$LT%S!/&SQ7$$\4BR0SPOY4B$%1U-/$8+-< Z?]I8',,!+$14Z'UO
M+LSPE#$4%K&OAJF-P6&HU%-<K<J%6O"47H[/F"\)6<9?#>Z36O36U_7IMIU1
MI1%B6W$' '3/?/J3Z<_A4U-4@YP,?AC^5.I1G&:O'IH_7];]_P @"BBBJ **
M** "BBB@"BA?Y\Y#.V^-N"5$AXP&^7(X/.5Z \5_&'X2^+__  4;_:__ &RO
M^"@/P>_X) 6?[(?[$'P?^!/[1?BSP?\ '+XB?$#2[BZ^,GQA^->EZK>:?XE\
M=7UG9VVL27FAZQJL&J7-C<R6-G;FUDLP;B>:>2*/^SV1BJQN-S94XQ@8P5(X
M)4$X!X) /48'-?RS?MQ?\$OO^"5'Q]_:+^)?QY\*?M]7W[%G[0OBS69;;XSW
M?P2^/'A[P;!XF\1Z6'T_4AXL\,2ZE%##KAFM9#?2EENVF:XGD3S3YAYZEE6T
M27O+165M4O+T[^7;2%_8KSZ^B>_]?=UI?L[?MT_\%4_V*O\ @H3^SA^P3_P4
MR\3_   _:+\+_M9VVOZ9\(/BQ\#X9-.\9>&/$VAQ2ZC<2^/-"N8[*]BTR[@9
M((WDTY;6*!$>VGF8R!/ZH-,A\B$J9&DD+OYPWEXXIE;]ZD.>4C9FWA.<$L3R
M2!_-5_P3I_X)N?\ !+;]F/\ :+\._&O0OVU[W]LO]JVYLIO#'P\\7?%[XWZ%
M\0/$^A#4K"&0V_@O1$U"Z2'5#I)2*&5B\HLWDE(20LP_HLU_QEX.^'?AJ^\4
M^.?$GAWP+X9TW9)J.M^)-<T[1M#L!+MBA>?5M0N(+%!<B-&C#RF5Y9' 4\FN
MJ=^16W_6RZ.R_K=G/'XY'>5YQ\8/^25?$S_LGGC;_P!1S4*AU3XN_"O0/"FF
M>.];^)?@32_ ^O/91Z+XQU#Q9H5GX8U6;491!I\.EZW<ZBFFW\]Y,P6WCLYY
M-Y1@V.,P?%BY@G^$7Q+N(KA)89OASXPFCGC=)8Y(6\/7I62*2)Y(GCE7YD:)
MBK*RL#@YK)<]_>6FO1?(T/Y_/^#4W_E%S?\ _9U?[2?_ *G#5_2O7\TG_!J:
MZ?\ #KF]7?R?VJOVD".",@^.2!U'?&.O&>>>G]+=6 4444 -?A3C/;IUZCW'
M7IUSZ<UGO>+&Q67S% Q\P!P"<=MX/<'/ Q]<5?E&488!Z=3@9R,'/;'6OFS]
MI;XC?%#X3_"SQ+XX^#?P;O?V@/'^G?V:FD?#33?$6F^%+S6S+<+#="+6]6'V
M"U:&V9YOWRXD,1&=V*NC2G7KT:$)Q4J\_9QIR<8\SLW=3DXJ/9N4HQ5KWW+H
MX:KB\30PM!P5;$U%2ASN@HKK=NO7HQ2WU;LNKWM]!FZ7./,8JK*,@A&!8_+N
M).2,'D>V1P,4Y;Z/) ;?B0*2 QX(XY]!CYB3P?8U^*'[%/\ P4\_:'_:U^*_
MB3P-KO[ GC/X1>!? 7C'Q'\./B;\3-5^*?@[7++P3\2?#=CINH7WA6ZT>Q2.
M^U%H;35]-F^V6H:!C.8@0V2/T@^,O[4G[._[.6@7'BKXY?&KX;_#/1(DRQ\6
M^)-.TBZF*IN,-MIQ>2\FN'R/*@MHI))BZKP0N>S&91F.'Q<<!/ 8_P!K>$8+
M#PA57-))J[BYR;=U>ZZI[-,]C'\/9OE>*I8#%8/%5\74E",*.#IT*R_>).G=
MX>=>S::YDY7V=DG=_0\LT#!$<DL0RJR?.I(!S@C@8R"N>0=W!&#7XK?\%T;S
M]G[0_P!@CXQ:A\63\.K3X@>)/"VI^#/A!JWC'2M,O_$>H^(IC%K-UX>\'7%S
M;2WMMJ;VMA+=AX9(XXHXR\C[05/SOXZ_X."_ OCK79_!/[ '[*G[0?[:WB.V
MGN;6[UCPKX8N/!?@ZQ</)!;75OJOB.WA_MVU>Y>T+"U>V62UD$BRKR3^2W_!
M4;X(_P#!8_\ :Z_9VD_:%_:S^%_P:^$'P/\ @A>WOQ#L_A/9>++.;QSH%G=V
M$^C7'B#5HMM^SZK;VU^\9TN*^C,B2%U3*(C?<\(<(8BCQ!DT\\QV%R>C_:&7
MIK'YA1PN.<)XBI>-+#I-Z>[S1J*2::YU9P/TK@'@3%8?BS(:_%&;X'A+"O,,
M-*A#,\1.AF.(IN=22A0PU-N-3VC7)*-2T4G%;N)^HEK_ ,%-O@9\'OA9\&_V
M;_\ @F9\#/#O[1O[9/Q3^'O@V-O#WPM\.66D?#[P1JT&@6%KJ/B_XU>-;/3K
M..WMM,N/M#K:WK2SW]W!Y4<JL<GZ&_8P_P""4NJVGQ(M_P!L+_@HAXDL?VF?
MVOK^Z.NZ,-5\V\^&/P3>4,(- \ Z!<B33Q<V F,(O9+5,-%NW%L2-SG_  0.
M_8:^(?['?[,>KWOQE\+> M&^(WQ3\0#Q1I>O>&-0L]?U36? &HZ7;:GX9MM6
MU>%([J-HH)1/)I \L64SERC-EC^\D\(9"29$6.0%"JM$SL1R0Q)#J=Q(/ (Y
MZUQ\39C@LDSG.LIR+$2Q-"O6K2JYJY*>*Q]25>M.I2P^(@H3I.-24HR="=-U
M+2;DU(\/C#/L-DF/XCR3@^JL94QF97QO$,[//LQ4ZE9U<-',;\N P49SJ^S=
M-JK."C[6<I-W66TG5(!'!I[*@4H<%4C\M0%9(R%150*"$7:,  \5^57C?_@B
MI^P%\1/''B/X@^+_ (6:QK7BWQ3KFO\ B#6]=O?'7C0ZFVI>)[JYO]8DT^X7
M6Q%I\4MQ<-B&P2)%$:*JC8IK]:R4 5"V#'EB26 XR1SC..,9]#[$TWSH2P17
MC)7&]>CJ"22V.N-RX) ZDDX-?$X/'8W+*BKY=B/JN+GAZE/$5%=8BIAYPE&I
M#V\5[:TX2E'^(E[WF?#9;FF895-U\MQ,\!B\10G3Q$Z,G2K5:=2$HSC*M!QJ
MRYH2DKNHVKZ;GF_P6^$O@SX#_#'P7\(/A_:7]EX)\!:,FA^'+;4]5O==O8+&
M.:2>..?5M3NKG4;J3,KY>Y+$9X<*%!]1DE"8*X+8V\>N"<?G^&:J.ICDDD,L
M:J0'4 \L. 3G)!(4<D Y(& >*622%T'[Q,/G:2<;6X/.W)#8XP<>PXKDJ5Y3
M4JE5U%*KS+FIQ=2HI5'9RC%W<I\TD[7NW=-W."4ZDZE2I6E;VC<G.3;;<VW*
M4KO5N3NW>[ZMMG#?%+XG^&/@]\/O%?Q0\<W.H6/@_P $:->:_P")+W3M/N]6
MN[+2;&(RW=XFG6"37UU]GB5W\FUAFE?!*KD C\N_A]_P7=_X)K_%+QYX<^&O
M@?XW:YK?C/Q5X@T3POI>A1?#GQO%=0:[K]PEIIEAJR2Z(&T<W)E\_P _4S;V
MHCAFQ*6CD"_I]X]\7^"/!&@:IK?Q!\4>%?"_AC3],O+C6[KQ7J>G6.EIIBH!
M=/>)J3A9;<QNNZ+8ZRN4A=<2K7\.GP)_X+8?L1_ /]N/_@IC\7]'^"_BGXJ0
M_&KQK\)D_9>\.^"OA]IDFH>(-0^'&C:[X;UZW@FCAN#H$'B+6KZTU;2;U8]\
MUK 9$56G3/\ 2?@#X(8WQFX:\1\5EOAEXE<89MPCP[E.:9;BN',;@<CRFE7S
M'/:644Z&?RS>*H4X8"U3/L5B*684:?\ 9N&Q$<15I4'*1Y&:9K1RNI@82Q-%
MNM*7/&4;MQ2E)I.-W?1*.CNWMI<_O(DN3Y9&92\;A9$!4S+QN.<.%0E=KDR,
MJ!2#P",?GM^V-_P5&_8@_8;T4WO[0?QP\.:3KES:W<^C> /#DR>(_'.N26P9
M9K:QT/39[E8GW^6N[4I[-&8D(6;BOPDDOO\ @O[_ ,%5;N.'3-)T'_@FC^S#
MJFHS3R:UJGFK\7=7T1[-XHH[O2//BUO58+J"9GBNK!=%MX3]F9WN2@#?>G['
M/_!O;^QA^SCJUC\2OC FN_M>_'!FCN+SQ]\;[I_$>FQ7;2%[IK#PS?2&P>/S
M29+==4BOY8,YW%L..M^$7A'X6JIF7C9XI9?G_$-&IR5_"_P9KX;B/.*<J.)G
M3>69YQU6?^J&1U\2G^_EED\_QE%57&C&<J=.*FGC\;C'*I@<*Z.'YO\ >L1%
M\LW;WHTZ;]^R3<KN-/1=$C\A_P!L7_@HE_P47_X*Z?!OXD?!O_@GQ^Q=\5OA
MG\")K&RU;Q?\;O&>JS^#?%NN:-I_G7]WI_AZ:1["VLM-U6QM!%*FF7%Y-+#*
M\#$$ABO_  ;7_P#!,+1O'WP^3]M#]JWP'8_$/3-&U;4?#7[*?ASQWJ,GBO1_
M"5GHVK7 \7>+-)\,7!N-)LWU3Q#'?)9WD\"RQ^09Y$=PSC^F;]L+]C3X@_M&
M^"_ O@7X-?M-_$;]D;0O"JZA'J%I\(-$\.PVWB72-2TV72$T.\2[L3'96T*/
MMB6U "I]U3DFOG__ ()S?\$N?&'_  3WE&@:/^UY\7OB]\($T.[TG1/A%XTT
M[0;?PYX?O]4O[C5K[7K6YM+)+U9VOKBY=(5E 8W&7(Y(_7,7])+@[+_HW<=^
M&'A?4X-\&I9WG^7XK+.',LR?BK->/9Y)2H8^CFT,X\4<324J^;9U6Q&6TXK!
M5<NP^&P3S/ K#4L/C'#$<<<FJ5,TPV.Q6(E5E&-3W+J-).\'_"5X[WT:DT[.
M^A^N:03O'#M\L0&,""V,2Q)#$H"B.0#"%E&%C554*@X VBKHLW\ILOM;.058
M@!\8W9Y.0HZG.1@9P.)8=R[8R"VU0"3R.!UR?XCT[_AWN0C*<\YVYSSGY%K_
M #ZIRC7PLZ'M'.I1C&%:M>KSNO%RE.U6I3I3FXRJ27-%<MY3UYI3O]-*\9.$
M4E#>\4EY+;71*WXG#:EX#\,:W?G4=;\*^%]:U!(T@BU+5M$T[4;\0 _\>XN;
MFVDN!"#\PCW[!DC!#'&_H'A[2_#EA_9VC:3I&BV/VB:=;'1-/M=,LEFG8---
M]FLXH8?-E;!D<1[V*Y=F/3< P<GHW&.01DY'\A]/PIWIUSQD=CS@GV[GC'J:
M].%;$?5:.$EBL56PU*,?9T:N)Q%6A%K5.-&I7J4H6;?+RTH\MW:UV8J,:,W*
M*TJ6OMJUIK9:M=+]+I#@,=**,]?8X_0'^M%1:W]=]?QO?YF@4444 %%%% !1
M110 4444 %-+;0S'[JC/')R,D_IC]:;+Q&V/;^8I)6(C8HH<\_*, G!Y],D8
MY^E*^J7?3_AP,#7/$^@^&=)U+7_$6MZ9X?T/2+4WVIZSK=_;:7I6G6@;;]JO
M[^]>*VL[0/\ (US<O''O(50S$"OY3_VDO@3^W?\  3]M+X]_M=?\$E/VVOV%
MM5T?]K1O"FN?&_X$?M&_$70X]+T;Q?H&CG1=/\7^$M0M+J[2[0VOV=42>;39
M(I9Y5:RND=8S_1;^U;\%/@W^T-^SE\9/@S^T#=BU^"OQ'\%:AHGQ.U ^(&\*
M?9O"5O/!JMW(WB9)(FT6UTZ2S)EN6*Y61D9E1VK_ #\?V@?V./\ @F7^TA\0
M/$_['?\ P11_9>\?_M+?&ZV-OX?\:_M9>)OC/XD\/_LX_ ^VDO/L=YJT.IW^
MHVL?B^YM(ECG2\LU-G%*!)%!>+'ALJ<XU,0Z4M'!K6VW-KNM>B6MO6UQR=N7
MS]/+T[_T]#]H/ 7_  1V_:M_:0^&7C>X^,G[;?P/^)_QH_:T_:W^ ?QS_;XU
M+X4>(XM=\":)\(?@08]1\(_"?X:Z?IMB9Y]:N[VP@M?[:U*32[6&UL(\K<QQ
M/!-]@_\ !5[6OVPO"/[=O_!,>72?BOX?\$?L=ZM^U9\.?A]:?#3P5/J<7Q"^
M(WB_5-!U6XU.]\>7R1+:?\(AX7L=.2#3M#@FNCJ<UTTL_E.D;/ZO_P $-?\
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M+OQ'J(@=M.\-Z#;RR"YU#6=<E,5G9VL$<BQRRF>X:.U@FD3TWXG?$SP5\(/
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M+I5JM.E3JX>G6A.4)2GAJ^C:U=FDFVXM+7_/Y_X)!:?^W?\ M4_'/XG?!O\
M9^_:]\3_  3;QSX;U#XC?%[QIKMUJGB>_P!=GGN;6SNO$>E6]P!:0>+[ZVFA
MM)]3>8FX^R)(2P4LO]4?P0_X-^/V1/"FO6?Q!_:9\2?$W]LCXI;X;FY\4_&W
MQ'=ZOI+7H,CS7C>'HYWTV99YW5H#=JX2.*-8?E\PGGO^"<_['W_!1C]EKXS>
M.[GXF:'^Q_>_";XW_%OQ9\5OBA>?#N35XOB%X/U/7=$T?2_^$?\ "$DFDVL<
M7A>VN]&@U"VT8.8[;[=<%H8I';/] 'E('!+23N(-D41@ F>*$I;M,[!L2!I
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M4EB<55@W*/(E"$(QZ\'0I82G&C&-Z<$HQUT45I%+HDET4;7Z,J*FU05C5B2
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MU%N,L132C*DO*EF\ZE=X;+:,\2Y2Y98AI_5Z;3LVIRC9Q3_Y]J5[.SN?G?\
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MBG^POJ/[5/Q=^,7[-7P^_;P_9!^,?P]^)NK_  X^+?\ P4P_9)\&HW[/EO\
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MDUGPI^R)+KEP?VI-9\51Z1%9>,_B?#J<9LH=.\/?V8^J:99SH\L6K3R3*\0
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MXS\6^-;;Q1\,;3[3_P )1X1TNT.H6O\ 9.MZH'M18ZRDF+,I*620,%/[P_\
M!*_]IKQG^V/_ ,$__P!E[]I+XC0Z1#X]^)WP]DN/&1\/O<'1+SQ%X7\2Z[X)
MU34]-2Z8S1VVK77AN34_+PJQ374L8 "H!^@40#%B1G 7&><9R#USW'Z4JDO9
MSY&F];75K?CKW^XB$E./,DUUU^7^?X,_FCU+_@U(_P""1,NDWL%E\-OBI:ZN
M^E2065ZOQ<\47#6^IR6KQ07DI>8FX4WCBZ:.)X9'2!X5E4Y!^7O@#_P:'_L7
M^$?V?]>\'?M">)==^*O[0MQJ'CR[\/\ Q<\,Z_XO\)^$]*L-4D<> ;6Z\(3Z
MM>2WC>%8GB34)K>ZMFUB=+I[G,!MX8O[ 55222HRK$ X'&.F/IV],GUIVQ/[
MHZD].Y!'\B1^)JBD[Z_UU_R/XC[[_@SL^$DG[(_@OX?6GQNBT_\ :]TWQ_'J
MWCKX_&'QC=>!]?\ ARWB&]OKWPG8> SK"-9:BWAJ33K*VO+F:Y0ZI;FX*B&2
M56[_ ,>_\&?W[,.O_%;XU>(?!7Q)U;PC\)_$_P #6\*? GP!>WOC#4]<^%_Q
MTGM8(Q\2M=UU]8=M=\.I>175R_AR2 *6G:,O)"B+7]F'EIG.T9X&<>F<?EDX
MK%UB\FT[2=5O[;3I-2NK'3[V]MM.ADV7&H7-G;RS6^GQ2G($][<*MO'D$#S0
M&##*@ _A";_@R^NEM(EC_:]TX:FUI\-X8KJ?PUXBDM8+S1;R1OBB]Y =;_XF
M-IXWL)FMO#5I$(6\+W(BEGFOK<7%O/\ NC_P;[?\$_OC=_P3L^ 7[27PA^,W
MANU\.6/B+]J7QWXK^$=K%XA7Q'=7'PHD2UT_PE<7L@)F@DELK>&ZE@FNKB<2
MO,;EDN=^?A;0O^"J?_!03P%H'_!<'XP?M(^#O#/P^\9_LD?!_P"&/BKX"_LZ
MV^I0ZWH?PN@\=6%W:^$=5\2^(8%8ZYXHO7O])\4>(+!%B2*\MSHT1B@D5AY[
MX\_X*!_MW?L>^#_C?^S5XF_:,U#XY_%/XA>'?V%?$WPI^._COPKX=T/Q-\+M
M0_:[UZQT+XF6\>@Z G]D7FE>"6DO[OP=;W2M,(&BCFD:2 NV/MEI[KU\UWM^
M9HZ4DF]-%=^EK]^WW]#^RE)'11YA5G5?G(!C3. 3MC+,8U'\.\LS#@-T-60P
M)8#^''TY (_G_G-?C'_P2Q^-OQO\2>+OVX/V2?CQ\1]3^-WBG]B3X_6/PQ\,
M_&[Q)INFZ1XP^(_@GQ-X/T;Q9HMSX\L=$5=$77-,DU*>"-M*CA2;3OLDEU''
M<ET'[*P9!<'&1MR06(+  $KD?=Z#KU'3TZ)1Y5%W3YGLKZ:7N9EFBBBI ***
M* "F[1]." 03D9S_ (TZB@!I  '&[!7J<G[P.<DY^7KUZ#'-9\S!))""2(]S
M2(Q.&+AB&0D':ZJ&155T#%AN(S6EUJC<KNW '#%XR,'#,4VR*@.0,LRX ;*G
M)!!XK.IS6;3TMMW?^6W7U&G9G\M'CG_@EO\ M@ZY^UA\1?A=IOA;P0?V1/BA
M_P %(O#'_!235OCV_C%(?%>@R^'(;&_F^".G?#]+)KA-0DUW3K9+?7GO38R6
MK3"ZA>-BM9?_  7@_P"""_@;]NZS\4?M*_L[?#?4-?\ VT/$OB[X6Z5K]SKG
MQ!U'0O"6H_#OP[-;:5JL<&BW FTY-0E\/J9;>4Q.WFQSNK(@MT&I_P %0_VU
M/VO_  K^TU^V-%\ /CI>_"#PA_P3<_95^&'[3L7@?3?#>A>(]$^/'BKX@>(+
MD:QX=^)<FJQKJ-IX7L_#MK=6MI%H[O=0:A+%<)\CNM???_!17]KWXN?#7]A[
M]G+QG\&-;D^'_P 0?VO?B3^S%\(;'QO'IT.KZY\,=)^//]C+XA\4Z#I6KN^G
M7WB_0[74KO\ L2'57.E>>EJLP"QER0=J7,[OWI*W71_ET7XBE&52M&FK)M)W
M>WHUOT=^A\BZ'_P:E_\ !(:33=-_MGX5?%DZI!IVF6^H*OQA\2PQF^M[..*_
MGQ;,8Y!/>1W#F8-@C[H*[7>W>_\ !J5_P1]:ROUTSX6_$Z#4GL;I--GNOB_X
MLO;6&]N+5XK2XN;'SPEY!!<O'<&W?8K;,(REF=O ]8_;Y_X*._";]AS_ (*7
M_#3X5O8?M-_M%?L&?M'?$#X%Q?M*>.;OP]X.N-$^"6B_#33_ (A:;\7_ !WX
M>AM1HNN>/= LIKS1/[$T2*WLM7UEH&D\F&!2_P#0+^P3X]\3_%K]CG]DWXH^
M/M8N/$?CWQU^SW\-/%_BSQ!+;Q:>=7USQ!X8T[4M5O[JUM\P137-_<33M!%F
M&*1B(\*0!K!<\'/X;7]U[Z7^73\43.7)-0MS7V:V];/7;7^KG\\O[*G_  :.
M_L'^ _A2V@?M97?B[XX?%9?$WB+4U\>>"/&_BSP1HK>%IKS&@^'TT)+J9?M6
ME686.ZG*.DLH,FXG%1S_ /!HO^PPW[7&E_$6QU'7_P#AD-/A7?:#JOP!N_$W
MBNX\:S_%*>YSI?CBV\?R7HF@TB"UWI/IC0F>2=8DC>.(2A_ZZU10  %X&,@
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M=G$6Q?!O!/\ P:=_$3X?_P#!0#X:67Q+^(&J?M ?\$_==;Q3J/C:?3?'6O\
M@7QOX0N8-!,7A?2=5AEO[ZXU6>Y\1M#,+ZPD@AEL&\EMCJ7K^D[_ (*B_&?X
MV0_%_P#84_8H^!7Q5\1? '6/VROBGXW\/^,/C3X.TG0M:\8>"_!G@'P+J/BN
MZM?"UCXCAGTA-2U;4+6WMY+JX@E:UM%F:.-RS(_6?\$H?VO_ (P?M3_\$_=/
M^,OQ.L(?'_QI^'GBOXU_"3Q3=^%[6WT-/BQXA^"GBO6?#=AK&EP2(=+T^_\
M&UOINF"ZGA7[!::A<7\ELH6-%KOQF:YKG-7$YOF.9XO&8K&U*KQ6(Q.*Q\\7
MB)XG$2J5)XG$K,%.M*I)I7M%\T4_ADT)Q]DHT83JN#=DI2C)636Z]FNRZKR/
MB]O^#5K_ ((_M=?:I_A?\6@C2K*\'_"Y/%RVCR(!&TC*UU)<,]U('FE9YFC<
M.$C2.'"'R3XZ?\&GO_!-WQ7\)_'GA_X"Z/XU^%WQBU+P]=VGPY^(?BKQUXK\
M8Z'X-\222)/8ZKJ6AK>6E[J5E;F-EBMAJ">4TC-#RH ^JO\ @D'^UK^VM^TE
M^TG_ ,%*?"/[:>D:/X"USX,?%7X:Z7X#^"/A_4M)\0:1\'?"7B7PG?ZM8>&X
MO$NEP6LGB35;NUM[._U_4;^$2#49)1;)!;R^1'^]4: X+D"9BS;E'\!8X0>V
MU1P>XSC^&L,-6S+*IT5A,RQF#Y+U:2PE>OAJD[IMQKU85G4KTIQE:<9S?-%J
M]TD3-*I-TI1O&"3;<8ZO=6TT6Z=S^7KX0_\ !J#_ ,$P?#?PP\ ^'_C5X8^(
MGQ&^+.E>#M"L_B/X[TCXG^+M$T?Q;XQLK:"/7O%6E:&ER9-%MM7OA<FTL?,9
M[6W*QLSR)YC>3? __@T<_8=\+_&3]H#Q'\<KSQ/\2?@WXMUW0;G]GGX?Z1XW
M\8:%XC^%OA^P%^VNV'B;Q)'>B;Q.=5>:P$>2RP1V[JD:*_S?UT11IN8[5R%1
M0<#(52Y"YZD EB 3WR0"<";RT_NC\O;'\N/ICTK"]2<YU*KAS3E*35.$=7-\
MTI2G-2J2<IMR:;M=W3N:K1**T2[)*_KHC^,CPW_P9]?LT67A_P#:WT_Q'\2;
M_5M7^(NJ:G/^R1JD%YXIAC^ .EW"74FGQ^-H8M3M1\0KNTF>T6(3+%']FB99
M4DD)8YNA?\&?/[/NGS_L;-J_Q6NM9M/ANWB!OVU4:3Q?9']HY-1AB?03\/I8
M=6Q\/7T&\66%8KK[:6MYO-\TNBK7]I/E1\_(.>O'7ZT%$"D!0 0>G!Z8R#U!
M&!@]L9'2FG.,J<H5)P5.M&ORTN6C&I.$91BJT81FJL5S-I24;2UM+8%IMK??
MFUT\NWGWT/X,;K_@S-@.KZA=C]KK1QH]OJOQ<GM=)F\+^+)K]O#OB&"^B^#.
MFZG>KXBE-WJ/@FXETZ[UZ_A,;^()+,0Q);K(ICU_V+O^#3CPCX4_:I^)GA+]
ML_P]J7Q1_9HTCX+^#].^'_Q$\*?$C5_#-]XO^,XOK=O%>K+H%O-)JF@Z?)9^
M>MI8RW$\$)7*NKO(!_<^[2%IV#*OE?9F2.,!6\PE5^RAB!DW"'R%E)'DNXE0
M!D!'X _L+_M@?MQ_&G_@K9^UK\%OVFO"UE\&OA7X,_9\\*>,O@M\$-)NDUZ>
MUT"^\;7FD:1\1/%'B$R![?Q=XFL;>=[K1+2&.QM;=X0H)0M()/5M)2DYRERW
MM><I2:5];+FLE962MLD'I<XP_P#!J7_P1TD.4^$GQ:0@!=K_ !F\7N0%&W^.
M8Y4@8^8L <D8)Y^6_P!I3_@T5_8<\8:G\$I/V:+WQ/\ !W3O#/Q(L]9^-MKX
MI\8^+/%\_P 2/AI'"!>^#O#TTEZL?AK6KB<&2'6VCFCA0E3&S;-O]<=B5:$L
M!(K,<O$Y)\MQP0H/(!QN/)R3FKA56^\ ?J/0Y'Z@'ZT65K6T[ ?S'>,?^#4+
M_@DWJ7A3Q%IO@KP#\4O#'BZX\.:QIOAOQ+<_%KQ9J::=XAOK20Z3KNH6SW,;
M:A'IMV\*S6D,T"W,$$L3(2B/7S)\+O\ @T1_8T\/?LD2?#WXI^)=9\:_M>S^
M'/%-HOQYT3Q#XMT7P9;^*M3U#4KGPI?V_@=M3N91;>&-.DTZWOXTG@;4?(DE
ME#"2-%_L,*J<9 ."2/J>_P!??K3?+3@[%R.0<#.3C)^I"@$]P .E-*VB _BW
M\2?\&?'[/UW^R#X(^'?ASXKWND?MDV&O>';WX@_M#W%SXTN?!WBS0[+6;VY\
M5:7I7@)]9+:+/K7AV:SL;*]DGN8K'4K2*>2"5IKEIZ/BO_@SS^ M_P"(?VG+
M[P=\9+O0?#7C7X9>$M$_92TW49?&&HWGP+^)^GVVE?\ "7^._'ETFN0KX^T_
M7Y[&_6RTZS.FQZ:-8E0HQAMFA_M7V*,?*.#D?7@9_(#\AZ4UTCV$&,,H5AMV
M@Y4D,R@'CYB!QT) S2;=MEI_P?(#^##X@?\ !F4NH>/? NM?#O\ :JTK0_ .
M@^%?"9\?^"-1T'Q1?:[XZ\5Z5 @\5W^A:_\ \) B^';;Q5<QRK:&\M[Y[%IP
M8V$:@1?0?_!-_P#X-5?V:9_@5KS_ /!0_P"$?C,_&Z'XM_$"WT'_ (0_XQ:Q
M#I,GPJAU13X%N)5THQAKF73V9;L7<DEXVW?*WFG]W^E/_!:K]L']NS]F63]F
M[1OV<?"MIX+^!OBC]HS]GGPI\<_VD+K4=+O?%4-CX\^)5EHL/P>\">#[F)EF
M&MV4ZCQ'XKFNFN=/T^*XM+)(WD:8?*O[;_[?G[87@_\ :!_;G^/'PO\ C=?>
M!_A1_P $R_C7^QU\,O\ AFVT\.Z%JG@CX\Z'\?O%N@^'_BCJ_P 3==U")?$F
MG:A8Z1XHEN/ L?A:2-;+5;.T6\:6(RQ2%!^VC?X7;[7?HM/^&*F]6]]+Z?U_
M7S/H-O\ @U+_ .".,A,H^$WQ3",5(\CXS^,43J!F+]_(RA<Y;()) SE<JWR_
M9_\ !HM^PU!^UEKGC^\U7Q+<?LEW'PUM="T7X#0>*?&47C/3_B3ND%]XVE^(
M1U4+-9K$8Y(-,DM/*B<,3&RLH7^M30[]-7TG2]408@U;3+/48XR=_EQW]M#=
M+'O")N5(YD17=5DD.YF   &QL4C!4$9R01U.,9/KQQS3ZM=K?BK_ *$)W5S^
M13]J_P#X-%_V$O'OPH'AW]DJ]\6? OXKKXI\-W8\=^.O&'B;X@:4?"=C?AO$
MFGG3?/M72^U33=_V34)7GD295W$+N5K7[3__  :.?L)>.O@E<^%_V6;[Q'\$
M/CN=2\)SQ?%/Q7XJ\7>,M!MK"P> >*(8_"OVZ)XFU^V65K9(KV-X)IBTDTFT
M;/ZX/+3D;1ALEN.N1M.?JO&.F*78N2=HR3D\=3C'/KQQ0,_CX\0?\&A_[&MU
M\=/V?O%.A^)=8TWX$>#?A\VA_M%?#>?7?&5UXD^+WQ">#]WXR\+^)#JC'P59
M"XE\VYTUTO%2(I! Z/&&/SUI/_!F]\-H+G1GUK]HHW\5M^TOXJ\6ZM:P0>*K
M8WW[+.H:7IEMX8^#(F.L-*/&^C7EI<7UWXU58[>[MKV2R:S&RW,7]P5V$6*3
M(5=RDJYQ_K/E !SQ@[4'OMZ&OA#_ (*(?&7]I7X&_LM?$;QS^R=\*M*^+WQQ
MBT>_3P_IOB#7X?#GACP9:1Z)J%YJ?C_Q!>NDGVVP\.6^F3ZA#IJ&%]3NA:6$
MTBVRED!-737<_BI_:J_X,Z_CQX2^%VK^*_V9OC[X<^)/Q(TCQ5XPU&S^'.IV
MGB3P[<>(?!^H:[9-X)T.V\3:CKU]9#4O"VA?:/[5G_LVVEU"61<2R.D1B_O,
M_9I\#:S\,_V<_@1\/?$ME!I_B7P)\'? 7A7Q%I]I-)=P6FK:1X9TNQUFW@NI
M%W3 :A83Q)+(Y9U)D+%CN/\ ,_X9_;'_ &S_ (__ ++_ /P1H^!.E?M,:Q\*
M_BO^W5X#_:)^*'QO_:9T'PKX=UCQ1##\!-,&M:;X;\,V5\O]@6D'B?Q!KFDZ
M==.L)GM]#TJ54*O,<^,Z5_P4D_;J_:^\ ^#- \'_ !_NO@/XZ_9N_P"">/QW
M_;2^(_BSPGX+T36Q\>?C#\"_B,/!7A_PGK^F:ELBT/X<ZYH5CJFJZ[!I,A:\
MU6^M[>.576,JHS_>0HWLZB<DWLN737K]KT_ T<6J$ZNZI.*DNKYDVFKZ:<K3
M]5ZG]HBLA1025&T':3DCKU/3OS@?3@45\M_L=?'34/VBOV4/V=_C[K%C'8:Q
M\7/A%X&\;ZSI]JGEVUKK&NZ#:76JBUA)!2RDU'[7)9QOEH(&2)2R@X*RGATI
MR7LYRL]U+1^EVCG52$DG=*^MF]4?5=%%%;&H4FT>@_(4M% 'P-_P4+_8HL_V
MW/A3X%\)Z;\0]1^$'Q2^$?Q>\&?'/X)?%/3-'@\02^"_B;X$>[;2;J]T.YDA
MMM6T6_M+^]T_5["::)+FVF\DM\^T_)OPP_X)8ZQ\,_@SH?P,MOVFM>U32?B9
M\6?C%\7/VW[Z3P+HT*_M8WGQJ\.:GX>\8>$VCMKQD^%&AV#ZA9W>A'2#J%Y&
MVE6T4B-N9Z_::5=VP_,=I+ *H;G& 3GCC)QSGGOBJL5HD.X(I+.ZR.1A%+QL
M7#9'5F,FT''.W/&VE)<T91VYDDWZ3I3\KZTDK/36_1!>3Y%)WC"?M%'HY*%:
M"[[>U;]4MNGXW?L"_P#!*B;]CKXPP_%[QU^T/XD_:"UGX>? \_LJ_L\V6K^#
M],\%VGPD_9YB\61^+X?#%P^F75[/XT\5IJ-KI]K=^)KX6@ETZW)$7FRD)],_
ML#?L3VW[$'A'XV>%O^%B3?$0?&7]H;XB_':6XGT9-$.C2_$?5DOUT2&.*><7
M2:>0$6X/E^:1YA"EJ^_4@"A4 8H@*J6VDCEN1G+=<8Z C'&.L8M$$K3A7\UU
M",Y;+%5)/*-\F,@ 8/(P>:?6_7]Y_P"5*TJS]+.37XWZ!T:Z-4E;M[*E&DOO
M4;O[O,LA$<9YYZ@<<]>G..I[GKUJ6@=!GKCG_(R/RHI)6;=][:=K!Y=%LNP5
M$?\ 6KUQCWQT?\.N*>QP,GH""><=QS^'4COTK"U77=.T6WO]2U;4]/TK2=-B
M>YU+5-5O(=-T_3H8T#M)=W=TT4$,2IAFEED1 IRQ"\E2ERN.WORY=7:VC_S
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MR\$:)+K$R7.K7S6337.J:MJ=R@$<VH:QK5SJ.K7;1!8A)J&Q0Q0D?1L1QG\
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M)?Q3\:_\(9XS_9AO?BS%]A\:VS>%GN%F\<67V:6WNM-M;1+EXKG2[AO.7^T
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M_P#8?\=V7@7]IOQ=\/Y-2M+#X@_!_5]7@L(7^'5UI]_.FG>(;VXC2VFGEN7
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M92@U-6NUI%P>I4E%1YD[J+I.H[II4Y5W2FTTMTN5K?5WLUHO@?PC_P %IO\
M@M!\6/V1?VO_ -LCX:?#7]DR#X1?L2_%_P"(/A_QSJGB1-93Q)\1_"/@KQ%
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M*/\ @B)\?O#EV^F>'?VY_P!B/PO^R=\>-(M9)O[-\17_ ,//!&DZY\*==N(
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MM<B?2)+F.Y?[MS.JS,HC)7^V!R0K$=0I(^H!QW'\Q]17\M/[37_!-[_@IO\
MLF?MW?&W]O'_ ()&ZS\)/&%K^U,--?X_?LY?%K6+#PUIFH>)=,MO+@\5:'KF
ML-::9"XF)N_)%Y#<9EN8BKB0$@/56/=/V?OV._AS_P $!_A3^W5^T5#^T'X_
M\:?L>>'/"\OQ+\"_LXZU)-JUS\*+K2(&$6B:%JNIWMS*\OBC4Y[32+9_*L8%
M%S')Y;L<M\+W7_!6[_@L1\$/V?\ X4_\%/OVE/V>/@"O[ 7Q,\0^&;OQ!\'?
M!%YJ/_"^OA5\*_'FK0:9X.\<7%]?SE-8OM0@O+>>?3(K=KV.6XA2ZM+:.:+=
M]+_LR_\ !'7]KKXP? C_ (* 7O\ P4W^/-OK_P </^"@_@[_ (1+4O G@+5[
MW5OAE\#;*WMEFT,:%:I<#2[O4]*U:.T47.E![<VMHDHDEG<E?E#6/^"<?_!;
MW]H;]D_X7?\ !);]HJR_9J\)?L@?#V_\%>%_'_[8/A/QY/KGQ)^*OP8^'&JV
MNH:%X:L/AE*[:CHGB&>PL;&P?5K^&$>;:I=2JC,QH=NNQ=.R:3M9[M[K1Z^M
M_)[[,]@\0?\ !3W_ (*J?M _\%#/VSOV-/V%?"'[,VK^#_@]\.O 7Q=\!?$W
MXKG5K(:-X3\3^&-)U?3X;ZUM[F/_ (2'4?%&H7TMG 8,6NC^6T\SB%I6BX?P
M5_P<$?M'_$;]@K]E;4? /P3^'NI_\%$_VH_VE_'O[(GACPEJ^J7>G?"'1O%O
M@#5I+36/B7JUW)MGC\,I9"W8Z2)9)X+Z&[MO.ELK9+N7[R_8F_X)U_M"?LZ?
M\%2O^"A/[1VJ^%O"NC?LX?&;X(_"+X4_L^W6G>*='O\ 6;JS^&OA^PT2&SUO
MP_:LFHZ*H-F]TUS=QQK,\Q"Y(W+^5_PK_P""%O[?G@K]DWX7^)-%/PU\)?MJ
M?LE?\%!OBK^UE\$/"VJ^,['7?AY\2/ ?CG5#/+X1U_Q!ILSQ>&Y]7VS7"R2&
M.6))G@OTA=59W4Y8J*@KW<;W\[\VUMM/O>C,XV]I6BW[L?@?5_#:_36\MK;=
M&M?U$\*_MM?\%)OV,?A!^V=\2_\ @JA\%_A#JWPS_9J^&VG?$+X9?&_X#^(V
MTVT^,?B'4X%$?PZMO!E_,VJP7UE>F#3[O69%M(D\J1%CD+1!OS3_ &5?^#AC
MX]W'QU_9,/[2GQ0_8:^)OP@_;1\6S^#8_A=^S3XWU#7_ (Z_LEZMKT4&H_#Y
M_C/IDL$5K<P:E;3V>FZG-:-<1V-_'=P-(D\3Q+^B,7[+W_!6/_@HE\&OVT?@
MY_P4?T3]GK]G#X._'/X1R^!?@W\'_A)KT7Q)\0>!/'T%Q]IA\=ZMXXLI)+:]
MT^_N88;N6P-V;J.5V/DPAI(Q\O?L _\ !.W]NWX0_$'X!_"WXX?\$T?^"8_A
MWX7_  '@30_$W[6.CRZ/K7Q?^*D.AV#6GAGQQX8\/:.TVK>$?%S&VM[G6[C6
M"KZA?7#7#>6(V)J,8NK33?N--R=TM;76KTU]-^X2:6'Q$U?VD*4Y4UIRN4;6
MNM)-/72+3?=:GSAH?_!73_@M9\7O@S^W=\=O@[\-_P!E-/AM^P%\>/B/HWBO
M7O%L.IP:[\4O#/A75)XY_!WAO1K?44CL=1\-^&YX=4O_ !#?3);:OYGV"U<W
M*^17B/\ P5T_:J_:^_;,\%_\$-_VAO@5K_@/X>_"O]HWXL?#OQ#X2^&6L7NL
MB:']I2&]18W\<MI]U$NO_#C3)X9&L[18D-HMP1,)YERGZ@_LC_\ !+_]L/X1
M?\$[_P#@K/\ L[>-O"OA"R^*?[6?QP_:&\:_ [3=/\<:!JEEJ_A_X@6.FP:(
M=<UQ)!8:#)JC6!\^VU*59+$;FN/+8KGP?XS?\$D?^"@</_!.+_@D9X&^#G@S
MX8^(OVI?^"=OQ4\/?$OQG\)/$GC_ $71?!WBI[&>ZGGTFQ\<1W*:083(;8R3
M17 9EDE,:NT:JSM2?(YR<5+'X.C/E:36$J3K+%5(II_O(0C3<):Q3;<H3NK5
M/EC"*B[U$JO,FT]8X>C5AYZSG-.[=TDE:2;?I7PA_;^_X+&?M#?\%+OC]^PA
M\/(_V4M#\,_LJ>(?A-J_QM^*>N:%KP5_#%[#X>N/&/A[P7IB70OK^_\ %CW>
MH)HU_/:!=)CMC)=,KLD,GF__  42_P""MG_!5[]A;7OBE^T!XZ\*_L/_  [_
M &>_AE\6M!\*>$_V9-;^)EKXJ_:6^,?@.YUN+2M1\<Z;%X4U748=!34;>1[V
MW&K6]L]C TDSVY>U"2?>7_!./]B#]L3X4?\ !0S_ (*+_M<_M(>"O OP\T/]
MKG0_AC>^$QX*\<Z?XON=*\3Z1X?6V\0Z<(()9;VTM-$OUD:SO+I0M\R)-;CH
M1^#OQ9_X(3_\%:_$7P'_ &V/V7;#X2?LI>/[OXR?&/5OC)IW[:OC7XBB_P#C
MG\5/#\?B6T\3:+\']*BUBZN;SX?0_:K2 7.I:PEEI:V2WFEI*+>Y$KX4).3P
MKJ;U<)S5H+:-5U,2DE=NWNQH.TI-MREK9QY::5E'[//6?-Y4U'EL]FF[W5KO
M3EZGOGB?QA_P4$^)'_!Q[\&O$/@?QS\(K/PGKO[+FC?%#X>>"/%;^(;S1]%_
M9E\5:)#J^MZ%K6B1WL9NOBU?0O>6=UJ\*1)+)':3K'';D-72_L:?\%9[G]E'
M_@DYK'Q?^&/[,/PRL_C5\;?^"@'Q<_9U_9W^"'PXM]4\,^#/&'Q&U;Q8<:YX
MFDN[F\;3[BS6X^UZS,7M7U%8H3&BRR-&GV!XZ_8%_P""B/P^_P""CG[%O[;?
MP/\ A)\*OB%X>T3]C'P-^R]\>_"'C3XGZ1H&L_#.;3/#EMH?B35O#FKQW*'Q
M5=;%FGL[G1UG6=X41GC67>OS7\+O^"#?[8-[_P $O[?X%>(=<\&_"/\ :]^!
M7[=?Q!_;$_9OUB+Q)8^+_!EY?WNM"]T.P\2ZCI4DCI%K]BBQ3_:BEUIS&/[2
M 0X%N<8TW&/*I*G6J-/^;Z_*A".^J=)*I;?F]Y>[9!&4)3BY27)*KA8/E:O&
MC++%7K/5.U18NU.-TTJ;49)R?,?7/@W_ (*-_P#!2G]D/]J+]G_]G+_@J?\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>gtbp-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauN2bP9z5Z8qekhvWB0bQkanyEutmDE5SxS6LR20a0F -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:GTBP="http://gtbiopharma.com/20240331" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20240331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
          <link:definition>00000008 - Disclosure - Organization and Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
          <link:definition>00000010 - Disclosure - Fair Value of Financial Instruments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayable" id="AccountsPayable">
          <link:definition>00000011 - Disclosure - Accounts Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>00000012 - Disclosure - Warrant Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000013 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000014 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeases" id="OperatingLeases">
          <link:definition>00000015 - Disclosure - Operating Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvent" id="SubsequentEvent">
          <link:definition>00000016 - Disclosure - Subsequent Event</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
          <link:definition>00000019 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableTables" id="AccountsPayableTables">
          <link:definition>00000020 - Disclosure - Accounts Payable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>00000021 - Disclosure - Warrant Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
          <link:definition>00000023 - Disclosure - Operating Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" id="OrganizationAndOperationsDetailsNarrative">
          <link:definition>00000024 - Disclosure - Organization and Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
          <link:definition>00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" id="ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails">
          <link:definition>00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" id="ScheduleOfFairValueHierarchyFinancialAssetsDetails">
          <link:definition>00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" id="ScheduleOfWarrantLiabilityTransactionsDetails">
          <link:definition>00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" id="FairValueOfFinancialInstrumentsDetailsNarrative">
          <link:definition>00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
          <link:definition>00000031 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" id="AccountsPayableDetailsNarrative">
          <link:definition>00000032 - Disclosure - Accounts Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" id="ScheduleOfDerivativeLiabilitiesAssumptionsDetails">
          <link:definition>00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>00000034 - Disclosure - Warrant Liability (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>00000035 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>00000037 - Disclosure - Schedule of Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" id="ScheduleOfStockGrantedAssumptionsDetails">
          <link:definition>00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" id="ScheduleOfOptionsOutstandingAndOptionsExercisableDetails">
          <link:definition>00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000041 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" id="ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails">
          <link:definition>00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" id="ScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:definition>00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>00000044 - Disclosure - Operating Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
          <link:definition>00000045 - Disclosure - Subsequent Event (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="GTBP_OfficersEmployeesAndDirectorsMember" name="OfficersEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CorporateNotesAndCommercialPaperMember" name="CorporateNotesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MasterServicesAgreementMember" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ThirdPartyProductManufacturerMember" name="ThirdPartyProductManufacturerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PlacementAgentWarrantMember" name="PlacementAgentWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseWarrantMember" name="PurchaseWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwentyTwentyThreeWarrantsMember" name="TwentyTwentyThreeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwentyTwentyWarrantsMember" name="TwentyTwentyWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonSharesAndCommonWarrantsMember" name="CommonSharesAndCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreFundedWarrantsAndCommonWarrantsMember" name="PreFundedWarrantsAndCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantAndPlacementAgentWarrantMember" name="CommonWarrantAndPlacementAgentWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" name="BoardOfDirectorsEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesKPreferredStocksMember" name="SeriesKPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesKPreferredStockMember" name="SeriesKPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScientificResearchAgreementMember" name="ScientificResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityNonCurrent" name="WarrantLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" name="StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" name="StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationCommonSharesForServices" name="StockBasedCompensationCommonSharesForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" name="StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" name="ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashOnHandAndShortTermInvestment" name="CashOnHandAndShortTermInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilitiesNoncurrent" name="WarrantLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_Extinguishment" name="Extinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" name="IncreaseDecreaseInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" name="StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LicenseMaintenanceFeeReceivable" name="LicenseMaintenanceFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WrittenOffRightOfUseAsset" name="WrittenOffRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>gtbp-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20240331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20240331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20240331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20240331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20240331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20240331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvent" xlink:href="gtbp-20240331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20240331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20240331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20240331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="gtbp-20240331.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20240331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20240331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfStockGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20240331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:href="gtbp-20240331.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityNonCurrent" xlink:label="loc_GTBPWarrantLiabilityNonCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_GTBPWarrantLiabilityNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationCommonSharesForServices" xlink:label="loc_GTBPStockBasedCompensationCommonSharesForServices" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationCommonSharesForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="00000012 - Disclosure - Warrant Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvent" xlink:title="00000016 - Disclosure - Subsequent Event" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="00000021 - Disclosure - Warrant Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000023 - Disclosure - Operating Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000031 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000032 - Disclosure - Accounts Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000034 - Disclosure - Warrant Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_GTBPLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_GTBPLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:title="00000045 - Disclosure - Subsequent Event (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>gtbp-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20240331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20240331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20240331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20240331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20240331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20240331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvent" xlink:href="gtbp-20240331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20240331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20240331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20240331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="gtbp-20240331.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20240331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20240331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfStockGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20240331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:href="gtbp-20240331.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="00000012 - Disclosure - Warrant Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvent" xlink:title="00000016 - Disclosure - Subsequent Event" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="00000021 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwentyTwentyThreeWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyThreeWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyWarrantsMember" xlink:label="loc_GTBPTwentyTwentyWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000023 - Disclosure - Operating Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WorkingCapital" xlink:label="loc_GTBPWorkingCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWorkingCapital_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilitiesNoncurrent" xlink:label="loc_GTBPWarrantLiabilitiesNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWarrantLiabilitiesNoncurrent_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapShortTermInvestmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000031 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000032 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="loc_GTBPMasterServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPMasterServicesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ThirdPartyProductManufacturerMember" xlink:label="loc_GTBPThirdPartyProductManufacturerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPThirdPartyProductManufacturerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwentyTwentyThreeWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyThreeWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyWarrantsMember" xlink:label="loc_GTBPTwentyTwentyWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_250" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000034 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PlacementAgentWarrantMember" xlink:label="loc_GTBPPlacementAgentWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPlacementAgentWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseWarrantMember" xlink:label="loc_GTBPPurchaseWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPurchaseWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_GTBPIncreaseDecreaseInFairValueOfWarrantLiability_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIncreaseDecreaseInFairValueOfWarrantLiability_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedGain_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedGain_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_GTBPShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_GTBPShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PrefundedWarrantMember" xlink:label="loc_GTBPPrefundedWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PlacementAgentWarrantMember" xlink:label="loc_GTBPPlacementAgentWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPlacementAgentWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonSharesAndCommonWarrantsMember" xlink:label="loc_GTBPCommonSharesAndCommonWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonSharesAndCommonWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsAndCommonWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPreFundedWarrantsAndCommonWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantAndPlacementAgentWarrantMember" xlink:label="loc_GTBPCommonWarrantAndPlacementAgentWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantAndPlacementAgentWarrantMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPPreFundedWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" xlink:label="loc_GTBPBoardOfDirectorsEmployeesAndConsultantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPBoardOfDirectorsEmployeesAndConsultantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="loc_GTBPSeriesKPreferredStockMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStockMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesGainLoss_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable_250" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_250" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_250" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_250" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_250" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_250" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_250" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_250" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_250" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="loc_GTBPScientificResearchAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPScientificResearchAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable_180" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WrittenOffRightOfUseAsset" xlink:label="loc_GTBPWrittenOffRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_GTBPWrittenOffRightOfUseAsset_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:title="00000045 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_20" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>gtbp-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US">Short-Term Investments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_lbl" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="GTBP_MasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServicesAgreementMember" xlink:to="GTBP_MasterServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MasterServicesAgreementMember_lbl" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ThirdPartyProductManufacturerMember" xlink:label="GTBP_ThirdPartyProductManufacturerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ThirdPartyProductManufacturerMember" xlink:to="GTBP_ThirdPartyProductManufacturerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ThirdPartyProductManufacturerMember_lbl" xml:lang="en-US">Third Party Product Manufacturer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantsMember" xlink:label="GTBP_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PlacementAgentWarrantMember" xlink:label="GTBP_PlacementAgentWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PlacementAgentWarrantMember" xlink:to="GTBP_PlacementAgentWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PlacementAgentWarrantMember_lbl" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseWarrantMember" xlink:label="GTBP_PurchaseWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseWarrantMember" xlink:to="GTBP_PurchaseWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseWarrantMember_lbl" xml:lang="en-US">Purchase Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyThreeWarrantsMember" xlink:label="GTBP_TwentyTwentyThreeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwentyTwentyThreeWarrantsMember" xlink:to="GTBP_TwentyTwentyThreeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwentyTwentyThreeWarrantsMember_lbl" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyWarrantsMember" xlink:label="GTBP_TwentyTwentyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwentyTwentyWarrantsMember" xlink:to="GTBP_TwentyTwentyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwentyTwentyWarrantsMember_lbl" xml:lang="en-US">2020 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseAgreementMember" xlink:label="GTBP_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PrefundedWarrantMember" xlink:label="GTBP_PrefundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantMember" xlink:to="GTBP_PrefundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PrefundedWarrantMember_lbl" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsMember" xlink:label="GTBP_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsMember" xlink:to="GTBP_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonSharesAndCommonWarrantsMember" xlink:label="GTBP_CommonSharesAndCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesAndCommonWarrantsMember" xlink:to="GTBP_CommonSharesAndCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonSharesAndCommonWarrantsMember_lbl" xml:lang="en-US">Common Shares and Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="GTBP_PreFundedWarrantsAndCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsAndCommonWarrantsMember" xlink:to="GTBP_PreFundedWarrantsAndCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PreFundedWarrantsAndCommonWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants and Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantAndPlacementAgentWarrantMember" xlink:label="GTBP_CommonWarrantAndPlacementAgentWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantAndPlacementAgentWarrantMember" xlink:to="GTBP_CommonWarrantAndPlacementAgentWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantAndPlacementAgentWarrantMember_lbl" xml:lang="en-US">Common Warrant and Placement Agent Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" xlink:label="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" xlink:to="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember_lbl" xml:lang="en-US">Board Of Directors Employees And Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="GTBP_SeriesKPreferredStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesKPreferredStocksMember_lbl" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="GTBP_SeriesKPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStockMember" xlink:to="GTBP_SeriesKPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesKPreferredStockMember_lbl" xml:lang="en-US">Series K Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantsMember" xlink:label="GTBP_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeOneMember" xlink:label="GTBP_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeTwoMember" xlink:label="GTBP_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeThreeMember" xlink:label="GTBP_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="GTBP_ScientificResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScientificResearchAgreementMember" xlink:to="GTBP_ScientificResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScientificResearchAgreementMember_lbl" xml:lang="en-US">Scientific Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Patent Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Lease Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityNonCurrent" xlink:label="GTBP_WarrantLiabilityNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityNonCurrent" xlink:to="GTBP_WarrantLiabilityNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityNonCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Preferred stock,&#160;&#160;par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock,&#160;&#160;par value $0.001, 250,000,000 shares authorized, 1,380,633 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative&#160;&#160;(including $102 and $718 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized loss (gain) on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other (Income) Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Private placement of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Private placement of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Initial recognition of fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_lbl" xml:lang="en-US">Issuance of common shares in settlement of vendors payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_lbl" xml:lang="en-US">Issuance of common shares in settlement of vendors payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationCommonSharesForServices" xlink:label="GTBP_StockBasedCompensationCommonSharesForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationCommonSharesForServices" xlink:to="GTBP_StockBasedCompensationCommonSharesForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationCommonSharesForServices_lbl" xml:lang="en-US">Stock based compensation - services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_lbl" xml:lang="en-US">Stock based compensation - officers, employees and board of directors</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on extinguishment of share settled debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">(Decrease) in operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sale (purchase) of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of common stock and prefunded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US">Initial recognition of fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Fair value of common stock issued to a vendor to settle accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="GTBP_WarrantLiabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="GTBP_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="GTBP_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Short-Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Financial Instrument</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy Financial Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Granted Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding and Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Information Related Leases Under Non-Cancellable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Revers stock split ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="GTBP_CashOnHandAndShortTermInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashOnHandAndShortTermInvestment_lbl" xml:lang="en-US">Cash on hand and short term investment</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WorkingCapital" xlink:label="GTBP_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WorkingCapital" xlink:to="GTBP_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash and cash equivalents, and short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilitiesNoncurrent" xlink:label="GTBP_WarrantLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilitiesNoncurrent" xlink:to="GTBP_WarrantLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US">Unrealized gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_Extinguishment" xlink:label="GTBP_Extinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_Extinguishment" xlink:to="GTBP_Extinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_Extinguishment_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable to a third-party manufacturer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility amount utilized in the value calculation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:to="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of the warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGain_lbl" xml:lang="en-US">Recognized gain of change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of warrants, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of lower excercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants outstanding, weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants exercisable, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Options Outstanding Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Options Outstanding Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, Options Exercisable Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US">Range of excercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options exercisable, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_2_lbl" xml:lang="en-US">Issued shares for vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:label="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_lbl" xml:lang="en-US">Fair value for vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="us-gaap_DebtSecuritiesGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesGainLoss_lbl" xml:lang="en-US">Debt securities gain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Preferred stock shares designated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Convertible shares issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Purchase an aggregate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Stock options expire</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Stock compensation expense unvested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Shares return, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Shares return</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Aggregate research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Proceeds from upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">Net sales percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">Sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cumulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="GTBP_LicenseMaintenanceFeeReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_lbl" xml:lang="en-US">License maintenance fee, receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Other Information Related Leases Under Non-cancellable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureOperatingLeasesAbstract" xlink:to="GTBP_DisclosureOperatingLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GTBP_DisclosureOperatingLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Minimum Lease Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">After one year and within two years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">After two years and within three years</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less &#8211; Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xml:lang="en-US">Lessee, operating sublease, option to extend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease, right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WrittenOffRightOfUseAsset" xlink:label="GTBP_WrittenOffRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WrittenOffRightOfUseAsset" xlink:to="GTBP_WrittenOffRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WrittenOffRightOfUseAsset_lbl" xml:lang="en-US">Written off right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityNonCurrent" xlink:to="GTBP_WarrantLiabilityNonCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityNonCurrent_doc" xml:lang="en-US">Warrant liability non-current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_doc" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable_doc" xml:lang="en-US">Stock issued during period value common shares in settlement of vendors payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_doc" xml:lang="en-US">Stock issued during period shares common sharesIn settlement of vendors payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationCommonSharesForServices" xlink:to="GTBP_StockBasedCompensationCommonSharesForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationCommonSharesForServices_doc" xml:lang="en-US">Stock based compensation common shares for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:to="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors_doc" xml:lang="en-US">Stock based compensation officers employees and board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during the year for [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiquidityPolicyTextBlock" xlink:to="GTBP_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashOnHandAndShortTermInvestment" xlink:to="GTBP_CashOnHandAndShortTermInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashOnHandAndShortTermInvestment_doc" xml:lang="en-US">Cash on hand and short term investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WorkingCapital" xlink:to="GTBP_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WorkingCapital_doc" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilitiesNoncurrent" xlink:to="GTBP_WarrantLiabilitiesNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilitiesNoncurrent_doc" xml:lang="en-US">Warrant liabilities noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_Extinguishment" xlink:to="GTBP_Extinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_Extinguishment_doc" xml:lang="en-US">Extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityTextBlock_doc" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsMember" xlink:to="GTBP_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PlacementAgentWarrantMember" xlink:to="GTBP_PlacementAgentWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PlacementAgentWarrantMember_doc" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseWarrantMember" xlink:to="GTBP_PurchaseWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseWarrantMember_doc" xml:lang="en-US">Purchase Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:to="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInFairValueOfWarrantLiability_doc" xml:lang="en-US">Increase decrease in fair value of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwentyTwentyThreeWarrantsMember" xlink:to="GTBP_TwentyTwentyThreeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwentyTwentyThreeWarrantsMember_doc" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwentyTwentyWarrantsMember" xlink:to="GTBP_TwentyTwentyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwentyTwentyWarrantsMember_doc" xml:lang="en-US">2020 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantMember" xlink:to="GTBP_PrefundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PrefundedWarrantMember_doc" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonSharesAndCommonWarrantsMember" xlink:to="GTBP_CommonSharesAndCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonSharesAndCommonWarrantsMember_doc" xml:lang="en-US">Common Shares and Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreFundedWarrantsAndCommonWarrantsMember" xlink:to="GTBP_PreFundedWarrantsAndCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreFundedWarrantsAndCommonWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrants and Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" xlink:to="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_BoardOfDirectorsEmployeesAndConsultantsMember_doc" xml:lang="en-US">Board Of Directors Employees And Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:to="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_doc" xml:lang="en-US">Stock issued during period fair value common shares in settlement of vendors payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStocksMember" xlink:to="GTBP_SeriesKPreferredStocksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesKPreferredStocksMember_doc" xml:lang="en-US">Series K Preferred Stocks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesKPreferredStockMember" xlink:to="GTBP_SeriesKPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesKPreferredStockMember_doc" xml:lang="en-US">Series K Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScientificResearchAgreementMember" xlink:to="GTBP_ScientificResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScientificResearchAgreementMember_doc" xml:lang="en-US">Scientific Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LicenseMaintenanceFeeReceivable" xlink:to="GTBP_LicenseMaintenanceFeeReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LicenseMaintenanceFeeReceivable_doc" xml:lang="en-US">License maintenance fee, receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WrittenOffRightOfUseAsset" xlink:to="GTBP_WrittenOffRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WrittenOffRightOfUseAsset_doc" xml:lang="en-US">Written off right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:to="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_doc" xml:lang="en-US">Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_doc" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Two..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CorporateNotesAndCommercialPaperMember" xlink:to="GTBP_CorporateNotesAndCommercialPaperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CorporateNotesAndCommercialPaperMember_doc" xml:lang="en-US">Corporate Notes and Commercial Paper [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MasterServicesAgreementMember" xlink:to="GTBP_MasterServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MasterServicesAgreementMember_doc" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ThirdPartyProductManufacturerMember" xlink:to="GTBP_ThirdPartyProductManufacturerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ThirdPartyProductManufacturerMember_doc" xml:lang="en-US">Third Party Product Manufacturer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantAndPlacementAgentWarrantMember" xlink:to="GTBP_CommonWarrantAndPlacementAgentWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantAndPlacementAgentWarrantMember_doc" xml:lang="en-US">Common Warrant and Placement Agent Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xml:lang="en-US">Share based compensation shares authorized under stock option plans exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of warrants oustanding and exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilityTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_2_lbl" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_2_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">Warrant Liability Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Derivative Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>gtbp-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheets" xlink:href="gtbp-20240331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:href="gtbp-20240331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperations" xlink:href="gtbp-20240331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:href="gtbp-20240331.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:href="gtbp-20240331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:href="gtbp-20240331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:href="gtbp-20240331.xsd#OrganizationAndOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayable" xlink:href="gtbp-20240331.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiability" xlink:href="gtbp-20240331.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquity" xlink:href="gtbp-20240331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeases" xlink:href="gtbp-20240331.xsd#OperatingLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEvent" xlink:href="gtbp-20240331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableTables" xlink:href="gtbp-20240331.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:href="gtbp-20240331.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:href="gtbp-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:href="gtbp-20240331.xsd#OperatingLeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:href="gtbp-20240331.xsd#OrganizationAndOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:href="gtbp-20240331.xsd#FairValueOfFinancialInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfAccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:href="gtbp-20240331.xsd#AccountsPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:href="gtbp-20240331.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfStockGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="gtbp-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="gtbp-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="gtbp-20240331.xsd#ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:href="gtbp-20240331.xsd#OperatingLeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:href="gtbp-20240331.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityNonCurrent" xlink:label="loc_GTBPWarrantLiabilityNonCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_GTBPWarrantLiabilityNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationCommonSharesForServices" xlink:label="loc_GTBPStockBasedCompensationCommonSharesForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationCommonSharesForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:label="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPStockBasedCompensationOfficersEmployeesAndBoardOfDirectors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapLiabilitiesAssumed1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperations" xlink:title="00000008 - Disclosure - Organization and Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstruments" xlink:title="00000010 - Disclosure - Fair Value of Financial Instruments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayable" xlink:title="00000011 - Disclosure - Accounts Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="00000012 - Disclosure - Warrant Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="loc_GTBPWarrantLiabilityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquity" xlink:title="00000013 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeases" xlink:title="00000015 - Disclosure - Operating Leases">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvent" xlink:title="00000016 - Disclosure - Subsequent Event">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LiquidityPolicyTextBlock" xlink:label="loc_GTBPLiquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="loc_GTBPWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables" xlink:title="00000019 - Disclosure - Fair Value of Financial Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableTables" xlink:title="00000020 - Disclosure - Accounts Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="00000021 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwentyTwentyThreeWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyWarrantsMember" xlink:label="loc_GTBPTwentyTwentyWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesTables" xlink:title="00000023 - Disclosure - Operating Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:label="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_GTBPScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative" xlink:title="00000024 - Disclosure - Organization and Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CashOnHandAndShortTermInvestment" xlink:label="loc_GTBPCashOnHandAndShortTermInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPCashOnHandAndShortTermInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WorkingCapital" xlink:label="loc_GTBPWorkingCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantLiabilitiesNoncurrent" xlink:label="loc_GTBPWarrantLiabilitiesNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GTBPWarrantLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" xlink:title="00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaapShortTermInvestmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapShortTermInvestmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CorporateNotesAndCommercialPaperMember" xlink:label="loc_GTBPCorporateNotesAndCommercialPaperMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_GTBPCorporateNotesAndCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_Extinguishment" xlink:label="loc_GTBPExtinguishment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_GTBPExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative" xlink:title="00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="00000031 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableDetailsNarrative" xlink:title="00000032 - Disclosure - Accounts Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_MasterServicesAgreementMember" xlink:label="loc_GTBPMasterServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPMasterServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ThirdPartyProductManufacturerMember" xlink:label="loc_GTBPThirdPartyProductManufacturerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPThirdPartyProductManufacturerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" xlink:title="00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwentyTwentyThreeWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwentyTwentyWarrantsMember" xlink:label="loc_GTBPTwentyTwentyWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwentyTwentyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000034 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PlacementAgentWarrantMember" xlink:label="loc_GTBPPlacementAgentWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPlacementAgentWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseWarrantMember" xlink:label="loc_GTBPPurchaseWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPurchaseWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_IncreaseDecreaseInFairValueOfWarrantLiability" xlink:label="loc_GTBPIncreaseDecreaseInFairValueOfWarrantLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPIncreaseDecreaseInFairValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedGain" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedGain" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000035 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails" xlink:title="00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_GTBPShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_GTBPShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PrefundedWarrantMember" xlink:label="loc_GTBPPrefundedWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PlacementAgentWarrantMember" xlink:label="loc_GTBPPlacementAgentWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPlacementAgentWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonSharesAndCommonWarrantsMember" xlink:label="loc_GTBPCommonSharesAndCommonWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonSharesAndCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsAndCommonWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsAndCommonWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPreFundedWarrantsAndCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CommonWarrantAndPlacementAgentWarrantMember" xlink:label="loc_GTBPCommonWarrantAndPlacementAgentWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPCommonWarrantAndPlacementAgentWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PreFundedWarrantsMember" xlink:label="loc_GTBPPreFundedWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_BoardOfDirectorsEmployeesAndConsultantsMember" xlink:label="loc_GTBPBoardOfDirectorsEmployeesAndConsultantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPBoardOfDirectorsEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStocksMember" xlink:label="loc_GTBPSeriesKPreferredStocksMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SeriesKPreferredStockMember" xlink:label="loc_GTBPSeriesKPreferredStockMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesKPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapVestingAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000041 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ScientificResearchAgreementMember" xlink:label="loc_GTBPScientificResearchAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPScientificResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LicenseMaintenanceFeeReceivable" xlink:label="loc_GTBPLicenseMaintenanceFeeReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPLicenseMaintenanceFeeReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails" xlink:title="00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_GTBPLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_GTBPLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative" xlink:title="00000044 - Disclosure - Operating Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_DisclosureOperatingLeasesAbstract" xlink:label="loc_GTBPDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapLeaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingSubleaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20240331.xsd#GTBP_WrittenOffRightOfUseAsset" xlink:label="loc_GTBPWrittenOffRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_GTBPWrittenOffRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventDetailsNarrative" xlink:title="00000045 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609235888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8000
Marina Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665701851856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="nump">$ 1,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">9,885<span></span>
</td>
<td class="nump">14,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">9,912<span></span>
</td>
<td class="nump">14,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,213<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityNonCurrent', window );">Warrant liability</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Preferred stock,&#160;&#160;par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock,&#160;&#160;par value $0.001, 250,000,000 shares authorized, 1,380,633 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">689,641<span></span>
</td>
<td class="nump">689,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(684,331)<span></span>
</td>
<td class="num">(682,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">5,312<span></span>
</td>
<td class="nump">7,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 9,912<span></span>
</td>
<td class="nump">$ 14,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702243152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,380,633<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,380,633<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665608524064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative&#160;&#160;(including $102 and $718 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively)</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Income) Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(658)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss (gain) on marketable securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other (Income) Expense</a></td>
<td class="num">(825)<span></span>
</td>
<td class="num">(3,438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (2,266)<span></span>
</td>
<td class="num">$ (227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (1.64)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">1,380,633<span></span>
</td>
<td class="nump">1,082,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">1,380,633<span></span>
</td>
<td class="nump">1,082,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665778662048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609440496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 686,200<span></span>
</td>
<td class="num">$ (674,468)<span></span>
</td>
<td class="nump">$ 11,734<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Private placement of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,268<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Private placement of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Initial recognition of fair value of warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,831)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable', window );">Issuance of common shares in settlement of vendors payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable', window );">Issuance of common shares in settlement of vendors payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">687,746<span></span>
</td>
<td class="num">(674,695)<span></span>
</td>
<td class="nump">13,053<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">689,539<span></span>
</td>
<td class="num">(682,065)<span></span>
</td>
<td class="nump">7,476<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,266)<span></span>
</td>
<td class="num">(2,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 689,641<span></span>
</td>
<td class="num">$ (684,331)<span></span>
</td>
<td class="nump">$ 5,312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common sharesIn settlement of vendors payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares in settlement of vendors payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665608892800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,266)<span></span>
</td>
<td class="num">$ (227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockBasedCompensationCommonSharesForServices', window );">Stock based compensation - services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors', window );">Stock based compensation - officers, employees and board of directors</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(658)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of share settled debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right-of-use assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss (gain) on marketable securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease in prepaid expenses</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">(Decrease) in accounts payable and accrued expenses</a></td>
<td class="num">(1,347)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">(Decrease) in operating lease liability</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(4,163)<span></span>
</td>
<td class="num">(2,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sale (purchase) of investments</a></td>
<td class="nump">5,034<span></span>
</td>
<td class="num">(6,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities</a></td>
<td class="nump">5,034<span></span>
</td>
<td class="num">(6,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and prefunded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash</a></td>
<td class="nump">871<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at Beginning of Period</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">5,672<span></span>
</td>
<td class="nump">$ 5,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at End of Period</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">$ 1,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Initial recognition of fair value of warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock issued to a vendor to settle accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationCommonSharesForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation common shares for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationCommonSharesForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation officers employees and board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665604456048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Operations</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zuKniZyAOYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_829_zw3rnRodgrXa">Organization and Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. (the &#8220;Company&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms.
The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics designed to harness and enhance
the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Reverse
Stock Split</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240331_zdnGeCHni2Pl" title="Revers stock split ratio">On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#8217;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol &#8220;GTBP.&#8221;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined
into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be
issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of
common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the
exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission
and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the
reverse stock-split from <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240201__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD51QIzkfSo" title="Common stock, shares outstanding">41,419,000</span>
shares to <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzwQiqLOInWi" title="Common stock, shares outstanding">1,380,633</span>
shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock
remains unchanged at <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zvKDYFyJ4lti" title="Common stock, shares authorized">250,000,000</span>
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proportionate
adjustments will be made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise
of outstanding stock options for the Company&#8217;s common stock and to the number of shares of common stock reserved for future issuance
pursuant to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest
period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665603423440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z2LbUE27wQTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_824_zvp92HVSTil3">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKyLiYhH32Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zyYcfzOdQBgg">Basis
of Presentation and Principles of Consolidation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis
Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in
consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the &#8220;2023 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--LiquidityPolicyTextBlock_ztvOBpbPDzn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zK55U4OwHnBa">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a
going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. For the three months ended March 31, 2024, the Company recorded a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn5n6_di_c20240101__20240331_zZjeFnGaQNyi" title="Net loss">2.3</span>
million and used cash in operations of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_di_c20240101__20240331_zcjp7FkflkT3" title="Cash used in operating activities">4.2</span>
million. As of March 31, 2024, the Company had a cash and short-term investments balance of $<span id="xdx_901_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20240331_z5Ty4ChJRDzd" title="Cash on hand and short term investment">9.8</span>
million, working capital of $<span id="xdx_90A_ecustom--WorkingCapital_iI_pn5n6_c20240331_zQmvhpkx9zw8" title="Working capital">5.3</span>
million and stockholders&#8217; equity of $<span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20240331_znLVYy7Bxlvj" title="Stockholders' equity">5.3</span>
million. Management anticipates that the $<span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20240331_zDrTFXH2Muy7" title="Cash and cash equivalents, and short-term investments">9.8</span>
million of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at
least one year from the date the Company&#8217;s condensed consolidated financial statements for the three months ended March 31,
2024 were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock,
issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to
secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and
financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which
could adversely affect the Company&#8217;s business prospects, ability to meet long-term liquidity needs or ability to continue
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--UseOfEstimates_zUVg9VrPMp53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6t4ee2Icaxd">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Significant estimates include management&#8217;s estimates for continued
liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of
equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1WACwPISCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zgZSVwxfG11b">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to
approximately $<span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_z1qIwaqjlvrc" title="Cash equivalents">1.8</span></span> million and $<span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zEvm5EQIkkWe" title="Cash equivalents">443,000</span> at March 31, 2024 and December 31, 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. Total short-term investments amounted to approximately $<span id="xdx_90B_eus-gaap--ShortTermInvestments_iI_pn5n6_c20240331_zqBU4sK70doh" title="Short-term investments">7.9</span> million and $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zwmFAX9C0CFg" title="Short-term investments">12.9</span> million
at March 31, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziorEyji2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_zR0fvFg2ypda">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90B_ecustom--WarrantLiabilitiesNoncurrent_iI_c20240331_zg7MQ6A73nl3" title="Derivative liability">394,000</span> and $<span id="xdx_90F_ecustom--WarrantLiabilitiesNoncurrent_iI_pn5n6_c20231231_z41BwTznGcol" title="Derivative liability">1.1</span> million at March 31, 2024 and December 31, 2023, respectively,
was based on Level 3  measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, short term investments,
prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity
of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_z8IOXlHZtJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zAhXxLgpaH99">Warrant
Liability</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z8e9I1ofZKs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zpmiwBRniANe">Stock-Based
Compensation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees and consultants for acquiring goods and services from non-employees, which include grants
of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,
<i>Compensation-Stock Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time
vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation
cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees
is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated
using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility,
expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation
expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf4anFW7U5ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_861_zLctfluGIJxk">Research
and Development Costs</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zzz6StdiIpWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86F_z207zpcRr3Z8">Leases</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its lease in accordance with the guidance of ASC 842, <i>Leases</i>. The Company determines whether a contract is,
or contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease
term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets
and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zrSKWJL8FbG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zTjO7SIvIG17">Net
Loss Per Share</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_ziTwc5JANzOl" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">126,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">115,598</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">431,227 </span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">420,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zHA8mjrPcXB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zAwNsizvEos4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_860_znK4J0WXdxqh">Concentration</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember_zzjwvS7vwja5" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4 &#8211; Accounts
Payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztFFzE5GUkBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_863_znDNkrSM22G8">Segments</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment
to determine if it includes one or more components that constitute a business. If there are components within an operating segment that
meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting
units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the
segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zalqMxs3jpag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_862_zHxP7rgoIAAd">Recent
Accounting Pronouncements</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, &#8220;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>&#8221;
(&#8220;ASU 2023-07&#8221;), which introduces new reportable segment disclosure requirements related to significant segment expenses
and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable
segment&#8217;s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact
that ASU 2023-07 will have on our segment related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_85A_zzqzHA7mS5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601296496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zDWkE3gWpGy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82A_zYk4NlRReWBg">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z0JGDFi1Cl33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BD_zJRjVFMd1Z32" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztMhNO7KMYr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">7,859</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z75GnK4zHuN5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zp666a7kKvb5" title="Unrealized losses">(2</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zJBSCKjyYFGd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">7,857</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331_zIBgnI06Z5d1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">7,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331_zFKY3IUdVtAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331_zALzbXn8tCcc" title="Unrealized losses">(2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331_zWxLHr3Cze82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">7,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztD6YbVVb1ah" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">12,845</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zKnlikL4Dmf4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zc69T67D7b06" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTVqr9UN7zl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">12,893</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zo1kL0JkJFV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">12,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231_zXhPl2cGd6b9" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">48</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zdX4QI6oQTXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231_z49XaFaMCKca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">12,893</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z6kUn2CK73qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6N7hXlixww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_zlICH7SXekdi" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zI4CqUzkaq0f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zat1NRDsdKNf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaMvr4KLzTFa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49F_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzVZLZmo8op4" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlUo8F3oXLHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zzMDrpR0qKij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk8h9fLN7Mz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zPt7Kezepuw5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0DshjjNxMf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLjCYqnJkp1j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO95dlZITBtb" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCy8B65m789g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zuqbxTpRKdG9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zlE1xueli5Lf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,336</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">443</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,893</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zSVXB5MBAOv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the fair value of the warrant liability was $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeld04ELtMl" title="Fair value of warrant liability">394,000</span>. The details of warrant liability transactions for the three
months ended March 31, 2024 and 2023, were as follows (in thousands):</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3X6zCdBQdJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zKaOILP8WDw" style="display: none">Schedule
of Warrant Liability Transactions</span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240331_zoEgPTSb6eq1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zWtO1ZXEo27i" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ending</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zDZXJi8Y42ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,052</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zvWZYgOyU3B9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_zVpfyUou9429" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(658</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,924</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--Extinguishment_pn3n3_zgbpFKBU3Ljg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zRGyrzfGHjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,926</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zfEROGaAN4a5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601291568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGW5Emi670le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_823_z6MAQFpyjPD5">Accounts Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z55uojEbEr1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_z7ui9O5coLsj" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zH4MAVKOBf92" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zhChP46WleE5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zQInsufFB5dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zrcHkyXb61Bk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;1,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz5ku_z8mP4v5MQFLh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_zDG4bxIYvNL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently executed a number of Statements
of Work for the research and development of products for use in clinical trials. The Company&#8217;s commitments in relation to these
SOWs and any related Change Orders totaled approximately $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxZT0xfvYGog">15.6</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, existing agreements with the third-party product manufacturer were amended. As part of the amendment, the third-party
manufacturer agreed that services to be rendered in future periods, will be paid or settled at the Company&#8217;s discretion, in a combination
of cash and issuance of the Company&#8217;s common stock. The amendment also eliminated future financial commitments of the Company.
As of December 31, 2023, outstanding accounts payable balance to the third-party product manufacturer amounted to $<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zPBsKadKIgr5">3.5</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2024, the Company recorded research and development expenses of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zDmmXi0sFz57" title="Research and development expenses">268,000</span>
to account for services rendered by the third-party product manufacturer. In addition, the Company paid cash of $<span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zzzbPZ0eISW4" title="Cash">1.8</span>
million towards the payment of accounts payable. As of March 31, 2024, the outstanding balance due to the third-party product manufacturer
amounted to $<span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_z7QQGoIzNsxg" title="Accounts payable">2.0</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665608718976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_803_ecustom--WarrantLiabilityTextBlock_zLBXuv206jP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82A_z5Evn97Nviue">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2023
Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zsXpY1iKlVCf" title="Warrants to purchase">216,667</span>
shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;), and placement agent warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__srt--RangeAxis__srt--MaximumMember_z4lRsGpCBP51" title="Warrants to purchase">13,000</span>
shares of the Company&#8217;s common stock (the &#8220;Placement Agents Warrants&#8221; see Note 6 - Stockholders&#8217;
Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Warrant provides for a value calculation for the Purchase Warrant using the Black Scholes model in the event of certain fundamental
transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLoBESIUeu3g" title="Volatility amount utilized in the value calculation percentage">100</span>% or greater.
The Company has determined this provision introduces leverage to the holders of the Purchase Warrant that could result in a value that
would be greater than the settlement amount of a fixed-for-fixed option on the Company&#8217;s own equity shares. Therefore, pursuant
to ASC 815, the Company has classified the Purchase Warrant as a liability in its consolidated balance sheet. The classification of the
Purchase Warrant, including whether the Purchase Warrant should be recorded as liability or as equity, is evaluated at the end of each
reporting period with changes in the fair value reported in other income (expense) in the consolidated statements of operations and comprehensive
loss. The Purchase Warrant was initially recorded at a fair value at $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240331__us-gaap--StatementEquityComponentsAxis__custom--PurchaseWarrantMember_zPmlmKZ5itid" title="Warrant  fair value">5.8</span> million at the grant date and is re-valued at each reporting
date. Upon the closing of placement, the fair value of the Purchase Warrant liability was recorded as a cost of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the fair value of the warrant liability was reduced to $<span id="xdx_904_ecustom--IncreaseDecreaseInFairValueOfWarrantLiability_iI_c20240331_zC85MaUmViNi" title="Change in fair value of the warrant liability">393,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
changes in the fair value of the warrant liabilities are recognized as a change in fair value of warrant liability in the Company&#8217;s
condensed consolidated statements of operations until they are either exercised or expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQqnUtf6DJn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zFmm3Da7Ieli" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common Warrants and Placement</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agents Warrants</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zgX4hwLo0IW3" style="width: 16%; text-align: right" title="Stock price">4.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_z2QSCVtGDDqe" style="width: 16%; text-align: right" title="Stock price">7.80</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGtU07RSD04c" style="text-align: right" title="Warrants measurement input">4.21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zxKCPjUGvB8j" style="text-align: right" title="Warrants measurement input">4.26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zEUGR9NUYtij" style="text-align: right" title="Warrants measurement input">103.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zzrFgCoZn1Ej" style="text-align: right" title="Warrants measurement input">115.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zrB2KlOieMdd" title="Expected life (in years)">4.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQYX5gLaxnph" title="Expected life (in years)">4.25</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGVo7FcTT9Gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zbLdhCL8hEVi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zOjR9XpeBfOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">393</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zFbN9ZDk9WS" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">1,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zcCr9j28pP8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2020
Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued certain warrants during the year ended December 31, 2020 that contained a fundamental transaction provision that could
give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance
with ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheets and will be
re-measured at the end of every reporting period with the change in value reported in the Condensed Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zagaFcjcLmP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zIzFK6VVkV5c" style="display: none">Schedule of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZDgjZpvR0Xk" style="width: 16%; text-align: right" title="Stock price">4.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZEZmFaYpCMj" style="width: 16%; text-align: right" title="Stock price">&#160;&#160;&#160;&#160;&#160;&#160;7.80</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zazWhJfVHMqk" style="text-align: right" title="Warrants measurement input">&#160;&#160;&#160;&#160;&#160;4.21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z99g2NXT9Su1" style="text-align: right" title="Warrants measurement input">4.54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zbP6o7EEGvQh" style="text-align: right" title="Warrants measurement input">89</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_znim9ugh62Me" style="text-align: right" title="Warrants measurement input">89</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znn9f4bEwZq1" style="text-align: right" title="Expected life (in years)">1.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgtzzt3R7Hd4" style="text-align: right" title="Expected life (in years)">1.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zjgWYePrXu17" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zv9TvHP75Oxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zRy7N8jay5ca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z869XvUVSoy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zVGwXgiDRV1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. For derivative instruments that already matured, the Company used the estimated
life. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized a gain of $<span id="xdx_902_eus-gaap--EquitySecuritiesFvNiRealizedGain_c20240101__20240331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zHEW7KbaOjlk" title="Recognized gain of change in fair value of derivative liability">658,000</span> and $<span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiRealizedGain_pn5n6_c20230101__20230331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zIH8kAO1q2Vb" title="Recognized gain of change in fair value of derivative liability">2.9</span> million to account for the change in fair value of the warrant liability related to all
warrants between the reporting periods for the three months ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601314752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z6eadgVTQBvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_824_zbL92Mvdhzvh">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of March 31, 2024 was <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zZeIwkjlAwLk" title="Common stock, shares authorized">250,000,000</span>
shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zAW4fZvDzj1a" title="Common stock, par value">0.001</span>
per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331_zafpZSKjGZ47" title="Preferred stock, shares authorized">15,000,000</span>
shares of preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331_zhbf6OmuyRd9" title="Preferred stock, par value">0.01</span>
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Private
Placement of Common Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, GT Biopharma received gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsvccVIaL47d" title="Proceeds from private placement">6.5</span> million, before deducting placement agent fees and other offering expenses
of $<span id="xdx_901_eus-gaap--NoninterestExpenseOfferingCost_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvFVG8bGZeXd" title="Other offering expenses">232,000</span> in relation to a purchase agreement (the &#8220;Purchase Agreement&#8221;) signed on December 30, 2022, between the Company
and an institutional investor (the &#8220;Purchaser&#8221;) for the issuance and sale, in a registered direct offering (the &#8220;Offering&#8221;),
of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbpkpmXp2wRi" title="Direct offering">120,000</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6bqrRbfzphh" title="Common stock par value">0.001</span> per share (the &#8220;Shares&#8221;), pre-funded warrants to
purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4KvcLLQhTQ7" title="Purchase of warrants">96,667</span> shares of the Company&#8217;s common stock (the &#8220;Pre-Funded Warrants&#8221;), warrants to purchase up to
an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsWANHk0Y4Q6" title="Purchase of warrants">216,667</span> shares of the Company&#8217;s common stock (the &#8220;Common Warrants&#8221;) and placement agent warrants to
purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrcrcoVzKo5j">13,000</span> of the Company&#8217;s common stock (the &#8220;Placement Agents Warrants&#8221;). The Common Warrants have an
exercise price equal to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyVVX9C51rV8" title="Warrant exercise price">30.00</span>, became exercisable commencing six months following issuance, and shall have a term of exercise equal
to five years following the initial exercise date. The Pre-Funded Warrants had an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zkzwSBRf3i99" title="Exercise price of warrant">0.003</span> per Share, were immediately
exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The
Placement Agents Warrants have an exercise price equal to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z64WUh9dvlAk">37.50</span>, exercisable commencing six months following issuance, and shall
have a term of exercise equal to five years following the initial exercise date. The Shares and Common Warrants were sold at an offering
price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zFFHwbAaGhzj" title="Price per share">30.00</span> per Share and accompanying Common Warrant and the Pre-Funded Warrants and Common Warrants were sold at an offering price
of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zagF6hVz1oca" title="Price per share">29.997</span> per Pre-Funded Warrant and accompanying Common Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants and the Placement Agents Warrants contained a clause not considered to be within the Company&#8217;s control. The Company
determined that the provision represented a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option
as defined under ASC 815-40, and thus the Common Warrants and the Placement Agent Warrants are not considered indexed to the Company&#8217;s
own stock and not eligible for an exception from derivative accounting. Accordingly, the Common Warrants and the Placement Agent Warrants
were classified as a warrant liability, and $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230102__20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantAndPlacementAgentWarrantMember_zfmzVSmNCkci" title="Change in fair value of warrant liability">5.8</span> million of the initial common stock offering was classified as a warrant liability (Note
5 &#8211; Warrant Liability).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issued for Services</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zwxPF1EHfUMb" title="Shares issued">2,449</span> shares of common
stock with a fair value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zf0jcw5LmQpk" title="Shares issued, value">315,000</span> to members of the Board of Directors, employees and consultants. The shares were valued at the respective
date of the agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock Issued for Vendor Payable</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 13, 2023, the Company issued <span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zLdDiHJTc01f" title="Issued shares for vendor payable">16,228</span> shares of common stock with a fair value of $<span id="xdx_906_ecustom--StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zxes7k1OcUl" title="Fair value for vendor payable">287,000</span> as settlement of accounts payable of $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20230313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjKWgCTNh678" title="Accounts payable">820,000</span>.
As a result, the Company recognized a gain of $<span id="xdx_904_eus-gaap--DebtSecuritiesGainLoss_c20230313__20230313_zwh4SWNYZlQ4" title="Debt securities gain">533,000</span> to account the difference between the fair value of the common stock issued and
the accounts payable settled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Preferred
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
C Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2024 and December 31, 2023, there were <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDID1ATxVCYd" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYmJJO5K8xv2" title="Preferred stock, shares authorized">96,230</span></span> shares of series C preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zgthDmlXk1M4" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaFk8ckhh8Je" title="Preferred stock, par value">0.01</span></span> per share (the &#8220;Series
C Preferred Stock&#8221;) issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNR2ORFnhtK2">96,230</span>
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#8217;s board of directors
(the &#8220;Board&#8221;). No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2024 and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
K Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2021, the Board designated <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zCnF2Iqf9Vp5" title="Preferred stock shares designated">115,000</span> shares of Series K preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zoal3xURm6Pa" title="Preferred stock, par value">.01</span> (the &#8220;Series K Preferred Stock&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#8217;s common
stock at an effective conversion rate of <span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zfWaCn0IcVp4" title="Convertible shares issuable">100</span> shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred
Stock have the same voting rights as the shares of the Company&#8217;s common stock, with the holders of the Series K Preferred Stock
entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#8217;s common stock on all matters presented to the Company&#8217;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in
any dividends to the holders of the Company&#8217;s common stock. In the event of the Company&#8217;s dissolution, liquidation or winding
up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#8217;s common stock and will participate,
on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024 and December 31, 2023, there were <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zDMRUNVAwg5k" title="Preferred stock, shares Issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zZWZCRTrcI27" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zxw5MZ4IF5B1" title="Preferred stock, shares Issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zkTYGUArUIt" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of Series K Preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants
and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2tPo8CIo4ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zJSsz6wWDxN7" style="display: none">Schedule
of Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331_zFgQFfaV9pq4" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zIGIdThyDFg3" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240331_zG9izbUoO0Na" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240331_zyiVyk7gfszk" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240331_zrN6MpnB5kn6" style="text-align: right" title="Number of warrants, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240331_zqjcpfPExbb2" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331_zELmq5581LK2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z0WfWztEl4k2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240331_zAADC3aQD8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zfBUQ6XTWVb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240331_zLod2FftuVD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zLit3LkKzhD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance">63.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z6rNClZLJAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, all issued and outstanding warrants are fully vested. The warrants had an exercise price greater than the market price,
which resulted in <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20240331_zyGekKgKbU95" title="Options outstanding intrinsic value">no</span> intrinsic value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLghJun5l3oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zFsysDk5g4db" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zHSXupPjHcl8" title="Range of lower excercise price">10.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFl86VL9kfyf" style="width: 13%; text-align: right" title="Number of warrants outstanding">1,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zaDMAyWFSLt5" title="Warrants outstanding, weighted average remaining contractual life (years)">1.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrZ18LkAiiu6" title="Warrants outstanding, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2tqakX7I8M4" style="width: 13%; text-align: right" title="Number of warrants exercisable">1,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><p style="margin: 0">$</p></td><td style="width: 13%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWK5HAPKw5Rh" title="Warrants exercisable, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember__srt--RangeAxis__srt--MinimumMember_zq7kwz31DJJj">30.00</span> &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfGc974mkT82">37.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpDhACuY5xZj" style="text-align: right" title="Number of warrants outstanding">229,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNKpgoJuj9a8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztykbqq9dBQc" title="Warrants outstanding, weighted average exercise price">30.42</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgTFTPjeIgvc" style="text-align: right" title="Number of warrants exercisable">229,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZayCWSq0m22" title="Warrants exercisable, weighted average exercise price">30.42</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcCzcyF5N1Dg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zb9ESKTsNg5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">73,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4PbyfDlbyB5" title="Warrants outstanding, weighted average remaining contractual life (years)">1.9</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDx2yi10Rg2j" title="Warrants outstanding, weighted average exercise price">165.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z6VPcThUb686" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable">73,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zm0QuDITJYRi" title="Warrants exercisable, weighted average exercise price">165.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHv4f51WjhB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zBoEGCRAsyga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zMCWz3yZTG5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXZMBd9rtAbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock option transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zoaMKYCdkRq1" style="display: none">Schedule of Options Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zcVqTVH0N2K9" style="width: 16%; text-align: right" title="Number of Options outstanding, Beginning balance">126,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zNGchUfePBZ6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Beginning balance">39.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240331_znlrYWxW9IH1" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zGX43NE281Ek" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20240331_zzsIcVpT9Ei8" style="text-align: right" title="Number of Options, Forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z1AyspYR5ZYi" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20240101__20240331_zuuz5VEEG3Y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zJ5CFwpa7Ehk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_znrqOLcJ9Nn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options outstanding, Ending balance">126,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_z1AkLGh0qJwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Ending balance">39.60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240331_zh1U7KDOLYL8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, Ending balance">123,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zR3HGKbcfKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Exercisable Ending balance">40.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zpJSv0EPpID6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is recognizing the corresponding stock compensation expense for options granted to certain consultants, employees, officers and
directors based upon their vesting term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2023, the Company granted stock options to employees and members of its board of directors to purchase an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230127__20230127_z5KcVKInIGNf" title="Purchase an aggregate">66,667</span>
shares of common stock. The stock options are exercisable at $<span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20230127_z9gD8Tkc0IOf" title="Exercise price">25.50</span> per share, expires in <span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230127__20230127_z7YO7G1OH8K4" title="Stock options expire">10</span> years, vest over twelve months and had a
fair value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn5n6_c20230127_zfijgjyT7Zk2" title="Fair value">1.4 </span>million at the date of grant. determined using the Black-Scholes Option Pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDKnzZsy89Hj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z64iAGTdjEh" style="display: none">Schedule
of Stock Granted Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240331_zlLUphoekLNa" title="Stock price">0.85</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20240331_zmVDb47kBZjg" title="Risk-free interest rate">3.62</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_z37MaOpycdxc" title="Expected volatility">121</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zuk9yHJ3G7K7" title="Expected life (in years)">5.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20240331_z851IfkqMDy7" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zJivgjuq3bvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended March 31, 2024, the Company recognized stock compensation expense related to the vesting options of $<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20240101__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z0IeEY6zHwC5" title="Options granted">102,000</span>. For
the three months ended March 31, 2023, the Company recognized stock compensation expense relating to the vesting of options granted on
January 27, 2023 and prior years of $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230127__20230127__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zSYaefcCmem" title="Options granted">507,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFFWobc17Um2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zk0iKTjrTA1f" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEu5lvIcQeD1" title="Range of excercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIlgHWsDRiyj" style="width: 13%; text-align: right" title="Options outstanding">16,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4emyU2pKeb9" title="Options outstanding, weighted average remaining contractual life (years)">9.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlr2bLcigTj6" title="Options outstanding, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCOru1e9nLwe" style="width: 13%; text-align: right" title="Options exercisable">13,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zTH2nGfEPzz5" title="Options exercisable, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZMmrm9gsfZa" title="Range of excercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zx28sGLBYmJg" style="text-align: right" title="Options outstanding">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJmBSepkNhK8" title="Options outstanding, weighted average remaining contractual life (years)">8.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKeMlT7s7BF6" title="Options outstanding, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeBMZmMjCsUb" style="text-align: right" title="Options exercisable">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zvlKbe2sMeV" title="Options exercisable, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zYDjUUnRoUM" title="Range of excercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzfqVJGqVc1g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding">42,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPpDH0Rgs3m8" title="Options outstanding, weighted average remaining contractual life (years)">8.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGh62hqNMmt6" title="Options outstanding, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpo6d4ydV4p8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable">42,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z89HeQBVZbyh" title="Options exercisable, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331_zTK6HreRNjRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">126,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331_zKGqKNtlxUk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">123,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zl4emZr4pBzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2024 and 2023, there were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331_z0UhHnasdJda" title="Stock compensation expense unvested options">2,778</span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230331_zhKSoFcBpqE9" title="Unvested options, shares">53,225</span> unvested options with a grant date fair value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20240331_zCWpb7ql73pf" title="Stock compensation expense unvested options">12,000 </span>and $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn5n6_c20230331_zMECEqnUi4a4" title="Stock compensation expense unvested options">1.3</span> million, respectively,
which will be recognized as stock compensation expense in future periods based upon the remaining vesting term of the applicable grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no intrinsic value of the outstanding options as of March 31, 2024 as the exercise price of these options was greater than the market
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601930800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zpbGazLfjp99" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_826_zkuQmjEfQone">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being
handled in, the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 14, 2023, former interim Chief Executive Officer, Dr. Greg Berk filed a lawsuit alleging that GT Biopharma
discriminated and retaliated against Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX").
The Parties are proceeding with litigating Berk's SOX claim. GT Biopharma is vigorously defending this matter and believe it to be without
merit. At this early stage in the proceedings, GT Biopharma is not able to determine the probability of the outcome of this matter or
a range of reasonably expected losses, if any.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he
    breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among
    other relief, monetary damages estimated at $<span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20220513__20220513_zDlBgfPdifVi">470,000</span>; the return of <span id="xdx_901_eus-gaap--TreasuryStockCommonShares_iI_c20220513_zLqRlBJhDtB2">13,903</span> shares of our common stock received without authorization;
    and an award of the Company&#8217;s attorneys&#8217; fees and any forum and arbitration fees. As a component of Mr. Handelman&#8217;s
    contract with the Company, disputes shall be fully addressed and finally resolved by binding arbitration conducted by the American
    Arbitration Association (AAA). In connection with any such arbitration, the Company shall bear all costs not otherwise borne by a
    plaintiff in a court proceeding. On March 20, 2024, the Arbitrator issued an interim award in favor of the Company in the amount of $<span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_c20240320__20240320_zGK1Mi3WgfYh" title="Shares return, value">409,000</span> and directed
Mr. Handelman to return the disputed <span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20240320__20240320_znKlwXj4fES8" title="Shares return">13,903</span> shares of common stock . The Arbitrator also awarded the Company its attorney fees and forum
costs in an amount to be determined at the time of the final award.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles
    naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;)
    and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated
    damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the
    terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its
    Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint
    for Interpleader against TWF and Z One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme
    Court to determine if the Company&#8217;s shares of common stock are properly registered to TWF or Z One LLC, as both of these entities
    have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for
    entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One
    and that the Company be released from all associated liability and claims. The Court has not yet ruled on the Company&#8217;s motion.
    The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these
    claims. The Court denied the motion without prejudice, and will reconsider the motion without further briefing upon the filing
of a party affidavit. &#160;Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled
their dispute over the entitlement to GT Biopharma shares.&#160; The Company believes that any claims related to the Notes are without
merit and will continue to defend vigorously against these claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota (&#8220;UofMN&#8221;), effective
June 16, 2021. This scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#8217;s
TriKE<sup>&#174; </sup>product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans;
and (3) investigation of the patient&#8217;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE<sup>&#174;
</sup>constructs in support of our product development and GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> platform drug delivery
changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of
changes in the patient&#8217;s native NK cell population as a result of TriKE<sup>&#174; </sup>therapy. Most studies will use TriKE<sup>&#174;
</sup>DNA/amino acid sequences created by us under current UMN/GTB licensing terms. This agreement expired on June 30, 2023. The Company
and UofMN are negotiating the terms of a new scientific research agreement and expect to finalize it in the first half of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense of $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zfCU2cbFMxHc" title="Research and development expense">0</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zv2YFuaqDUD5" title="Research and development expense">192,000</span> pursuant to the scientific research agreement, for the three months ended March 31, 2024
and 2023, respectively. The Company has recorded an expense in the aggregate of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240101__20240331_zeIq1F6V3uy1" title="Aggregate research and development expense">2.1</span> million as of March 31, 2024 pursuant to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2016
Exclusive Patent License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#8220;UofMN&#8221;),
to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup> technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE<sup>&#174;</sup>
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zYwo2fdewkec" title="Proceeds from upfront amount">200,000</span>, and an annual License Maintenance fee of $<span id="xdx_90B_eus-gaap--CostMaintenance_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrcTZsX8fg8k" title="Maintenance fee">100,000</span> beginning in
2021. The agreement also includes <span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zHvLYnrU9msc" title="Royalty fee percentage">4</span>% royalty fees, not to exceed <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z4gHd9UT17Vi" title="Royalty fee percentage">6</span>% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20240101__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zh2PtjoVOpji" title="Annual royalty payments">250,000</span> to $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZxBKxXuRlLj" title="Annual royalty payments">5.0</span> million. The agreement also includes certain performance milestone payments
totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zE0tiY6rn7e7" title="Milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_903_ecustom--SalesMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zTNuAZL6d4h5" title="Sales milestone payments">1.0</span> million upon reaching $<span id="xdx_909_ecustom--GrossSales_pn6n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zahPrlRR3LSl" title="Sales">250</span> million in gross sales, and $<span id="xdx_90D_ecustom--SalesRevenue_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFSCZ4h0vOtl" title="Sales revenue">5.0</span> million
upon reaching $<span id="xdx_903_ecustom--CummulativeGrossSales_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zfzQgI4kdSPk" title="Cumulative gross sales">500</span> million dollars in cumulative gross sales of Licensed Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zlFs0RZ7GEr9" title="Research and development expense"><span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJ24rCVrRzoj" title="Research and development expense">no</span></span>t incur any research and development expense relating to the 2016 Exclusive Patent License Agreement for the three months
ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2021
Patent License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE<sup>&#174;</sup>. Under the agreement, the UofMN received
an upfront license fee of $<span id="xdx_90C_ecustom--UpfrontLicenseFee_pp0p0_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zC8YYMr4Y4y7" title="Upfront license fee">20,000</span> and will receive an annual License Maintenance fee of $<span id="xdx_900_ecustom--LicenseMaintenanceFeeReceivable_iI_pp0p0_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAekNhVjLpM1" title="License maintenance fee, receivable">5,000</span> beginning in 2022,<span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zbKgAI24RvZk" title="Net sales percentage"> 2.5</span>% to <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsfxhzfaQGUl" title="Net sales percentage">5</span>% royalty
fees, or minimum annual royalty payments of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zcVROWjNFwi9" title="Annual royalty payments">250,000 </span>beginning in the year after the first commercial sales of Licensed Product, and
$<span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zrFU9TBLljNj" title="Maintenance fee">2.0 </span>million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $<span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8SESXBk1IJf" title="Performance milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zP6KlujjvTd1" title="Sales milestone payments">1.0</span> million upon reaching $<span id="xdx_904_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPAw0UjFYQo7" title="Gross sales">250</span> million
in gross sales, and $<span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zlHPwsdWeIw1" title="Sales revenue">5.0</span> million upon reaching $<span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zMU48DRCz5kb" title="Cumulative gross sales">500 </span>million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zGASnhLh5sY4" title="Research and development expense"><span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z1OEprRL42L8" title="Research and development expense">no</span></span>t incur any research and development expense relating to the 2021 Patent License Agreement for the three months ended March
31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601942816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_z4V9GplAVXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_823_zUp3xSVRmYO2">Operating Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components
of its leases as a single lease component. Rent expense is recognized on a straight-line basis over the lease term. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease Right-of-Use (&#8220;ROU&#8221;) assets and liabilities are recognized at the lease commencement date based on the present value
of lease payments over the lease term. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and
lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Generally, the implicit rate
of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present
value of lease payments. The Company&#8217;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its
understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 16.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2021, the Company entered into a sublease with a third party for <span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4uzA9sYnlFk" title="Area of land">4,500</span> square feet of office space located in Brisbane,
California, with a <span id="xdx_909_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z7JfDtSs6Rwa" title="Lessee, operating sublease, option to extend">commencement date of January 1, 2022 and maturing on June 30, 2024. </span><span style="background-color: white">As a result
of this agreement, the Company recognized</span> ROU asset and liability of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z5HWeoxXsaJ5">247,294</span> <span style="background-color: white">pursuant to
ASC 842<i>, Leases.</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022, the Company entered into a copier lease which will end on February 7, 2025. As a result, the Company <span style="background-color: white">recognized </span>additional
ROU asset and liability of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20220208__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwUDstuSnJOg" title="Operating lease liability">13,000</span>.
In October 2023, this lease was cancelled and the remaining ROU asset of $<span id="xdx_901_ecustom--WrittenOffRightOfUseAsset_iI_c20231031__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zkm0vN5wWo9l" title="Written off right of use asset">6,000 </span>was
written off against the cancelled lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these lease agreements, the Company recognized ROU asset and liability in the aggregate of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zU1LwKRVGscf" title="Operating lease, right of use asset"><span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zh7O5CRvq3v7" title="Operating lease liability">260,294</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total rent expense related to these leases reflected on the Company&#8217;s Condensed Consolidated Statements of Operations totaled $<span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20240101__20240331_zM1YPSkg3YHk" title="Rent expense">25,000</span>
and $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230331_zs5BUmHYGhs3" title="Rent expense">29,000 </span>for the three months ended March 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zgyhERp1OFh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zHTu9T5tgbwl" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zjZ0ZDAuVWH7" style="width: 16%; text-align: right" title="Operating cash flows from operating leases">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zZBCB8oTyJX9" style="width: 16%; text-align: right" title="Operating cash flows from operating leases">30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zueD2O4kKHTg" title="Weighted average remaining lease term operating leases">0.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zNwuuCxB1ZYj" title="Weighted average remaining lease term operating leases">1.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_z9iTzikCOhih" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_ztH3xINMvmsd" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zNSnTTZlmjPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8XIVHA2puYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zES8LvCr8qmg" style="display: none">Schedule of Future Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240331_zrBxMW6DDhQ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maOLLza2F_zXaoO2aCjEGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLza2F_zCWaZYDpAHGj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLza2F_z2lWo4z7ZMT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maOLLza2F_z6XOr6JiqEVf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLLza2F_znT7mT1b0eEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXgqXZWxrnD7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z7j9PSEov4Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zY3eELXOJT3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665603597328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zRtpbyyxFbX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span><span id="xdx_820_zjcaH3K39nVa">Subsequent Event</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsyzOAe4Xw11">36,018</span> shares of common stock to settle $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLgB68NJvmdk">278,500</span> of vendor accounts payable. The shares were valued at
the month-end closing price of the Company&#8217;s common stock for the months for which services were provided by the vendor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665701921328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKyLiYhH32Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zyYcfzOdQBgg">Basis
of Presentation and Principles of Consolidation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis
Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in
consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and
applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the &#8220;2023 Annual Report&#8221;). The consolidated
balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_840_ecustom--LiquidityPolicyTextBlock_ztvOBpbPDzn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86E_zK55U4OwHnBa">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a
going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. For the three months ended March 31, 2024, the Company recorded a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_pn5n6_di_c20240101__20240331_zZjeFnGaQNyi" title="Net loss">2.3</span>
million and used cash in operations of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_di_c20240101__20240331_zcjp7FkflkT3" title="Cash used in operating activities">4.2</span>
million. As of March 31, 2024, the Company had a cash and short-term investments balance of $<span id="xdx_901_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20240331_z5Ty4ChJRDzd" title="Cash on hand and short term investment">9.8</span>
million, working capital of $<span id="xdx_90A_ecustom--WorkingCapital_iI_pn5n6_c20240331_zQmvhpkx9zw8" title="Working capital">5.3</span>
million and stockholders&#8217; equity of $<span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20240331_znLVYy7Bxlvj" title="Stockholders' equity">5.3</span>
million. Management anticipates that the $<span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20240331_zDrTFXH2Muy7" title="Cash and cash equivalents, and short-term investments">9.8</span>
million of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at
least one year from the date the Company&#8217;s condensed consolidated financial statements for the three months ended March 31,
2024 were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock,
issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to
secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and
financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which
could adversely affect the Company&#8217;s business prospects, ability to meet long-term liquidity needs or ability to continue
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zUVg9VrPMp53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_z6t4ee2Icaxd">Accounting
Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Significant estimates include management&#8217;s estimates for continued
liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of
equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those
estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1WACwPISCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zgZSVwxfG11b">Cash
Equivalents and Short-Term Investments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to
approximately $<span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_z1qIwaqjlvrc" title="Cash equivalents">1.8</span></span> million and $<span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zEvm5EQIkkWe" title="Cash equivalents">443,000</span> at March 31, 2024 and December 31, 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. Total short-term investments amounted to approximately $<span id="xdx_90B_eus-gaap--ShortTermInvestments_iI_pn5n6_c20240331_zqBU4sK70doh" title="Short-term investments">7.9</span> million and $<span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zwmFAX9C0CFg" title="Short-term investments">12.9</span> million
at March 31, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziorEyji2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_862_zR0fvFg2ypda">Fair
Value of Financial Instruments</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90B_ecustom--WarrantLiabilitiesNoncurrent_iI_c20240331_zg7MQ6A73nl3" title="Derivative liability">394,000</span> and $<span id="xdx_90F_ecustom--WarrantLiabilitiesNoncurrent_iI_pn5n6_c20231231_z41BwTznGcol" title="Derivative liability">1.1</span> million at March 31, 2024 and December 31, 2023, respectively,
was based on Level 3  measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, short term investments,
prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity
of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_z8IOXlHZtJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zAhXxLgpaH99">Warrant
Liability</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z8e9I1ofZKs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86A_zpmiwBRniANe">Stock-Based
Compensation</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees and consultants for acquiring goods and services from non-employees, which include grants
of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,
<i>Compensation-Stock Compensation</i>. Stock based payments to officers, directors, employees and consultants, which are generally time
vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation
cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees
is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated
using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility,
expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation
expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf4anFW7U5ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_861_zLctfluGIJxk">Research
and Development Costs</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zzz6StdiIpWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86F_z207zpcRr3Z8">Leases</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for its lease in accordance with the guidance of ASC 842, <i>Leases</i>. The Company determines whether a contract is,
or contains, a lease at inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset during the lease
term, and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Right-of-use assets
and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zrSKWJL8FbG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_86C_zTjO7SIvIG17">Net
Loss Per Share</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_ziTwc5JANzOl" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">126,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">115,598</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">431,227 </span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">420,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zHA8mjrPcXB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zAwNsizvEos4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_860_znK4J0WXdxqh">Concentration</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember_zzjwvS7vwja5" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4 &#8211; Accounts
Payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztFFzE5GUkBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_863_znDNkrSM22G8">Segments</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined its reporting units in accordance with &#8220;<i>Segment Reporting</i>&#8221; (&#8220;ASC 280&#8221;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment
to determine if it includes one or more components that constitute a business. If there are components within an operating segment that
meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting
units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the
segments are economically similar and, if so, the operating segments are aggregated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has determined that the Company has one consolidated operating segment. The Company&#8217;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#8217;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zalqMxs3jpag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline"><span id="xdx_862_zHxP7rgoIAAd">Recent
Accounting Pronouncements</span></span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU No. 2023-07, &#8220;<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>&#8221;
(&#8220;ASU 2023-07&#8221;), which introduces new reportable segment disclosure requirements related to significant segment expenses
and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable
segment&#8217;s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact
that ASU 2023-07 will have on our segment related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665602000832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BC_ziTwc5JANzOl" style="display: none">Schedule
of Anti-dilutive Securities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2023</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(Unaudited)&#8239;&#8239;</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Options to purchase common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">126,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">115,598</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Warrants to purchase common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">304,962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">431,227 </span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">420,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665701824976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Estimated Fair Value of Financial Instrument</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z0JGDFi1Cl33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of financial instruments outstanding were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BD_zJRjVFMd1Z32" style="display: none">Schedule
of Estimated Fair Value of Financial Instrument</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztMhNO7KMYr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">7,859</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z75GnK4zHuN5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_909_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zp666a7kKvb5" title="Unrealized losses">(2</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zJBSCKjyYFGd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">7,857</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331_zIBgnI06Z5d1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">7,859</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331_zFKY3IUdVtAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331_zALzbXn8tCcc" title="Unrealized losses">(2</span></td><td style="padding-bottom: 2.5pt; text-align: left"><p style="margin: 0">)</p></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331_zWxLHr3Cze82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">7,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unrealized</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Fair</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Cost</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Gains</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Losses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztD6YbVVb1ah" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost">12,845</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zKnlikL4Dmf4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zc69T67D7b06" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTVqr9UN7zl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value">12,893</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zo1kL0JkJFV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">12,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231_zXhPl2cGd6b9" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">48</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zdX4QI6oQTXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231_z49XaFaMCKca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">12,893</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy Financial Assets</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6N7hXlixww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the Company&#8217;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_zlICH7SXekdi" style="display: none">Schedule
of Fair Value Hierarchy Financial Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zI4CqUzkaq0f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zat1NRDsdKNf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaMvr4KLzTFa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49F_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzVZLZmo8op4" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlUo8F3oXLHe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,845</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zzMDrpR0qKij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk8h9fLN7Mz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,702</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,845</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zPt7Kezepuw5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0DshjjNxMf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLjCYqnJkp1j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO95dlZITBtb" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCy8B65m789g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zuqbxTpRKdG9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Corporate notes and commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zlE1xueli5Lf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,336</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">443</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,893</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Warrant Liability Transactions</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3X6zCdBQdJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;<span id="xdx_8B2_zKaOILP8WDw" style="display: none">Schedule
of Warrant Liability Transactions</span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20240331_zoEgPTSb6eq1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20230331_zWtO1ZXEo27i" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ending</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zDZXJi8Y42ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,052</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zvWZYgOyU3B9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_zVpfyUou9429" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(658</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,924</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--Extinguishment_pn3n3_zgbpFKBU3Ljg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Extinguishment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zRGyrzfGHjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,926</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601965664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z55uojEbEr1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B3_z7ui9O5coLsj" style="display: none">Schedule
of Accounts Payable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zH4MAVKOBf92" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">March 31, 2024</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zhChP46WleE5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zQInsufFB5dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Accounts payable to a third-party manufacturer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zrcHkyXb61Bk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;1,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz5ku_z8mP4v5MQFLh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,213</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702380864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Derivative Liabilities Assumptions</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQqnUtf6DJn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following
assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zFmm3Da7Ieli" style="display: none">Schedule
of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common Warrants and Placement</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Agents Warrants</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zgX4hwLo0IW3" style="width: 16%; text-align: right" title="Stock price">4.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_z2QSCVtGDDqe" style="width: 16%; text-align: right" title="Stock price">7.80</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGtU07RSD04c" style="text-align: right" title="Warrants measurement input">4.21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zxKCPjUGvB8j" style="text-align: right" title="Warrants measurement input">4.26</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zEUGR9NUYtij" style="text-align: right" title="Warrants measurement input">103.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zzrFgCoZn1Ej" style="text-align: right" title="Warrants measurement input">115.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zrB2KlOieMdd" title="Expected life (in years)">4.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQYX5gLaxnph" title="Expected life (in years)">4.25</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGVo7FcTT9Gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zbLdhCL8hEVi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zOjR9XpeBfOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">393</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zFbN9ZDk9WS" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">1,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember', window );">2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Derivative Liabilities Assumptions</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zagaFcjcLmP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8B5_zIzFK6VVkV5c" style="display: none">Schedule of Derivative Liabilities Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZDgjZpvR0Xk" style="width: 16%; text-align: right" title="Stock price">4.43</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZEZmFaYpCMj" style="width: 16%; text-align: right" title="Stock price">&#160;&#160;&#160;&#160;&#160;&#160;7.80</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zazWhJfVHMqk" style="text-align: right" title="Warrants measurement input">&#160;&#160;&#160;&#160;&#160;4.21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z99g2NXT9Su1" style="text-align: right" title="Warrants measurement input">4.54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zbP6o7EEGvQh" style="text-align: right" title="Warrants measurement input">89</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_znim9ugh62Me" style="text-align: right" title="Warrants measurement input">89</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znn9f4bEwZq1" style="text-align: right" title="Expected life (in years)">1.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgtzzt3R7Hd4" style="text-align: right" title="Expected life (in years)">1.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Expected dividend yield</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zjgWYePrXu17" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zv9TvHP75Oxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of warrants (in thousands)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zRy7N8jay5ca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z869XvUVSoy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665726915184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2tPo8CIo4ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zJSsz6wWDxN7" style="display: none">Schedule
of Warrant Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Warrants outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331_zFgQFfaV9pq4" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zIGIdThyDFg3" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240331_zG9izbUoO0Na" style="text-align: right" title="Number of warrants, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0734">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240331_zyiVyk7gfszk" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240331_zrN6MpnB5kn6" style="text-align: right" title="Number of warrants, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240331_zqjcpfPExbb2" style="text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331_zELmq5581LK2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z0WfWztEl4k2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0744">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240331_zAADC3aQD8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zfBUQ6XTWVb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240331_zLod2FftuVD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zLit3LkKzhD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance">63.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXZMBd9rtAbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock option transactions for the three months ended March 31, 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zoaMKYCdkRq1" style="display: none">Schedule of Options Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zcVqTVH0N2K9" style="width: 16%; text-align: right" title="Number of Options outstanding, Beginning balance">126,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zNGchUfePBZ6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Beginning balance">39.60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240331_znlrYWxW9IH1" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zGX43NE281Ek" style="text-align: right" title="Weighted-Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20240331_zzsIcVpT9Ei8" style="text-align: right" title="Number of Options, Forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z1AyspYR5ZYi" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20240101__20240331_zuuz5VEEG3Y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zJ5CFwpa7Ehk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_znrqOLcJ9Nn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options outstanding, Ending balance">126,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_z1AkLGh0qJwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Ending balance">39.60</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240331_zh1U7KDOLYL8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, Ending balance">123,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zR3HGKbcfKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Exercisable Ending balance">40.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Granted Assumptions</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDKnzZsy89Hj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_z64iAGTdjEh" style="display: none">Schedule
of Stock Granted Assumptions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240331_zlLUphoekLNa" title="Stock price">0.85</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20240331_zmVDb47kBZjg" title="Risk-free interest rate">3.62</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_z37MaOpycdxc" title="Expected volatility">121</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zuk9yHJ3G7K7" title="Expected life (in years)">5.3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20240331_z851IfkqMDy7" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Options Outstanding and Options Exercisable</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFFWobc17Um2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zk0iKTjrTA1f" style="display: none">Schedule
of Options Outstanding and Options Exercisable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Options Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEu5lvIcQeD1" title="Range of excercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIlgHWsDRiyj" style="width: 13%; text-align: right" title="Options outstanding">16,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4emyU2pKeb9" title="Options outstanding, weighted average remaining contractual life (years)">9.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlr2bLcigTj6" title="Options outstanding, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCOru1e9nLwe" style="width: 13%; text-align: right" title="Options exercisable">13,888</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zTH2nGfEPzz5" title="Options exercisable, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZMmrm9gsfZa" title="Range of excercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zx28sGLBYmJg" style="text-align: right" title="Options outstanding">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJmBSepkNhK8" title="Options outstanding, weighted average remaining contractual life (years)">8.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKeMlT7s7BF6" title="Options outstanding, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeBMZmMjCsUb" style="text-align: right" title="Options exercisable">66,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zvlKbe2sMeV" title="Options exercisable, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zYDjUUnRoUM" title="Range of excercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzfqVJGqVc1g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding">42,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPpDH0Rgs3m8" title="Options outstanding, weighted average remaining contractual life (years)">8.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGh62hqNMmt6" title="Options outstanding, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpo6d4ydV4p8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable">42,932</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z89HeQBVZbyh" title="Options exercisable, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331_zTK6HreRNjRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">126,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331_zKGqKNtlxUk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">123,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLghJun5l3oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of March 31, 2024 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_zFsysDk5g4db" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Outstanding</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Contractual</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercisable</p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zHSXupPjHcl8" title="Range of lower excercise price">10.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFl86VL9kfyf" style="width: 13%; text-align: right" title="Number of warrants outstanding">1,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zaDMAyWFSLt5" title="Warrants outstanding, weighted average remaining contractual life (years)">1.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrZ18LkAiiu6" title="Warrants outstanding, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2tqakX7I8M4" style="width: 13%; text-align: right" title="Number of warrants exercisable">1,867</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><p style="margin: 0">$</p></td><td style="width: 13%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWK5HAPKw5Rh" title="Warrants exercisable, weighted average exercise price">10.50</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember__srt--RangeAxis__srt--MinimumMember_zq7kwz31DJJj">30.00</span> &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfGc974mkT82">37.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpDhACuY5xZj" style="text-align: right" title="Number of warrants outstanding">229,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNKpgoJuj9a8" title="Warrants outstanding, weighted average remaining contractual life (years)">4.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztykbqq9dBQc" title="Warrants outstanding, weighted average exercise price">30.42</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgTFTPjeIgvc" style="text-align: right" title="Number of warrants exercisable">229,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZayCWSq0m22" title="Warrants exercisable, weighted average exercise price">30.42</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcCzcyF5N1Dg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zb9ESKTsNg5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding">73,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4PbyfDlbyB5" title="Warrants outstanding, weighted average remaining contractual life (years)">1.9</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDx2yi10Rg2j" title="Warrants outstanding, weighted average exercise price">165.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z6VPcThUb686" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable">73,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zm0QuDITJYRi" title="Warrants exercisable, weighted average exercise price">165.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHv4f51WjhB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zBoEGCRAsyga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable">304,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrants oustanding and exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665601918768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock', window );">Schedule of Other Information Related Leases Under Non-Cancellable</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zgyhERp1OFh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zHTu9T5tgbwl" style="display: none">Schedule of Other Information Related Leases Under Non-Cancellable</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zjZ0ZDAuVWH7" style="width: 16%; text-align: right" title="Operating cash flows from operating leases">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zZBCB8oTyJX9" style="width: 16%; text-align: right" title="Operating cash flows from operating leases">30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average remaining lease term (in years):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zueD2O4kKHTg" title="Weighted average remaining lease term operating leases">0.25</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zNwuuCxB1ZYj" title="Weighted average remaining lease term operating leases">1.5</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Weighted-average discount rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_z9iTzikCOhih" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_ztH3xINMvmsd" title="Weighted average discount rate operating leases">10</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8XIVHA2puYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum lease payments under non-cancellable operating leases were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zES8LvCr8qmg" style="display: none">Schedule of Future Minimum Lease Payments</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240331_zrBxMW6DDhQ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2024 (Unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maOLLza2F_zXaoO2aCjEGh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Within one year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLza2F_zCWaZYDpAHGj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">After one year and within two years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLza2F_z2lWo4z7ZMT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After two years and within three years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maOLLza2F_z6XOr6JiqEVf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLLza2F_znT7mT1b0eEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXgqXZWxrnD7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less &#8211; Discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z7j9PSEov4Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702066768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Feb. 02, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Revers stock split ratio</a></td>
<td class="text">On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#8217;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol &#8220;GTBP.&#8221;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,380,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
<td class="nump">41,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702059152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">431,227<span></span>
</td>
<td class="nump">420,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">126,265<span></span>
</td>
<td class="nump">115,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">304,962<span></span>
</td>
<td class="nump">304,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609381520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,266,000)<span></span>
</td>
<td class="num">$ (227,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(4,163,000)<span></span>
</td>
<td class="num">(2,906,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CashOnHandAndShortTermInvestment', window );">Cash on hand and short term investment</a></td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WorkingCapital', window );">Working capital</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">5,312,000<span></span>
</td>
<td class="nump">$ 13,053,000<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
<td class="nump">$ 11,734,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents, and short-term investments</a></td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">7,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CashOnHandAndShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash on hand and short term investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CashOnHandAndShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609224816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 7,859<span></span>
</td>
<td class="nump">$ 12,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Fair value</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">7,859<span></span>
</td>
<td class="nump">12,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Unrealized gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Fair value</a></td>
<td class="nump">$ 7,857<span></span>
</td>
<td class="nump">$ 12,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702358352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Hierarchy Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">$ 9,702<span></span>
</td>
<td class="nump">$ 13,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">12,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember', window );">Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=GTBP_CorporateNotesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702355024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(658)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_Extinguishment', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending balance</a></td>
<td class="nump">$ 394<span></span>
</td>
<td class="nump">$ 2,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_Extinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_Extinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609389168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="num">$ (658,000)<span></span>
</td>
<td class="num">$ (2,924,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609467424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable to a third-party manufacturer</a></td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="nump">$ 3,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="nump">$ 3,213<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665703563760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 777,000<span></span>
</td>
<td class="nump">$ 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_ThirdPartyProductManufacturerMember', window );">Third Party Product Manufacturer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember', window );">Master Services Agreement [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_ThirdPartyProductManufacturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_ThirdPartyProductManufacturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702013984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liabilities Assumptions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="num">$ (658)<span></span>
</td>
<td class="num">$ (2,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember', window );">2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | 2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | $ / shares</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | $ / shares</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwentyTwentyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609206560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility amount utilized in the value calculation percentage</a></td>
<td class="nump">121.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInFairValueOfWarrantLiability', window );">Change in fair value of the warrant liability</a></td>
<td class="nump">$ 393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGain', window );">Recognized gain of change in fair value of derivative liability</a></td>
<td class="nump">$ 658,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantsMember', window );">Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_PlacementAgentWarrantMember', window );">Placement Agents Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility amount utilized in the value calculation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_PurchaseWarrantMember', window );">Purchase Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PurchaseWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PurchaseWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">304,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 63.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of warrants, forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted average exercise price, forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">304,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 63.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable, ending balance | shares</a></td>
<td class="nump">304,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, ending balance | $ / shares</a></td>
<td class="nump">$ 63.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665703518112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">304,962<span></span>
</td>
<td class="nump">304,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">304,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of warrants exercisable</a></td>
<td class="nump">304,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of lower excercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Warrants outstanding, weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of warrants exercisable</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Warrants exercisable, weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">229,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Warrants outstanding, weighted average exercise price</a></td>
<td class="nump">$ 30.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of warrants exercisable</a></td>
<td class="nump">229,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Warrants exercisable, weighted average exercise price</a></td>
<td class="nump">$ 30.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="nump">37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member] | Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants outstanding</a></td>
<td class="nump">73,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Warrants outstanding, weighted average exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of warrants exercisable</a></td>
<td class="nump">73,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Warrants exercisable, weighted average exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665702242448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options outstanding, Beginning balance | shares</a></td>
<td class="nump">126,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Outstanding Beginning balance | $ / shares</a></td>
<td class="nump">$ 39.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Forfeited/cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited/cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options outstanding, Ending balance | shares</a></td>
<td class="nump">126,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 39.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable, Ending balance | shares</a></td>
<td class="nump">123,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options Exercisable Ending balance | $ / shares</a></td>
<td class="nump">$ 40.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665780703408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Granted Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 0.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">121.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665726243472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Outstanding and Options Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,265<span></span>
</td>
<td class="nump">126,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.60<span></span>
</td>
<td class="nump">$ 39.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">123,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Range of excercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Range of excercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Range of excercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665598329696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jan. 27, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (658,000)<span></span>
</td>
<td class="num">$ (2,924,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable', window );">Issued shares for vendor payable</a></td>
<td class="nump">16,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable', window );">Fair value for vendor payable</a></td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesGainLoss', window );">Debt securities gain</a></td>
<td class="nump">533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Purchase an aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Stock options expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">53,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Stock compensation expense unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember', window );">Series K Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember', window );">Series K Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GTBP_BoardOfDirectorsEmployeesAndConsultantsMember', window );">Board Of Directors Employees And Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable', window );">Issued shares for vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Preferred stock shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantAndPlacementAgentWarrantMember', window );">Common Warrant and Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Prefunded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,667<span></span>
</td>
<td class="nump">96,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,667<span></span>
</td>
<td class="nump">216,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Placement Agents Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Shares and Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants and Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.997<span></span>
</td>
<td class="nump">$ 29.997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period fair value common shares in settlement of vendors payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common sharesIn settlement of vendors payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesKPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_BoardOfDirectorsEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_BoardOfDirectorsEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantAndPlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantAndPlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_CommonSharesAndCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_CommonSharesAndCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PreFundedWarrantsAndCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PreFundedWarrantsAndCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665608763840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>May 13, 2022</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares return, value</a></td>
<td class="nump">$ 409,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares return</a></td>
<td class="nump">13,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777,000<span></span>
</td>
<td class="nump">$ 1,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Aggregate research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember', window );">Scientific Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Proceeds from upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Patent Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LicenseMaintenanceFeeReceivable', window );">License maintenance fee, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LicenseMaintenanceFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee, receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LicenseMaintenanceFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_ScientificResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665701941840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Other Information Related Leases Under Non-Cancellable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating leases</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665726238560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Within one year</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">After one year and within two years</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">After two years and within three years</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less &#8211; Discount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Two..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665609197824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 08, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Lessee, operating sublease, option to extend</a></td>
<td class="text">commencement date of January 1, 2022 and maturing on June 30, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use asset</a></td>
<td class="nump">$ 247,294<span></span>
</td>
<td class="nump">260,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WrittenOffRightOfUseAsset', window );">Written off right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WrittenOffRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written off right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WrittenOffRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139665701934736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,268,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">36,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 278,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$RJ] ,XOI-2'G?0/BE7ZP7]02P,$%     @ $(BO6.N*TV0?!0  2!,  !@
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M7ET"K_#K'_&;XX<#4F+66.WH[H+D5)(MY1LXE%KI-2R\S!S9AD[/<2?VMIE
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M'N1I<7@G/ZI G"B@\(P"JA106P&=4? K!;^EX.,S"D&E$+0MC,XHA)5"V%*
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M\</?  X#R3;ES]8/3$J6EX]K2A+*M8#Z?L68?!GH7\+K/V/,_@-02P,$%
M  @ $(BO6*C:U1-#!P  V"4  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6RU6N]SHC@8_E<RWLY-.[.N$!2UUSICI=XYL]5.;?<^IQ"56R!>$MOM_?67
M1 H",;8,_5*!YGV2]^']\02X?"'T)]M@S,&O.$K856O#^?:BTV'^!L>(?2-;
MG(C_K B-$1>G=-UA6XI1H(SBJ ,MR^W$*$Q:HTMU[8Z.+LF.1V&"[RA@NSA&
M]/4:1^3EJF6WWB[<A^L-EQ<ZH\LM6N,EYH_;.RK..AE*$,8X82%) ,6KJ];8
MOO <9:!&_ CQ"SLX!M*5)T)^RI-9<-6RY(IPA'TN(9#X><83'$422:SCWQ2T
ME<TI#0^/W]"GRGGAS!-B>$*BO\. ;ZY:@Q8(\ KM(GY/7O["J4,]B>>3B*F_
MX"4=:[6 OV.<Q*FQ6$$<)OM?]"LEXL! X.@-8&H RP;=(P9.:N"4#=PC!MW4
MH*N8V;NB>/ 01Z-+2EX E:,%FCQ09"IKX7Z8R/N^Y%3\-Q1V?#0A22#N(@Z
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MY0#Q_Q4A_.U$3I!]S#7Z'U!+ P04    "  0B*]8V,$SYMH&   A$   &
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M[ZT3Q_YV1Q?:-DN%Q.K3%U/TZ4JKA;$^Z(*$R7%UT*>5\J3-%JC$"X4EDY>
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MB18?E[C#LY,-^#ZWF.R[%Q&P_:_ V7\!4$L#!!0    ( !"(KU@/NM 7L!
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ML_DS2Q:#V'"1+3:@95CQKJ:# ;FZ=30$R;L=;+W2K78E+$#/]59$8$/]VK)
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M2'N& GG4T_>!304/IT-AY^*Q.;(+H5_D@H]RCL?$<>28?1! WVT)5V']GI,
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M8&6)3$]>P-[.*$@UE;-WK$IHX#MUC#1W>GHRF<UF(V7!L6S03,AP^HXHC,C
MJ+%!_2;DK41DA'3EMI:A7"@^5\,X)T[PTX C0XU8:P(]@D>A(R0<<B46**H&
M'L(Q$]W'L"('6P4;P"\D<?;(_*4'9?L=N4UF[U+%DTWC8@;.PGB;/:%PP5D<
MZY%HX( \$VX(@CEM291^P&3N.K1=0$>$F(J]B)!*]NZ?\^1 A789\@?LE>$$
MJ0!A+.H,5N*0( D&-I3[>\EY'0R60*[+PSO5/7TK84DDU39<_Z[ B0.Z@A-I
M/P!EX&*YXS[6N<GP=L25H_/N5WKNG.J^<[Z<OE+'<_SW"><H?HLP]2F%R.<,
MA-*O1=:HNNYP*E3Y7EU8_$E]@$_GUQ>I$;!W_*6M!^^+T\ZOA_;!V7QV>#Q+
MB5(1_C)F$->01*:+AQ@[Q/>(L"ULMWXL-1)O1?[X3^"$1)FRGZR8:%Q_$A0+
M-I@.M!'<@XA2%4A<2B^9;$#BZ\MX*"!U"LJQ^.7> Y!3LY^P,<GS9'.IU^*H
MP)K RG1HT4CW(P9;WDG#J.Z6JA8B<IQ\$9A&"WDM!),;I.XF=8$R.=<&S@<T
MV'$\$%4' 0:5?*U^I"G%L?HM9C0?(AL[HA;F4A'?_N@M]U@<IS(3[Q0"KDK*
M12IIN3$8S4:Y(;-:8M+L&%(RL(X$.@KR]ZKB"!:IYGNE&HO"*1:LM2G=_FTG
M#V6/0@LYDX(T'(AIL*5&# 9N^\X7:9!=4"IGAR$&(K4"\-U9+B2PPV*7#P((
ME")>OP 4,!EI=F*9'EC(@1],M5?RJ(:3O6H0\88S].VP]P1[;@-@+0A(NTZD
M;FW,A*%,V 4J&!;Q&2V#.<9>5#PM+/>P@;2<RX/?CUO2B<S=8AAM$>?OI.H\
M>77*:?=X>KQOM?L=[K2<V&L(P_VH,9&N8&0CG)T?T ?&9/4@$4KE8#(^3--E
MWQBK,3&F?ORVW(DQF)CJ8?(DQW4Z$30\J!DVUE79^\3@1:; P79%ED,37"+%
MBTJ+'Y-*<_*BA;"2^W=^/^)*11C8AS)+T58^@!QD(,3L +'OM=3<' KN^ ?X
M*U$-J)JZ?74-GIY/W-/@):C]8K<HS<^.GT]BOU%]R&:1QG_0]8H<(CM;\H*@
ML8RR[S^GR7OR5/"&7!N<,I'WQ6Y4/TM+T3)6<(G*W5U8!/N5W'8-=4 '-M%)
M#B#6XW369O'CD $O"RN2\/O%Q<*Y[FBC<,?"3 4D;XN\2B45M40.+P@?6#=P
MM>%R*9Y"*C9IX,A!O?12#@58JGPBE&*I_X *88(,CF-TECY22\ON=+ )<1Y4
M*JRZ4<'CJ 'EJ W)?;'8J_$%Q56L+HW3P1FX K/2)*%\C-@QR-UUI+6IUR-]
MW>M!Z@*1EGSX+TC,Q0J7MRM+34ON%<53,+]L;7N8UHA%1JQ65^PV%)=QB*@4
ME(\Q>Y*<(!"4IVY!$KX++/#:4E7E"/%(!+T\/IN,;'_(6E(C=_@%V$%<H*!C
M?J ,8[?LKI?6=U[^+W"VGBM3TH\+,Z0ED<V@<P508^>.L^0VP(. R3WC O&V
M-+$-9V^T6^N2[. %U.&5WK:MYO9JW5?,/%TN9[[K(UD B$I3!:?R&Z='Q8]X
M/%57H52J"68IH!L_"GCJ&4,.U#!XV@9TZ0GRI,0A)Z;Z,"J#4G?I];C<3HF!
MR1+^-C1FGRWI>"O4/K&UR43T=#Z)J_ZL ?34K+U"_KE>T_9T[UP5.&<+W7GU
MC.J6[TFQ2!^L$,^QW1/84:$DW8Y;?G5#UX<XGT,UJMJ>KV>RABS-AI' -:@2
MH(E#*R@U@#Z8AE>.^Q?_W_O'AE5-&Y'VM?341EVQ/<(6>X2]BJTAJK?C>@]6
MB5$.VKB1:XJLJ2#QS8A$5(^K8'U'U;\DH5'\<X,V99?L"OPN^&BZYJJ#&KD1
M/^@.:%V%^\O$#00>@A8,[=&9PW@:(6/"\:6S,C3-1VV86\T1/+Z=%3NE+@-?
M/<3;@4&H;Q+DM;JN .%]P^3Q/'^475(7XSL*]>S7> GW/47WR:LWX<_X,N/D
M\8'%OV+_U:8VR%@+Q_,7D_F+Y^H8=./YJ[/B]VB?1V><S$XGKU[,X]]"BOC1
M<94?+MY/(>5\_E*=SF>3YR]F],)'!9V'[C.W[ S==/)%GRC?MO=)@.GZ]$9$
M]A:%;D)6-/?)7)C 3\T&8ZE1LF"0">TJ:A?HFN@/P)\W+SZWX;8#0DJ[*B_Q
M/WWX/-3X)@UEYL3+]5M2VG=J_GS&]#UK;"UT8P"XH8H:)[U,W "VU'W9"^U"
MV%TV&^'H :9<_T\& D%7^N"OAN_)D(A,IYSQ\/D[!&ZH4?(;JW)4\50C$U$^
MCVP_I4.F=/<(OL0O+04!M+H![;$.I01X +U'I$[3>T2AK^*+*YD)%J-7#_NR
MB89+GW'HM_>MM/P>)(S(E\-RX7*>I@S&*-9\LYZ6?G"Q1<_)!4=-K-"VPDI>
MUA9?O&^A0<8P+-Y"2XF_*9'=J:0N8@\&1ET;O<S6KS70DQ1/5RI$.F[H/<34
M!P\M1%MQ&8-?+:(TU)W?( Y1=I&%6SG<F29,0E)_<$0A"O$R;O2NU6I%+\E$
M_]A ,GK+Y^$2GN[)R9GRWMN5LRT^5X'J?6Z+G\&%..$1G,E]'37B8@ER?OTK
M7&C*3P]G+R=/V/F95$_SL]GWK]7G#<C0C4Z<6(:QK\:9'[+W=/954]DM%_E%
M+""EC2M71W2\6$4@"!=]Q_K:(5=(.N!^2O96E$^]1%)P(C@2^\2P."V&L],=
MCK-4VZ12C%63^C-IM4/4W;S^ I6-'JZ;!6ZX5Y9=B/DGKL3(Y@6=(>!6:-9T
M<K\KZ9Q[?H@6+H^W8XOR'2LG^#(1R<14]K_*L_^-CV+O&Q]3M>]=RJ/L%=B-
M=BM^T9?OC=I.WH9-OZ9WB<_E%=IAN+R(C/2ZHL9WHY>8.IN^?'X _.27>^5+
M9[?\0NW"=IW=\$=B\MK1 #Q?6@!>^$(;I#>LW_\?4$L#!!0    ( !"(KUA?
M<:?4-P0  %4+   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*U636_;
M.!"]ZU<0:E$X@#>2)=NQ$]M /ML :1$T27M8[(&6QA81BE1)*D[VU^^0DF6Y
M39P@V(M$4O-FW@P?J9FLI+K7&8 ACSD7>NIGQA2'0:"3#'*J]V4! K\LI,JI
MP:E:!KI00%,'RGD0A>$PR"D3_FSBUJ[5;")+PYF :T5TF>=4/9T EZNIW_/7
M"]_9,C-V(9A-"KJ$&S!WQ;7"6=!X25D.0C,IB(+%U#_N'9[TK;TS^,%@I5MC
M8C.92WEO)Y?IU \M(>"0&.N!XNL!3H%SZPAI_*I]^DU("VR/U]XO7.Z8RYQJ
M.)7\)TM--O5'/DEA04MNOLO5%ZCS&5A_B>3:/<FJLHV'/DE*;61>@Y%!SD3U
MIH]U'5J 4?@"(*H!D>-=!7(LSZBALXF2*Z*L-7JS Y>J0R,Y)NRFW!B%7QGB
MS.R",D5^4%X"D0MRP005":.<7 IM5(G5-WH2& QDS8.D=GI2.8U><!J3KU*8
M3)-SD4*ZC0^08,,R6K,\B78Z_$K5/HE[71*%47^'O[C).G;^XM>S/F,ZX5*7
M"C3Y^WB.6:-0_GDNY\IE_WF7]O <ZH(F,/7Q=&A0#^#//GWH#<.C'83[#>'^
M+N_OW::=3I^G_$T:\&+RZ<,HZO6.R!L"D]L,/-"&X1F!E"PLXL$BM(4L&@AK
M0?!ZT(:*E(DE68$"0C592(Y7A"8=)HC)9*GQN]X[)#=X$:4E!P^]G3=A7B?F
MH6J2K)$-Z=P)6J8,P7O>G< ;C+-_T5%K:'UZIU(;\AFO,TVNI-:8A8OBW612
MF;\,J!PS><!\JTP^DH/N:##&MRM9=(2C3D3VZ@\'WJTT2.M5LS-(()^#6O.-
M_U>.O:@[Z@]PT!]M4;#KX[CAN-O,;72U2W;?#)USP(O9:<>&,1F04YD75#PY
MZ,&1;JF!9 R4W9$GW&E%& (VVJ"8!"YT$JHS K]*AA#G$S703F5OISI:FOC2
M!-M(X]@%\5I65_  G/3J=U2_XUW*>0M:"GC"2UK=XT]U42)/6\*ZLNOWIKCU
M"#=5%5*AN(G ,UBEGL@\!^78%[1 =3BQ-."M6;V+?Q3U(QEW#\*H%;N";2*_
M(:<_Y?G>0O3[<?-\9Q%J.:[1V].7R]"+NW$\;(+7L V+8VU%M+WW7:?JEHK1
MPJZLJ%)4&,(9G3/.S!.NV!CQN-\-PW!+EC]KVZO&]A;GFKJ^1/\NMJTI'LU,
M ;3^IWCR7D&TU+JEW!-8,B'LR9U3CK4!IXAPX)0Q]BZU+MTJ,JZSP_*;=N[K
M0@VZH[CGG694+ %/9]ND,QR,\%;K1-TQ,MOSSA\-1BR9SNSY;3RL]ZI*J$4(
MZX=/BQZ2Y_Z;0:O505$L74.G42*E,%77TZPV/>-QU2IMS*N&$\NVM#<HAP5"
MP_V#@4]4U<15$R,+USC-I<$VS TS['M!60/\OI HT7IB S2=].P_4$L#!!0
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M^]JRO:;\,&\O>Z"^T96C@M=P'0]?G\1DVPM4N_"F#I>6E?&X H7'''=.MF*
M]VN#6=DMY(#^%KOX#U!+ P04    "  0B*]8('Y&3$<&   R$   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6RM6-MNVS@0?==7#-P+6B"Q)=_BMDF
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M(A?:?/W5-(XF[]G'7QII-Q<#"_ZT:Y"UO*X]K_@57@G[055V9=C'*A?Y(?T
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M.;,KP78FS)>"%K8[,I0'<!(J<I85O#&"5<K2M)$( >:M8@\"$&!7LG+,CD-
M++0J0M*@6PQR884N'6.[XM81POPGV4*GBW]EG=PGKB5_*(3?*8W3@%=,5G5C
M23X1+[C4V%DT@KS'7;[$P_<+^2SR<YP$Y^[+S2*+5$T &R#H@$.G10, T&Q^
M?\.FT>@\'?9;YS2F,^I+/+>W0;_PE(2(9^^Q$WX*U+IBQN4-,2=:4<BE),.A
M/QDLGC/A%&<+K4JH[C(0"823(E--966U#-D<WSK'9['I_T^Z!VNH2]$V1BXD
MA0 TJ!"WR@K$0A:H-^^A,S8*IX>%\;TQ#:A(Z7O4L,R$81\:#8T"$FM76@A6
M>MP5A+N'Q9AXQG6C34,"6W<]"4/V,<H;'V+LC1A?@AL9T=]W*K+$Z1#WTW0&
MQJZ.7]7R)VB!GUN^<6F&LO4*H;!:A4ZP1O'%\93%TXGC/6TK=)3X:KS%42TT
MPMZ*@R>D,,'-;J$%B;D-CK"(K/\ 9"@?D)$[IT 'A,7%!@ 0)RTFS4U 0&)P
MII-;M'@",HHVDTR-2!ED'HI+/$F%;-X(KG<YL'6?\ZOQF9;_IVE]C1V:F@0'
M26XD"DY5:0!@PGC'M-JT%O[MA87PY[?B03L<A-=<W#SEM>(Z1QX;N:P<VZB-
M%!EV[T0$K6#/G;WD3H6&(H/5UM4*)VS8,(L^K,]:9/'EWMG0GAY]N 6YY2WI
MUEZ"ETN9MBX=[(C%0KC&K!7K$0OJ$X\(RL^=TK\[J)7:52#M_N24-H=9NRUB
M-PRZHD1O4!F>>0**X9<46NKE<J(HT.J:=^P>'73>%((,:$4!3V LZCWXL7'*
MTY+K',%O#OO1" =;M3X^"YU)Y!].QVQO'LVUL;"*L@IN?.$)G%5I?S:.Z=Q+
MPF08?$=TD'#.S@,TLPLA,1IDO,K0#K?SG3 _>DW6D<W'@K9DPG/C;1*]378R
MR,BWHNCP@4*XK\EZ_V18-$6Q<9 F<G\P;I=7//=8WSJR)D>B01#(,(HK]Z<L
M[B./N "YU7ZP7DGHX5' G30'V73@D%/=#ZET8/[;*6'8IWV.,/3CCC@XN>DX
M0=S..UXM7=4<9@UK$^V _BCCV)V@^QLMW5!_@=QOT-O]72X$^^:?!'%_?DES
M6LR>1K]%$IRAP*FSBOI3:KS"A!W.M*/ =UZ^"XOC&=JT,4M#RO(PC;<S;A1$
MXQ&;)/TTGH$A_L8CHNUFW"CHLJ_[/<"$(Z#P6-5"WA\-#!2M3MZ7 $.W]\B/
MW?1OPD(4XW"!@\Y8,@O'.UAP !V_[WY/0L3QGAU<'*^\HLZ14XYUZ:C>!HX(
M,)].*37281B/]F\IU,OB"J"6E?RU.V[1NZ&,:^65\+'$(50+A-%%5#S3M^\)
M5:O!LO4*CK,,YR *P_6=  .JN3X395VHC: #6RT6"(#O ()<0KQ5&-$S 9K@
M6CETH59ZK]T*]V\R\>144]1IL)]\AO39BG8X4;KP.@BBON3!G?\8[!0!"3J_
M; 5]" ;Y$LBW; _7<7OO&;F"P[\P/8 G7PY=BLR!PZ57I"T4#Z5GZ)NFH^!.
MFL?S!14"V@"DN['^$$]"U->?D"PU- *;)X6.QS6\"&6TOU(XL(&O-QYO1F&R
M6\Q1&CEJBVVD*.B 0H9^4?N;'CJVRX^M;T\F0]>6'?7*71S<?3(:^KOD:.@[
MUC9]_[C3H:N'X\/A" ,<])_:>VK?__$1,788/PNCW1F1]*?3Z?:0\'G<)O44
MMZB#"3<()FF8#ED:]V=)C#T).YAP@Z##I0YI3M\H7O2;<7\RF>*^@FL,T?IW
M!DCX3%L">A!!#X':P,7-R&QWMW8-]9[?NR0[G3O^^GS4S7@N1FQI2=HK+4[@
M2$)VZJUJL/>*6 J]=&^EU+3C+NP?%+>SV^?8N7^%W&WW;[G0>PE#62$6(!V&
MDU'/7WVZ@56U>Y-\4-:JTGVN!,=%@C9@?:&4[08D8/M(??5?4$L#!!0    (
M !"(KU@W2AJ6@ D  .@6   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;)U8VW+;.!)]YU>@E*EL4J65)?F6Q)<JV[G-C)VDXF1G=[;V 2);$L8@H0%
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M;" V0.:6E3YQ,@96:N0:+*!4J?*E-B%-?2:'$2@W*,74FG5H'(H:-@,,8V2
M2&/):?&U+)5';M[L8!E<ZU%4<(.EV5H*DDQ/WGT5F$2I.8\W'L:0>-K5B@H
M#"QRNQ$K5*[616J%W5K&/P16NB6YMF2[F0RRC=A!*D+F*V65(RM#LFTA)P(F
M%'&BL'HKZ0G%6,B6%$I@ QF3MH@0:U&+4UY'#MFH8@-020DZ+Z$"U+G 7ZL5
MPN)@W UF"\UJD"E8/6SL%+G%5K(IUNMCDA<<(7A]+26"'#'5#0[NF'7F-AJ[
M+F+LNAB-74D-]AY2WI('#X6Q42K#8:PCG472'-%<.(K!X4 M0ELF*$@"Z.":
MD9 2ELBZ?,NRS+_ T.(JY 1=>/*VG6C*X4[RM&VL<I(8E<8D^M[!3^]_M"FL
MG!V:XU:AV!S \T&0=H@=0V[3>@;DPXZB/FRSY:R)25G$SCXM$@9M6DZN+I4Z
M2RT5MFT"Z-$V$=.TUW[HI!?JP$[$T:2[092:@U&6633>"<4! S;<B!T  L:
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M?P- F@MXOA28"^7"&*C^6,S_ 5!+ P04    "  0B*]8@NQ([)4"  #%!0
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MHG8.=)\K9?N#"S!,[N0/4$L#!!0    ( !"(KUBZ 6G7EP,  "8+   9
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M970R-2YX;6S-5EUOFS 4_2L6DZ9-:LM7($F7("5IIU5:M:C9UH=J#P[<!*N
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M <0MH(Z<WRBKW5I039.I%#LBC36RF4$=FQJ-WK#2'.-22WS*$*>3)=Z+K.)
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M!U$8Z/L+KKMN>U)\EE5]AC?Y'U!+ P04    "  0B*]8K;J'8_0"  "G"
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MS0S_)$#9 /P^D])L.G:"ZM\D_@E02P,$%     @ $(BO6,9GR3=Q @  B 8
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M(<P;?$06V12VIJ-%96O#2FBL-+:9XUL T@3@?":$?NV8<M.]+O$_4$L#!!0
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M0S@GI;K, *= 90?Q?$L(/S7D -V18O@?4$L#!!0    ( !"(KU@I)).X1@8
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M,CIGHKA!?[[(<_5\401HCI9-_P502P,$%     @ $(BO6*O6YUCP P  )1,
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MS\A&8DDY$V-;*F.TI#W+.[[*.B8'.G;1;1++I4 ?8I_YN^UMY43A"=EZ<D5
MP5O*SY&+SQ!Q2*_"GFNX^0V;%<U=P!RW"*R;ZKD']*Y#*D0IJBCA*)TDZ.LG
M]2KZ*%DD_JF*6Z;;J];5T_I"K.B,32PU;P7CS\R:_O(3]IS?JIQN26PG!+TB
M!#U(??KG.GIB7,=@L\VLQ&16E>N97C_5TPO0\]1U>B./C.WGLE-'7]LQMU^8
MVP?-+=+_ZRW3AE<.#BA1=W!:$MOQUBN\]3K*3Z_-$+0DMA."01&"0<OY.3@M
M/\%N&SHU+)P:UG6*F>6[RJGA:4Z!W39T:E0X-:HW-=%_Z('&"X;N5*I"\Q74
MK9NL+8GMA  [IE(['<W87+BE*+2EMAN&$K!@,!>R<5=A4 2J$IV]S-+L9FC%
M@UEE@N>"@U*&8^>\OY??<+=-W2+&+=+R8I0+EB<N'GJ#?;? ;INZ92@(@X1A
M9F[)F3.T2>F:^8@^,ZY^+:@?!/HGA^;-F:)"KN!^34,4!G,%G*^,<O&N,@)P
MWQCIILA%44::>(A\^EK%JM>P4M,H&5#","F=&*5\(8=2O7=2JH/6-/76<!:&
M0:M^B<H%CZ5Z%SR%#5!A$%;,():<:3:(WDF#V 4Z8<-.&(:GPR7YKTT"EF18
MN'8UZ@*VL*$M/.RJ*+<$5'D8NL S;/@,PX#6H'J-WDQI0D:>Y^VG>1?010QT
M$9!FNJU?1_KNI?5+G%3 8*FF83)01F H:ZV D;>LYCKGO?T?([ Y3=TUL$9J
MP]J1"D;>PEIENL,=-W7,X!HY$=>^MX;E_1P=QRZXBQCN(C!W/>K-R_=75"C?
M[NEKQ-0"?JDCL&#Z^@S=K?1F\]EV!Y2A>^UP5NC.T.?52F5!5O4^!5$@*R.1
MF3 J1V+PIIK#AC8-A$$R4G/OJ[*:JX>W:I6+UA%8X.&^ZE:VMM1V(V.HCG2U
M3T9:W2AK2VTW# ;W"(Q[/V2F9"9X.VO&_CSI O>(P3T"[ZX!\V3)&;P5!4O7
MSH<N@(\8X".CKJ9%JUMR;:GM_H_'X*$+(UI][LT%RR P<'MDM)?G<+]-_3(\
MY[;"<\VP]TC?^;8-=K;82WH'L1>6:AHFPX$NS(&M86_>3WGIP]X^(\#&-'6V
M] ]-F WK0V\N>#37NX! UT"@>^+FV_<R;][/D4'L O1< WHN#'H_HH[G)AR)
M0ZM89Y=.0$2,+]*#(4*M2NM89H<ABJ?%X9/+],B%;5[/3J[<4KX(8H%"-E=-
MG?.!,I1GAT&R&YFLTO,43XF4291>+AGU&=<OJ._G22*W-[J#XDC.]']02P,$
M%     @ $(BO6+B+B]$Y P  J@P  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&ULK9?=;]HP$,#_%2N;IDUBY(N/MH-(T+*/AZY5JZT/TQY,<H!5QV:V
M@5;:'S\["4FVIFY3]D+LQ'?WN[-]=XQV7-S*%8!"=REE<NRLE%J?N*Z,5Y!B
MV>5K8/K+@HL4*ST52U>N!> D$TJI&WC>P$TQ84XTRMY=BFC$-XH2!I<"R4V:
M8G$_!<IW8\=W]B^NR'*ES LW&JWQ$JY!?5M?"CUS2RT)28%)PAD2L!@[$_]D
MZO>-0+;B.X&=K(V1<67.^:V9?$G&CF>(@$*LC JL'ULX!4J-)LWQJU#JE#:-
M8'V\U_XQ<UX[,\<23CF](8E:C9TC!R6PP!NJKOCN,Q0.98 QIS+[1;MBK>>@
M>",53PMA39 2EC_Q71&(FD 8/"(0% )!QIT;RBC/L,+12/ =$F:UUF8&F:N9
MM(8CS.S*M1+Z*]%R*KK6VYQL*""^0!=K$RB))B921-VCMV>@,*'RW<A5VI:1
M<.-"[S37&SRB-T3GG*F51#.60/*WO*L92]!@#SH-K K/L>BBT.^@P MZZ#5R
MD5QA ;)X6"R$92C"S$+XB(79KXUQ^L=D+I70I^5GD]>YBEZS"G.%3N0:QS!V
M]!V1(+;@1&]>^0/O@P6P5P+V;-JCKYMT#J*^4_J:28590MBR@Z:P)(SIH3ZF
M%+,8T._&X.2.Y*;ZF2ES=;>1'PR"07_D;AL0^R5BWXIXD]T"2-Y/MB#TK4:S
M.Q QD8 N!8FA4Y)?5.2-X-4&-\'G$,,:?'C<'32C#TKT0;OH=M G@9EVQAI'
MJ]+F X$L9V%8T@X/"W3%;@^EU4Q[_J.2_ZAMM'6670#1S&YL#@&E3T3>:J ]
M^7%)?GQ8Y)O]L.^"U61[7WRO2O]>VWW8^V./OEWO"Y!K%<L_; /J#MC#;K?T
M B>"RHG@D%P^RS/C<Q)Y8>BYF=RORJ%O+68OR^4/P)_8@+!%)O>K0NFWK90%
M.YY3:!?=ICH9]HZ&CR!6A=+_3Y6R1MXZN@_K9,_K!O^>#+?6/J8@EEF3+%',
M-TSEG63YMFS$)WG[62W/NWC=I>E:+A&%A1;UND--(/+&.)\HOLZ:T3E7NK7-
MABO]9P*$6:"_+SA7^XDQ4/X]B?X 4$L#!!0    ( !"(KUB@P>8 I0(  -P&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(U56V^;,!3^*T=LFCII
M"Y=<U1&DI.TN#Y6J1ML>ICTX< A6#*:VDS3_?L<X8:E$45_ -N>['-OG$!^D
MVNH"T<!S*2H]]PICZFO?UVF!)=,#66-%7W*I2F9HJC:^KA6RK &5PH^"8.*7
MC%=>$C=K#RJ)Y<X(7N&# KTK2Z:.2Q3R,/="[[SPR#>%L0M^$M=L@RLT/^L'
M13._9<EXB97FL@*%^=Q;A-?+F8UO GYQ/.B+,=A,UE)N[>1'-O<":P@%IL8R
M,'KM\0:%L$1DX^G$Z;62%G@Y/K-_;7*G7-9,XXT4OWEFBKDW\R##G.V$>92'
M[WC*9VSY4BET\X2#BQU1<+K31I8G,#DH>>7>[/FT#Q> :/P*(#H!HL:W$VI<
MWC+#DEC) R@;36QVT*3:H,D<K^RAK(RBKYQP)EG1*6<[@2!S6!F9;N&;8I7!
M#!::#JJV6Z?AZA8-XT)_C'U#HA;JIR>!I1.(7A$8PKVL3*'AKLHP>XGWR6SK
M.#H[7D:]A/=,#6 8?H(HB$;P'GS0!5.H>ZB'[68,&^KA*]1W3SMNCO!GL=9&
MT7WYVY6NHQAU4]@:NM8U2W'N49%H5'OTD@_OPDGPI<?@J#4XZF-/W G5BJ?8
M9<V!IPW85N,^"0:S<>SO.R3'K>2X5_*1Z^WG7"$"IVM!*1E0S'3*.Z(P>J$?
M#"=1MX-)ZV#2Z^#NN:82IANYEX(9+NB(NM0=21A>J(>#*.S6GK;:T[=I"YXC
M7/$*CLA4=QWT,XT=$H90NGH(9Y"Q8]^UG;4F9V\SF?$]S[#*X,A19%T>>XFZ
M+R]T.?0O.DZ):M/T50VIW%7&-9]VM6W="]>Q_H>[OD_UO.'48P3F! T&4[I&
MRO52-S&R;OK76AKJALVPH-\/*AM WW,IS7EB!=H?6O(/4$L#!!0    ( !"(
MKU@5P'PSHP4  *<I   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;,5:
M;6_J-AC]*U8V3;M2+TF< *$#I)9LVIW6M6KW\N%J'UQB(+IY88XI[;^?G808
M0VKBUJA\:!/P<QX_)WXY!SS>YN1;L<*8@N<TR8J)M:)T?6G;Q7R%4U3T\C7.
MV">+G*2(LENRM(LUP2@J@]+$AHXSL%,49]9T7+YW1Z;C?$.3.,-W!!2;-$7D
MY1HG^79BN=;NC?MXN:+\#7LZ7J,E?L#TK_4=87=V@Q+%*<Z*.,\ P8N)=>5>
MAA[D 66+OV.\+?:N 2_E,<^_\9LOT<1R>(]P@N>40R#V[PG/<))P)-:/_VI0
MJ\G) _>O=^B_E,6S8AY1@6=Y\D\<T=7$"BP0X07:)/0^W_Z*ZX+Z'&^>)T7Y
M%VRKML.1!>:;@N9I'<QZD,99]1\]UT3L!;C^*P&P#H ' ;#_2H!7!WA=,_AU
M@%\R4Y52\A BBJ9CDF\!X:T9&K\HR2RC6?EQQI_[ R7LTYC%T>D#&TC1)L$@
M7X#;-7\4!;C=T(*B+(JS)6#_FO=_?L9D'A?HD37_,<04Q4GQ"7P&WP,;%"M$
M<#&V*>L31[;G=?Y9E1^^DM\#-WE&5PP\BW DQ]NLEJ8@N"OH&BH!?T-9#\#A
M!8 .]-KZHPZ_0:0'/+<,]UO"0W5XB.=-N*>HQFL>CU?B>:\]'D[KYVLVL"-P
MAU[8A*/@BA"4+3&_OJB?S<7NV6!P1^(Y!O>\!?CZ.X,#7RA.BW];:KFN<OOM
MN?F*<UFLT1Q/++:D%)@\86OZPW?NP/FIC5>38*$A,(ESO^'<5Z%/=\,]%].@
MC3PEB"YY%5B_!.-+]=/4A0,XZ(_MIWU:3C:3"NXW!?=U"[X VW+%9,,./6'"
M=@"VR/-MA*\)<S9C"5NP-R@!2;Q@B\$+1J3XU,:2.K/K@#*TC1)EI.YX,@0F
MT3MHZ!T8H!?O)O":3^ V*I59= =<!3;<&TG>J#<X&&XG&DEL#!LVADHV_MBD
MCYCP[2:O><%B6VDK>W@\YGV'O^3.SEK:0<\/A@<U*7OWQI$0-+4'G4;"7L5O
M&@G!T7.!_=[!6C%3=D5W_A@"DU@;-:R-E*Q5>]DMV\F^WF ^>%KW,B6&[NPP
M"18: I.X<QVA[YP/5!!U<D.T&T4+3:')Q.\):[?#L&7K''Z>GYK0:BAM&MVC
M]<%U#M>'T%1.F1XHZ($F5)8:19L9>+Q)#-CKD!I#265JA.9WE?+VK'I,G5J;
M3W4AHTK= 1>DW.2! 8C02YO8"TUU2V9<*'Y76_*_:6-6I]%FU^\TCPWEE*D3
MWL%52WAM/:?&T^:H?SRCO2 (#DDZAP%PA0-PNUF ]PH_=1IM[H[U?=OX,I13
MID[8!5?M%ZIM],]MKE1_:A!M8DRBA:;09 *%YW"#CQ2 )FW&S"A:: I-)E[8
M%K>+;^DH (W:EQI-;1!#4SGEKVF%,8%*_=U5 *I1=)FIT?:W"Z[_#K\D,)54
MID98!ZBV#N<4@.K4VGRJ"PEJ 3BJ!"!3@L&K$M!4QV3.A1^!VG[D35NT.HTV
MO[#+3#:54Z9.^!6HEOG:$E"-I\V1UVU.G\-B0&$Q8#>+\5X)J$ZCS=VQQ6@;
M7^>P&%!8#*BV&+4$7!&L_@I0#:--C=$?($RAR10* P(''R@"H5%;8A0M-(4F
M$R_L"^QB7[J)0#64-HW#HZD]]'O53R?URSV<Y^=P*E X%=CMYY%3BM"HY:C1
M]G</'XX\>$C-.;P$%%X"JKW$616A4>]QHI"=(O2Z*,)S&!1/&!1/VZ"\:<=6
MI]$^9N%H3VM3'9!Y%&[&4YL ;7FHQM,FS.TTP4TEE4D2]L/K9C_>*P_5:;2Y
M.[8?)P>;42]B[YUL2S%9EB<$"[:\;3):'7)KWFU.(5Z59^]LT;PZPGB#R#)F
M#"=XP4*=WI"-"%*="JQN:+XNS\D]YI3F:7FYPBC"A#=@GR_RG.YN>(+F;.;T
M?U!+ P04    "  0B*]8)[+MLJ$/  !DUP  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6R]W6]SFT8"!O"OLJ.[Z;0SB25 @)PZGDG,_KMKKIZFO;[H
M] 66UA)32:B [.2F'_Y PEZMP"M(GR@O$MO1_A8[3]"*1\#58YK]D2^4*LBG
MU7*=OQTLBF+S9CC,IPNUBO.+=*/6Y=_<I]DJ+LI/L_DPWV0JGNT&K99#=S0*
MAJLX60^NKW9?N\VNK])ML4S6ZC8C^7:UBK//[]4R?7P[< 9/7_@IF2^*Z@O#
MZZM-/%<?5?'+YC8K/QL^*[-DI=9YDJY)IN[?#MXY;V1X60W8/>*_B7K,#SXF
MU;=REZ9_5)_(V=O!J-HBM533HB+B\H\'=:.6RTHJM^//&AT\SUD-//SX26>[
M;[[\9N[B7-VDRU^36;%X.Y@,R$S=Q]ME\5/Z*%3]#?F5-TV7^>YW\E@_=C0@
MTVU>I*MZ<+D%JV2]_S/^5/\@#@8XXQ<&N/4 M^L KQ[@=1TPK@>,NP[PZP%^
MUP%!/2 X'N"_,""L!X1=9YC4 R9=!US6 W;Y&N[__7;_^%%<Q-=76?I(LNK1
MI59]L$O0;G3Y;YZLJ[!_+++R;Y-R7'']L4BG?RS2Y4QE^3?_F+A.^#VA?VZ3
MXC/Y-E)%G"QS\I\XR^(JD]^1U^27CQ'Y]I_?70V+<O;*&$[KF?A^)O>%F3SR
M(5T7BYS0]4S-S/'#<JN?-]U]VO3WKA7\$&<7Q/%>$7?D>BW;<V,?_J]X?4'<
M\,7A48?AH_&+P^G?&\[LPYFZ*[_W8#?<:?NWZ/"C\YS=\''+<-%]>-O&2_OP
M2$U?&FX$P7O.L+?SO!>\=]/I=K5=QH6:D1^+A<K(3;HJ=_V+:I_\H(A<3].5
M(M_^D.;Y=^2W'\KA1!9JE?_>LNWO]W.-V^>JGGO>Y)MXJMX.RAERE3VHP?4W
M_W""T?=M$41B$1*C2(PA,8[$!!*3(,P(^?@YY&.;?EU&>E4N#O)J?_V*Y(NX
MG(+$VV*19LG_CO>G^R1;P;Y)1F(1$J-(C"$QOL?\'5:M.A^N77^T_W4U?#B,
M*7):V65:(X/^<P;]SADDFS@C#_%RJ]JB9W7Z1@^)14B,(C&&Q/@>FQQD8'0Q
M&CE'L4-.*4]-:40N>(Y<8(W<;?G:1V59^<S>9\]G-?O&#XE%2(PB,8;$>-#8
M!3E^ZXX/.:OL,*L1PO YA&&_$%KW?5:K;_B06(3$*!)C2(SOL=#<$1WO^I S
MRA,S&J&;/(=N8@U=E&1J6I#TOHQ>LIZW)<T*]$T:$HN0&$5B#(GQ27.'XTU&
M@><=A0TYJ3P]J9&WR^>\7=H7=XMX/5<D69/[.*EW;V7ZR&-U]&==D&42WR7+
MI/C<ED0KW3>)2"Q"8A2),23&]UAP$(K7@3]I/M^V/,Z]=,>-!TK0UAE1=$;Z
MJ.3(&L:/^U5>DN=;-7OU\G.MG>D;/*@6034*U1A4XU!-U-IA1KW=.NXHH:A9
MS8@>'#AWK!&5NVP^O1ZY3\M=IEK/RC\V\>?X;MD>5Z>Y[PY<=V)^9S?VF7OG
M$*E1J,:@&H=J JI)E&:FU=5I=:UI9?HYO6-4W<;_0G<2-OX7WMCG[9U5I$:A
M&H-J'*H)J"91FIE57><XU@/IUY&Z*TBNIMLL*9)RWSJ/DW5K1+W&WM3WO):(
M0EL8J$:A&H-J'*H)J"91FAE17<8X]C;FQTWU5HV<I-LB+^+UK'R!7KYR*LH7
MZGDRM2Q7H94,5(N@&H5J#*KQ6CM\:CM^F02=4*(T,ZRZM7'LM<WM-ILNXER1
M>$WB^3Q3\[AHCR>TMJFUP]US4/X*S1]U!)V40C4&U3A4$U!-HC0SHKKE<>PU
M#_VDLFE21G23)=/V;$([G5H[/&+K^A?^<32A;0U48U"-0S4!U21*,Z.INQ_'
M7O[LWB%'TOH)7WW:)%E[0*&]SXF-<D;DLXJSO/6)'%KS0#4&U3A4$U!-HC0S
MM;H\<NSMD7Z]WYI5:'/DM#02XY:R-X).2Z$:@VJ\[4?B>N-)>+S.A#9#*,W,
MG"Z0''N#],OZ0>75FS#KG>73FS5:$PAMC*!:!-4H5&-0C=>:\5:Q,)P<A[3Y
M*-]S7?_X>/S7J(Q<71FY)RJCW?/T-%UMU#J/=V=2E$_6Y<>*;(^"V19(N]XW
MD% M@FH4JC&HQMUF]^.XS1:S[6%>RS..1&V=F4G=$;GVCJ@^DV)_M(C\]D&M
M[E3V._F+[/K-U^_+%^4S<AM_7JEU0=Y5/?M<51^_(C^7'T\7BOR\R)1Z'MD:
M7&1-<0/5(JA&H1J#:ARJ":@F49KYGT!73^Z^+CC/Z1DNLNFX@6H15*-0C4$U
M#M4$5),HS8R[;J]<>WOU5 W,JW=-M;\]V2[TSK#7>#+T1\VF-H+.2J$:@VJ\
MY2?BC-J6$=!*"J69N=.5E&NOI#ZJK"I+;XA^M_)^26Q=/$ +*:@6034*U1A4
MXU!-0#6)TLQ4Z^[*]<^Y>( 67% M@FH4JC&HQJ&:@&H2I9EQUSV8V_-T)^N9
M)G:L=YRA)SI!-0K5&%3C;K-+;#G?!#JG/#6G&3_==;D]3W2JW]UZ\#:7UAQ"
MJR^H%D$U"M485..U=GB8]C)PO<:B%UISG9S43*+NKUQ[?_52$O?ONFX-(;33
M@FH15*-0C4$U[C:+K]800GNODY.:(=2%EFLOM.J75/\^?DF5VU]30:LMJ!9!
M-0K5&%3C4$U -8G2S*OEZ*;,&YWQ-94'+<Z@6@35*%1C4(U#-0'5)$HSXZY+
M.,]>PO5[367'>L<96J=!-0K56*W97P5QZ)P"JDF49L94UV2>_0RMHY@^+7AG
M*D_FZ_B%)L%N]DXKM V#:A2JL5HSWI_5<HXIA\XJH)I$:69>#RZZ9^^Y;M+U
M@\J*Y&ZIGK):G:[]TOF$=JUW4K$7UL->60][:;WF26Y.,Z;8:^9A+YKW-6HQ
M3]=B7J=:K/$:SOH2SF[V#BNT%H-J%*HQJ,:AFH!J$J69J=:UF'?.6LR#UF)0
M+8)J%*HQJ,:AFH!J$J69<=>UF/=E5P$\T4O8U=ZYAO9C4(U"-0;5N->\+-_Q
MX6#HA-(ZH9E W8QY7]:,O=Q'V,'>X8.68E"-0C4&U;C7[*<:X8,68M8)S?#I
M,LRSEV'OTS@KG^?OR?Z:@&F6$[K:+-//JDS@N_6L?/)?Y]MEN2<L[-6$?9[>
MF81V9%"-0C4&U3A4$U!-HC0SZ;IQ\R[/N:Z%-G%0+8)J%*HQJ,:AFH!J$J69
ME_373=RXQV4.VQ)L']\WP5 M@FH4JC&HQJ&:J#7CI,OQ^/+HS#74G&8R=6DV
MMI=F72_ :6=Z!Q1:ET$U"M485.-03=3:R0MPHF8U(ZH+L[&],*OO1G'Z:*[=
MZ9U1:$D&U2A48U"-0S4!U21*,Y.LJ[3Q.6]@-88V;5 M@FH4JC&HQJ&:@&H2
MI9EQ/[B3U8E*[N2J%UJ_0;4(JE&HQJ :AVJBUHQ5;\N2XFO4:F-=JXWM5TKL
MO.J%%F90+8)J%*HQJ,:AFO@2C;3N7;]&5S;67=G8WI5]R77I[63O/$.+,JA&
MH1J#:ARJB7'+W;""ECWNU[BZXECW:F-[KU8N?=-M55O8TADV7H].W.;%?F[L
M4_7.';0C@VH,JG&H)J":1&EF/'7S-NYU&EJW-^7:S=Y[4VC+!M4H5&-0C4,U
M,6Z[H&/+!<=0LYIYU?W9^,1-O/;'Q'ZM[]D5KV?D=EE.M[_ V+SZ_>GOK$?,
MH,495(N@&H5J#*IQJ":@FD1IYGV(=7'FG_,4-A_:LD&U"*I1J,:@&H=J JI)
ME&;&7;=QOKV-^UOW9K3;O=,-K>C\9M6TNVOA\?,JA4[+H!J':@*J291F!E=W
M=/Z)D]J>;CWR;IZI_2K$MNZP:[VC"FWJH!J%:@RJ<:@FH)I$:6:>=5/GG[.I
M\Z%-'52+H!J%:@RJ<:@FH)I$:6;<=5/GVYNZVRR=*C7+R7V6KJI[\SR4R2>;
MIU>4K9F&=G=0+8)JM-8.URZ!W[)V8=!I.5034$VB-#.NNK[S[?7=?H^<WM^K
MK+HA7WWY_];+_=NEWC&%-GA0C=::<2-7KUF],NBL'*H)J"91FIE27=#Y)TYF
M>WE-3/ZJ3E,F;+N>E0N,^DB=_90.^V2]@PRM[J :A6H,JG&H)J":1&EFW'7#
MYX?G7#)#SZJ#:A%4HU"-034.U014DRC-C+MN#'U[8VC>R?+@(%UKFJ%-(52+
M:FURL&X878Q&WO&!N4X/8]!MXU!-0#6)TLS\Z0;0MS> ]M5%Y_?,VV?IG4QH
M PC5*%1C4(U#-0'5)$HS<A[H!C X9P,80!M J!9!-0K5&%3C4$U -8G2S+CK
M!C XT0#N=]S[=R%9+V!IAWI'&5KWU=KQ8N'H*I&TV\,8=-LX5!-03:(T,WRZ
MQ0OL+=[^LA//!]9:4P=M[J!:%+1<[+'EO5NTX^,8=.LX5!-03:(T,W>Z;0OL
MEY@\>:3LWCA09EW0VJ?J'5!HUP;5*%1C4(U#-0'5)$HSPZZ[MF!\S@4MM(:#
M:A%4HU"-034.U014DRC-C+ONZ@)[5_>\;]='R%J+.CO3.\C0HJ[6S/N.!$%X
MO*[H]# &W38.U014DRC-C)XNX(*_4\"9;Z&WEV_VB7J'$UJ^034*U1A4XU!-
M0#6)TLRHZ_(M.&?Y%D#+-Z@6034*U1A4XU!-0#6)TLRXZ_(M.'&Z7M=%!;1W
M@VI1T#S3S'7:5A7='L>@6\>AFH!J$J69X=/-6V!OWGHUOW:K=P*A_5JM&=?_
M:APK._T8!MTJ#M4$5),HS4A>J+NPT'X9R1/'R<P30/-N2UO[E'T#"M4BJ$:A
M&H-J'*H)J"91FAEZW8B%SAF7MB&T-8-J$52C4(U!-0[5!%23*,V,N^[@PHYG
MTIU8VMJ9WD&&%G%A2\'F-7NX;@]CT&WC4$U -8G2S.CI&BZTUW"]%K9VJW?^
MH#U;K1W>H](++_SC^'5Y%(-N&8=J JI)E&:F3_=BH;6(Z/B&QOUU>>+=O3"Z
M'[^U3]T[K-"6#*I1J,:@&H=J JI)E&:&7[=DX3GO\Q9"NS2H%D$U"M485.-0
M34 UB=+,N.MF+CQUG[=J@;$I8[Z[T%IKAJ&5&U2+PN8E%QL'SCH\AD&WBD,U
M =4D2C/SINNQ\,1=W4Z]P>SU\:F8O5<8T,H,JD50C4(U!M4X5!-03:(T\[^
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MT] \:GXQ2,?'91KJY*!HIG#:R0G<3D[W,MVA&\2=J[>Z4),'2F-06H2BF<>
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( !"(KUB@$3X$[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( !"(KUB97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $(BO
M6$#+_<7>!0  L1\  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( !"(KUCKBM-D'P4  $@3   8
M      " @2$.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  0B*]8YJ06(NT"  "7"@  &               @(%V$P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $(BO6&$B=Y<I!0  &Q,  !@
M             ("!F18  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( !"(KUB*P8@+JP(  "<&   8              " @?@;  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  0B*]8RZ,A):<%  "8
M(0  &               @('9'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ $(BO6*C:U1-#!P  V"4  !@              ("!MB0
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !"(KUC8P3/F
MV@8  "$0   8              " @2\L  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  0B*]8#[K0%[ 0  !M+0  &
M@($_,P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ $(BO
M6%]QI]0W!   50L  !D              ("!)40  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  0B*]8:1[YQ\@$  #1"@  &0
M        @(&32   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( !"(KU@@?D9,1P8  #(0   9              " @9)-  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ $(BO6). 6B)3"   L!8
M !D              ("!$%0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  0B*]8-TH:EH )  #H%@  &0              @(&:7
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !"(KUA8G?8L
M%08  /T.   9              " @5%F  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ $(BO6&:&/@DI @  W@0  !D
M ("!G6P  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  0
MB*]8D1XV5;<1  # -   &0              @('];@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !"(KUA(V@MYWP(  &H&   9
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M970R,BYX;6Q02P$"% ,4    "  0B*]8C%3@OF(#  #8"   &0
M    @($'E   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M !"(KU@F"R-PN ,  $$-   9              " @:"7  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ $(BO6 )WH@ 3 P  IPL  !D
M             ("!CYL  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  0B*]8=:.RDW8$  #V%@  &0              @('9G@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !"(KUA55CI7< ,
M /H,   9              " @8:C  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ $(BO6##T>5KS!   DB<  !D              ("!
M+:<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  0B*]8
MK;J'8_0"  "G"   &0              @(%7K   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !"(KUC&9\DW<0(  (@&   9
M      " @8*O  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ $(BO6*R_S61Z @  :08  !D              ("!*K(  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  0B*]8H8MA#\4#  !>%
M&0              @(';M   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( !"(KU@I)).X1@8  &8V   9              " @=>X  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ $(BO6*O6YUCP
M P  )1,  !D              ("!5+\  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  0B*]8^C7.9QP#   S#   &0
M@(%[PP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !"(
MKUBC[^2-9@4  )XC   9              " @<[&  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ $(BO6+B+B]$Y P  J@P  !D
M         ("!:\P  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  0B*]8H,'F *4"  #<!@  &0              @(';SP  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !"(KU@5P'PSHP4  *<I
M   9              " @;?2  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ $(BO6">R[;*A#P  9-<  !D              ("!D=@
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  0B*]85]>G
M894(  #(5P  &0              @(%IZ   >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( !"(KUBNDO09K@(  '<'   9
M  " @37Q  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M$(BO6&38QRZ? @  B <  !D              ("!&O0  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  0B*]8P^M#MN8$  "E(0  &0
M            @('P]@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( !"(KUBR19@,%P,  'D-   9              " @0W\  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ $(BO6(Z_(5 W P
MS!,   T              ( !6_\  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  0B*]8EXJ[',     3 @  "P              @ &] @$ 7W)E;',O+G)E
M;'-02P$"% ,4    "  0B*]8V,!Y9P<$  !G'@  #P              @ &F
M P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $(BO6+@VQ-RI 0  +AL
M !H              ( !V@<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ $(BO6%/9*RFR 0  4QL  !,              ( !NPD!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@  G@L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>161</ContextCount>
  <ElementCount>238</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayable</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OperatingLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Organization and Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative</Role>
      <ShortName>Organization and Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OrganizationAndOperations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails</Role>
      <ShortName>Schedule of Estimated Fair Value of Financial Instrument (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails</Role>
      <ShortName>Schedule of Fair Value Hierarchy Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative</Role>
      <ShortName>Fair Value of Financial Instruments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Accounts Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableDetailsNarrative</Role>
      <ShortName>Accounts Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails</Role>
      <ShortName>Schedule of Derivative Liabilities Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Warrant Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>Warrant Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiabilityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails</Role>
      <ShortName>Schedule of Stock Granted Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails</Role>
      <ShortName>Schedule of Options Outstanding and Options Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails</Role>
      <ShortName>Schedule of Other Information Related Leases Under Non-Cancellable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Operating Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>Operating Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OperatingLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Subsequent Event (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>Subsequent Event (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvent</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>gtbp-20240331.xsd</File>
    <File>gtbp-20240331_cal.xml</File>
    <File>gtbp-20240331_def.xml</File>
    <File>gtbp-20240331_lab.xml</File>
    <File>gtbp-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
    <File>form10-q_002.jpg</File>
    <File>form10-q_003.jpg</File>
    <File>form10-q_004.jpg</File>
    <File>form10-q_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="476">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gtbp-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 202,
   "keyCustom": 36,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 25,
   "hidden": {
    "total": 80,
    "http://fasb.org/us-gaap/2024": 67,
    "http://gtbiopharma.com/20240331": 9,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 161,
   "entityCount": 1,
   "segmentCount": 53,
   "elementCount": 413,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 476,
    "http://xbrl.sec.gov/dei/2024": 30
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "GTBP:StockBasedCompensationCommonSharesForServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://gtbiopharma.com/role/OrganizationAndOperations",
     "longName": "00000008 - Disclosure - Organization and Operations",
     "shortName": "Organization and Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstruments",
     "longName": "00000010 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://gtbiopharma.com/role/AccountsPayable",
     "longName": "00000011 - Disclosure - Accounts Payable",
     "shortName": "Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://gtbiopharma.com/role/WarrantLiability",
     "longName": "00000012 - Disclosure - Warrant Liability",
     "shortName": "Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://gtbiopharma.com/role/StockholdersEquity",
     "longName": "00000013 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "longName": "00000014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://gtbiopharma.com/role/OperatingLeases",
     "longName": "00000015 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://gtbiopharma.com/role/SubsequentEvent",
     "longName": "00000016 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "00000019 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://gtbiopharma.com/role/AccountsPayableTables",
     "longName": "00000020 - Disclosure - Accounts Payable (Tables)",
     "shortName": "Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityTables",
     "longName": "00000021 - Disclosure - Warrant Liability (Tables)",
     "shortName": "Warrant Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityTables",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://gtbiopharma.com/role/OperatingLeasesTables",
     "longName": "00000023 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
     "longName": "00000024 - Disclosure - Organization and Operations (Details Narrative)",
     "shortName": "Organization and Operations (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "longName": "00000025 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "GTBP:CashOnHandAndShortTermInvestment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:LiquidityPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails",
     "longName": "00000027 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "shortName": "Schedule of Estimated Fair Value of Financial Instrument (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails",
     "longName": "00000028 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "shortName": "Schedule of Fair Value Hierarchy Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
     "longName": "00000029 - Disclosure - Schedule of Warrant Liability Transactions (Details)",
     "shortName": "Schedule of Warrant Liability Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
     "longName": "00000030 - Disclosure - Fair Value of Financial Instruments (Details Narrative)",
     "shortName": "Fair Value of Financial Instruments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_WarrantMember63927609",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "longName": "00000031 - Disclosure - Schedule of Accounts Payable (Details)",
     "shortName": "Schedule of Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
     "longName": "00000032 - Disclosure - Accounts Payable (Details Narrative)",
     "shortName": "Accounts Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
     "longName": "00000033 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)",
     "shortName": "Schedule of Derivative Liabilities Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "00000034 - Disclosure - Warrant Liability (Details Narrative)",
     "shortName": "Warrant Liability (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "GTBP:IncreaseDecreaseInFairValueOfWarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "00000035 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "00000036 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_WarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "00000037 - Disclosure - Schedule of Options Activity (Details)",
     "shortName": "Schedule of Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails",
     "longName": "00000038 - Disclosure - Schedule of Stock Granted Assumptions (Details)",
     "shortName": "Schedule of Stock Granted Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
     "longName": "00000039 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)",
     "shortName": "Schedule of Options Outstanding and Options Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_custom_RangeOneMember",
      "name": "GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000040 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-03-132023-03-13",
      "name": "GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000041 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2022-05-132022-05-13",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-05-132022-05-13",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails",
     "longName": "00000042 - Disclosure - Schedule of Other Information Related Leases Under Non-Cancellable (Details)",
     "shortName": "Schedule of Other Information Related Leases Under Non-Cancellable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails",
     "longName": "00000043 - Disclosure - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
     "longName": "00000044 - Disclosure - Operating Leases (Details Narrative)",
     "shortName": "Operating Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative",
     "longName": "00000045 - Disclosure - Subsequent Event (Details Narrative)",
     "shortName": "Subsequent Event (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45",
      "r48",
      "r799"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "totalLabel": "Total accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r666"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable [Default Label]",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r833"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable to a third-party manufacturer",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r666",
      "r837"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r723",
      "r724",
      "r725",
      "r726",
      "r801",
      "r838"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r138",
      "r139",
      "r140",
      "r141",
      "r151",
      "r186",
      "r187",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r240",
      "r241",
      "r244",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r413",
      "r414",
      "r425",
      "r426",
      "r427",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r484",
      "r485",
      "r486",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Initial recognition of fair value of warrant liability",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r26",
      "r72"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangement, expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r98",
      "r116",
      "r133",
      "r163",
      "r167",
      "r180",
      "r181",
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r365",
      "r367",
      "r415",
      "r490",
      "r567",
      "r638",
      "r639",
      "r666",
      "r679",
      "r768",
      "r769",
      "r824"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120",
      "r133",
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r365",
      "r367",
      "r415",
      "r666",
      "r768",
      "r769",
      "r824"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r236",
      "r489"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Principles of Consolidation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "GTBP_BoardOfDirectorsEmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "BoardOfDirectorsEmployeesAndConsultantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors Employees And Consultants [Member]",
        "documentation": "Board Of Directors Employees And Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r492",
      "r537",
      "r562",
      "r666",
      "r679",
      "r709"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r115",
      "r631"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Short-Term Investments",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at Beginning of Period",
        "periodEndLabel": "Cash at End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r64",
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase (Decrease) in Cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r64"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r834"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CashOnHandAndShortTermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CashOnHandAndShortTermInvestment",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash on hand and short term investment",
        "documentation": "Cash on hand and short term investment"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CashPaidDuringYearFor": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CashPaidDuringYearFor",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the year for:",
        "documentation": "Cash paid during the year for [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r117",
      "r118",
      "r119",
      "r133",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r220",
      "r254",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r281",
      "r282",
      "r285",
      "r288",
      "r295",
      "r415",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r554",
      "r576",
      "r594",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r700",
      "r720",
      "r727"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrant",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase",
        "verboseLabel": "Purchase of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r246",
      "r247",
      "r626",
      "r759",
      "r764"
     ]
    },
    "GTBP_CommonSharesAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CommonSharesAndCommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Shares and Common Warrants [Member]",
        "documentation": "Common Shares and Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r723",
      "r724",
      "r726",
      "r801",
      "r836",
      "r838"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r554"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Direct offering",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r554",
      "r573",
      "r838",
      "r839"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock,\u00a0\u00a0par value $0.001, 250,000,000 shares authorized, 1,380,633 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r494",
      "r666"
     ]
    },
    "GTBP_CommonWarrantAndPlacementAgentWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CommonWarrantAndPlacementAgentWarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrant and Placement Agent Warrant [Member]",
        "documentation": "Common Warrant and Placement Agent Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r80"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r102"
     ]
    },
    "GTBP_CorporateNotesAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CorporateNotesAndCommercialPaperMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Notes and Commercial Paper [Member]",
        "documentation": "Corporate Notes and Commercial Paper [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintenance fee",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CummulativeGrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "CummulativeGrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative gross sales",
        "documentation": "Cummulative gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r87",
      "r89",
      "r134",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r664",
      "r721",
      "r760",
      "r761",
      "r762",
      "r819",
      "r820"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r134",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r664",
      "r721",
      "r760",
      "r761",
      "r762",
      "r819",
      "r820"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gains",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Fair Value of Financial Instrument",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738"
     ]
    },
    "us-gaap_DebtSecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt securities gain",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r715",
      "r716"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r546",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r609",
      "r610",
      "r611",
      "r612",
      "r669",
      "r671",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r84",
      "r543",
      "r546",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r609",
      "r610",
      "r611",
      "r612",
      "r632",
      "r669",
      "r671",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r815",
      "r816"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "GTBP_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Other Information Related Leases Under Non-cancellable",
        "terseLabel": "Schedule Of Future Minimum Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r693",
      "r694"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r154",
      "r157",
      "r158",
      "r159",
      "r162",
      "r354",
      "r363",
      "r391",
      "r392",
      "r488",
      "r501",
      "r633"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r154",
      "r157",
      "r158",
      "r159",
      "r162",
      "r354",
      "r363",
      "r391",
      "r392",
      "r488",
      "r501",
      "r633"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r161"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r108",
      "r124",
      "r125",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r164",
      "r224",
      "r230",
      "r241",
      "r297",
      "r342",
      "r343",
      "r350",
      "r351",
      "r352",
      "r355",
      "r362",
      "r363",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r390",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r426",
      "r428",
      "r445",
      "r499",
      "r509",
      "r510",
      "r511",
      "r526",
      "r594"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized gain of change in fair value of derivative liability",
        "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_Extinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "Extinguishment",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment",
        "documentation": "Extinguishment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value of warrant liability",
        "terseLabel": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r405",
      "r654"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r405",
      "r654"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Hierarchy Financial Assets",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r803",
      "r804",
      "r815"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r657"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r657"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r657"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r405",
      "r407",
      "r454",
      "r455",
      "r456",
      "r645",
      "r646",
      "r650",
      "r651",
      "r652",
      "r654",
      "r657"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r487",
      "r654",
      "r658"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r301",
      "r306",
      "r395",
      "r405",
      "r454",
      "r650",
      "r651",
      "r652",
      "r654"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r301",
      "r306",
      "r395",
      "r396",
      "r405",
      "r455",
      "r645",
      "r646",
      "r650",
      "r651",
      "r652",
      "r654"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r395",
      "r396",
      "r397",
      "r398",
      "r405",
      "r456",
      "r645",
      "r646",
      "r650",
      "r651",
      "r652",
      "r654",
      "r657"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r405",
      "r407",
      "r454",
      "r455",
      "r456",
      "r645",
      "r646",
      "r650",
      "r651",
      "r652",
      "r654",
      "r657"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total financial assets",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r803",
      "r804"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r279",
      "r293",
      "r380",
      "r412",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r642",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r667",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r745",
      "r746",
      "r747",
      "r748",
      "r802",
      "r805",
      "r806",
      "r807",
      "r814",
      "r817"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on extinguishment of debt",
        "negatedTerseLabel": "Gain on extinguishment of share settled debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ]
    },
    "GTBP_GrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "GrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross sales",
        "documentation": "Gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r245",
      "r399",
      "r401",
      "r406",
      "r504",
      "r506",
      "r579",
      "r629",
      "r656",
      "r835"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r245",
      "r399",
      "r401",
      "r406",
      "r504",
      "r506",
      "r579",
      "r629",
      "r656",
      "r835"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r129",
      "r340",
      "r341"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "GTBP_IncreaseDecreaseInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "IncreaseDecreaseInFairValueOfWarrantLiability",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of the warrant liability",
        "documentation": "Increase decrease in fair value of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease) in operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r717"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease) in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r167",
      "r170",
      "r171",
      "r181",
      "r423",
      "r638",
      "r639"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r600",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r671"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r600",
      "r602",
      "r604",
      "r607",
      "r608",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r671"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants at fair value",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "GTBP_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Two.."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After one year and within two years",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After two years and within three years",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Within one year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less \u2013 Discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, operating sublease, option to extend",
        "documentation": "Description of terms and conditions of option to extend operating sublease."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r133",
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r366",
      "r367",
      "r368",
      "r415",
      "r553",
      "r634",
      "r679",
      "r768",
      "r824",
      "r825"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r90",
      "r496",
      "r666",
      "r722",
      "r750",
      "r818"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial recognition of fair value of warrant liability",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r114",
      "r133",
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r366",
      "r367",
      "r368",
      "r415",
      "r666",
      "r768",
      "r824",
      "r825"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LicenseMaintenanceFeeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "LicenseMaintenanceFeeReceivable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License maintenance fee, receivable",
        "documentation": "License maintenance fee, receivable."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity",
        "documentation": "Liquidity Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r337",
      "r643",
      "r766",
      "r767"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r337",
      "r643",
      "r766",
      "r767"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized loss (gain) on marketable securities",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "GTBP_MasterServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "MasterServicesAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreement [Member]",
        "documentation": "Master Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r308",
      "r337",
      "r398",
      "r482",
      "r503",
      "r505",
      "r519",
      "r545",
      "r546",
      "r601",
      "r603",
      "r605",
      "r606",
      "r614",
      "r627",
      "r628",
      "r641",
      "r649",
      "r653",
      "r657",
      "r658",
      "r662",
      "r663",
      "r668",
      "r770",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r657"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r657"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r308",
      "r337",
      "r398",
      "r482",
      "r503",
      "r505",
      "r519",
      "r545",
      "r546",
      "r601",
      "r603",
      "r605",
      "r606",
      "r614",
      "r627",
      "r628",
      "r641",
      "r649",
      "r653",
      "r657",
      "r658",
      "r662",
      "r668",
      "r770",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "label": "Cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r94",
      "r112",
      "r122",
      "r123",
      "r126",
      "r133",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r156",
      "r220",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r354",
      "r363",
      "r392",
      "r415",
      "r498",
      "r575",
      "r592",
      "r593",
      "r677",
      "r768"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering expenses",
        "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Other (Income) Expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Income) Expense"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OfficersEmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "OfficersEmployeesAndDirectorsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers, Employees and Directors [Member]",
        "documentation": "Officers, Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r635",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r434"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease, right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r665"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOtherInformationRelatedLeasesUnderNon-cancellableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r665"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Leases",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r67",
      "r68",
      "r83"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale (purchase) of investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "GTBP_PerformanceMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PerformanceMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance milestone payments",
        "documentation": "Performance milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_PlacementAgentWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PlacementAgentWarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents Warrants [Member]",
        "documentation": "Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "GTBP_PreFundedWarrantsAndCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PreFundedWarrantsAndCommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants and Common Warrants [Member]",
        "documentation": "Pre-Funded Warrants and Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible shares issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r836",
      "r838"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r554"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "verboseLabel": "Preferred stock, shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r554",
      "r573",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred stock,\u00a0\u00a0par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r493",
      "r666"
     ]
    },
    "GTBP_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrant [Member]",
        "documentation": "Prefunded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and prefunded warrants",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r521"
     ]
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ProceedsFromUpfrontAmount",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from upfront amount",
        "documentation": "Received upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "GTBP_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_PurchaseWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "PurchaseWarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrant [Member]",
        "documentation": "Purchase Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r300",
      "r308",
      "r331",
      "r332",
      "r333",
      "r337",
      "r398",
      "r457",
      "r466",
      "r482",
      "r503",
      "r505",
      "r519",
      "r545",
      "r546",
      "r601",
      "r603",
      "r605",
      "r606",
      "r614",
      "r627",
      "r628",
      "r641",
      "r649",
      "r653",
      "r657",
      "r658",
      "r662",
      "r663",
      "r668",
      "r671",
      "r763",
      "r770",
      "r806",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r300",
      "r308",
      "r331",
      "r332",
      "r333",
      "r337",
      "r398",
      "r457",
      "r466",
      "r482",
      "r503",
      "r505",
      "r519",
      "r545",
      "r546",
      "r601",
      "r603",
      "r605",
      "r606",
      "r614",
      "r627",
      "r628",
      "r641",
      "r649",
      "r653",
      "r657",
      "r658",
      "r662",
      "r663",
      "r668",
      "r671",
      "r763",
      "r770",
      "r806",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "GTBP_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "RangeOneMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r307",
      "r446",
      "r447",
      "r491",
      "r497",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r599"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r307",
      "r446",
      "r447",
      "r491",
      "r497",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r599",
      "r823"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r629",
      "r638",
      "r832"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r72",
      "r495",
      "r513",
      "r518",
      "r525",
      "r555",
      "r666"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r224",
      "r230",
      "r241",
      "r342",
      "r343",
      "r350",
      "r351",
      "r352",
      "r355",
      "r362",
      "r363",
      "r372",
      "r375",
      "r376",
      "r379",
      "r390",
      "r426",
      "r428",
      "r509",
      "r511",
      "r526",
      "r838"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r163",
      "r168",
      "r169",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r298",
      "r299",
      "r483"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual royalty payments",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "GTBP_RoyaltyFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "RoyaltyFeePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales percentage",
        "documentation": "Royalty fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales milestone payments",
        "documentation": "Sales milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "SalesRevenue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales revenue",
        "documentation": "Sales revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Transactions",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r85"
     ]
    },
    "GTBP_ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Information Related Leases Under Non-Cancellable",
        "documentation": "Schedule of Other Information Related Leases Under Non Cancellable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r438"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding and Options Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Granted Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule of warrants oustanding and exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ScientificResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ScientificResearchAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scientific Research Agreement [Member]",
        "documentation": "Scientific Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r182",
      "r184",
      "r636",
      "r637",
      "r640"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative\u00a0\u00a0(including $102 and $718 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively)",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711",
      "r771"
     ]
    },
    "GTBP_SeriesKPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "SeriesKPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series K Preferred Stock [Member]",
        "documentation": "Series K Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesKPreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "SeriesKPreferredStocksMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series K Preferred Stocks [Member]",
        "documentation": "Series K Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested options, shares",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility amount utilized in the value calculation percentage",
        "verboseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, forfeited",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, beginning balance",
        "label": "Number of warrants outstanding",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, weighted average exercise price",
        "documentation": "Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average exercise price",
        "documentation": "Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, beginning balance",
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Exercised",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercisable, Ending balance",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Options Exercisable Ending balance",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options outstanding, Beginning balance",
        "periodEndLabel": "Number of Options outstanding, Ending balance",
        "label": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Exercise Price, Options Outstanding Beginning balance",
        "periodEndLabel": "Weighted-Average Exercise Price, Options Outstanding Ending balance",
        "label": "Options outstanding, weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Share Based Compensation Arrangements By Share Based Paymen tAward Non Options Exercises In Period Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Forfeited/cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of excercise price",
        "documentation": "Share based compensation shares authorized under stock option plans exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of lower excercise price",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercisable",
        "verboseLabel": "Fair value",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense unvested options",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfStockGrantedAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Forfeited/cancelled",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, weighted average exercise price",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual life (years)",
        "verboseLabel": "Stock options expire",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r712"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r618",
      "r619",
      "r630"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r131"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r117",
      "r118",
      "r119",
      "r133",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r220",
      "r254",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r281",
      "r282",
      "r285",
      "r288",
      "r295",
      "r415",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r554",
      "r576",
      "r594",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r700",
      "r720",
      "r727"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r55",
      "r56",
      "r108",
      "r124",
      "r125",
      "r126",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r164",
      "r224",
      "r230",
      "r241",
      "r297",
      "r342",
      "r343",
      "r350",
      "r351",
      "r352",
      "r355",
      "r362",
      "r363",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r390",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r426",
      "r428",
      "r445",
      "r499",
      "r509",
      "r510",
      "r511",
      "r526",
      "r594"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r164",
      "r428",
      "r483",
      "r520",
      "r538",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r672"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r164",
      "r188",
      "r428",
      "r483",
      "r520",
      "r538",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r672"
     ]
    },
    "GTBP_StockBasedCompensationCommonSharesForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "StockBasedCompensationCommonSharesForServices",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation - services",
        "documentation": "Stock based compensation common shares for services."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "StockBasedCompensationOfficersEmployeesAndBoardOfDirectors",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation - officers, employees and board of directors",
        "documentation": "Stock based compensation officers employees and board of directors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common stock issued to a vendor to settle accounts payable",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "GTBP_StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value for vendor payable",
        "documentation": "Stock issued during period fair value common shares in settlement of vendors payable."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in settlement of vendors payable, shares",
        "verboseLabel": "Issued shares for vendor payable",
        "documentation": "Stock issued during period shares common sharesIn settlement of vendors payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for services, shares",
        "verboseLabel": "Shares issued",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private placement of common stock, shares",
        "verboseLabel": "Preferred stock shares designated",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r72",
      "r521",
      "r594",
      "r621"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase an aggregate",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r72"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in settlement of vendors payable",
        "documentation": "Stock issued during period value common shares in settlement of vendors payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for services",
        "verboseLabel": "Shares issued, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private placement of common stock",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r72",
      "r526",
      "r594",
      "r621",
      "r678"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares return",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r72",
      "r524",
      "r594",
      "r623"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares return, value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r72",
      "r526",
      "r594",
      "r623",
      "r678"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquity",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r556",
      "r573",
      "r595",
      "r596",
      "r666",
      "r679",
      "r722",
      "r750",
      "r818",
      "r838"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r132",
      "r280",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r381",
      "r597",
      "r598",
      "r625"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revers stock split ratio",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r449"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r449"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r449"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r449"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r449"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r450"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ThirdPartyProductManufacturerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "ThirdPartyProductManufacturerMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party Product Manufacturer [Member]",
        "documentation": "Third Party Product Manufacturer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r822"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r279",
      "r293",
      "r380",
      "r412",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r500",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r667",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r745",
      "r746",
      "r747",
      "r748",
      "r802",
      "r805",
      "r806",
      "r807",
      "r814",
      "r817"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "GTBP_TwentyTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "TwentyTwentyThreeWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Warrants [Member]",
        "documentation": "2023 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwentyTwentyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "TwentyTwentyWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Warrants [Member]",
        "documentation": "2020 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Patent License Agreement [Member]",
        "documentation": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Patent Exclusive License Agreement [Member]",
        "documentation": "2016 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r138",
      "r139",
      "r140",
      "r141",
      "r151",
      "r186",
      "r187",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r240",
      "r241",
      "r244",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r413",
      "r414",
      "r425",
      "r426",
      "r427",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r484",
      "r485",
      "r486",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "GTBP_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront license fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r100",
      "r101",
      "r103",
      "r104"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ]
    },
    "GTBP_WarrantLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WarrantLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Warrant liabilities noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WarrantLiabilityNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Warrant liability non-current."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability Policy [Text Block]",
        "label": "Warrant Liability Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Text Block]",
        "label": "WarrantLiabilityTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant fair value",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (in years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807"
     ]
    },
    "GTBP_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r159"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r159"
     ]
    },
    "GTBP_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "GTBP_WrittenOffRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20240331",
     "localname": "WrittenOffRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written off right of use asset",
        "documentation": "Written off right of use asset."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001493152-24-019970-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-019970-xbrl.zip
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M+5"-5LBM0I&TK%FCEX.V[-M"Z:6B_P%02P,$%     @ $(BO6+:R+))#"
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M0S6ZASXZ@'J0Q2^Y _,QD#873Y'%\UP\?,]<?X/;RDOGN?(^#!I@\,BV:$F
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MP-A;<)#F&P &>B 8+R\TQR// NELJ'[Z@.:Y%6"1\@R8N1S,1$D9 FG>$5Z
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ML,ZU$M2'L5DE46>4SVFE4]PV2;Q.!FDHBB0M7:@>(RT]Y!1>2QQ"OFO1S(S
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MZ;\NS(;)TZ 7G$+SQ!TM/0/E.(7B:2RK ]\16+2A"#+C)<', '24(!S/T+,
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MKS[$4V^26^&[(VL?#<V?9IP"HCRI$3%Q.PJ88^#(RP,JL ,OHFUDT_7#&OK
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MSJYC)*</#E&V8#7V#7$^%P7W %[^_:JT?TS8^8_9D<J%4.2.8 H6JE\[KRE
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M,Z6X5401H25*D1();_JI@K-@8\?E>][M69W1!R] 4$%;$N<P=,1-CIXX9=;
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MMF$9)8^U:V^!Q_KV 52O,M0P R"]< RX!Q(GLGW B%,!/W&T>NE7?K#B[=M
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M8C?HEI1X]I."3C-<93*9KPOC@1.XR,\$F8?(&W)S(!-=\$KTQ3DM9+4OLL0
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M^&6AP0[C&0S\:16V%VI#JNIP"6ZWO$-<5?4!4.NEH\/YMBZ(W7NR7AB-K<R
M5&<8*&6*,=FK+K#P&TD%[.U:;2*A=HJT;KN45"SG[YZ:DV-'6A^,97Q$<DSK
MBS F.&*]3VOK.)9P>S@+>Z _G."7(JWD(+.%8IC1:R=..4:-=0^=4(K6+X[:
M@;OVY\#A>-7 Q-)-^-G['Q6ITFCD_YXN(G.=?&57#YO)F*U=ALUW;CPM: .'
MV(SG\$WDD"HFVOR[]Y9&.G@E&LIZJ;%H)^H<=";+OL7$J.!L:.@W9:W?YG2C
MT>HW5L_D[6CUQ'67O_*ORE_ES^$BV9UC_/"YTP>]!,U<!K%>Q[DSO'^*AM1E
MX39(7'B^F"7+P7O7O%]UMB=UO?19I#$PE:WE@[<(.^28*7=G*KZ9IE@!XVA/
M6M[VI".\ #G*PRG^DYX;)U(ZW<?6(#V1LC_5K8U387B(J\/;H@0ISP# RDCA
M:%3'OR#OP2'=69E3H]5;K5ZX9:KL'7_8DHT-#>.S\!(J.>+#0I68&8Z2Q ET
M+,QE)=[<[+8VWG0-YT.4(ZWQ*F7S!>]ZI'38:!2D]7 @RGNV$-=RY]E:-7CS
MWU"A$!7*=#F%0DB3V4*A^G.I<??SYV-/YD\9"AG+(<9+XH,>%WTDS$6=4V 4
MRG-V(&](G;9GZ^M4E44<$_FEK)=*BS3>/;AN2V.B6'C';6_#TM:ZK\8@)FIW
MNO5N(XV)]J9ZV1H36;TJ65;18(>>A,*)WL28\K-U=/^)6XY6T\[P[;H@3BN5
MTY6PNSH6QK*("5P7P>D+0V$1@P\;PI>@DVIH7WDA@8F*FED9IU;.P,7P64P/
M*>=:3/_>K+=''.(I)F&,=B6*NL!REBI'N-46J C%O\UP"D:0&K$%(X_W;W3Q
MI=*];H;9@SY(,&(NY:Q"$+_ZH93JA[W"-@=!"*4GH@C:CJ,G4L<^%BZ>=0 V
M8DST'[)3+Y WH(?3AR&GQ#$*8-$/=8&U?V&Y\AY(G,ANER<PO(KXI/7&X'+M
M/JV UF0"4%"P5O,6U?Y'&-0FR^?Q6RF,M^@[9D ZW "6L%<-H86=M&KUN'0(
MEQZJ1-$_HUKQ'J85SR,@,2"1ERF(M$RYD"W[*.<)EJR.3/6,N(&F28ZWW79Q
MA1U 6B&NP903T"0K%#-JE#US%V8O6KD,DR*I+0:N1M&*@\SF*Q'F)]^%BQH]
M?2E'^D8Q+*R4+5>\CQ%&%].VH]-9K= ZR^, A;%*RJZH6@+K7T4E>8)=]/SK
MZ %5H]@;)K.U4CX=.WE:X^-$W'"5T)L%@_EBA&,GTT Z)L!X=N<:J(L%CV<'
MT3QB030WJ"-H_ 19X'#;8I O10F_XS.!MBHDGA,<977P<']_V[IK=8?U6Z+9
M&31N>X.'?FM ]-J$N9U&=+KM7O^N/NSTNND)ZC!,45IW<L19/YICFZH$I?T7
MH*6V*!VSZRWV _"I9Q:#@*9J$DL(!U)T*7GW/R"O  D:'D3C=8>BPQZ/=3'L
M!B@)]P-\[CW4"O[W'L[;<?*+L&+$"/-S!%V<@R']!F0D'EV@["4AARH),,4'
M04LH"-QWPA$[>N6E(N2$L!W-M(_NSV\8C/C:T%@!X]FVLRL*J/__NNQ28,U=
MVHX"YL<91Q.)1]_M=7/8J[><%NHVTSJYJ-C&>@+9TDFB+LOJ'+"DI3!N]?,W
M];2ZN9\/Q_1A?<, Y@X"2_-X#,84?18%E"?TV:?YK/5\,1^@[NV\#>/.I)P#
MSX?8LBSFHZAR*V6K!>]=Y>C\7.NY0=RK'E7];0A]H]S\F7]I*5*#BY^[V[8)
MNJWJE<-+0=-P:.(%"*PHH<]:L^>MWDL)9W"_&B% I=L[U@A620BE"J(H9*.J
MP3N0!%($GW 34#2G?F$\S_\@^#DM33DAIXB+SP266/T+ Y(M*3;F-MI8%4]E
MG-!SCE]^]GHCOE;F5D #<+TFG9L7>ZT$0[S^[]"P?^6NAC.005IH#I^Y1!E-
M0530L!@)]8$C./C&J00=FP4MX5;UR@S( +*(/O02<26+&L3A3WBSG$9?3S0G
M']XH*_ +?';T$O+1U=YXVD:(+RXX,,4S7_\KER/:'.#9S\0]/87B/@!_52 P
M\*[R%P)/;H""0>1RN@)BN1?_Y0=>"RSC!6H=E!G \[I _G.1O\!_AY RQM_M
M+X7FD:<7,H3-^/2%,.;;Y=%(QVV><0^O(7Q.4N\2%QC4L[P.7FO!HX'!+\1P
MN8#OKTO00V*^$%VH)34L=T6$T++UID_&7>B7M:8QU,S73Q#Q#B20 /V<&P.H
M+N&C%YB 5J277;DJ$-+M2T5@!4#-IO)T6I(5$0A!F-_.2,X2:B.^CJ]NAIGK
M3N_^6[U_5\\2G6[C$J</!@_7@TZS4^_CM,%X?_T8C]5J#T/.B,".\LC?TQ?6
M[0U;@\RP1SQTZP_-SK#5)!J];K/5'6B?!KW;3K..OM83*_5;8C"$7Z"DS#EA
MZ(Z6F%FF0&8)5!N#S\9I<\_/8X5.LJMYD5T8VDH<X[M@&D#/=('THZ2"#?^V
M>K$Y-4*:TH(^&*)A^B.H6D!@[R7HN0B*/OFL;3@H ],_:7(RPXNR*J&6I@.(
M%VX"C9N@Z/U.H2J_A\]C8'P^A'!?\] YAQA;F&%LU3Z0Y<B@C%;J=X'[O:SW
M?G6*%P?Q/W5K'J44=*&SF2&)__WO*D627XBUVL (I6JCU6M!$OHB.Y5^TA=7
M5J1BD=%[G$'\FJP6F?SLQ 6:P<5-EK$U=\<&'H41C"@M4)X=H%.^,+H$LBQ*
M*&BX&1+7G+B8T3 6S:(3(UFBR=%3081@,$235K1O+[/$*XU&$9@/P@T;48D%
MCB+0HQIP"=!)$S@:_436RJ7+K6=ET+,(K?X?/D&Q/A(QCB+:G]D$//V* A[X
M6Q."/1\#B:"@9B9K%0JSF?592..@1S2;'>(>+XD!*G:#96T5Z#&:=B?Q,ZH0
MQ)X ,;=0M$=7T+>U8G;'(Z"*1.][Y909@2L1! PZC*<@(AL\)Z"+]6L1@/#;
MMZ4"F!DQN*Q?6F'.6&'N_>P,[,_3GP'A^U?EEP190?8(_=_U4B=<;!'XDOB
M4(SDFLI_:6C1)?X;^>7C94)Y//$"JM.!X&!\3S Z%R$Y@('"V*"?P8J$GA.
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M$YMD"?0=,O:<I"R)#X7\1XV]L=76MX"1H1=5!?I; J:_C1U? =IQ4141'6^
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M5Q"(2F'RT,^0[FM,**)I/+W)I(*=Q1&<23).[,%22:PBL$PGBN)2Q'^8)+9
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M'EP!,/QF\V;<7F>Q:%+G.IQ%BZ58!WM.#G7VPY$-&4%>Q9XZXL LXJK<'D?
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MEKH,-F]YYX7:#H/;%9V3[.H.^+4CDC[4[-[/8S+<8Z6$_W,EC,'KVQD.Z^[
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M>IZO5+Y.WR];@U1!@3A C1Z7&#*P4U'A(!'LA_#_#3^U0-_F?\,\DP!G.;'
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MOKBXV&UGZ2L%Q8U>>0I9D-1IWL-"PQ %V&XUS'O>+T^) \[F 6Q[*$ *K!K
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M[4Q"8E!/T8L5<:9S*=*_L4GC33;GS06--UG5<!H.EF[!^'K*7<1.<L/9H 9
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MZ+C>U(V@N(]8Y'VXS99()]=4+Y8O;6$--X7:F#.=NX;>.U+D(UWQ=RKC1OY
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M-;8P:=,4%YAL=22S8\TVR^2]0PP&I,CP1 .*ENAF$7D%)L-%V!Q>FJ(TS\Q
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M)UUKN >7@GS5&WH*4Q!8,X7MKYA/4 A9-JK"!4#_55C/8'_ ?T3:@A^X)!G
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M/+L@^%:.DEOO[GC1RCW:V=&?FJM2O;($,5GE3L[+G]HX_R-6HN\EN:J2)?N
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M5\EIBR]O*]2CV:P?C^@![GU_R$]/"O1H@_1D8QU T(ETB;_Y4WX.#R'PVA+
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MWBA/6I7<2<J,^-Q/$D1O08,3CZ"D#+:=%"=<-(M]R7SD9V+Z;Q)NGD32-F@
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M.\,S?/N1L^63CK3S48']-VU\[HU?(W[BW-Q0GS48.)T*^=G'G/(\,1,J677
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M'7LD$)**!*#[B'Y8\SV!;C?\J1F")Z;.)&.K+\W.),V^EZG'0+[/*4[!I3Q
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MD;R\;L)B&![WW(44&*+CX^O:)I&CJW*_^=#MZK>EYOW*QT)?:+^J*%Y.?5>
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M6T-%?_MS(X$ 8U X^YTQ2 ,'\5=7."G*D 54HR8<=&&>PD#<W;FI,0IMY^1
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MUSP_R[KM2%8#SR\-XWY6*-1..^*OWGI4^#IN.? 82RDP:]#)B4.#GJDB2(S
M;5DV2, &M-9077?J,-!N*ZUQ^F?H=T %HUT@9N/34MO?AGYT(E2G+(VU-H,N
MH7[HE&..E/3SM-UX)\7)_/=57MS3>K^92# &NI=_6U/==FR5V/Z6Q;NZ3>(0
M7>3:K;-HU(M="<B=?3"<@%(TIXU!&;J66?,YS+H/:1<">=9?%1:YVFWW0N-M
M+^'U?0LS:K20^6@I8NQB'8$=6B3PZ/=6L=NB[*/C&A:%UGFGDE95QM0M5<J.
M.O+O>4#@6]I?DSMZ9UUT!B:V>N1$IF- QI^:5R'"SV)'ZG$/@J=^Y1$DJ"]P
M>TK&'/F(/G+8(1JFH8W0'.V;5Y)BL# DF_1QE\M4ZI[GL?Y:+/J$LO"#X[A%
M-%]^%A+PR>Y_* JF_MLUAFXSHOZAEJS91B@TQ/(+Y5@HA%]_7E64#)!)384^
ML@BR_3;!/$2]/I1F$20F?3AYO9Z*!)[3F-W>=6_)4:5)[*2>%GBX@BE/W%F]
M3GO]6_'D7P9U!K%:2+O8\^K!, I42N7+?1PM;P7E+P7[-]=6[-#VO;8OIXB.
M= N_3>7/%7=&&F.?[%(FJF>^M\7FT6/IFEX4VUL ^UPY/SEYMXA.8KQZ7P96
M"5NEM4#+P0D">D_D"&(,ICQI[.T-9B#*=W7/O.S0^X&BN!9*%N!"[,3@(7O\
M;!L;5<H3R?Y5R%EXV4,^F;(@L61O+QG[QW3*4*,R^""0=M83FS=O 03"^=)K
MG\J4F&R@=! RY/I[:";3M<C'R4>;J?+3(G%1NQ/)[^D1IJ2DSF:262RJ/%P(
MRX'$3N.^R9-UULNFX3ABQ"464P*##GQ^DH@3'+GS2K.\YC& !T@-E%G,-]@T
M^WHO*+><.G[C&/DEG O%-U+/54@3JZE:5TAF)+-$SUWGM0/V*Q[JY(S2@ 8M
M)% 8YTDV5G.7JBS=((\$ID_DZ.3_!1_[/P5\GQEYR'YE5ZP )V\=! E,-LC^
M[BG;S\.6&;)' C)32& #->'_KZ.@+?K'S()]9..G(B7C\%C+($$]SOAZ),"H
M<G;S$PD,3V%@GQ:EL2;Y"XHL:O;MAN8C@>#9@?[#WO0^P1!Q="F&.Q/Y\HW5
M)9L,@T9/Q1PH9+7.9$GO'3AAL,('9-P]?Y;V2(1]*>]I*8;9'Y_5-QS7W^M!
M/>D+04)(H.$7X0VP#MK8!\';AM[,1\9N&"#Z6VXE;<?L*'Y$>L%81 *1@"J1
M\=D=N^&<H:6*RWNC66M7K\JD'>LXU[J@X^=L2K]ZSTSP:Z*$,<\7&BO4'E.D
M%</ 9'^JFN+)AG>B*,T5*:4T,2>O<QZ(EJ.9O+TG_.OLXC\^ZNOX1!R](E+D
M*22O<_7>\>4?HGP1WD?77RK+-#36Z^P.^00;S%M4L#GQ_C[2RJV^]C,U-KC%
M6HQ'@XJ]R0:M+%V_,X(B]8JKYU/QEZCW^[(_/8L=)58A RY!8:EHI=(N"O8"
M=,K"(!SI.S^O"4>F[TURC(\57"1#(54'#!<8M0^;V0<)7!')4=C\"Z7L_Q3^
M@\+G#PLK']Z(;Q$MLA="P*V->:9Z _%@/!G1'-\/2N Y/10<OTYIJ!O-JI#:
M//Q6CF<)C7WN)PI<US.MOAB7QL534NI3.L((#%X (R SW?OL5D@ M'AG@R:V
ML:\!<@>KV=.:]Y*I3 +Z09^W[)+%T7_2NLZDF8#DF[II=/Q,C)0E5P<(M H_
MN:?O:Q@3V)64V>;;30;LV7L=T?UJ,U*-D7"G9*VESPQFD:X?$#*P4;.VL!=I
M14^"&(TYM.;P&8J:M(B=DJ)D ,7.%7#?>0]XATSBD"=S8[]VSZ=\)>UXN6'Q
M57[XC9[>DZ22,:)H-9GY0JZ&LB@7130ZZ<AM+A+%YFFAGC.9>FL_E_%PJPRE
M7KF8NA?!LVC=_AF0_\ /BC-3],:KU@CL&;'DM>\%>(!(3DBZ$A)(Y(Z\]QM"
M GG19:5'$@:S/#USQR-\+0S=9J>Y'QN+0,/D?8C.K8>45QXP*8CF /X>U>P#
M]&*=M3 \>IKSW<_":G9*=P?DRB+RZ(&5Z]WWSH8G%2.GGC3.F'?.W7.>K3(3
MX"/RIW2=J[F'?=6K%:+.[3?1P-+TG6M-5[/WYHE[WX%]):Y>2SW?:U/<6,+V
M=@8>-0LU&,60[LVOZDC1T&,][;:HD@B&9FNW:C?W6(*(TOW IPM6\-R2 SZ?
M[]R!WYU%5((=G<B83(K*TZ@FG=R-/AXPG$_14U!1(<9S$VY/@TC>P)! S+/&
M3I:7S><316V-)U%M:6O5L)W:#Q@O+=#?/[^SU^BC%Y\[N]-BC[B3SX_CU;F5
MA9@3C;,IJOZ\A+1L1)GW(GAM#DJ/M&T6AEZ;+]:I[+317;Q#.YNI@+_>I6&(
MFK3=C+-'$//[@ELSKL]^QZ&52F)]D8T4&_Z=1V@ ,_M$TV>(UQ;F14%QZ:0/
M;0Y6?C;N(N!'J*,O0PE;.\VO.)3@_>0!.N[4'ETY<8CB2*+F$9^T&"XEC+I3
MV^06V=*!=8AH6'6)%3JR"C8X]._D>O%UBE?+JK3-GOC;0G$=231;%JZ.UIZH
MQ!P-!V5 ,?>PXWU8L,)_7^<19/9U$TL]A])DLH?V-K.HMJ8[K^B^>ZO#2GXP
M&YWR%AY7]1(JK?-Z6HI=IK+-K])-A33/?^"E!>7O>ZY)CQ$A:9ZMWM_TV(N-
MN-D*NP=,+=\R''+9X:&#!"1HTF)GVC[!4FPT\+9[X7OSOG[=16=6336^L*_N
M%\?RLA(Y03FN<O0Q4$*&PS31:PF9N,WK[H4/]13I(F<\O4Y?MDG6ZA^,K[I-
M%AN>L3'01=L\7P7U\?\^PLKC9N$I9B4;YQN?6A6'!34IJ8-^79AH)"20__KD
MSTLED33ZH1VICQD'@3B]S#[41NG:+!W=.3YN_)_9 41$D#3YWUTP(V ?DN&9
M\XBY%Y0[OV_0.<K(9."81%23TIET@FX&RPS,_%],W2F"#8^T#(\,K8X<DJ'?
MUY*J-"I #VYFL3SW<5['5(=]'GR!1KSZV&'ZY$P;8Q56Z.$B+2X\? CI@1'&
M'3M)L53ZQ%^K9 YOMS;ALGJ=*_!A;Q.JYJS9H.7#9#]UL?AXOZEM]LO&'BI;
MI_$S-FKEFASKWKUB*=:',41)>6^.X9,O[&XI..IISU&O*M6*?B:Q64DT8MP3
METFUAF8YW>R%O%8XIGB+GJKM.ELM\98AKFYEN(ORUD%0Q9)WY829]8,SK_/$
M+"2(>QE>,2@A&ML0P-"OJ-09^N;#*T<I@8Y7>*>,*0,?":H\W:V*UE:7ESMW
MQK4$Y9W"T%@LPD=J'LV2O(P<HF< 17I)5+K?%SK^:0GO!UFS.HVX#E%MZQ5V
M1L9>X<:]-$PW1*PV1+$ET[%Q]ZLNB[\E3!FF7X4&"7IH4/ITS0Y2F\9!_4S$
MXG0I4EGJ)[_:-U@3N_F<Y)Z7BVP\EC*K-A7)SS>PU3XP/\F+^&X08F)<D"58
MK8]B($+=E%WC+S\MS/!H>;VWU%0PVT?*@<B")=6\CPHKGW[^P3PL#SYZ!9?9
MI$N8/,16_D,4!U.QK.SV15M=6L=!#2@'VOS=^RWGQ\L^O4+2*$*UVA-.[(X*
M&L^><@>A65,=#$@:P+RC&]8D^R :RQZ;T !S/=53;F?B&LD6J7/%(^.]Z(3P
M*G\][X>TNCOR-.?01(:?[-PZ37R5!_N5UH6(^Y&!B*9=(.V,% J4SAQR;* _
MZ9+B].(,G<>=_*?XP3T'VIP4%C1;T02Q,.M9^BY&=\8I<%*\>3*=49KJ^;:'
M\-)BQATO89E]US,8Y\MG7A)Q^^1QS&0"S*&7[RY7]8K_^9,JI5&JU[482KU8
M^<4%08+=FPS3H'U",!+X*0 *9SA/V.^^PII]2%6I9+\WV.3A;< 5K\QNT Z0
M !PO=U/QCN6&]Q[E"@G<86J<5W%RH(DBB.XI$$$W( 0:.UP;"7R7+7CP]0P:
M2*#'$@G@3/^G)6P LA>E  % 5V;SGV]R=J3TI\L2.S?2' F==Z6"BI\=<R-F
M*1U'EK*:C=_>L_3?%"=$^1LY9/!45;S*R"$Z6<-Y)57T!W.7\M?60ID/A4YW
MV]P=T][::DNN>I>OMO*CU>_O,,^TL4A1,L'*,%G%%QG.H1Y&PM*OB#CWCB++
M<K7@]6S;W@F;:DS5A=IE_'$JI=)RDA<8'TUKH)T4\AWQ@[\U(V@.4CSX1-SN
M(\1^U?"==S4'9).8S8&:\E.T!)(\V8;]_, <XTQ\>[_M^"\>"UY<+@01GSI'
M4X=5<)^%>JA\)?.*S"!SPRI1\0 ;K-V]F?T=$/.=FKOIK'.[ORRWFKK&QEMT
M01>!O;BBW=G2ME@MU0XOSLY@)U8X%<G?]"(#+&@_M$U^DN%J.V^.K.9Y5EE=
MW'KQ6U'@^:X\%1[6#S?^+)@<K26D>^#HBRG5G6#Q&$FL@$2$+GT817F;0S>I
MD$^.M& OA#M#?.P9$>>I#!*0%3Y<D"B;]U!V&LC>^0KI&VN/&0O$,K:$F8J_
MAP98:,#?^X+MFB\;%B$6ZP=ZNR_H6O]L<F>=F1;.,=@!C38R;$NF(W[6/[-Q
MUD\UNH4TR]L#)0]X]*!O=V[,UGS87V3 9(XO7A0/@24/ \P&(%VI4,+'2RL3
MGJ0"G2%J96U?F6;-?=Y0#/V.DE7?[312J8M\.578'**2V;(9V_R5-<+@@[3R
MR*$:X"M2+#J ;\X:HW/N%>-+33=:/UA)>A/;^3$A;.,M"&\YV^X'KN1YD3(Z
M#BHC>A" OA6K2QAYY^Y> :_7F66;_J64%P?55TW+],\J,9J0;!DY.#$9^ ^'
MT;Y[T1U46_@6_8*F!_1\F6KU'G)IH^.HB7P:M&[V1($T_G)R+WP0EE@I#2V3
M.[H>2(!^U7 _D#%D=]:DO37B L;<%C)=%,_W"((6S]==;.O#KC_GW'B+[73V
M(8/]?*UXC*OI>>J74U!9'IX97$_V\=#='%?"[<F!8E_N)PMP_U^?CSIA#-$-
M)X0:<[*SQS^*G1TN%6TN2Y,^:2N.95W72$[?:9397N]IM<S] K?D*N7 F.;R
MM#!6RC'7",1CGR)(YGWS'DT^S&:-L*,;NK^^RCVOEF$"3;]H00)=ZTU"3QL=
M:<S.Y_0^SN\6T[=:L:RRC: K"A1T[9]CSF_'=;]>@'7'0<^+^ J>2Z4+J&'+
M[L](.-BB-H\7TM1EX>V)Y1'(^8O"@XI2X<$":=N)QM9'1XIW7*!/&*$,GTB<
MT%"^_4$[,D%45.+6H-E]+ [5>$2NTZ'&ZDA3P=E$0(E*(.][ HX5;CPW-OP
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MA 1([@R>I'C[LDU$-\CK"CV^&->0C> 2[^*%]W QB P[#MVU(X%?^VA+5T@
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MQ'YRX-G7G3/B[D(2 ^0CW+OM]0<M@*WU$VMCT\S6[$X"O?8S@&UQPZ&\S6P
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M6I;9&=_X6&A$XBVD7AP,+ST@]_7F+2&E,4CXV[_Q;M)OK?8%0[L+XW393]R
M85\%O;;EM-%6+(-$R1BV FER?E:>JL]5:G:#I =8Z9/+"AK%TN/$WG@R![S9
MT;QG!_X;##RKX,O=I)CGTAU,&W%\1_S9'Z'A<Y.'2^1OJ9L?1OF%OC48KYZ[
MMRSOV@1R5GZ?2Z/?L1C]TS5U3:C/=_8NL!O+79J-J)3"0?\V*QXTGOV$([M
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M('?ZP[4Z0PC3Z)DMT5R4,DARJ[;!']@<-/0F58SG(K@\?>(;BXL>.,O= =T
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MF&Z+S?Z5H7>[C_B3?!"0@C3O9_QB.([JW6WT+22((B3C9B):4\X9?C$>V3-
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M,B%!BBQ%C@^SJ/,AL!4_%C><G3#.*=/5 /L0+354R&3A&2!\,6<;=?CKL$G
M:@QT$NK]Q[ XAV='X:GB'N^)SZ<O7_5-C>);*]\DPA#CWUCS+;A1U5OWXJN2
M>"=6*!U?!B?]2#W!UI\4,4P5S(82&>A?3Q1U$"ZF#:<X<Z4"+5:*17A2!+XY
MH+\RQH:UV]K;XKUY\#+MEU=_01JARO@GPF= A&F.B- W:!Q:(%<ETIL&"O=#
MA#93Q%'.B/9Y]LUWLM+DO=>L2Q-GO"S]F,FJD\.995;'(GMN&;"')$><9P"D
M-_<.HY+@LO)4_QF0I+JY?H<(?'P%P63=P11Q!"S*B1*[?DFB]_TBFB@^WT49
M;]M?&[5ZY75\PT.;4HZ*@R%TJSI=*XKERZV_LM^EFBJ<I!^(!):*[]16W=2]
MO/=8%OVMKZ\PM"9,;7+$NC!2E0*'9S$N[59?7O 7T2<K7:Q'>%BR+K/61PSP
MEFJKN":Q9D_2R]?ID#X#6OD?[4K.P.&5HA)Y^_4-Z8K.+"+U:A0<WOVJC(V/
M'!\8.NKE^_6'&ZECO5-+SA7EW*=N>&P'P"MV#2"'7PQC*_AU&9PC_\QS_:X?
M[#@-WWIE=I65%;:(JF\CT2X=]$S>4(^WH:G4QA\=6)!#1ECKFDC$O!Y817JO
MR2])"Z(Q2/53U:.$2DH]&MK\3V<F@=JBY++-1$L9"D'2'[4']W@,^_[J'7@F
M<'\Z^">J$^^UDG<?=:9K>LZQ&^.\4]7G3[SAGK#GP2E$Y?S#W&-_OD9E'"K4
MYMD#4;82KE5\+^JKC]LJ3T%VIIM:T+BTA5WTRC?JKO1NS&JU\>H3*RR0>,],
M'F*.[$SS:[%["U769NUD8S&NV#)VG"MML$^^FEZ#WT510,1+S7GRJWS?EDXW
M#"U!]77MI03V@4_MQ#46H[O6[4+]6ZL5R/ZE6 XU!J&0+GW#Q^3D\D+TAP&O
M]MY]?)L[R[T5]!^5@\)5-W?:;MS,.%7F'TG>:" RR,O\=?0,^&'?B<36\C#3
M>Y:TQL$!\QZ)M\D2-.^" )03MHBCO_EQ_,IU(V6.OQ?J[-^S NT8Y1)W(IV#
MI_AU<M7W6!Z6C(5?98R64M2&T0L=GO@?>JB&M=.D!K>J]0(DN+*HQ 1+6F5^
M\\=O$M<H9)B0.YK*HHG9=8CTF=A.?<E*3IU?C8%F:<:K9!PX/%!,/-#=G03"
M\I\!>WRS7C*%RH;[&OA[DP---T@UZ<=K38$A U24$-5[LV> 5&5R5T-5H-WJ
MY[Z&(6P3IQ@YU+N$CQ)DMZ7.;1@CDW NA6> K<DCO>=7=1F7'/C__#=Z*I0:
M5P>1J?@TT<&#_KF$I9:;P-U=2(/$K:O\4: S@S&;O7>\ 0AYUSU_RO?8,_ZD
MZ;^-&@^XZ7.K54-C,(,_ [Y,<U1P'AL^02]4Y?1HW;U.JDHTVG4FD )Q>J9S
M-W*Q1_+Z2@W7^AR)"DK7^%9[/;93XD59D"7'A80&-.Q*\X.8;9O%<FHHRSVC
M1NLA7*MR=561;W<4KB=L'6I^+QS.2YBU1]0:VBJ>9Q>Y?+2 ':!:3TE2$/>=
M/0,("$*><OZK5:*L,VBW[0;Z#/A_:R;89( E>'L557P96_*G,92W]$Y_CJCJ
MCLG2.BSR$7X'2<&FW;?R@AR]3A+]K433<[ X&PTE>J\+@)_S0N)ZQGY=V:.T
M!MPCV0%&9-<DS3SH88C$!"&]!O\M2)L$J\1LW'BD%<KRV-37+X^**D -7 UK
MZY*_ULK;>UK2)!YK]+H+">WKK_T2L<DH6HIA6,)KDM</%2]:JC@0;CLI('B[
MXNTL#:!N,8+2Q61\(T[7_K@F0\#U$VR**7WQ/9@;'>S@1:91A*D1I:%<1W!9
M=W\7P)2K4L^S(#2.E7'O3;7ZQX:*')+_;QY:%6R#-IIT/# J?$*)@39?T^JY
MI>@OOK"?IMGG[,FA+8GS63$.E\)JJ?$9@(/HN<?JA B;MA[Z)MFO.O]8A:#E
M*ET<ZJ^E\P?/^X0<P 1B%.)9?+:*!_P@,=4PS*0R@R]J(=6*>H>W'$6&[QO^
M124#.Z3?RIZOHR=CGPNJ3[Q*CKH&A_EL-#7DRG6X7M_SBPH!"-!0T-HEBL$$
M#;=D0M(E;K2=5S27%7CN?'T[?<NE9:.+K*3[>B;G"-/BV;C(^J5 ,7%M\NOV
M15;?V  F/:CBR"D)HA\ZYF 61?Y^$$S33^PI2/7G&<"R?:6H\,T=Q4RD0)'\
M\5)(FV1CEKM[9G2ZMKPZ.;LK3G5+RP*5/H8M=#E06X@>4J0=W#WM=VXX1M]D
M7W%:UI%K:EQ6>J(1 #-K1@1"_]:<X8.42=-8\__M$*/BFEV"[=F*J[?SBTF9
M!,%9EU,,:65F3F?-N^JUS#MQSM\1$.>MB;<'4]UL<]"P>7TZ0G)SR\6D/U8-
MQ==@:JZ1?:W>;D%?!H9S82U^2*MJI=>,7)C>X-%V2U.C3>I-?\]()TJHT'X,
M+,YN."&2*2$'!^I]-\M-)WMT2\TIYH/[I66SF/=PN>S/[ Y>7H-E/'M,QWQ#
MF31N.K3XO'ZMX>">8H[U7#-EAS*NK%LX+K1HY3:]:M!!GQ#_YPV]V9V_\UIS
M_#L&\#7O^<3[<ID X+AKSL]K,$.=,>7,Z$JIER-HLFDV:;]VH3+]$1_RS0*)
MB;6%/M?5X%>8RJ'6=:G**G#DMY'.C[U[H\X!220:BJV8V9_8G[(VKOK$84?Y
M3\[F.LL.CVN;P:C"$T-V]^ZY/W6[!Y&ZNF[ D2D$K(*JYD\F*K8V7^:;#MIQ
MSM)^U2]_\?6V7X$*_K'$KES+<N/;QXS"^QF2;*CNOB%E56+#8Z-9-Y=20R>O
M&#2UE5-07'FH#J%M:9B]7.4^YYVK@)!3^/?$X3;"*CRWK#=W!$<P'^?KSN>7
M,ALKR$1S^R%$Z61SO1^'J51%=ND2> 9 ^[6JY,N+1J"]&Y!S&/,7O<B&<]Q/
M.CY6E*S?Y]SV[1GB2/45 UG3S&-@$E"%(;!!-3PWW#V694 K9W'^ G/Z7T(9
M3XS_YLJ9W#TA2_4/,(,]V0FGNPAE:B-N.H>3\'^U/T4Q&,-_)#/WPU!HW,?<
MA;,G:Z<Y*FDUCBED)9%SG+C1""_BVDH.!<;/;06('>B_)3)N_+H$P+ET-^#X
M?;(:,4F*'1I4B4VOX[T]S<JD&7.:6DVJQ9&Z)$"7JRC]=VTY353Q4$<6=1=)
MQ5 :;^.SG*R8,T/%;_$,VXIX%@FY"67&(5<5A[XB0WQEYDV*OQS,4^DP.*2I
M?SIA@('L/>K@L*3LVHZ*.]Y[4A>(>\&(@Z+=&JP,<6^0WEV?]O3YO6[ES0\/
M45H2&.4=)-X@>M]=P:)C8$D/!X:2(X;J(]<7='.VC_<YG@XM]4M^&HM3(P7P
MY_Z-HE5IP?"XNM&;QNV0Z=JN1TW<X%C;J/..";G?%7__9B!\;IH..S"N2/_.
MG%8PW&[6LVC.OIX@1(M]HC6P%D[6L9G_1TJ ?*'$,^L$>*HSVER="\VZBU_<
M39Q7Z#7]*(Q[N%9P!@QGXZ,T4I_EJ"OS^LY:S\G)!#!+SNGXLAVJ3ZCD5JIE
M"#O\K3'_4'Y1$=CKV4[;U)!SEM#,,57EG.L'M-N@)EG<=R%GG:R2IAG(;:%5
M$7SE>P?).GA/V-*+K0OH=.%J6:<L5?.4<\A'(I64%@]X=#?^YZ7D\+XZ:J8H
M,65WTY[3?Z+0X8S>"IN?\$WB#%7=YAK_;.WAHXS&T.(2OE8N-:L_KL]>N:A7
MVAJVO["TRUU4OVF4TIL\*J2)?U=@X9RYX2%^#!D:H@% KD]_FDJ!2GD5SDJ+
M^&YUM![[.$0/MBD1WO&_BVG,E8=Z@@CUS77?\/_TL;3%^FVB&6VP2RO7M*6Q
M#BEI*O68_;MUWL_5-!PJMN4WI)XR[VCQ?-M=0.O-IBHI=@B[=;/+YETR4"G_
MIWK1N4+-B[+\P.K:M\;8>"9*-#5 &LPLQ2BVB/H8R FZ2TV:*6$Q' 9&(W[9
M<N^XV#GVJI(CNJG?E7\BU\3\#$/=QM:;B9N+W41] Q7YZ).^=1@U/BNZ',^P
MQFQZGD[=LN795-&!]">V7$&4:'<7NO8>+HDC($2#G2N5!2%R# LEFRQ0T-7K
M\+!2<2TAG* "+MR4 92+8\Z=(4NQ*BOMJ;Q2+OQ4'5_ZX. (B;HMZTJSM^O+
MNR*-0?U#0GMBK 4I;_%YA@=_^-OUEZA\W=YDGW)1%N'9C77@I ,E!Z'@)1I]
M1BAO)7^N3D*3B_U-8K%-!C]VZ#IMU22LZV5<]UO3=?+T:^H,D !=&Z$B7+:Z
MF[^EU1P@[RE<%*M]ZG>><EVXJC 0=OZ[G-Z:,3/(5NX&8:6C0Q\<TL=AA3E2
MK?P2_0SG8M@<-#O-N%JG[BI?1_A_J]7HMTKTO'6LBL)1P768VQ"N)?;(*.CS
M;=0'"(3;CXK%MU%U^>+:C8)]]<#%%84C_ (*-FPN$;UA MA:Z2R^&_=D=W1?
MFNH[X*O9#_QGW<F?RM]'F&C. D2 (?OBE)D:-1DGI*94^KZC%G'[)('HZFMM
M5E+L-ALM!N*Z6(HU)OH;Q:+'XN%9SON&:U:@6#\^)E+?X:''/M]YSX;TAW?#
MXC3*]@*1U(/V?:^'T*G[<N=K TAMWR[:7=!/[)3UZ_,+VY-*%)IY@17LJ0Y$
MO&$*''&&,BJ?S.$\*W-OR# XZN2/3=WELK%MQSJO!K:F6X=F>LH__; Z:6%\
M!H"Y]@K-]N3YQNAT),XXVQ63&B\(N=%O=IOBR:71KL6VJ__)7QN_6[GWF9<(
M%Z7T_'NHS7- S([=<].N%"@P+/'CWU7)$_WM76A%J5Z)6Y12HZ0"?0S*]P7M
M"8PPK\;I4,6^D][I/45XT%:/.(UXC,0EBMZ+\F"XX.2CRTF4>5C[)_X..8?T
MC(:.7/5IT!;6O6?<WC@[.A6^D+ EUN3S)2..K%IEG[>#9Z!7^K$]IN4#5;AW
M^?+"^)0B05^(+'>>\2D]MNLRQ3, -/6WUKJ72(;>C=XRVU#]X']V__Z?%P5Q
M/^[MVQ<5 ?[9D>W%USKF*#Q<' /,<TXT4O0:D:F"/(C/"X?>+.1Q%_RJ1J.!
M"VUE7)PBM)X(J2_X [?EBU$F3""5IAZ!-2#>F%"L"+B3G4/7.]",B< TFW.W
MWHB\SFM'S:C]CDU=+\VB!X:"IZ>^)SY'%83WIKWXO@.P]Y &$,-;M;'M;P=R
MM]6T5?/X-V-G-NRN=^\]O+0H4[W&.&3J,BV@E O_,WV2T&O<8O4V>(R<9DA6
MK&J%[+( WM+];<6K%ED592PJHIW$2UG0B#AD^?&;T1:00LMZ]KI4]:??^$U3
M_QNNHCK%:+&+/R%(3DBO<#/%LU]4TTA3@Q?OA<L906SNB(8<0U7&U;W1*VLB
M'^6Y%/$/2PVOWC']H@+.XE983L />Y*69&R88B82\1CH+DP[P5JPQG2%F8.[
M%)C_U'9:$XJ'4P_%?%]]P9O^$JP#]=NA[G\R6"TK+RMQB?Y$@E G^ [ME-.\
M7^CH_V,4)DXL"H[RN5.@](*7:.# [=]FRJ%!+:/>R"_I]5!(\6>]1ST0MFIS
M?1?S14\45N$;5K;AB'T Y!H3B"R(DXDT$TR3R*0\_/!$C/@BG8M0A.3>V1$C
MYK1ZM4I3K%@7')1/O)^BH:P50GGX+*J8XH_5V+G@6: "5,Q4+GC#4)9,L3,>
M"]MJ!(U./"?G:E(.7M;]@'JFZ["B0&AMFX,,G\^#B[8SZCQ$:"-%TFUC?CU4
MR>V^>FA#4JB(YVWLJ)KE13\6>$S3,V>3[8K4R8%5N&H7Q^DHS%#ZLT(F>G Q
M4E[2+0SK'@JKL6@P3(&X>QVS-ZX,.GI*(M$:U= #A2F^+6L#O;MI9U=ECL(/
M)?V#\<[)B+3S3FN9U9MC0I*0/)T)A:KU'EBJ\R ,SXX)'SUCT^P-N-08HL(]
M[)/F[)' 5.5-PB5D7EGL'B%":P#=":]\V5&9"OUCHO+#9GB_Q4.T'8HE_]4;
M&.#7FXV@9J8::.,?/U 4B1=FB/GW"G"8:)@O3NAE+#L=3Y#++H^]O-7)5,2;
M"Z\094039S>ZOR=&0 :'550S]&JL2GKWU]CG[#E-LV&,] :Q^/ 6UUE<T,(\
MYW&K4.EC\S0G__6^WP ;#+.H4@RCXA2AO8;_#/C=%'AZ^1)\?*K("*.OS7:1
MHD R"RWD\BEC ->A%EERL"T'9,73*GY]+;,EV0UOZV<]],ER"^$#U-OD)%J7
M<;6W=_W@M<R,(:9 ]^I):XHZC J/CAJ>#GY\BGZP]94(%\>O;0JS.+,5BNPQ
M'B/"P0VPXR([W6)E_X _H=GX>-B._K1Q Y9 A$!%CEUT3/C_4@H3,5 ZC= >
MN8B5577 <4/=R>^CFT2UO_]UV<;(I[%J /WP$X,/@Q1LV[G5L1)TL:NHY ):
MU3+UD+;?GO< <KS$4Q>MU_@[9L!Y:;N\C9&"I-2\QO ON85N9WY<\/PL<+2T
MU5.&C&9@=SV\7F+;EOKF7-BF5N2G.,O9FUGBA,<P8[I4U'XH3XL8:VC';%&;
MSK1%J =5"8G^H]TB9RO69O3",=Z#2N2UUV?)2+K;H!,[AG82A,S0B[;L\A)]
MNN; A<D#!==11UCL5"F48\^X^GV_)^IZIO.L3=!#N'D&CY,P-H"E-@%(\/;,
M$BE/M&CU/Y'5!"-$N T@\Q=@?6!BZ(U_B4<0XPU[PWAT3$ZV-<H QUWI5I85
M7VDU2.3S7QAVYVO+3UJXFV,^;+G8HG2LVX@V*0IC16+$U#, <Z2;Q?O,)^24
MS6C+0/";EC[O[;X(5Y%97,?T>"9N-E\OKL/^S\+H[.,]I-+8$AM'>\J"98,!
M'&F%>DF71P'?1]9IL!_>IN*RG8C'F;E\6M61&F-TKNN8AL2;5MIG@'1PX/I>
M1W]#GZ5.C)*WK1AFRK(VEY_D6S\V.#PV4K5VJ#8Q6'9&W[TVC:LO.MI[UV/<
MXY]:ARKH6@^,Z66F!A\+>]%-&*+B6BEA4N_'2"T'!T3GY1$FFQI>9SIWWHG
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M>N#'OWS<U>]82$7C,GG8P?Y#QCTEFZMW68K2(Q&I2V)<>C)9J0TRJ2\[8UN
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MY[M)(%+SXT/MU;:UC7N*J9'BF6"N$GW][CU%6Q<W8TL.QY4A(@P3 4G?<X[
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MDFWO.Z@Y!L!+70^>21E5K5EC+(J18XR'K?3#LNCQ79<_G?#Y<(NT6N_&C#C
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M-ETZJ\-OI,O8P95N9X# <IUWV#=A]SX;\&,"_(4H-R^=N?_)NS? 1$NAWUJ
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M/E>]&/5T,^]GX$9_@%_AJ#U\BY8,F8X<82UZ=!IFH&"I?@\):6@/ 9&6":;
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M^PI_4!D_PO1[C9!998G=AL]W;N40H&27Q'&AK4R77Y?,M:FN*70-Z:FF)X#
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MQ7,$>'AX1$0$)&1L%.27+Y$),+'0L$D(R4A)"(F)7U$QT;RB8* D)G[#3<O
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M;#Z!ZE+W2PFLSM;A,*1E]TGXR:+F=EF!DI+1+IF)"R(+VH&F@8GDTKC 5[O
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M';_!ISR78.KGVC+C(>DRW["SQ^NU[PO^VMC<2)1B,P)_?R9R_\JNPSJXHTB
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MX!YO<LR_@ 43P([^&#XPUQZTZE*J&+__//2))9YB+*B!+NF9$;%Q?9"8?!-
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M/ZP29F]<+7Y7LRN<B=\PO3@LQ)+2R8K_3JO0\Y@+F!V@TO_AS$,Z$?&IT.G
M7CCV9!'33?I'_2_\]I@YYUD';\,A6V'2+C'G+;]&T&KA$H%4KGF,F.49-2D]
M 2X'[.'&O#?B6@7L=- Y'Q"B]8M* X[5_^/*[VV_F?7/+RF%8W^!%(E9(=SX
M.0F8G<O#*N!R( 3A*.O1A<#(_3<O-OV_8(\S_P-02P,$%     @ $(BO6&*^
M9\3X+0  @3   !    !F;W)M,3 M<5\P,#0N:G!GG7H%5!S-MFX/-D#P ,%)
M\. >7$)P@EMP]X'@SB#!'0($=PCNGB#!@P9W"(-KT.#SR/^?<^Y9]]W[UKVO
M9NVUIJIK=G][[^KN[ZL>^!Q\#<"1DY*5 D @$&#T^ '@BX $@(J" D9!1@6#
MP6AHJ.@8^)@83YY@$.,]Q<8G)Z&D("<A(WM.PTK_G(J9FHR,X=5+9G8.;FYN
M2GI^83Y.(58N;LX_3D"H:&@83S"(,#&).%^0O>#\7S=X)X"+"L0BB"&"J  $
M7! B+@C> U "  @9]%<#_M% "(A(R"A@5#3T)X\3&G  !! B(@(2(C(R$M+C
M4=_'XP 2+C+>"PYQE*<JQF J1WS.@/A<5.K7-5T$JC]^T7"9. 6BH1,^(R(F
MH:6C9WC)R,W#^XJ/7T#BC:24M(RLG)JZAJ:6]CL=4S-S"TLK:QMG%U<W=P]/
MKZ /P2&A8>$1"8D?DY)3/J6FY>47%!85?RXIK:VK;VAL:FYI_=;=T]O7/S#X
M?6)R:GIF=FY^X><Z;&-S:WMG=^_D].S\XO+WU?7-G[A  "+HG^V_C OW,2X$
M)"1$)/"?N$ ([G\FX"(AO^! P1-7 1L[/J7B#$#%?QV?6].%1LVE^HO Q.D'
M.B$-]T_:DS^A_179_RRPP/^OR/X5V'_$M0!@(((>BX>("X@"O\]Z38K#RU=[
MV7+"-L^2A5?<1-T,@4]=#[]422F2:KT<]4RND%6HVO2E' X_?+UU;&%>>1?7
M-"ST!88L8E@(N"4]6=;MNS7+HC6>XO*W:GP:YNCTH[Z%GZ-$H\]C+7&18-.0
ML)S;VU=>\6ORRN)A$Q.-*O<OIGPZ8$G6_#HERLDKBP%Q)BD(4 _$?OW2EJT[
M$/=G)K/8J1#5!$LTU:%)FQ0:>;2-,D@2___;P-D>V>]F<TXH\AV*!GU,ZJME
M?[ 8A4_QLPRG#_!=2RMY'7)'CAUB4GP_&XY1$D&*J_=<D 4R+#,T]"6Z27C+
MW.RK[*C3G )YG626\G/XA&*4=#J0HQO*@]>"36D)L%90IG> '0XQ0H9RWIJV
MEN;FYB#E3-2DE$$W.B'L8NI?W)Y%<^L/@@/2=Q<Q%@E<5S'2ZPR(3A'YF%^_
M]IC(V!?%8TO)#E*.9LPPXL>S##Y_+P0; ?3R6HA<;\T3Q*$$FQ$T55C7K$'F
M*<3 2YH+ M$[&A'*4QV)4L52=O;1M<0$/G E>L:-T3A82=)L.*X]V?[0OMC%
M#)NTO"<06T*S-X( /-H,!SKZ_%E^:(AT9I\MP![@  ^ED=+UH2,<@*;]C\9)
M*B]S#'MQLF"FU!P4UGL<8B0N&DK5]'>7?UR/2,\]??#6@ZYNY3SYKX9A8H0[
MI=G_<AS[KPF/X^6+\BJ,<@;>@9I:*K>3XQ2,T'\_^M_]ZK_WMFA(]V-#]@@1
MX<MU\11Z]@$:'!"N%#T^4T9N92S^)\S\_\TP3"&""Z5X,]S<C#VYN\7>2=@*
MX0)?10S9T[UG*+1UBN5GB'7<@C3]4=J(98PLL=2$N#!8*$:\2J6*\:K.'%W)
MTO'I7)?0Y\W?8K%"FVYK""K-0)8WF3+8VL'ALZB_42#IH,F4:-T4VK2$R*^@
M.&R?65Q7^FC<<_<&B)QNU4&/5I,K$V5Z0Y/,<08AV.&[[8\O0C049)-O"A4"
M9X1[I5#<HF !=V5R_D*KW6E;;876OS(5Y&F>Z7QP^P6UEE'="$$G"H@1@\Q=
M5LE4FO:9WWTE>YGB<)G9?AB/0NGC"[NC7FGU ACR(OX'%G>>@YQ76P$'&J&-
M]LB==0\C"^VR;U<LCJX/]?QJL,-SIAK"#Y)/UV>V;E9H_?$PY(3JMOH?QE8P
M1$D@VK)9D9). BQP((R-MBWFA$X9DAIN"V4;3'<$X< !HCXLSYLS[?<V%%Q!
MTB&2MBD:5KE0WLG?$;SF!3NR@NT&'T.\- BV4KSZHUFA/V9FM@@]T&5,&ZEM
MB2+!:C$B]OS"'KTZ,6=]V Y;_=RW",,J-#6@=).BX>V,%I9K97#.#P-/AW*/
MF:U=6,+4XG&21HV=MEAAYP -L,JJI*:S0I*NFZC?]C!CFYEM^83(RDVJU\R5
M61"%J1ZVXB^PP)#GS[6>":EP*'XO)TD3,[?OS_7N\H&U!A+IC3_#QFQ-(\]X
M=$;0"EG,R.(G+UV0MSI96=13\)>E+GMI1X8;D0_)V]$\E:#6^W+:72]UIM1<
M^ODYP^5U-/#,?84R]I[6(7E!2IP^'1+7*S-@ CR/PBK0.$]7">3QD8:"@-#8
MC42*YAVHW/;1'4NA$(5^\N?+T<%-[I"WPU1=I,_&C6:5D*>3ON!^:^)(BGX=
M5;V#PH#(85?/\MI5*ZJP,[7XM) YA@Q&#ZY:)N<KJ11B*EA&/F-9=,)3Z8Y3
M3V9^[SOT:EOSB':2%3;__O*4S:B'S%>8,9NPF%>@U X.9+W"_ I%N>V^R'F2
M\EX:DO\%EW4.%L48*\9X>O_CO-+O6#_TP$G"+4LABK>,VC.^9NQWJ%(/^IS\
M_NO\9^PWOB=BA+:I,T73:GH!$,S1D1I/>9*M5X)CJ5]@4:P<NG  T@@'LL,Z
MCG.E%RN@VUMLMP?*8"Y?WW5!P?VMA@]Z8I-V 114;M@LB@=! \M9HCI[N7C,
M#+1&$Q#23Q@(WB<+>;>N57=WO7# -T)DU1H.B++#@543?V8-?N@&$_C>";KU
M$@XL$$+/+K#O+QG+5A9XB]%T/X7A-M/PP>+%2'S+7NEG5M3;IFH=FB=)(:<=
M?3S[(2UT>UD&A33\#:Q&>A$"W5YGN]U1!E,;.Z]+E%B54"G1!E@+77ML,_:
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M"UEEG$4],S,7GM'V)-]"SD%;KJ7.D'=FX2G.9#$$LKM7$ZZ49NK&SV;5LN'
MA[&>;D[?P($RZ2>HOW'$3<_\U(^OE'A:Z.9:]1B$!M68^^/R-T7#*Q,()R^(
MM [=C&0W^T9#P_&S CZZE(7G[K(NP@*<T.AMLXHKK6^5CO+T6-HL"1]$9H)+
MP$H!]G@,9A:#C/*-J+VR< !MJWQ4A3F'?BR-.66WQ@E+<%:+/J2"1-/5Q+_T
ML[( ,C_9E.&<?2U*-QZ-^U[Q,88[OK?24<[F&=_QE;; ?/U@?0 MX0\%722,
M.J.8K"31.]J;KG;MX>0ND6F:-_;&IQ\&MAW(9N7IX@6ZJL.QCTQC/VAND$VV
M#Z]OF!L96;IUYZI*K6X?RS\^SEW!]*D#E,]L)G3JLZUJ,"_?)(K:BGJTHZUY
M:09Z1&K8;D9U/V5;6.&(//G^8:"?HKWA\PSOBOA9_3?HCX^4S&!*[T+&W1N.
M-OXHJ:W=V!$*$4BVG'"]]PMO42[4JU@=WCY3)!'+N9XLE?;[K<.K,053 JM]
MDF[]X%LDD-]\M6?*=M)\ULJ%+_=;YGE/JYF##G/T9R;Q36Y>OC9KXRS(?3\Q
M2TR=V^@ S_F9[ ;]."?/C&_[).-U&(V:C^S.A*U1< OL=N=UH_%[NL&PB=E2
M&B2Y7CSFQZ^?*NAY40$>AT3'QQXD8W58,-5W-44O<V*^O0^V:)*,237]LL1D
MKGY_^&E,F*_X\-EI9-)O]D2=:<R.]/M@?DK3^*NO2$?8 2N/4L%^B7:2::>U
M-+9!*KLMT:-+(>N>L?/7UB<CCDPZ(-O"Y5KVMK#6^V9R+/2 <*UU<:EGU4I:
M1&]4Q*B9,H1A.]9HTW?X^$HV=AXQDTUW;+[()Y@^;HY\S^*$1MZ%H)PGR;#^
M=2A'(ZKYX/%$EH^@4?(MGG?S[,%I'[I"-RB=YE38>VIUS@T.6)TA7ZQ1>9AW
M9;A*=E+&[DL+"?J]^'Z;3D$RQ7S!0C]6BT%U5F"8QAGZ(M94E]R6J?O'M8Y!
M-W-"/'.H2PS1:<\%0:D' >OL>&&-(I-N04>R^U?+X"ED_QP0ZI[X_LC[WP:D
MT[0GA;U[[VJB+X@LW\GU5_=0H\_['),_*+/;-D9J-&6K)/<BK;C(E??TO5X[
M[]JQ36DY"<D%1]!-]A88FL9<"BIQ]UTAC^/T/NQL!,2<A]KBB/]D&CB".+#D
MO179TW\M6VQ%P($A3DZM+$"!.M9&4D$?TF",H<*3..;1="A@^$S\XUF3<8B3
M?XR?@;?F!Q'6Z1>MXI[6R+WE*2.6I//4=2WJ)CTO]Q Q_%R*^]P/;<EOWKUI
M-#E?5*@DDHG<LL/HOD+A'SSN!;AZTFCO9\-&-K,R)@5IF$A;I,,.[3+G7\"H
MI[G2(B7''8RGN->Y8VO>0MR%FK3:$G^?U/@P+#C-+Q5O[4;,SEQ$&RK.5D!R
M;]'JTEY:,.]L26IW,O/QT6Q'#'RYBH'01,<DO3>-?Q76N"6&X3V5@0<<*1F+
MD5\0]$JN1UM G&^%C1M=9-;<DU=6WL5=!PFQ\R&2H]W,VHHA/ZIM F;HYO9#
M6]-Y.02J,,W&8\L4+;*NG:^=]E).OLE>'XV/.K&>?<QFON:12F??'$W;^_,Y
M%WMT:>YBP@8H%%[B?7[A3D8 !_S7<!Q7TE'"URL24MFV8JSQ!044V2?L)#N)
MULQ>-?$LFT0 ZX630@9-'J$JI@@AN'A[BIRK4.K$P.;S7MU)ETP;3/L9[Z&2
M(Y9U+;WZSM.!U('.@152BM3*T@B@[#,<&."%W7<;>/I^3XS)9!IO$+U&T8,#
MLUP&4(%D P:$#U#G&$SSE8+CYQQ9XAN6%58=1^'DXL5!I$9KE@2<L9PU+EL_
M:6G'1VMCM!]^(V57,AYTFE;(?C"0V5!W2,5"X5A(T]1$&QE55/J</-3D;/K5
MQKK\U<@1LHKZ0G-9FN?U:A-"*G+_1;^PP"S'>D'\(7[NVM/.RM10>F%AQO)Q
MFN\J'_&IXR0!3Q\U"7Q5FNIG<><\#3_-/NJ';-MCVK_]64:?Z(B5<TF0#S%%
M_B@75PDNV7C@P0V,=&AID!LM,"5,_N"/AYUS*+-A2K2A'GJWGA>W5=XST^1P
MSM?\0&$=!0Q05O!.UUGY4TP5.(Z)3O@+P8&>7;;%S!C'C!FANH(^VA!LEH"-
MV4(#Z_&5(CJ%K!Y7@G3L4&98BK=YV*'R6KKJ 01]X@,M,D1J!S2KV'WJ'*_S
MG>BT&[R2A&M"J@Z &U[R;?-84$F)M41.NAI^1!D0YGH7!O7+/M:,].FN %2G
M7O%DY'(TE^P;6 MZOIK/HJ9R0JU2=04_!SWP)'KG+NKC'13JMO3KI$JG:D]D
M+/._K S%--+1EW!A:A1>8BOTPC#_4K^ 1H,1KU%>;ZO+T<I-?%$&"T;T%RXI
M-#=6U#MU\GUSFY.XK[N"#0=B;ZMNMD0SC?@[^PTK[*_XX$#Q,G26XVXWSDW]
MCWS8%L7/P*\.9(+6ZPE\[\(9^XH/:E5XTQT,JVID^E$V[$>[2S)R<5'7_W1%
MV\XW'"5[6Q8C70Q=KC:S:M3;48Q\.[0Q&\NZC;5]*ML\]JF_]"?>V/0LS]\5
MC+EY-"<[FFC.".("BWTTX0!Z=+T9P =HW ";=Y8=%K'U\DVWBJMN_>@=/KYK
MGM2[^I).?J].X<"Z=,?!;4?#\_FMEVR9L"/<\7MOK7=BR#P_S%3+06I=X*\"
M$<#VA3 -FL[6@F1=4I3MM@2%7FFC6\8O27&*?-JO"]V?^U@*DZU]BH(CJ0&N
M9&'0)<\DKCHK<\B,AJ25-D<\*;,N-4K1<C1^*\?S=BH"R_L-;X(OO?PLV84&
M6IK$JMBPB98@8U_3I^0\/TQP>TK,.0]E?BW%25/OJHF7+,@Z43E=IJ"LOWGS
MT8Y5;%2K#IT5Z]DT.3E&;@@JDO>,CU:"-$FJ]*=VG19S2@[ZA<I^;B=+TZ#Z
M-5A-D628P3?"T?$!F<53,L?=F"3BNH\B/QF;5_3*Z/6B3'F\N57,J/'>ON+M
MXZV)>MBAPXG5NU73&9VWQ-P<P>4Z&M6&8G'IUJLZ2K3Q=SE$JFVLRC4W/3</
M@C[[^HYCI6)V2$A19%SDU#2Z?;K\ER2=>U]T5MM'DK"YK@ZG$+4V]^\]SO(?
M64W+5FGTNC%"#XY_&U+V'JOY5IHW0RY5X4"5>-)S.(!I(. )A&T[GN)?^PL]
M392!5!*^7LSW&:!LWN&0&VO6&WF8^*#KL\_IMRYQ)@7]JGK?.GTD=J8EXB*!
M9)K9($C[K:LAQS1LR:> 0G8]#0YPY[MP&@V$?AHS'B$)"=Y_CMP.(&[;!]WG
M:S)FI9+V6A!L<N(<GN'&;%5JY*)%#$.Q=K%+,B7+36QKUR5># Z!_.=VXX"M
M!H8B9+[S,H;D9=/&:,FV^K@UWSZ[C5CGQ.MI:Y]7^2/O$]NSG\C$F&'&E"NN
M*U4)G:TT6.6@3\[I+,LEC"'(4E%3U6&]KN[&[B? \&+-)/B^1)O!Q,D@^?Y+
M\)-Z[*&(#DG I.I#/4T2;:QBS"LQA(\6>J#Q]]Z:TX_:53PO AAI#''W3B0?
MC/:YO'9#5+O/VG^ *MW?XO]#O]DTB1&(C+G" ='BA_N(__C6=\+ZU3E_>:'
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MC_,?N$';1<N<6#^R"X4J?^C_OJ.^L?SGV>GOJ%O?/=YR5>" +^5)#K8(7=F
M[#;!+KC;2W;?2O2X\3&TL=9?ST*.[86NS]<G((OQ0I']XSR \P)4P$>B'?NL
MA!R*JZ]?'.*23BIS"*EPDR#Z5O6I'W%/T09Z("SZX L'3F"/"#KE;1)<5:[5
MK2W"_#2JQ 6PTKP6X0"L_[$<G9.BV_](0& ?7U'+>MOQE?1Y-QQ@[7ZX$84I
M0#&M60MUQG&DL$=786*C*!CWC5BK?!6[*#\S9H*;'N=A+.A)")$X,\<U[@PV
MQZT]L.B"I6N$C1_3'HW -VB"Q2YE*Z+/^\SN(\&.X5PC^$$;"NM+?"R>Z.G?
MJ<K!PF)Z$^93RJA@6N$&!^9T'!\S KWS^*LZ+I./0.# /XI,8Y> #+D2%'5H
M';L[HQQMJ/)YD;N'$U9IUY1CU(FF[WF'*9OO82@S3I>FSSOU[0RH?<K4+K;[
M.SP'&S[_?P!02P,$%     @ $(BO6#]E8#PR3@$ <E,! !    !F;W)M,3 M
M<5\P,#4N:G!GK+AW5%/1URT:NO3>2T104)H@11 (@G3I2H>HH @(41$($@B"
M]"8@H%21WJ47@1 Z*""]0Q(4I">4<(00+K_[[G??>&.\/]ZXWSMGK#^RSSXG
M9YZU]IIS[O/9<PR(S4C/4 ]$04$!<KTX0><+()W__/IO'?]YR'_W&13GG2#V
M2Z ]RC0JBBL@2G8**G:*\QX0& 2BH/F_)H#^UT%!245-0TMWB9Z!\6)" QN(
MDH**BI*:BH:&FOKB:M#%=1 U.PV'J/Q=6DZ+QW177G$IO$O*NR2F78/FMAS#
MB]]Z\CJ4GH&'EX]?X.HU"<GK-Q25E%5NJZKIW-/5TS<P-+)Z\-#:QM;.WL7U
MZ3.WY^X>/F]\_?SA 6_#WH='1$9%QR2G?$Q-2__T.>-K?D%A47%):5EM77U#
M8U-S2VM7=T]O7__ X-#XQ.34],SLW#P6M_K[S]KZWXU-PO[!X1'Q&/AW\A]<
M%""J_PW]_Q47^P4N2FIJ*FJZ_^"BH/3_SP1V:AI1>5J.NQ9TCU]Q7E%X=XE+
M.RFO!DTO=LL2S_WD]1@#C[@B]BKA/]#^)[+_;\!"_X^0_6]@_S>N>1 3%<5%
M\JC801 0^8S)@T+\&U6RL1#%ICL_%]4/G_YELMVN&EDD5>R-QEN1K)SL2)\-
M9]@J-+J#"O!K52>K$Q(C$:+N.)E ,_QHY&Y#I?-(;\,>AT=MU)LSNOL)[DF[
MOE+%G3'3BXJYHMY<G!8[/#$[RN,VC7O>*/P]8G#BO@9%"$C^):W-G2@0HGMF
M0@.^*NQCJ0EI"\M'].?<%7I]^S)XX.35OD0(Q!LV)X=+[$\$!__L )U]"18$
MRE=7NMV]94@N^ F]Z<J5G@S=I9CK[0W)BP,_D*\>.>G^YEG3#]GEH*B) < D
MKE'B O#NE!LA"SPM(]W$Z[]OLU@=C3L'\9*4\)'=.:) *<X0P8J'8I?ZVH5[
MN^$SN-&X58NSR"]:::\7%O+@X4M'PY7E"E0_I[*-9%DJ5^E?_!'TD?CZ9ZUA
M8A]6@IFZMSWQ9FK>1#FCD7@$@T+$#I= CKM/_YFYQ#?S=[L2]K^I'X32;UG^
M]AE8K6Z:&4=EW#L'A4X'_SH'L6NR!/]HS*4^!ST;I?. -/#V7STK\;T8A_OW
M:<I,*IZ#PMD1=\X2M1.C<N[@66.D=[S%"9#(8%%C'S>Z[NS'RO9./_<=5@P;
MI?S!52MU=#OM^'1BR-E'\J7@R9.]*-(=O$LW5%!=A;;.I0!A1+!^ATV?\!W0
M[:UJPI8[G%EOF36T9YJBOJ'VQQ<'[\SW>-N!%O6VF+"L7CPMXCNN$R8_'M;Y
M;<[DFYDOGP6>=*POAH3]"NN#JV(.(3IA1I<T6()3NP&)/F=NPMJGUN-0DA,6
M)0CX/6L.78'B&]N+@5B3-/AOD:#FR?K2W1=S&&FVOJNRD:$4U"Q+K]XE?.([
M<8GYP!,C^87R_Z>@12UIA/Q.Z00))9MI@7ZGC'_ -%+P]ZO'57?<R@D*"A?/
MET]J\K^AU95\Z9%."*944N^(VM<B3DB 9'F1D# D6@?B(3<[@UL/DWUC-C>!
MUKQ\EK';]A0?BSU:B3DZ!T7AW<]!G!URP SN.+:")'\.NM2$!E,Y%!QLVN>&
MBG4(K-5H;'+G7"(U1VD9K5L7U\4$_8&U,^N:+7E=[:B4"8(>_<MM:+%<>O N
M%1-*1:E0X%8R@#D8AHCQ#W1N^O3?/P?)!F?-' ROR@'2B3THUN#IX"OXI6(T
MDAFU_11CMB#5E?N--593Z@?.;@;GFBN,L'D,$X.']G?]LHMZA/>.K'*^BST^
M^.0T^M(MX(HN?>Z"C/_J*!I*Y]D4+$!([*L.=^8GR-3I<'4($202VZY_V<+7
MCPS"4-J3#0Y!NM;;7)[6/-M-1NBOLC=-<W[HVOQ+;LQX7AFXX."T2QKPJ?MC
MJ)QLK[1@HL'ZG)K]PUV1_"1=-_O%?WN<?<0#':5ZJUYU6>&K$4^<5:^\61*J
M48>_>?.D@N_F;?6_OY3*3*?W&22_O@OGLM"B^3\,;OK'B=E]_B =M]2M2?8^
M%GHF5GY+!=:#.^<@.IJ-'$6\?QP$D[O2(+S2B8HZ!]6;=4+FTG'KB>HV!$%L
M=;>D'*PA'H*C+<>D3P2S 8WK1M\LE(N+ &0?,],QVP^AXI^+O'\660\[?/:E
M7K\LTTZCL4L<3DD*_?>"[<&[12$!L@#$ S;/2TP9AUP4P3RCX1@*LP:;J\94
MQ3XF('&FT44(EID.5F'G<Q!6,[48F+")6,&N%4N?>/7XOXT,RU$:N]J>MHES
M2/UV^GJQQF,MN=U-<%[*K8HXME']V_$A-CCM[<G9RLQBP!Z)LYO(!4S@]X@1
M%U6I"'3; U2X7,;@&3!WAQAY$MH$WDDEX(Z[Y^.S^U+QZ?TG'2V%@ /F'!1_
M="WA]DA#Z;WIC*7&SR4_B+&*J)Y7.PQ)YR#C<Q#>!C9GMLJ[HXM?QS#ETK=Q
M8N42YLW0N8GV*KW(&&AM<6*;+CBB3?#4 ) SG? 5UC2C]VC=F>1]ZY0]$E^R
MK%NVD5CN?CSOXW0WLD%!A[$8&TGB/ >MKNSPXZH7=#"02'6[BTP(!H]"&W(C
MC\S NJ]*@T>760'G>3T4X8%FIC_7,O^$DN%A)KSBXZ?\C[0M$;>(UJ>WF73
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MFJH1<2PDLG#I8:?DUQC0?R>NQU\)E];T9@']3KX3_ ;WDI4:[Q,61NK?@*:
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M@DEC(2:1]:_UL@S@4@+03B$&V^[BH)Q_!ROL@= [C0V]/;6#E$/#5Q&]%]_
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M9IQ"8R2+*'2YS/\KJ,1/43'GH+_:7^DD[VZL<9- TIJ?-%-507'L'P(?*)2
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M?O-LU,HOTAMGA0>F\J"+W;.K.(8@E-Y&_4/>IR[T83Y M@66H;&P^MHDEA2
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M9I.I]1M2A^.HXSV$/ <^8T@$<ZFT7^;P;'3\E;)3SOU*=T683,61_U(YZ!T
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M(%D;1(%+S]'@5\;46[Z#8_M6WZ".BLMSNX>$0RI)'YI+O2USURTJ2BWO%6Q
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M$S=HY"^^W# B_[U=M#CW\W!JJGJ]WJJ0:[OK'(387&KH^@9,D"_E0$@LIX:
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M$]"-<*GAV<A'3"[9_'O:PP1CQ]UN"]Z^/>24%[0UYMZY,CC@^H>=,:*;_V+
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MN!*AGGIA_!+&Y5IU&%TH]>.YE682E\X?XK]"'H]3$NUB!]+PVU,K='&:TF6
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MK%+05JML6 E?7[#'OVV:^,2N<?M/&R$P?<^J6-T\)[%</T@[<-E\+ML<.65
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M/QP2H_+(!E@_[AUR_'DC>;'WV"YQ=G:V#8%:?6,BM6J?$)(UH2$O^=< <*3
M7-0_^;4(S2&* S[8<Q"*BX@%M'%H0&R_K\(DSIFF"^QIM[961/'!JA<?@W.J
M9 >[Q/!U0]@=:5/I5(M;8[ )\02/!(\QN 42;U/S!LP&]V#^UZNR%.^,F7NC
M!'GKS$86CN":;F"FABKH0-.L"+1E,JV?':2KWK6F+HN\N\\X*6$D9;IWEW^"
M.P*!&]''_VL7)Z0#]% 6UP<,@4DL^RN,J91 5X!Q.Y(4*6_'ZL8=QB:L)*I7
M1ZG$5BOEW1W_//%Y25B%6?/>-Q.B;G^._IW&+G"J3,=B0UID<IEON<^+XY#.
MKI"=*@.O::O,@)RV5V8Q)R>+VB5S>N0N"";'&6_@' 7'/ZP![.YC9?MKDN L
M$P-//LE\A4D!J.,!EJW+6%-H$WWAS5_UE]U;O;^GNB7%?J<VS;WXB5Q]9P#'
M.&SYECHR<$'HW2NY6T.KMQ+)!O_8BK??XC[QTSDHNC[@U)_<\S)KUZ"+,:?O
M/93IR(2U)DZ$,$'\_"O)?O<S6..9^OW[%S)M%MW\KM*ZVBK#&GO^+\:^,ZB)
M+WPW"D@5I'<"@J+T(KU$09I(KX* 2@<! 8$@,1$0D2Y=:?DATIMT@4#H5:2W
MT)(@*@*2H(1@"C?^9^[,G3OWP_VPF<G,[IZS^Y;G>=X]Y;(9EXHO_0/1U/_0
M;)F=)HQ-NF)#"_;?(SH++;0#"(=1WB<B"U^WM&.,@Z^?.%KN3;I&]A8SUYX6
MG 'B&Y [ MI1E")D'XQB7MJXF_?_&AK_%H62E>W-6_K;K?\M\8\_[C?U-I >
MME**@5-4G)T\[T<-3I]>@M"(^*/$5[ _XP_=TJS_]_($##S6IJ(Q1= ; !NS
MS'G=/Z-SV6%_J8GDZWKMO3V-OO7PW.ZXY:"@E4 >CY[UC.DW.K%[Q_V'J2.W
MO9D?>S*T?WVBFOG&\EE8C*?^(N_V(XE!)7_^2F%C)=<B+[;?RUEZX-HL=YN=
ML:IS;OL"U9JV83S<Z:K=PF9CTEJ5EKR*AY,;>9EK3A'SEO#W3?P9<N5\[[&-
M6GJ2DS'R+H>]U*2 Z-'A$!&-08Y7U!OX0_+E7FEB+$U-Y"<>RWN!K?H=Y6N)
MDT/O5\M\Y_Y<U.(4^_7KMO?1P4"W_ISGV!14@RQ)BX9-L!7V9!C<R_$#W@0[
M"*4%!:^_]I?L2O(=&"]19<OP(U&Q(C"R$59)K,5&;*PW#6,R6"]>GOO[][D!
MU31+\R"87@Q2W0H=(;O@4VE(PD<VPQ?'ME!G<;!870>LJ"+)Y9N.N6R/E>E,
MA*@!"A63- ;R_?0I;E7I@HHQNQ&LI'&?0K* +L!Q]ENH,P!6<7\O9-M-&FT/
MZNBMQ#B? ?R 7$2MD'Q;CT0:D_@C[QYSR 9VM58UT>4.Y"NM\_4JDE\L'IKY
M/$7_J_%D773@CVJ-X(B&Z*N$NWP.QKDNBS\MRQ4?3@LM*G0^FD])$#3K4$Q7
MBG?'_VU,7!=,Q!:U)#41)S3!Z.:[O24*O>J]DDJEU^P"REUR/DXRWP$_H\[Q
M%%4>U$@S&Q<]RO&^"ITG?K-* >$\.%!P#Z()!GC)G:A*98XFZ8#W=X%<Y'NE
M ;;WUJGS^G)S+QM0"HDQ_EW"T^Q&T4&]@F5YKH%^*_?75>Y;!7Z#V< N4H7
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MQAT7BXE/7W.PKYG#! .'3*1>_JB)_@7B=U@<U&=PXDZSY#DT8-:(;C#3TQ^
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M4%Q@*)GUZW.4*O=4Q"03ZT=T*F=V5K0 ^@P WWEYQ,[Q954WS Q(DY#?5#U
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MB??IX[2;OS9>>7'^A=Y1,@[TSQLK%1@/N''*!4JWXZE\C;&$H572?-?>RUM
M:[&;56")'D.2/?3S0(@D54@2_>0MHR<'6=Z#[K2FR;NH"Q8<?/<:55P%^@M[
M\S\.R'L$,RP@8[5T'@*CN?<NOP)/Y3"(7IV0>-6;I6!-V>M^5HW@J_D2U9?
M-JO]+TR.E/?0"\%>O^V!R9L,;(\T46O&79%??66&-'_%O=#[FXSS^->]_\X
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M>N9&O<'N.W2:_O3CG<L7OCE/F@D'%8!F=*]@$&OINH882^Z),#G]Z)+OI^E
MNH2^1WMS_=Z+3=F5(D;:S@@?R:PT-C73F.9:?6>W(PTQKVE/B2\J^F)?JKZO
MWXJK+O#^XRWTJ4A4L[ISIN*T9J!(="XL+M)?1\?OP!<')',/4EG_39U4(1;B
MD$.1(-SG$D5*"\0S:EO/T'RF]ZI?5P3RI:[H?VZ3CY$^N)/75]J<W[<DK[PY
M:LI^<"Z>G6=YZ\V_;6>>:"256;'[;^$L/>)*6);4C"ZY$I?MB24%)6FE2,UN
MQ/R2X?=J1GI9!C8.:R.H/W3D#( +E4XEJ^$"K4(X:*I&$\+(,+74&-8KN]3+
M"NX>0'(@KF/UGEW+)YF[B7'U%LA..G6)RXS\WJ@5V9< ;!Q[D&]GXL/4Z/\M
M+TXVF!7DTZ2'">D"+_DK*!/ Q2Y1SBN_K&?9CBPW7H12M(9!QE;\S53QSRHU
M);S@\(1A3)/FOMH=Q2%+EEQ>75Z3Q%I;Z'+*DYIB)DN;'&\7@6 _!9@O>(*Q
MLQ!<VP?>#QSR@HI^G>"],I60IR\X_ P?,'7G:56=/J<:KV*XJ:M'DBSI]R:M
M(^.;$EQ^*I7[I1CNVKRYC)1LLU?;5$[/R#W!)?&6=+,/"'/3\<Q+I2JY;'U/
M9$__:<F7L'Y=)+J:*D^I)T<UD.\1/;!;**N1$Y3O(%'-(Q7&HBL*>XA1O/0C
M!4/1'D"-FJ6/Z$2U]<[=F"%TO0#UN.;D>4KRG8,]X::R6M",Z+C84DV$$>@H
M12,)X&7^@KM"'0<V:%8]EV6SW+MY'P-P]P.#0H.J1LJE\BXHY]F(.PR0D2EP
MG+4B41Y)YJ4JHF0Q48ER"(=RZ'C+^C"&!&>#2! -MQ7/$0\'>V\@NA=L^4+X
MP!52"YC.EH5&Y.S5ID^=+:;UP6[]MISSF[C:'R?8DJ#A3Y_A"E^HZ>_H*K,]
MR]*+85S$L/>E(OI<,.?!B0:;M%$LI:ZG++[:R+[RCKW73ZW-K))3Z0QP+WMU
M:G4>+M+&:/O'EP23EV/^\[7 0'[ZW4=[I,=&.L:[FN,:8#.S&^\HO= ^4/-T
M?\BJ!B&8:(<.28 QM68DH%JIS+CCD[3AAG=,^. .[.0>4^,Q!FL1B9%:BKC^
MJC;TZ9QA=/C.6G/SJ!!YE52PP1<A3VK9Z1H:JWNO:>KQSE?<NXBRP&:\?F'Z
M#M6DKE<6UO],7]-?R#=)+62MD<K<25*9OG%IMP6L<Q>/C(^X:*D3N*8I#7==
M% APJ4H9:K<;OR%M%?@6RR'TYO5_56U1I//0)1B?A!#_ ?<9@)$SS60@JVK9
M9P;!N&V5*.2PV)'\_DWW9:N0AMTY-S_'_HU'+9RC;(%QG-&&1 6-_O2+92G#
MDZFZ,;@8A:&'>,TB!4G&G+GM7HV1*DP@5M)6P(7(+C;XH(E%S?YYJC_V>HS7
MFEWJPT-H^-M07LAW_J214?G/30Y-;;[)U;J3O+*VU;96)_;?7Q>[]'X16;*Q
MM2\3&,UC.0 N+K^&^&-@S/XGJ,HDA!L&?M'?Q>A#P:OZZ/H][>#\H$K_'P+C
M4=&A$:$BU@:EH;TF(FCV)QQ?3>*0:"0M@.^"1"#W\5O]/_1!NU"Q!5TZL883
M?26\1=U?DUC$+<HKC&(9;OFU+]![<4>^LYYOZ_+1E<AVA147\M(,")T(Q%E,
M\U@6G '^K?1*RS_9I%O$D<"*C.&NAEJ2 SAP$&65A-#^83LZ^*P]TQ_+VM'4
M%.=PS^%!;UOZ?9D<F2$Q5D(@+80 L'XYZ$7H#%2!",<;$BJ(LB0CLE2[4-TF
M@,BZ#1,C*LP;X;YJ#PZU9V W;*>'PZ>Q/G.7_?D&S!YVO'I@/<W6K/A6'YD
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M4#^BC'U?Y^D7]S8+SG9$,)3Z94]],$TXT]ZLIW7]K/Q=V8B5,> L>'N1)@M
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MZ4)576BASM,L:&!)-Z-HDBYA,( P\SB$_*>+P-?$8K[SWE1'=[IZ'1GZ,L
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M11>.)K\@O]<-?W<I4";?;<9[+Q9/](;@U98'DR$/9-2H#QEO.]6MEOWUJ=Y
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M"V[)6D$Y7!PPKH)K,O(ZI7T( IV2<!C 3[HTY6^D <3=>F&"Y*MIET1J^GZ
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M^\85P;9U;%RX9O^:SMP?C3ODX&/C(Z:8(>&R'XU?D>W)$O>*V)@9YZZSM+'
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M<V_NK@90 ?2'KR-"C_?G""UCXAGB4Y]I6)$BYDRHA%"8)>J+]1+S7-*@*M7
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M_=^JB)\5E!!\?Z5.!L$+K/#Q?U!+ P04    "  0B*]8L]2]>D<-  !JH0
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M:O# \:+\&_[&J3+&]N^CZA*U*%=VF431XLQJ:V8#;2%R&#-[-]'-P+%YN^P
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MF>JT4^_0)$$>S>6OBF*S[_V'@4((L +A]\$Z_$Y]6MHZ]-HLL/ 8]Y\&CB?
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M"ZF5_6VWF0Q2[\"I-,$P;Q1<R26'WMX<:K<V@#&2)XM8M'LJ5I4A*OECH,H
M-?.&&D 9IX!I9)JP30:2<>RQA3%L:Q1\,ZT/W,0R+@V:83V(MNSB^ZP@F:7.
M9V2MY9MCBHQ&EBJ@V6;.::2B7':@?$9['B6-=.FL-#T=.(UQYBS4P/#0'JOV
MI J0#R>D"C,Z<%H-3WRS<=TTXA#Y9>FT]7D%SV,3+-*Z:TIIK[Q2.VH*4;A\
MTKIH4BX!\<]&))NT4_'**(-;!CK-Y B05@2#Y(W1?(,;W&X &N(?E=(NN66
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M<61*7FE2\\M1N1%Z9O9UH,7"6>(=DK$1IVS<<H7F=A_(09/FUEF$85:E97-
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MQR!?DT=AIDK2(R!%M6.DI5T2]..?6K=4!S^"XI81(E.V>IZ1=H%Z'O@,\AY
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M^ \G]/AKP+N\-M?AAL0)%Z2%)UY/70W[.%N?&IA<1MGX-:)?&?OGSMI/G$"
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MF?WCMQF/ Q<L7]CO2[^V;%9L7:94>VSF7 8"J%")=QVT)"%$%:]V+(V^=ZL
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MB/$AUT=<%W!C'LX>@%LV?U^P/FZR.,O#VRD\<:9\"I?7LF."&& 6EXM9.LC
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M[@B7*0<#L#>GBX10,8/9+KU34VBQ0)TX["[GD0W6_J,4,6AHC.'9/X8H2IP
M-89(*NJ7T"OV",2[?.:!+\(0% ARXN;0XH:,:8D*.GV5^2E7F3#+0.&A*HU
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MV*U4_(;_P=_@9#_Y_U!+ 0(4 Q0    ( !"(KUBM67X 7P@  %M4   *
M          "  0    !E>#,Q+3$N:'1M4$L! A0#%     @ $(BO6+:R+))#
M"   -%(   H              ( !AP@  &5X,S$M,BYH=&U02P$"% ,4
M"  0B*]8<VW7SFT$   1'   "@              @ 'R$   97@S,BTQ+FAT
M;5!+ 0(4 Q0    ( !"(KU@/,#X6>00  +89   *              "  8<5
M  !E>#,R+3(N:'1M4$L! A0#%     @ $(BO6,[I@BTZ)P$ I^\+  P
M         ( !*!H  &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    ( !"(KUB[JY4U
MKS4  .$Z   0              "  8Q! 0!F;W)M,3 M<5\P,#$N:G!G4$L!
M A0#%     @ $(BO6!<7\UQ:_@  5PD! !               ( !:7<! &9O
M<FTQ,"UQ7S P,BYJ<&=02P$"% ,4    "  0B*]8_HYO!"(V  !C.P  $
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M,#(T,#,S,5]C86PN>&UL4$L! A0#%     @ $(BO6",';T'))P   + " !4
M             ( !^$,$ &=T8G M,C R-# S,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( !"(KUA[M;RG1%4  $3Y!  5              "  ?1K! !G=&)P+3(P
M,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    "  0B*]8E(!*R ,\  ":% 0 %0
M            @ %KP00 9W1B<"TR,#(T,#,S,5]P<F4N>&UL4$L%!@     /
-  \ FP,  *']!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20240331.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-05-15</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-01_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="AsOf2024-02-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">GTBP:CorporateNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_WarrantMember63927609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_MasterServicesAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ThirdPartyProductManufacturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ThirdPartyProductManufacturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:ThirdPartyProductManufacturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_CommonWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_PlacementAgentWarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwentyTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwentyTwentyWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwentyTwentyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-042023-01-04_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_PrefundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PlacementAgentWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_CommonSharesAndCommonWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonSharesAndCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_PreFundedWarrantsAndCommonWarrantsMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PreFundedWarrantsAndCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2023-01-022023-01-04_custom_CommonWarrantAndPlacementAgentWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:CommonWarrantAndPlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:BoardOfDirectorsEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-03-132023-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-13_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-15</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-16_custom_SeriesKPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SeriesKPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesKPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesKPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-272023-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2023-01-27</startDate>
            <endDate>2023-01-27</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-01-27</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-272023-01-27_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-27</startDate>
            <endDate>2023-01-27</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2022-05-132022-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2022-05-13</instant>
        </period>
    </context>
    <context id="From2024-03-202024-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ScientificResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ScientificResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:ScientificResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-18</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-19_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="AsOf2022-02-08_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-03-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-03-31" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-03-31" id="Fact000006">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-03-31" id="Fact000007">0000109657</dei:EntityCentralIndexKey>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockBasedCompensationCommonSharesForServices
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_CorporateNotesAndCommercialPaperMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:Extinguishment
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:Extinguishment
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember"
      id="xdx2ixbrl0621"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyThreeWarrantsMember"
      id="xdx2ixbrl0623"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember"
      id="xdx2ixbrl0647"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwentyTwentyWarrantsMember"
      id="xdx2ixbrl0649"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0734"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0736"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0738"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0740"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0742"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0744"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0803"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0805"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0807"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0809"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0811"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0813"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-03-31"
      id="xdx2ixbrl0841"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1002"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl1004"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-03-31" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-01-01to2024-03-31" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-03-31" id="Fact000016">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-03-31" id="Fact000017">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-03-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-03-31" id="Fact000019">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-03-31" id="Fact000020">GT BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-03-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-03-31" id="Fact000022">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-03-31" id="Fact000023">8000 Marina Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-03-31" id="Fact000024">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-03-31" id="Fact000025">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-03-31" id="Fact000026">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-03-31" id="Fact000027">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-03-31" id="Fact000028">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-03-31" id="Fact000029">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-03-31" id="Fact000030">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-03-31" id="Fact000031">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-03-31" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-03-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-03-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-03-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-03-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-03-31" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-03-31" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-05-15"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">1416651</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">1950000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">1079000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">7857000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000051"
      unitRef="USD">12893000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">78000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">84000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">9885000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">14056000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">27000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">53000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">9912000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">14109000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">3213000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">4328000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">963000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">1195000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">30000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">58000</us-gaap:OperatingLeaseLiabilityCurrent>
    <GTBP:WarrantLiabilityNonCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">394000</GTBP:WarrantLiabilityNonCurrent>
    <GTBP:WarrantLiabilityNonCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">1052000</GTBP:WarrantLiabilityNonCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">4600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">6633000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">4600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">6633000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000095"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000097"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000099"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000101"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000103"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000107"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000109"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000114"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000116"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">1380633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">1380633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">1380633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">1380633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">689641000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">689539000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">-684331000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">-682065000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">5312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">9912000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">14109000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">777000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">1650000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">2314000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">2015000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">-3091000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">-3665000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">142000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">164000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">212000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">-658000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">-2924000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">533000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">-2000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">29000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">825000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">3438000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000186"
      unitRef="USD">-227000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000188"
      unitRef="USDPShares">-1.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000190"
      unitRef="USDPShares">-1.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">1380633</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">1380633</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">1082871</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">1082871</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000210"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000212"
      unitRef="Shares">1381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000232"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000234"
      unitRef="Shares">1381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">689641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">-684331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">5312000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000242"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000244"
      unitRef="Shares">1091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">686200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">-674468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">11734000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000252"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000254"
      unitRef="Shares">1091000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">686200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">-674468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">11734000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000262"
      unitRef="Shares">120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">6268000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">6268000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">5831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">5831000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000282"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">315000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">315000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000290"
      unitRef="Shares">16000</GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">287000</GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">287000</GTBP:StockIssuedDuringPeriodValueCommonSharesInSettlementOfVendorsPayable>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">-227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">-227000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000304"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000306"
      unitRef="Shares">1229000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">687746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">-674695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">13053000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000314"
      unitRef="Shares">96000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000316"
      unitRef="Shares">1229000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">687746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">-674695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">13053000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">-2266000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">-227000</us-gaap:NetIncomeLoss>
    <GTBP:StockBasedCompensationCommonSharesForServices
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">176000</GTBP:StockBasedCompensationCommonSharesForServices>
    <GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">102000</GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors>
    <GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">646000</GTBP:StockBasedCompensationOfficersEmployeesAndBoardOfDirectors>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">-658000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">-2924000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">533000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">25000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">-2000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">29000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000348"
      unitRef="USD">-6000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">-16000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">-1347000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">-29000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">-28000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">-27000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">-4163000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">-2906000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">-5034000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">6989000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">5034000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">-6989000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">6268000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">6268000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">871000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">-3627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">1079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">5672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">1950000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">2045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">5831000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">287000</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000408">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zuKniZyAOYI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_829_zw3rnRodgrXa"&gt;Organization and Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. (the &#x201c;Company&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products
based on our proprietary Tri-specific Killer Engager (TriKE&#xae;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#xae;) platforms.
The Company&#x2019;s TriKE&#xae; and Dual Targeting TriKE&#xae; platforms generate proprietary therapeutics designed to harness and enhance
the cancer killing abilities of a patient&#x2019;s own natural killer cells (NK cells).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240331_zdnGeCHni2Pl" title="Revers stock split ratio"&gt;On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#x2019;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol &#x201c;GTBP.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined
into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be
issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of
common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the
exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission
and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the
reverse stock-split from &lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240201__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD51QIzkfSo" title="Common stock, shares outstanding"&gt;41,419,000&lt;/span&gt;
shares to &lt;span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzwQiqLOInWi" title="Common stock, shares outstanding"&gt;1,380,633&lt;/span&gt;
shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock
remains unchanged at &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zvKDYFyJ4lti" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt;
shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proportionate
adjustments will be made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise
of outstanding stock options for the Company&#x2019;s common stock and to the number of shares of common stock reserved for future issuance
pursuant to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest
period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-01to2024-03-31" id="Fact000410">On
February 1, 2024, the Company announced a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30.
The reverse stock-split became effective on February 2, 2024. The Company&#x2019;s common stock began trading on a reverse stock-split-adjusted
basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol &#x201c;GTBP.&#x201d;</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-02-01_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000412"
      unitRef="Shares">41419000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-02-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000414"
      unitRef="Shares">1380633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000416"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000418">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z2LbUE27wQTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_824_zvp92HVSTil3"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKyLiYhH32Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zyYcfzOdQBgg"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis
Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in
consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the &#x201c;2023 Annual Report&#x201d;). The consolidated
balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--LiquidityPolicyTextBlock_ztvOBpbPDzn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zK55U4OwHnBa"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a
going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. For the three months ended March 31, 2024, the Company recorded a net loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_pn5n6_di_c20240101__20240331_zZjeFnGaQNyi" title="Net loss"&gt;2.3&lt;/span&gt;
million and used cash in operations of $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_di_c20240101__20240331_zcjp7FkflkT3" title="Cash used in operating activities"&gt;4.2&lt;/span&gt;
million. As of March 31, 2024, the Company had a cash and short-term investments balance of $&lt;span id="xdx_901_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20240331_z5Ty4ChJRDzd" title="Cash on hand and short term investment"&gt;9.8&lt;/span&gt;
million, working capital of $&lt;span id="xdx_90A_ecustom--WorkingCapital_iI_pn5n6_c20240331_zQmvhpkx9zw8" title="Working capital"&gt;5.3&lt;/span&gt;
million and stockholders&#x2019; equity of $&lt;span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20240331_znLVYy7Bxlvj" title="Stockholders' equity"&gt;5.3&lt;/span&gt;
million. Management anticipates that the $&lt;span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20240331_zDrTFXH2Muy7" title="Cash and cash equivalents, and short-term investments"&gt;9.8&lt;/span&gt;
million of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at
least one year from the date the Company&#x2019;s condensed consolidated financial statements for the three months ended March 31,
2024 were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock,
issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to
secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and
financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which
could adversely affect the Company&#x2019;s business prospects, ability to meet long-term liquidity needs or ability to continue
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zUVg9VrPMp53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z6t4ee2Icaxd"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Significant estimates include management&#x2019;s estimates for continued
liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of
equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1WACwPISCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zgZSVwxfG11b"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to
approximately $&lt;span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_z1qIwaqjlvrc" title="Cash equivalents"&gt;1.8&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zEvm5EQIkkWe" title="Cash equivalents"&gt;443,000&lt;/span&gt; at March 31, 2024 and December 31, 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. Total short-term investments amounted to approximately $&lt;span id="xdx_90B_eus-gaap--ShortTermInvestments_iI_pn5n6_c20240331_zqBU4sK70doh" title="Short-term investments"&gt;7.9&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zwmFAX9C0CFg" title="Short-term investments"&gt;12.9&lt;/span&gt; million
at March 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziorEyji2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zR0fvFg2ypda"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90B_ecustom--WarrantLiabilitiesNoncurrent_iI_c20240331_zg7MQ6A73nl3" title="Derivative liability"&gt;394,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--WarrantLiabilitiesNoncurrent_iI_pn5n6_c20231231_z41BwTznGcol" title="Derivative liability"&gt;1.1&lt;/span&gt; million at March 31, 2024 and December 31, 2023, respectively,
was based on Level 3  measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, short term investments,
prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity
of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_z8IOXlHZtJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zAhXxLgpaH99"&gt;Warrant
Liability&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z8e9I1ofZKs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zpmiwBRniANe"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees and consultants for acquiring goods and services from non-employees, which include grants
of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,
&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees and consultants, which are generally time
vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation
cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees
is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated
using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility,
expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation
expense recorded in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf4anFW7U5ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zLctfluGIJxk"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zzz6StdiIpWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z207zpcRr3Z8"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for its lease in accordance with the guidance of ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company determines whether a contract is,
or contains, a lease at inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset during the lease
term, and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets
and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zrSKWJL8FbG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zTjO7SIvIG17"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_ziTwc5JANzOl" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2024&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2023&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;126,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;115,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;431,227 &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;420,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zHA8mjrPcXB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zAwNsizvEos4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_znK4J0WXdxqh"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember_zzjwvS7vwja5" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4 &#x2013; Accounts
Payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztFFzE5GUkBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_znDNkrSM22G8"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment
to determine if it includes one or more components that constitute a business. If there are components within an operating segment that
meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting
units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the
segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one consolidated operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zalqMxs3jpag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zHxP7rgoIAAd"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &#x201c;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;&#x201d;
(&#x201c;ASU 2023-07&#x201d;), which introduces new reportable segment disclosure requirements related to significant segment expenses
and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable
segment&#x2019;s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact
that ASU 2023-07 will have on our segment related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zzqzHA7mS5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000420">&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zKyLiYhH32Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zyYcfzOdQBgg"&gt;Basis
of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis
Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in
consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and
applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting.
Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed
or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K
for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the &#x201c;2023 Annual Report&#x201d;). The consolidated
balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to
fairly present the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all
adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not
necessarily indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <GTBP:LiquidityPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000422">&lt;p id="xdx_840_ecustom--LiquidityPolicyTextBlock_ztvOBpbPDzn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zK55U4OwHnBa"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a
going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business. For the three months ended March 31, 2024, the Company recorded a net loss of $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_pn5n6_di_c20240101__20240331_zZjeFnGaQNyi" title="Net loss"&gt;2.3&lt;/span&gt;
million and used cash in operations of $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn5n6_di_c20240101__20240331_zcjp7FkflkT3" title="Cash used in operating activities"&gt;4.2&lt;/span&gt;
million. As of March 31, 2024, the Company had a cash and short-term investments balance of $&lt;span id="xdx_901_ecustom--CashOnHandAndShortTermInvestment_iI_pn5n6_c20240331_z5Ty4ChJRDzd" title="Cash on hand and short term investment"&gt;9.8&lt;/span&gt;
million, working capital of $&lt;span id="xdx_90A_ecustom--WorkingCapital_iI_pn5n6_c20240331_zQmvhpkx9zw8" title="Working capital"&gt;5.3&lt;/span&gt;
million and stockholders&#x2019; equity of $&lt;span id="xdx_901_eus-gaap--StockholdersEquity_iI_pn5n6_c20240331_znLVYy7Bxlvj" title="Stockholders' equity"&gt;5.3&lt;/span&gt;
million. Management anticipates that the $&lt;span id="xdx_905_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20240331_zDrTFXH2Muy7" title="Cash and cash equivalents, and short-term investments"&gt;9.8&lt;/span&gt;
million of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at
least one year from the date the Company&#x2019;s condensed consolidated financial statements for the three months ended March 31,
2024 were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock,
issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to
secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and
financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which
could adversely affect the Company&#x2019;s business prospects, ability to meet long-term liquidity needs or ability to continue
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:LiquidityPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-5"
      id="Fact000424"
      unitRef="USD">-2300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-03-31"
      decimals="-5"
      id="Fact000426"
      unitRef="USD">-4200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <GTBP:CashOnHandAndShortTermInvestment
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000428"
      unitRef="USD">9800000</GTBP:CashOnHandAndShortTermInvestment>
    <GTBP:WorkingCapital
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000430"
      unitRef="USD">5300000</GTBP:WorkingCapital>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000432"
      unitRef="USD">5300000</us-gaap:StockholdersEquity>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000434"
      unitRef="USD">9800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-03-31" id="Fact000436">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zUVg9VrPMp53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z6t4ee2Icaxd"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Significant estimates include management&#x2019;s estimates for continued
liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of
equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those
estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000438">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1WACwPISCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zgZSVwxfG11b"&gt;Cash
Equivalents and Short-Term Investments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to
approximately $&lt;span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20240331_z1qIwaqjlvrc" title="Cash equivalents"&gt;1.8&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zEvm5EQIkkWe" title="Cash equivalents"&gt;443,000&lt;/span&gt; at March 31, 2024 and December 31, 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate
classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current
assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that
may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying
condensed consolidated statements of operations. Total short-term investments amounted to approximately $&lt;span id="xdx_90B_eus-gaap--ShortTermInvestments_iI_pn5n6_c20240331_zqBU4sK70doh" title="Short-term investments"&gt;7.9&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--ShortTermInvestments_iI_pn5n6_c20231231_zwmFAX9C0CFg" title="Short-term investments"&gt;12.9&lt;/span&gt; million
at March 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000440"
      unitRef="USD">1800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000442"
      unitRef="USD">443000000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000444"
      unitRef="USD">7900000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000446"
      unitRef="USD">12900000</us-gaap:ShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-03-31" id="Fact000448">&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ziorEyji2bCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zR0fvFg2ypda"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90B_ecustom--WarrantLiabilitiesNoncurrent_iI_c20240331_zg7MQ6A73nl3" title="Derivative liability"&gt;394,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--WarrantLiabilitiesNoncurrent_iI_pn5n6_c20231231_z41BwTznGcol" title="Derivative liability"&gt;1.1&lt;/span&gt; million at March 31, 2024 and December 31, 2023, respectively,
was based on Level 3  measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, short term investments,
prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity
of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <GTBP:WarrantLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">394000</GTBP:WarrantLiabilitiesNoncurrent>
    <GTBP:WarrantLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000452"
      unitRef="USD">1100000</GTBP:WarrantLiabilitiesNoncurrent>
    <GTBP:WarrantLiabilityPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000454">&lt;p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_z8IOXlHZtJz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zAhXxLgpaH99"&gt;Warrant
Liability&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000456">&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z8e9I1ofZKs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zpmiwBRniANe"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees and consultants for acquiring goods and services from non-employees, which include grants
of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718,
&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees and consultants, which are generally time
vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation
cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees
is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated
using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility,
expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation
expense recorded in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-03-31" id="Fact000458">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zf4anFW7U5ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zLctfluGIJxk"&gt;Research
and Development Costs&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000460">&lt;p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zzz6StdiIpWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z207zpcRr3Z8"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for its lease in accordance with the guidance of ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company determines whether a contract is,
or contains, a lease at inception. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset during the lease
term, and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Right-of-use assets
and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease
term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present
value of unpaid lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000462">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zrSKWJL8FbG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zTjO7SIvIG17"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_ziTwc5JANzOl" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2024&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2023&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;126,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;115,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;431,227 &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;420,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zHA8mjrPcXB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000464">&lt;p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9xtkeV67ctd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_ziTwc5JANzOl" style="display: none"&gt;Schedule
of Anti-dilutive Securities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20240331_zS8Ae7LXivsd" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2024&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230331_z7hhHInOaB5j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2023&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(Unaudited)&#x202f;&#x202f;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zWOlayAXYys4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;126,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;115,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zr8jSLBGPpqi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zW8SumapLbhf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;431,227 &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;420,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">126265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000467"
      unitRef="Shares">115598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000469"
      unitRef="Shares">304962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000470"
      unitRef="Shares">304962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">431227</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000473"
      unitRef="Shares">420560</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-03-31" id="Fact000475">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zAwNsizvEos4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_znK4J0WXdxqh"&gt;Concentration&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_pid_c20240331__srt--RangeAxis__srt--MaximumMember_zzjwvS7vwja5" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4 &#x2013; Accounts
Payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-03-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000477"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000479">&lt;p id="xdx_844_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztFFzE5GUkBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_znDNkrSM22G8"&gt;Segments&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined its reporting units in accordance with &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d; (&#x201c;ASC 280&#x201d;). Management
evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment
to determine if it includes one or more components that constitute a business. If there are components within an operating segment that
meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting
units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the
segments are economically similar and, if so, the operating segments are aggregated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has determined that the Company has one consolidated operating segment. The Company&#x2019;s reporting segment reflects the manner in
which its chief operating decision maker reviews results and allocates resources. The Company&#x2019;s reporting segment meets the definition
of an operating segment and does not include the aggregation of multiple operating segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000481">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zalqMxs3jpag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zHxP7rgoIAAd"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU No. 2023-07, &#x201c;&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;&#x201d;
(&#x201c;ASU 2023-07&#x201d;), which introduces new reportable segment disclosure requirements related to significant segment expenses
and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose
significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable
segment&#x2019;s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods
within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact
that ASU 2023-07 will have on our segment related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000483">&lt;p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zDWkE3gWpGy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82A_zYk4NlRReWBg"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z0JGDFi1Cl33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zJRjVFMd1Z32" style="display: none"&gt;Schedule
of Estimated Fair Value of Financial Instrument&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztMhNO7KMYr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;7,859&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z75GnK4zHuN5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_909_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zp666a7kKvb5" title="Unrealized losses"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;p style="margin: 0"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zJBSCKjyYFGd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;7,857&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331_zIBgnI06Z5d1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;7,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331_zFKY3IUdVtAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331_zALzbXn8tCcc" title="Unrealized losses"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="margin: 0"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331_zWxLHr3Cze82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztD6YbVVb1ah" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;12,845&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zKnlikL4Dmf4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zc69T67D7b06" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTVqr9UN7zl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;12,893&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zo1kL0JkJFV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;12,845&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231_zXhPl2cGd6b9" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zdX4QI6oQTXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231_z49XaFaMCKca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z6kUn2CK73qg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6N7hXlixww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zlICH7SXekdi" style="display: none"&gt;Schedule
of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zI4CqUzkaq0f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zat1NRDsdKNf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaMvr4KLzTFa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzVZLZmo8op4" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlUo8F3oXLHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zzMDrpR0qKij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk8h9fLN7Mz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0534"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zPt7Kezepuw5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0DshjjNxMf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLjCYqnJkp1j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO95dlZITBtb" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCy8B65m789g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zuqbxTpRKdG9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zlE1xueli5Lf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;443&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0549"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zSVXB5MBAOv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2024, the fair value of the warrant liability was $&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeld04ELtMl" title="Fair value of warrant liability"&gt;394,000&lt;/span&gt;. The details of warrant liability transactions for the three
months ended March 31, 2024 and 2023, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3X6zCdBQdJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8B2_zKaOILP8WDw" style="display: none"&gt;Schedule
of Warrant Liability Transactions&lt;/span&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240331_zoEgPTSb6eq1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230331_zWtO1ZXEo27i" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ending&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zDZXJi8Y42ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zvWZYgOyU3B9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Issuance of warrants at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0558"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_zVpfyUou9429" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(658&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,924&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--Extinguishment_pn3n3_zgbpFKBU3Ljg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0564"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zRGyrzfGHjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,926&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zfEROGaAN4a5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000485">&lt;p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_z0JGDFi1Cl33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of financial instruments outstanding were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zJRjVFMd1Z32" style="display: none"&gt;Schedule
of Estimated Fair Value of Financial Instrument&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztMhNO7KMYr3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;7,859&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_z75GnK4zHuN5" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0489"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_909_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zp666a7kKvb5" title="Unrealized losses"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;p style="margin: 0"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zJBSCKjyYFGd" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;7,857&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20240331_zIBgnI06Z5d1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;7,859&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20240101__20240331_zFKY3IUdVtAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20240331_zALzbXn8tCcc" title="Unrealized losses"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;p style="margin: 0"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20240101__20240331_zWxLHr3Cze82" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_ztD6YbVVb1ah" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Cost"&gt;12,845&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zKnlikL4Dmf4" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;48&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zc69T67D7b06" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Unrealized losses"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTVqr9UN7zl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Fair value"&gt;12,893&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zo1kL0JkJFV2" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;12,845&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_pn3n3_c20230101__20231231_zXhPl2cGd6b9" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zdX4QI6oQTXa" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_pn3n3_c20230101__20231231_z49XaFaMCKca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">7859000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2024-01-012024-03-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">7857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">7859000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">2000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">7857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">12845000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">48000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ShortTermInvestmentsMember"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">12893000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">12845000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">48000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">12893000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000519">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z6N7hXlixww5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the Company&#x2019;s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zlICH7SXekdi" style="display: none"&gt;Schedule
of Fair Value Hierarchy Financial Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zI4CqUzkaq0f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zat1NRDsdKNf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaMvr4KLzTFa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzVZLZmo8op4" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zlUo8F3oXLHe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zzMDrpR0qKij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0529"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk8h9fLN7Mz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,702&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,845&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0534"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zPt7Kezepuw5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zx0DshjjNxMf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLjCYqnJkp1j" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zO95dlZITBtb" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zCy8B65m789g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0539"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_hus-gaap--InvestmentTypeAxis__custom--CorporateNotesAndCommercialPaperMember_zuqbxTpRKdG9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Corporate notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0542"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0544"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zlE1xueli5Lf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financial assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;443&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,893&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0549"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">1845000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">1845000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">7857000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">7857000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">9702000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">1845000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2024-03-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">7857000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">443000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">443000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">12893000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_CorporateNotesAndCommercialPaperMember"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">12893000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">13336000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">443000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">12893000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember63927609"
      decimals="0"
      id="Fact000551"
      unitRef="USD">394000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000553">&lt;p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_z3X6zCdBQdJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;span id="xdx_8B2_zKaOILP8WDw" style="display: none"&gt;Schedule
of Warrant Liability Transactions&lt;/span&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20240331_zoEgPTSb6eq1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20230331_zWtO1ZXEo27i" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Three Months Ending&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zDZXJi8Y42ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,052&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_pn3n3_zvWZYgOyU3B9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Issuance of warrants at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0558"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn3n3_zVpfyUou9429" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(658&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,924&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--Extinguishment_pn3n3_zgbpFKBU3Ljg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0564"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zRGyrzfGHjk1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,926&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">1052000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">19000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000559"
      unitRef="USD">5831000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2024-01-01to2024-03-31"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">-658000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">-2924000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">394000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000568"
      unitRef="USD">2926000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000570">&lt;p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zGW5Emi670le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_823_z6MAQFpyjPD5"&gt;Accounts Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z55uojEbEr1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B3_z7ui9O5coLsj" style="display: none"&gt;Schedule
of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240331_zH4MAVKOBf92" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2024&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zhChP46WleE5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zQInsufFB5dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable to a third-party manufacturer&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zrcHkyXb61Bk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;1,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz5ku_z8mP4v5MQFLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zDG4bxIYvNL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development
and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently executed a number of Statements
of Work for the research and development of products for use in clinical trials. The Company&#x2019;s commitments in relation to these
SOWs and any related Change Orders totaled approximately $&lt;span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20201031__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zxZT0xfvYGog"&gt;15.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2022, existing agreements with the third-party product manufacturer were amended. As part of the amendment, the third-party
manufacturer agreed that services to be rendered in future periods, will be paid or settled at the Company&#x2019;s discretion, in a combination
of cash and issuance of the Company&#x2019;s common stock. The amendment also eliminated future financial commitments of the Company.
As of December 31, 2023, outstanding accounts payable balance to the third-party product manufacturer amounted to $&lt;span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zPBsKadKIgr5"&gt;3.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2024, the Company recorded research and development expenses of $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zDmmXi0sFz57" title="Research and development expenses"&gt;268,000&lt;/span&gt;
to account for services rendered by the third-party product manufacturer. In addition, the Company paid cash of $&lt;span id="xdx_904_eus-gaap--Cash_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_zzzbPZ0eISW4" title="Cash"&gt;1.8&lt;/span&gt;
million towards the payment of accounts payable. As of March 31, 2024, the outstanding balance due to the third-party product manufacturer
amounted to $&lt;span id="xdx_907_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyProductManufacturerMember_z7QQGoIzNsxg" title="Accounts payable"&gt;2.0&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000572">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z55uojEbEr1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B3_z7ui9O5coLsj" style="display: none"&gt;Schedule
of Accounts Payable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240331_zH4MAVKOBf92" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;March 31, 2024&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zhChP46WleE5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zQInsufFB5dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Accounts payable to a third-party manufacturer&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_maAPCz4Y3_maAPCz5ku_zrcHkyXb61Bk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;1,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccountsPayableCurrent_iTI_pn3n3_mtAPCz5ku_z8mP4v5MQFLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,213&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000574"
      unitRef="USD">1983000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">3515000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000577"
      unitRef="USD">1230000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">813000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">3213000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">4328000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2020-10-31_custom_MasterServicesAgreementMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000582"
      unitRef="USD">15600000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_ThirdPartyProductManufacturerMember"
      decimals="-5"
      id="Fact000583"
      unitRef="USD">3500000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_ThirdPartyProductManufacturerMember"
      decimals="0"
      id="Fact000585"
      unitRef="USD">268000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Cash
      contextRef="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember"
      decimals="-5"
      id="Fact000587"
      unitRef="USD">1800000</us-gaap:Cash>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-03-31_custom_ThirdPartyProductManufacturerMember"
      decimals="-5"
      id="Fact000589"
      unitRef="USD">2000000.0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <GTBP:WarrantLiabilityTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000591">&lt;p id="xdx_803_ecustom--WarrantLiabilityTextBlock_zLBXuv206jP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_82A_z5Evn97Nviue"&gt;Warrant Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2023
Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate
of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_zsXpY1iKlVCf" title="Warrants to purchase"&gt;216,667&lt;/span&gt;
shares of the Company&#x2019;s common stock (the &#x201c;Common Warrants&#x201d;), and placement agent warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__srt--RangeAxis__srt--MaximumMember_z4lRsGpCBP51" title="Warrants to purchase"&gt;13,000&lt;/span&gt;
shares of the Company&#x2019;s common stock (the &#x201c;Placement Agents Warrants&#x201d; see Note 6 - Stockholders&#x2019;
Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Purchase Warrant provides for a value calculation for the Purchase Warrant using the Black Scholes model in the event of certain fundamental
transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLoBESIUeu3g" title="Volatility amount utilized in the value calculation percentage"&gt;100&lt;/span&gt;% or greater.
The Company has determined this provision introduces leverage to the holders of the Purchase Warrant that could result in a value that
would be greater than the settlement amount of a fixed-for-fixed option on the Company&#x2019;s own equity shares. Therefore, pursuant
to ASC 815, the Company has classified the Purchase Warrant as a liability in its consolidated balance sheet. The classification of the
Purchase Warrant, including whether the Purchase Warrant should be recorded as liability or as equity, is evaluated at the end of each
reporting period with changes in the fair value reported in other income (expense) in the consolidated statements of operations and comprehensive
loss. The Purchase Warrant was initially recorded at a fair value at $&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240331__us-gaap--StatementEquityComponentsAxis__custom--PurchaseWarrantMember_zPmlmKZ5itid" title="Warrant  fair value"&gt;5.8&lt;/span&gt; million at the grant date and is re-valued at each reporting
date. Upon the closing of placement, the fair value of the Purchase Warrant liability was recorded as a cost of capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2024, the fair value of the warrant liability was reduced to $&lt;span id="xdx_904_ecustom--IncreaseDecreaseInFairValueOfWarrantLiability_iI_c20240331_zC85MaUmViNi" title="Change in fair value of the warrant liability"&gt;393,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
changes in the fair value of the warrant liabilities are recognized as a change in fair value of warrant liability in the Company&#x2019;s
condensed consolidated statements of operations until they are either exercised or expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQqnUtf6DJn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zFmm3Da7Ieli" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Common Warrants and Placement&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agents Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zgX4hwLo0IW3" style="width: 16%; text-align: right" title="Stock price"&gt;4.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_z2QSCVtGDDqe" style="width: 16%; text-align: right" title="Stock price"&gt;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGtU07RSD04c" style="text-align: right" title="Warrants measurement input"&gt;4.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zxKCPjUGvB8j" style="text-align: right" title="Warrants measurement input"&gt;4.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zEUGR9NUYtij" style="text-align: right" title="Warrants measurement input"&gt;103.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zzrFgCoZn1Ej" style="text-align: right" title="Warrants measurement input"&gt;115.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zrB2KlOieMdd" title="Expected life (in years)"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQYX5gLaxnph" title="Expected life (in years)"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGVo7FcTT9Gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zbLdhCL8hEVi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zOjR9XpeBfOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zFbN9ZDk9WS" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;1,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zcCr9j28pP8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;2020
Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued certain warrants during the year ended December 31, 2020 that contained a fundamental transaction provision that could
give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance
with ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheets and will be
re-measured at the end of every reporting period with the change in value reported in the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zagaFcjcLmP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B5_zIzFK6VVkV5c" style="display: none"&gt;Schedule of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZDgjZpvR0Xk" style="width: 16%; text-align: right" title="Stock price"&gt;4.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZEZmFaYpCMj" style="width: 16%; text-align: right" title="Stock price"&gt;&#160;&#160;&#160;&#160;&#160;&#160;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zazWhJfVHMqk" style="text-align: right" title="Warrants measurement input"&gt;&#160;&#160;&#160;&#160;&#160;4.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z99g2NXT9Su1" style="text-align: right" title="Warrants measurement input"&gt;4.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zbP6o7EEGvQh" style="text-align: right" title="Warrants measurement input"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_znim9ugh62Me" style="text-align: right" title="Warrants measurement input"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znn9f4bEwZq1" style="text-align: right" title="Expected life (in years)"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgtzzt3R7Hd4" style="text-align: right" title="Expected life (in years)"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zjgWYePrXu17" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zv9TvHP75Oxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zRy7N8jay5ca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z869XvUVSoy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zVGwXgiDRV1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its
common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by
the remaining contractual life of the derivative instrument. For derivative instruments that already matured, the Company used the estimated
life. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past
and does not expect to pay dividends to its common stockholders in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized a gain of $&lt;span id="xdx_902_eus-gaap--EquitySecuritiesFvNiRealizedGain_c20240101__20240331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zHEW7KbaOjlk" title="Recognized gain of change in fair value of derivative liability"&gt;658,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--EquitySecuritiesFvNiRealizedGain_pn5n6_c20230101__20230331__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zIH8kAO1q2Vb" title="Recognized gain of change in fair value of derivative liability"&gt;2.9&lt;/span&gt; million to account for the change in fair value of the warrant liability related to all
warrants between the reporting periods for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">216667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-03-31_us-gaap_WarrantMember63927609"
      decimals="INF"
      id="Fact000597"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-03-31_custom_PurchaseWarrantMember"
      decimals="-5"
      id="Fact000599"
      unitRef="USD">5800000</us-gaap:WarrantsAndRightsOutstanding>
    <GTBP:IncreaseDecreaseInFairValueOfWarrantLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000601"
      unitRef="USD">393000</GTBP:IncreaseDecreaseInFairValueOfWarrantLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember"
      id="Fact000603">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQqnUtf6DJn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following
assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zFmm3Da7Ieli" style="display: none"&gt;Schedule
of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Common Warrants and Placement&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Agents Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zgX4hwLo0IW3" style="width: 16%; text-align: right" title="Stock price"&gt;4.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_z2QSCVtGDDqe" style="width: 16%; text-align: right" title="Stock price"&gt;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGtU07RSD04c" style="text-align: right" title="Warrants measurement input"&gt;4.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zxKCPjUGvB8j" style="text-align: right" title="Warrants measurement input"&gt;4.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zEUGR9NUYtij" style="text-align: right" title="Warrants measurement input"&gt;103.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zzrFgCoZn1Ej" style="text-align: right" title="Warrants measurement input"&gt;115.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zrB2KlOieMdd" title="Expected life (in years)"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zQYX5gLaxnph" title="Expected life (in years)"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zGVo7FcTT9Gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zbLdhCL8hEVi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zOjR9XpeBfOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeWarrantsMember_zFbN9ZDk9WS" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;1,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000605"
      unitRef="USDPShares">4.43</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000607"
      unitRef="USDPShares">7.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000609"
      unitRef="Pure">4.21</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Pure">4.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000613"
      unitRef="Pure">103.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000615"
      unitRef="Pure">115.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember"
      id="Fact000617">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwentyTwentyThreeWarrantsMember"
      id="Fact000619">P4Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyThreeWarrantsMember"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">393000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_TwentyTwentyThreeWarrantsMember"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">1050000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember"
      id="Fact000629">&lt;p id="xdx_898_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zagaFcjcLmP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8B5_zIzFK6VVkV5c" style="display: none"&gt;Schedule of Derivative Liabilities Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZDgjZpvR0Xk" style="width: 16%; text-align: right" title="Stock price"&gt;4.43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zZEZmFaYpCMj" style="width: 16%; text-align: right" title="Stock price"&gt;&#160;&#160;&#160;&#160;&#160;&#160;7.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zazWhJfVHMqk" style="text-align: right" title="Warrants measurement input"&gt;&#160;&#160;&#160;&#160;&#160;4.21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z99g2NXT9Su1" style="text-align: right" title="Warrants measurement input"&gt;4.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zbP6o7EEGvQh" style="text-align: right" title="Warrants measurement input"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_znim9ugh62Me" style="text-align: right" title="Warrants measurement input"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_znn9f4bEwZq1" style="text-align: right" title="Expected life (in years)"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgtzzt3R7Hd4" style="text-align: right" title="Expected life (in years)"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zjgWYePrXu17" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zv9TvHP75Oxf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of warrants (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20240101__20240331__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_zRy7N8jay5ca" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_z869XvUVSoy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of warrants"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000631"
      unitRef="USDPShares">4.43</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000633"
      unitRef="USDPShares">7.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Pure">4.21</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000637"
      unitRef="Pure">4.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-03-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Pure">89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwentyTwentyWarrantsMember"
      decimals="INF"
      id="Fact000641"
      unitRef="Pure">89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-03-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000643">P1Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_TwentyTwentyWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000645">P1Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-03-31_custom_TwentyTwentyWarrantsMember"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_TwentyTwentyWarrantsMember"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EquitySecuritiesFvNiRealizedGain
      contextRef="From2024-01-012024-03-31_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="0"
      id="Fact000655"
      unitRef="USD">658000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:EquitySecuritiesFvNiRealizedGain
      contextRef="From2023-01-012023-03-31_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="Fact000657"
      unitRef="USD">2900000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000659">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z6eadgVTQBvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_824_zbL92Mvdhzvh"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s authorized capital as of March 31, 2024 was &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240331_zZeIwkjlAwLk" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt;
shares of common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240331_zAW4fZvDzj1a" title="Common stock, par value"&gt;0.001&lt;/span&gt;
per share, and &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240331_zafpZSKjGZ47" title="Preferred stock, shares authorized"&gt;15,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240331_zhbf6OmuyRd9" title="Preferred stock, par value"&gt;0.01&lt;/span&gt;
per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Private
Placement of Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, GT Biopharma received gross proceeds of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsvccVIaL47d" title="Proceeds from private placement"&gt;6.5&lt;/span&gt; million, before deducting placement agent fees and other offering expenses
of $&lt;span id="xdx_901_eus-gaap--NoninterestExpenseOfferingCost_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zvFVG8bGZeXd" title="Other offering expenses"&gt;232,000&lt;/span&gt; in relation to a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) signed on December 30, 2022, between the Company
and an institutional investor (the &#x201c;Purchaser&#x201d;) for the issuance and sale, in a registered direct offering (the &#x201c;Offering&#x201d;),
of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zbpkpmXp2wRi" title="Direct offering"&gt;120,000&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z6bqrRbfzphh" title="Common stock par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Shares&#x201d;), pre-funded warrants to
purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4KvcLLQhTQ7" title="Purchase of warrants"&gt;96,667&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Pre-Funded Warrants&#x201d;), warrants to purchase up to
an aggregate of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsWANHk0Y4Q6" title="Purchase of warrants"&gt;216,667&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Common Warrants&#x201d;) and placement agent warrants to
purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrcrcoVzKo5j"&gt;13,000&lt;/span&gt; of the Company&#x2019;s common stock (the &#x201c;Placement Agents Warrants&#x201d;). The Common Warrants have an
exercise price equal to $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zyVVX9C51rV8" title="Warrant exercise price"&gt;30.00&lt;/span&gt;, became exercisable commencing six months following issuance, and shall have a term of exercise equal
to five years following the initial exercise date. The Pre-Funded Warrants had an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pip0_c20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zkzwSBRf3i99" title="Exercise price of warrant"&gt;0.003&lt;/span&gt; per Share, were immediately
exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The
Placement Agents Warrants have an exercise price equal to $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z64WUh9dvlAk"&gt;37.50&lt;/span&gt;, exercisable commencing six months following issuance, and shall
have a term of exercise equal to five years following the initial exercise date. The Shares and Common Warrants were sold at an offering
price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonSharesAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zFFHwbAaGhzj" title="Price per share"&gt;30.00&lt;/span&gt; per Share and accompanying Common Warrant and the Pre-Funded Warrants and Common Warrants were sold at an offering price
of $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsAndCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zagF6hVz1oca" title="Price per share"&gt;29.997&lt;/span&gt; per Pre-Funded Warrant and accompanying Common Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Warrants and the Placement Agents Warrants contained a clause not considered to be within the Company&#x2019;s control. The Company
determined that the provision represented a variable that is not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option
as defined under ASC 815-40, and thus the Common Warrants and the Placement Agent Warrants are not considered indexed to the Company&#x2019;s
own stock and not eligible for an exception from derivative accounting. Accordingly, the Common Warrants and the Placement Agent Warrants
were classified as a warrant liability, and $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230102__20230104__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantAndPlacementAgentWarrantMember_zfmzVSmNCkci" title="Change in fair value of warrant liability"&gt;5.8&lt;/span&gt; million of the initial common stock offering was classified as a warrant liability (Note
5 &#x2013; Warrant Liability).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued for Services&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended March 31, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zwxPF1EHfUMb" title="Shares issued"&gt;2,449&lt;/span&gt; shares of common
stock with a fair value of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230331__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zf0jcw5LmQpk" title="Shares issued, value"&gt;315,000&lt;/span&gt; to members of the Board of Directors, employees and consultants. The shares were valued at the respective
date of the agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock Issued for Vendor Payable&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 13, 2023, the Company issued &lt;span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zLdDiHJTc01f" title="Issued shares for vendor payable"&gt;16,228&lt;/span&gt; shares of common stock with a fair value of $&lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable_c20230313__20230313_zxes7k1OcUl" title="Fair value for vendor payable"&gt;287,000&lt;/span&gt; as settlement of accounts payable of $&lt;span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20230313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjKWgCTNh678" title="Accounts payable"&gt;820,000&lt;/span&gt;.
As a result, the Company recognized a gain of $&lt;span id="xdx_904_eus-gaap--DebtSecuritiesGainLoss_c20230313__20230313_zwh4SWNYZlQ4" title="Debt securities gain"&gt;533,000&lt;/span&gt; to account the difference between the fair value of the common stock issued and
the accounts payable settled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
C Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2024 and December 31, 2023, there were &lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDID1ATxVCYd" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYmJJO5K8xv2" title="Preferred stock, shares authorized"&gt;96,230&lt;/span&gt;&lt;/span&gt; shares of series C preferred stock, par value $&lt;span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zgthDmlXk1M4" title="Preferred stock, par value"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaFk8ckhh8Je" title="Preferred stock, par value"&gt;0.01&lt;/span&gt;&lt;/span&gt; per share (the &#x201c;Series
C Preferred Stock&#x201d;) issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNR2ORFnhtK2"&gt;96,230&lt;/span&gt;
shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders
of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders
of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Company&#x2019;s board of directors
(the &#x201c;Board&#x201d;). No dividends to holders of the Series C Preferred Stock were declared or unpaid through March 31, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
K Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2021, the Board designated &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210215__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zCnF2Iqf9Vp5" title="Preferred stock shares designated"&gt;115,000&lt;/span&gt; shares of Series K preferred stock, par value $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zoal3xURm6Pa" title="Preferred stock, par value"&gt;.01&lt;/span&gt; (the &#x201c;Series K Preferred Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company&#x2019;s common
stock at an effective conversion rate of &lt;span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zfWaCn0IcVp4" title="Convertible shares issuable"&gt;100&lt;/span&gt; shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred
Stock have the same voting rights as the shares of the Company&#x2019;s common stock, with the holders of the Series K Preferred Stock
entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders
of the Company&#x2019;s common stock on all matters presented to the Company&#x2019;s stockholders. The Series K Preferred Stock are not
entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in
any dividends to the holders of the Company&#x2019;s common stock. In the event of the Company&#x2019;s dissolution, liquidation or winding
up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company&#x2019;s common stock and will participate,
on a on an as-converted-to-common stock basis, in any distribution to holders of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2024 and December 31, 2023, there were &lt;span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zDMRUNVAwg5k" title="Preferred stock, shares Issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240331__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zZWZCRTrcI27" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zxw5MZ4IF5B1" title="Preferred stock, shares Issued"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zkTYGUArUIt" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of Series K Preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants
and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2tPo8CIo4ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zJSsz6wWDxN7" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331_zFgQFfaV9pq4" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;304,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zIGIdThyDFg3" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;63.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240331_zG9izbUoO0Na" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240331_zyiVyk7gfszk" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240331_zrN6MpnB5kn6" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240331_zqjcpfPExbb2" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0740"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331_zELmq5581LK2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z0WfWztEl4k2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240331_zAADC3aQD8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zfBUQ6XTWVb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance"&gt;63.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240331_zLod2FftuVD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zLit3LkKzhD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance"&gt;63.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z6rNClZLJAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2024, all issued and outstanding warrants are fully vested. The warrants had an exercise price greater than the market price,
which resulted in &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20240331_zyGekKgKbU95" title="Options outstanding intrinsic value"&gt;no&lt;/span&gt; intrinsic value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLghJun5l3oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of March 31, 2024 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zFsysDk5g4db" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zHSXupPjHcl8" title="Range of lower excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFl86VL9kfyf" style="width: 13%; text-align: right" title="Number of warrants outstanding"&gt;1,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zaDMAyWFSLt5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrZ18LkAiiu6" title="Warrants outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2tqakX7I8M4" style="width: 13%; text-align: right" title="Number of warrants exercisable"&gt;1,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;p style="margin: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWK5HAPKw5Rh" title="Warrants exercisable, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember__srt--RangeAxis__srt--MinimumMember_zq7kwz31DJJj"&gt;30.00&lt;/span&gt; &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfGc974mkT82"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpDhACuY5xZj" style="text-align: right" title="Number of warrants outstanding"&gt;229,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNKpgoJuj9a8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztykbqq9dBQc" title="Warrants outstanding, weighted average exercise price"&gt;30.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgTFTPjeIgvc" style="text-align: right" title="Number of warrants exercisable"&gt;229,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZayCWSq0m22" title="Warrants exercisable, weighted average exercise price"&gt;30.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcCzcyF5N1Dg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zb9ESKTsNg5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding"&gt;73,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4PbyfDlbyB5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDx2yi10Rg2j" title="Warrants outstanding, weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z6VPcThUb686" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable"&gt;73,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zm0QuDITJYRi" title="Warrants exercisable, weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHv4f51WjhB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zBoEGCRAsyga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMCWz3yZTG5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXZMBd9rtAbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
stock option transactions for the three months ended March 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zoaMKYCdkRq1" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zcVqTVH0N2K9" style="width: 16%; text-align: right" title="Number of Options outstanding, Beginning balance"&gt;126,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zNGchUfePBZ6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Beginning balance"&gt;39.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240331_znlrYWxW9IH1" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zGX43NE281Ek" style="text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20240331_zzsIcVpT9Ei8" style="text-align: right" title="Number of Options, Forfeited/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z1AyspYR5ZYi" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0809"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20240101__20240331_zuuz5VEEG3Y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zJ5CFwpa7Ehk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_znrqOLcJ9Nn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options outstanding, Ending balance"&gt;126,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_z1AkLGh0qJwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Ending balance"&gt;39.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240331_zh1U7KDOLYL8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, Ending balance"&gt;123,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zR3HGKbcfKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Exercisable Ending balance"&gt;40.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zpJSv0EPpID6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is recognizing the corresponding stock compensation expense for options granted to certain consultants, employees, officers and
directors based upon their vesting term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 27, 2023, the Company granted stock options to employees and members of its board of directors to purchase an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230127__20230127_z5KcVKInIGNf" title="Purchase an aggregate"&gt;66,667&lt;/span&gt;
shares of common stock. The stock options are exercisable at $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20230127_z9gD8Tkc0IOf" title="Exercise price"&gt;25.50&lt;/span&gt; per share, expires in &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230127__20230127_z7YO7G1OH8K4" title="Stock options expire"&gt;10&lt;/span&gt; years, vest over twelve months and had a
fair value of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn5n6_c20230127_zfijgjyT7Zk2" title="Fair value"&gt;1.4 &lt;/span&gt;million at the date of grant. determined using the Black-Scholes Option Pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDKnzZsy89Hj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z64iAGTdjEh" style="display: none"&gt;Schedule
of Stock Granted Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240331_zlLUphoekLNa" title="Stock price"&gt;0.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20240331_zmVDb47kBZjg" title="Risk-free interest rate"&gt;3.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_z37MaOpycdxc" title="Expected volatility"&gt;121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zuk9yHJ3G7K7" title="Expected life (in years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20240331_z851IfkqMDy7" style="text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zJivgjuq3bvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended March 31, 2024, the Company recognized stock compensation expense related to the vesting options of $&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20240101__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z0IeEY6zHwC5" title="Options granted"&gt;102,000&lt;/span&gt;. For
the three months ended March 31, 2023, the Company recognized stock compensation expense relating to the vesting of options granted on
January 27, 2023 and prior years of $&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230127__20230127__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zSYaefcCmem" title="Options granted"&gt;507,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFFWobc17Um2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of March 31, 2024 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zk0iKTjrTA1f" style="display: none"&gt;Schedule
of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEu5lvIcQeD1" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIlgHWsDRiyj" style="width: 13%; text-align: right" title="Options outstanding"&gt;16,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4emyU2pKeb9" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlr2bLcigTj6" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCOru1e9nLwe" style="width: 13%; text-align: right" title="Options exercisable"&gt;13,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zTH2nGfEPzz5" title="Options exercisable, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZMmrm9gsfZa" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zx28sGLBYmJg" style="text-align: right" title="Options outstanding"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJmBSepkNhK8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKeMlT7s7BF6" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeBMZmMjCsUb" style="text-align: right" title="Options exercisable"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zvlKbe2sMeV" title="Options exercisable, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zYDjUUnRoUM" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzfqVJGqVc1g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding"&gt;42,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPpDH0Rgs3m8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGh62hqNMmt6" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpo6d4ydV4p8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable"&gt;42,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z89HeQBVZbyh" title="Options exercisable, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331_zTK6HreRNjRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;126,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331_zKGqKNtlxUk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;123,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zl4emZr4pBzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2024 and 2023, there were &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20240331_z0UhHnasdJda" title="Stock compensation expense unvested options"&gt;2,778&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230331_zhKSoFcBpqE9" title="Unvested options, shares"&gt;53,225&lt;/span&gt; unvested options with a grant date fair value of $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20240331_zCWpb7ql73pf" title="Stock compensation expense unvested options"&gt;12,000 &lt;/span&gt;and $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn5n6_c20230331_zMECEqnUi4a4" title="Stock compensation expense unvested options"&gt;1.3&lt;/span&gt; million, respectively,
which will be recognized as stock compensation expense in future periods based upon the remaining vesting term of the applicable grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was no intrinsic value of the outstanding options as of March 31, 2024 as the exercise price of these options was greater than the market
price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000661"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000663"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000667"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-01-042023-01-04_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000669"
      unitRef="USD">6500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2023-01-042023-01-04_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">232000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">120000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-01-04_us-gaap_CommonStockMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000675"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_PrefundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000677"
      unitRef="Shares">96667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000679"
      unitRef="Shares">216667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000680"
      unitRef="Shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-04_custom_CommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000682"
      unitRef="USDPShares">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-04_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000684"
      unitRef="USDPShares">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-04_custom_PlacementAgentWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">37.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-04_custom_CommonSharesAndCommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000687"
      unitRef="USDPShares">30.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-04_custom_PreFundedWarrantsAndCommonWarrantsMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000689"
      unitRef="USDPShares">29.997</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-022023-01-04_custom_CommonWarrantAndPlacementAgentWarrantMember"
      decimals="-5"
      id="Fact000691"
      unitRef="USD">5800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">2449</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_custom_BoardOfDirectorsEmployeesAndConsultantsMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">315000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-03-132023-03-13"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">16228</GTBP:StockIssuedDuringPeriodSharesCommonSharesInSettlementOfVendorsPayable>
    <GTBP:StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable
      contextRef="From2023-03-132023-03-13"
      decimals="0"
      id="Fact000699"
      unitRef="USD">287000</GTBP:StockIssuedDuringPeriodFairValueCommonSharesInSettlementOfVendorsPayable>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-03-13_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000701"
      unitRef="USD">820000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2023-03-132023-03-13"
      decimals="0"
      id="Fact000703"
      unitRef="USD">533000</us-gaap:DebtSecuritiesGainLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000705"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000707"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000709"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-02-152021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      id="Fact000714"
      unitRef="Shares">115000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2021-02-16_custom_SeriesKPreferredStocksMember"
      decimals="INF"
      id="Fact000718"
      unitRef="Shares">100</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      id="Fact000720"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesKPreferredStockMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000728">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2tPo8CIo4ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the three months ended March 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zJSsz6wWDxN7" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Warrants outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331_zFgQFfaV9pq4" style="width: 16%; text-align: right" title="Warrants outstanding, beginning balance"&gt;304,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zIGIdThyDFg3" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;63.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240331_zG9izbUoO0Na" style="text-align: right" title="Number of warrants, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240331_zyiVyk7gfszk" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0736"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240331_zrN6MpnB5kn6" style="text-align: right" title="Number of warrants, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0738"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240331_zqjcpfPExbb2" style="text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0740"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331_zELmq5581LK2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z0WfWztEl4k2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0744"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240331_zAADC3aQD8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, beginning balance"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zfBUQ6XTWVb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, beginning balance"&gt;63.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240331_zLod2FftuVD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zLit3LkKzhD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable, ending balance"&gt;63.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000730"
      unitRef="Shares">304962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000732"
      unitRef="USDPShares">63.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">304962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000748"
      unitRef="USDPShares">63.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">304962</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000752"
      unitRef="USDPShares">63.30</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember"
      id="Fact000756">&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zLghJun5l3oc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of March 31, 2024 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zFsysDk5g4db" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zHSXupPjHcl8" title="Range of lower excercise price"&gt;10.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFl86VL9kfyf" style="width: 13%; text-align: right" title="Number of warrants outstanding"&gt;1,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zaDMAyWFSLt5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrZ18LkAiiu6" title="Warrants outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2tqakX7I8M4" style="width: 13%; text-align: right" title="Number of warrants exercisable"&gt;1,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;p style="margin: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWK5HAPKw5Rh" title="Warrants exercisable, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember__srt--RangeAxis__srt--MinimumMember_zq7kwz31DJJj"&gt;30.00&lt;/span&gt; &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfGc974mkT82"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpDhACuY5xZj" style="text-align: right" title="Number of warrants outstanding"&gt;229,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zNKpgoJuj9a8" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ztykbqq9dBQc" title="Warrants outstanding, weighted average exercise price"&gt;30.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgTFTPjeIgvc" style="text-align: right" title="Number of warrants exercisable"&gt;229,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZayCWSq0m22" title="Warrants exercisable, weighted average exercise price"&gt;30.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcCzcyF5N1Dg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zb9ESKTsNg5j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants outstanding"&gt;73,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4PbyfDlbyB5" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zDx2yi10Rg2j" title="Warrants outstanding, weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z6VPcThUb686" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of warrants exercisable"&gt;73,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zm0QuDITJYRi" title="Warrants exercisable, weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHv4f51WjhB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20240331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zBoEGCRAsyga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants exercisable"&gt;304,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000758"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">1867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      id="Fact000762">P1Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000764"
      unitRef="USDPShares">10.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">1867</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact000768"
      unitRef="USDPShares">10.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000769"
      unitRef="USDPShares">30.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000770"
      unitRef="USDPShares">37.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">229666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      id="Fact000774">P4Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000776"
      unitRef="USDPShares">30.42</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">229666</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000780"
      unitRef="USDPShares">30.42</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000781"
      unitRef="USDPShares">165</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">73429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      id="Fact000785">P1Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000787"
      unitRef="USDPShares">165.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">73429</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_WarrantsMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000791"
      unitRef="USDPShares">165.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Shares">304962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2024-03-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Shares">304962</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000797">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXZMBd9rtAbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
stock option transactions for the three months ended March 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zoaMKYCdkRq1" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zcVqTVH0N2K9" style="width: 16%; text-align: right" title="Number of Options outstanding, Beginning balance"&gt;126,265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zNGchUfePBZ6" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Beginning balance"&gt;39.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240331_znlrYWxW9IH1" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zGX43NE281Ek" style="text-align: right" title="Weighted-Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20240331_zzsIcVpT9Ei8" style="text-align: right" title="Number of Options, Forfeited/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_z1AyspYR5ZYi" style="text-align: right" title="Weighted-Average Exercise Price, Forfeited/cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0809"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsExercised_pid_c20240101__20240331_zuuz5VEEG3Y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zJ5CFwpa7Ehk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_znrqOLcJ9Nn6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options outstanding, Ending balance"&gt;126,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_z1AkLGh0qJwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Outstanding Ending balance"&gt;39.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240331_zh1U7KDOLYL8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, Ending balance"&gt;123,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240331_zR3HGKbcfKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Options Exercisable Ending balance"&gt;40.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">126265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000801"
      unitRef="USDPShares">39.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000815"
      unitRef="Shares">126265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000817"
      unitRef="USDPShares">39.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">123487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">40.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-272023-01-27"
      decimals="INF"
      id="Fact000823"
      unitRef="Shares">66667</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-01-27"
      decimals="INF"
      id="Fact000825"
      unitRef="USDPShares">25.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-272023-01-27" id="Fact000827">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-01-27"
      decimals="-5"
      id="Fact000829"
      unitRef="Shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000831">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDKnzZsy89Hj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_z64iAGTdjEh" style="display: none"&gt;Schedule
of Stock Granted Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240331_zlLUphoekLNa" title="Stock price"&gt;0.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20240331_zmVDb47kBZjg" title="Risk-free interest rate"&gt;3.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240331_z37MaOpycdxc" title="Expected volatility"&gt;121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240331_zuk9yHJ3G7K7" title="Expected life (in years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240101__20240331_z851IfkqMDy7" style="text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000833"
      unitRef="USDPShares">0.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000835"
      unitRef="Pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="Fact000837"
      unitRef="Pure">1.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-01to2024-03-31" id="Fact000839">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-01-012024-03-31_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">102000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-01-272023-01-27_us-gaap_StockOptionMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="0"
      id="Fact000845"
      unitRef="USD">507000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000847">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zFFWobc17Um2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of March 31, 2024 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zk0iKTjrTA1f" style="display: none"&gt;Schedule
of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Contractual&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Number&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEu5lvIcQeD1" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIlgHWsDRiyj" style="width: 13%; text-align: right" title="Options outstanding"&gt;16,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z4emyU2pKeb9" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlr2bLcigTj6" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCOru1e9nLwe" style="width: 13%; text-align: right" title="Options exercisable"&gt;13,888&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zTH2nGfEPzz5" title="Options exercisable, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZMmrm9gsfZa" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zx28sGLBYmJg" style="text-align: right" title="Options outstanding"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zJmBSepkNhK8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKeMlT7s7BF6" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeBMZmMjCsUb" style="text-align: right" title="Options exercisable"&gt;66,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zvlKbe2sMeV" title="Options exercisable, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zYDjUUnRoUM" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zzfqVJGqVc1g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options outstanding"&gt;42,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPpDH0Rgs3m8" title="Options outstanding, weighted average remaining contractual life (years)"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zGh62hqNMmt6" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpo6d4ydV4p8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options exercisable"&gt;42,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20240331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z89HeQBVZbyh" title="Options exercisable, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240331_zTK6HreRNjRe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;126,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20240331_zKGqKNtlxUk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable"&gt;123,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">10.50</GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">16666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-03-31_custom_RangeOneMember"
      id="Fact000853">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000857"
      unitRef="Shares">13888</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2024-03-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact000859"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000861"
      unitRef="USDPShares">25.50</GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">66667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-03-31_custom_RangeTwoMember"
      id="Fact000865">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">25.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Shares">66667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2024-03-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact000871"
      unitRef="USDPShares">25.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000873"
      unitRef="USDPShares">74.40</GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">42932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-03-31_custom_RangeThreeMember"
      id="Fact000877">P8Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000879"
      unitRef="USDPShares">74.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000881"
      unitRef="Shares">42932</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2024-03-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact000883"
      unitRef="USDPShares">74.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000885"
      unitRef="Shares">126265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000887"
      unitRef="Shares">123487</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">2778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">53225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000893"
      unitRef="USD">12000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-03-31"
      decimals="-5"
      id="Fact000895"
      unitRef="USD">1300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000897">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zpbGazLfjp99" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_826_zkuQmjEfQone"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being
handled in, the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 14, 2023, former interim Chief Executive Officer, Dr. Greg Berk filed a lawsuit alleging that GT Biopharma
discriminated and retaliated against Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX").
The Parties are proceeding with litigating Berk's SOX claim. GT Biopharma is vigorously defending this matter and believe it to be without
merit. At this early stage in the proceedings, GT Biopharma is not able to determine the probability of the outcome of this matter or
a range of reasonably expected losses, if any.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he
    breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among
    other relief, monetary damages estimated at $&lt;span id="xdx_905_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20220513__20220513_zDlBgfPdifVi"&gt;470,000&lt;/span&gt;; the return of &lt;span id="xdx_901_eus-gaap--TreasuryStockCommonShares_iI_c20220513_zLqRlBJhDtB2"&gt;13,903&lt;/span&gt; shares of our common stock received without authorization;
    and an award of the Company&#x2019;s attorneys&#x2019; fees and any forum and arbitration fees. As a component of Mr. Handelman&#x2019;s
    contract with the Company, disputes shall be fully addressed and finally resolved by binding arbitration conducted by the American
    Arbitration Association (AAA). In connection with any such arbitration, the Company shall bear all costs not otherwise borne by a
    plaintiff in a court proceeding. On March 20, 2024, the Arbitrator issued an interim award in favor of the Company in the amount of $&lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_c20240320__20240320_zGK1Mi3WgfYh" title="Shares return, value"&gt;409,000&lt;/span&gt; and directed
Mr. Handelman to return the disputed &lt;span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20240320__20240320_znKlwXj4fES8" title="Shares return"&gt;13,903&lt;/span&gt; shares of common stock . The Arbitrator also awarded the Company its attorney fees and forum
costs in an amount to be determined at the time of the final award.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    May 24, 2023, TWF Global, LLC (&#x201c;TWF&#x201d;) filed a Complaint in the California Superior Court for the County of Los Angeles
    naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#x201c;Notes&#x201d;)
    and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated
    damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the
    terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its
    Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint
    for Interpleader against TWF and Z One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme
    Court to determine if the Company&#x2019;s shares of common stock are properly registered to TWF or Z One LLC, as both of these entities
    have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for
    entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One
    and that the Company be released from all associated liability and claims. The Court has not yet ruled on the Company&#x2019;s motion.
    The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these
    claims. The Court denied the motion without prejudice, and will reconsider the motion without further briefing upon the filing
of a party affidavit. &#160;Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled
their dispute over the entitlement to GT Biopharma shares.&#160; The Company believes that any claims related to the Notes are without
merit and will continue to defend vigorously against these claims.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Significant
Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a scientific research agreement with the Regents of the University of Minnesota (&#x201c;UofMN&#x201d;), effective
June 16, 2021. This scientific research agreement aims to work with the Company with three major goals in mind: (1) support the Company&#x2019;s
TriKE&lt;sup&gt;&#xae; &lt;/sup&gt;product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans;
and (3) investigation of the patient&#x2019;s native NK cell population based on insights obtained from the analysis of the human data
generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE&lt;sup&gt;&#xae;
&lt;/sup&gt;constructs in support of our product development and GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform drug delivery
changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of
changes in the patient&#x2019;s native NK cell population as a result of TriKE&lt;sup&gt;&#xae; &lt;/sup&gt;therapy. Most studies will use TriKE&lt;sup&gt;&#xae;
&lt;/sup&gt;DNA/amino acid sequences created by us under current UMN/GTB licensing terms. This agreement expired on June 30, 2023. The Company
and UofMN are negotiating the terms of a new scientific research agreement and expect to finalize it in the first half of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense of $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zfCU2cbFMxHc" title="Research and development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--ScientificResearchAgreementMember_zv2YFuaqDUD5" title="Research and development expense"&gt;192,000&lt;/span&gt; pursuant to the scientific research agreement, for the three months ended March 31, 2024
and 2023, respectively. The Company has recorded an expense in the aggregate of $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240101__20240331_zeIq1F6V3uy1" title="Aggregate research and development expense"&gt;2.1&lt;/span&gt; million as of March 31, 2024 pursuant to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Patent
and License Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2016
Exclusive Patent License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (&#x201c;UofMN&#x201d;),
to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology developed by researchers at the UofMN to
target NK cells to cancer. Under the terms of the 2016 agreement, the Company receives exclusive rights to conduct research and to develop,
make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology worldwide for the treatment of any disease, state, or condition in humans.
The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted
by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union.
Under the agreement, the UofMN received an upfront payment of $&lt;span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zYwo2fdewkec" title="Proceeds from upfront amount"&gt;200,000&lt;/span&gt;, and an annual License Maintenance fee of $&lt;span id="xdx_90B_eus-gaap--CostMaintenance_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zrcTZsX8fg8k" title="Maintenance fee"&gt;100,000&lt;/span&gt; beginning in
2021. The agreement also includes &lt;span id="xdx_903_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zHvLYnrU9msc" title="Royalty fee percentage"&gt;4&lt;/span&gt;% royalty fees, not to exceed &lt;span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z4gHd9UT17Vi" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequence license agreements or amendments to this agreement
or minimum annual royalty payments ranging from $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_c20240101__20240331__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zh2PtjoVOpji" title="Annual royalty payments"&gt;250,000&lt;/span&gt; to $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20240331__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZxBKxXuRlLj" title="Annual royalty payments"&gt;5.0&lt;/span&gt; million. The agreement also includes certain performance milestone payments
totaling $&lt;span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zE0tiY6rn7e7" title="Milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone payments of $&lt;span id="xdx_903_ecustom--SalesMilestonePayments_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zTNuAZL6d4h5" title="Sales milestone payments"&gt;1.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_909_ecustom--GrossSales_pn6n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zahPrlRR3LSl" title="Sales"&gt;250&lt;/span&gt; million in gross sales, and $&lt;span id="xdx_90D_ecustom--SalesRevenue_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFSCZ4h0vOtl" title="Sales revenue"&gt;5.0&lt;/span&gt; million
upon reaching $&lt;span id="xdx_903_ecustom--CummulativeGrossSales_pn5n6_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zfzQgI4kdSPk" title="Cumulative gross sales"&gt;500&lt;/span&gt; million dollars in cumulative gross sales of Licensed Products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did &lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zlFs0RZ7GEr9" title="Research and development expense"&gt;&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJ24rCVrRzoj" title="Research and development expense"&gt;no&lt;/span&gt;&lt;/span&gt;t incur any research and development expense relating to the 2016 Exclusive Patent License Agreement for the three months
ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2021
Patent License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. Under the agreement, the UofMN received
an upfront license fee of $&lt;span id="xdx_90C_ecustom--UpfrontLicenseFee_pp0p0_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zC8YYMr4Y4y7" title="Upfront license fee"&gt;20,000&lt;/span&gt; and will receive an annual License Maintenance fee of $&lt;span id="xdx_900_ecustom--LicenseMaintenanceFeeReceivable_iI_pp0p0_c20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zAekNhVjLpM1" title="License maintenance fee, receivable"&gt;5,000&lt;/span&gt; beginning in 2022,&lt;span id="xdx_906_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zbKgAI24RvZk" title="Net sales percentage"&gt; 2.5&lt;/span&gt;% to &lt;span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210325__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsfxhzfaQGUl" title="Net sales percentage"&gt;5&lt;/span&gt;% royalty
fees, or minimum annual royalty payments of $&lt;span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zcVROWjNFwi9" title="Annual royalty payments"&gt;250,000 &lt;/span&gt;beginning in the year after the first commercial sales of Licensed Product, and
$&lt;span id="xdx_901_eus-gaap--CostMaintenance_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zrFU9TBLljNj" title="Maintenance fee"&gt;2.0 &lt;/span&gt;million beginning in the fifth year after the first commercial sale of such Licensed Product. The agreement also includes certain
performance milestone payments totaling $&lt;span id="xdx_905_ecustom--PerformanceMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8SESXBk1IJf" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zP6KlujjvTd1" title="Sales milestone payments"&gt;1.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_904_ecustom--GrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPAw0UjFYQo7" title="Gross sales"&gt;250&lt;/span&gt; million
in gross sales, and $&lt;span id="xdx_909_ecustom--SalesRevenue_pn5n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zlHPwsdWeIw1" title="Sales revenue"&gt;5.0&lt;/span&gt; million upon reaching $&lt;span id="xdx_901_ecustom--CummulativeGrossSales_pn6n6_c20210325__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zMU48DRCz5kb" title="Cumulative gross sales"&gt;500 &lt;/span&gt;million dollars in cumulative gross sales of Licensed Products. There is no double
payment intended; if one of the milestone payments has been paid under the 2016 agreement no further payment is due for the corresponding
milestone above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_do_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zGASnhLh5sY4" title="Research and development expense"&gt;&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_do_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z1OEprRL42L8" title="Research and development expense"&gt;no&lt;/span&gt;&lt;/span&gt;t incur any research and development expense relating to the 2021 Patent License Agreement for the three months ended March
31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-05-132022-05-13"
      decimals="0"
      id="Fact000898"
      unitRef="USD">470000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2022-05-13"
      decimals="-3"
      id="Fact000899"
      unitRef="Shares">13903000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-03-202024-03-20"
      decimals="-3"
      id="Fact000901"
      unitRef="USD">409000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-03-202024-03-20"
      decimals="-3"
      id="Fact000903"
      unitRef="Shares">13903000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_ScientificResearchAgreementMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_ScientificResearchAgreementMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">192000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-01to2024-03-31"
      decimals="-5"
      id="Fact000909"
      unitRef="USD">2100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000913"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Pure">0.04</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000917"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact000921"
      unitRef="USD">5000000.0</us-gaap:RoyaltyExpense>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000923"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000925"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000927"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000929"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000931"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact000935"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <GTBP:LicenseMaintenanceFeeReceivable
      contextRef="AsOf2021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">5000</GTBP:LicenseMaintenanceFeeReceivable>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-252021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000941"
      unitRef="Pure">0.025</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-252021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact000943"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:CostMaintenance
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000947"
      unitRef="USD">2000000.0</us-gaap:CostMaintenance>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000949"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000951"
      unitRef="USD">1000000.0</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000953"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact000955"
      unitRef="USD">5000000.0</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2021-03-252021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact000957"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000963">&lt;p id="xdx_80D_eus-gaap--OperatingLeasesOfLessorDisclosureTextBlock_z4V9GplAVXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_823_zUp3xSVRmYO2"&gt;Operating Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Leases
with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components
of its leases as a single lease component. Rent expense is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease Right-of-Use (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the lease commencement date based on the present value
of lease payments over the lease term. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and
lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Generally, the implicit rate
of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present
value of lease payments. The Company&#x2019;s incremental borrowing rate is a hypothetical collateralized borrowing rate based on its
understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 16.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 19, 2021, the Company entered into a sublease with a third party for &lt;span id="xdx_900_eus-gaap--AreaOfLand_iI_uSqft_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4uzA9sYnlFk" title="Area of land"&gt;4,500&lt;/span&gt; square feet of office space located in Brisbane,
California, with a &lt;span id="xdx_909_eus-gaap--LesseeOperatingSubleaseOptionToExtend_c20211118__20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z7JfDtSs6Rwa" title="Lessee, operating sublease, option to extend"&gt;commencement date of January 1, 2022 and maturing on June 30, 2024. &lt;/span&gt;&lt;span style="background-color: white"&gt;As a result
of this agreement, the Company recognized&lt;/span&gt; ROU asset and liability of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211119__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_z5HWeoxXsaJ5"&gt;247,294&lt;/span&gt; &lt;span style="background-color: white"&gt;pursuant to
ASC 842&lt;i&gt;, Leases.&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2022, the Company entered into a copier lease which will end on February 7, 2025. As a result, the Company &lt;span style="background-color: white"&gt;recognized &lt;/span&gt;additional
ROU asset and liability of $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20220208__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zwUDstuSnJOg" title="Operating lease liability"&gt;13,000&lt;/span&gt;.
In October 2023, this lease was cancelled and the remaining ROU asset of $&lt;span id="xdx_901_ecustom--WrittenOffRightOfUseAsset_iI_c20231031__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zkm0vN5wWo9l" title="Written off right of use asset"&gt;6,000 &lt;/span&gt;was
written off against the cancelled lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of these lease agreements, the Company recognized ROU asset and liability in the aggregate of $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zU1LwKRVGscf" title="Operating lease, right of use asset"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20240331__us-gaap--TypeOfArrangementAxis__us-gaap--LeaseAgreementsMember_zh7O5CRvq3v7" title="Operating lease liability"&gt;260,294&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total rent expense related to these leases reflected on the Company&#x2019;s Condensed Consolidated Statements of Operations totaled $&lt;span id="xdx_90D_eus-gaap--PaymentsForRent_pp0p0_c20240101__20240331_zM1YPSkg3YHk" title="Rent expense"&gt;25,000&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230331_zs5BUmHYGhs3" title="Rent expense"&gt;29,000 &lt;/span&gt;for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zgyhERp1OFh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zHTu9T5tgbwl" style="display: none"&gt;Schedule of Other Information Related Leases Under Non-Cancellable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2023 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zjZ0ZDAuVWH7" style="width: 16%; text-align: right" title="Operating cash flows from operating leases"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zZBCB8oTyJX9" style="width: 16%; text-align: right" title="Operating cash flows from operating leases"&gt;30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zueD2O4kKHTg" title="Weighted average remaining lease term operating leases"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zNwuuCxB1ZYj" title="Weighted average remaining lease term operating leases"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_z9iTzikCOhih" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_ztH3xINMvmsd" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zNSnTTZlmjPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8XIVHA2puYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancellable operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zES8LvCr8qmg" style="display: none"&gt;Schedule of Future Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240331_zrBxMW6DDhQ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maOLLza2F_zXaoO2aCjEGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLza2F_zCWaZYDpAHGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;After one year and within two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLza2F_z2lWo4z7ZMT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;After two years and within three years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maOLLza2F_z6XOr6JiqEVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLLza2F_znT7mT1b0eEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXgqXZWxrnD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; Discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z7j9PSEov4Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zY3eELXOJT3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Sqft">4500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingSubleaseOptionToExtend
      contextRef="From2021-11-182021-11-19_us-gaap_LeaseAgreementsMember"
      id="Fact000967">commencement date of January 1, 2022 and maturing on June 30, 2024.</us-gaap:LesseeOperatingSubleaseOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-11-19_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">247294</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-02-08_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">13000</us-gaap:OperatingLeaseLiability>
    <GTBP:WrittenOffRightOfUseAsset
      contextRef="AsOf2023-10-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">6000</GTBP:WrittenOffRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">260294</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">260294</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForRent
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000978"
      unitRef="USD">25000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">29000</us-gaap:PaymentsForRent>
    <GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000982">&lt;p id="xdx_891_ecustom--ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock_zgyhERp1OFh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to leases and future minimum lease payments under non-cancellable operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zHTu9T5tgbwl" style="display: none"&gt;Schedule of Other Information Related Leases Under Non-Cancellable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2023 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240331_zjZ0ZDAuVWH7" style="width: 16%; text-align: right" title="Operating cash flows from operating leases"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeasePayments_pp0p0_c20230101__20230331_zZBCB8oTyJX9" style="width: 16%; text-align: right" title="Operating cash flows from operating leases"&gt;30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average remaining lease term (in years):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240331_zueD2O4kKHTg" title="Weighted average remaining lease term operating leases"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230331_zNwuuCxB1ZYj" title="Weighted average remaining lease term operating leases"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Weighted-average discount rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20240331_z9iTzikCOhih" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230331_ztH3xINMvmsd" title="Weighted average discount rate operating leases"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfOtherInformationRelatedLeasesUnderNOnCancellableTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="Fact000984"
      unitRef="USD">30</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000986"
      unitRef="USD">30</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-03-31" id="Fact000988">P0Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-03-31" id="Fact000990">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-03-31"
      decimals="INF"
      id="Fact000994"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact000996">&lt;p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z8XIVHA2puYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum lease payments under non-cancellable operating leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zES8LvCr8qmg" style="display: none"&gt;Schedule of Future Minimum Lease Payments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240331_zrBxMW6DDhQ9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;March 31, 2024 (Unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maOLLza2F_zXaoO2aCjEGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLza2F_zCWaZYDpAHGj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;After one year and within two years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLza2F_z2lWo4z7ZMT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;After two years and within three years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1002"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pn3n3_maOLLza2F_z6XOr6JiqEVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLLza2F_znT7mT1b0eEk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zXgqXZWxrnD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less &#x2013; Discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_z7j9PSEov4Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001008"
      unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">30000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-03-31" id="Fact001012">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zRtpbyyxFbX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span&gt;&lt;span id="xdx_820_zjcaH3K39nVa"&gt;Subsequent Event&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 30, 2024, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsyzOAe4Xw11"&gt;36,018&lt;/span&gt; shares of common stock to settle $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20240430__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLgB68NJvmdk"&gt;278,500&lt;/span&gt; of vendor accounts payable. The shares were valued at
the month-end closing price of the Company&#x2019;s common stock for the months for which services were provided by the vendor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001013"
      unitRef="Shares">36018</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-302024-04-30_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001014"
      unitRef="USD">278500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
